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Abstract		
Increasing	 evidence	 suggests	 that	 breast	 cancer	 (BC)	 progression	 involves	 interaction	
between	 the	 tumour	 and	 the	 surrounding	 stroma,	 the	 tumour	microenvironment	 (TME).	
Work	 presented	 in	 this	 thesis	 is	 based	 on	 the	 hypothesis	 that	 anti-cancer	 therapies	
influence	the	bone	microenvironment	(BME),	contributing	to	enhanced	treatment	efficacy.	
Thus,	the	BME	was	established	as	a	therapeutic	target	for	BC	using	in	vivo	models,	imaging	
and	molecular	analysis.	
	 	 Novel	 evidence	 of	 early	 effects	 of	 the	 bisphosphonate	 Zoledronic	 acid	 (ZOL)	 on	
cells	 other	 than	 the	osteoclast,	 its’	main	 target,	 are	presented.	 Indeed	a	 single,	 clinically	
relevant	dose	 rapidly	 affected	osteoblasts,	 bone	 volume,	bone	marrow	microvasculature	
and	 extra	 cellular	 matrix	 (ECM)	 composition	 as	 early	 as	 3	 days	 after	 treatment	 in	 vivo.	
Based	 on	 the	 finding	 that	 BC	 cells	 preferentially	 locate	 to	 osteoblast-,	 and	 ECM-rich	
trabecular	bone	and	 that	BC	cell	 location	 in	bone	could	be	 challenged	 in	a	ZOL-modified	
microenvironment,	 osteoblasts	 were	 identified	 as	 a	 potential	 key	 component	 of	 the	
metastasis	niche	and	a	novel	therapeutic	target	for	BC	bone	metastasis.	
Additionally	 this	 work	 provides	 evidence	 that	 the	 tyrosine	 kinase	 inhibitor	
Cabozantinib	(CBZ)	affects	bone	structure,	growth	plate	chondrocytes	and	haematopoietic	
bone	 marrow	 cells	 including	 megakaryocytes	 in	 naïve	 mice.	 Effects	 on	 osteoblasts	 and	
osteoclasts	varied	between	animal	model	and	treatment	schedule,	however,	these	studies	
suggest	that	therapeutic	response	to	CBZ	in	patients	with	bone	metastasis	may	be	partially	
mediated	via	the	BME.	
Although	 ZOL	 affects	 a	 variety	 of	 BM-derived	 cells,	 first	 evidence	 is	 given	 that	
modification	 of	 the	 BME	 with	 ZOL	 is	 not	 sufficient	 to	 affect	 peripheral	 BC	 re-growth	
following	cessation	of	successful	combination	therapy.	
	
Collectively	 work	 presented	 in	 this	 thesis	 contributes	 important	 knowledge	 to	 the	
inadequately	characterised,	initial	events	of	bone	metastasis;	and	provides	strong	evidence	
that	 the	 BME	 contributes	 to	 treatment	 success	 in	 metastatic	 BC,	 however	 its	 role	 in	
primary	disease	needs	to	be	established.	
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CLO	 Clodronate	
CTCs	 Circulating	tumour	cells	
CXCR4	 C-X-C	chemokine	receptor	type	4	
DAB	 3,	3'-diaminobenzidine	
DAPI	 4',6-diamidino-2-phenylindole	
dH2O	 Deionised	water	
dia	 Diaphysis	
DMSO	 Dimethyl	sulfoxide	
DNA	 Deoxyribonucleic	acid	
DOX	 Doxorubicin	
DTC	 Disseminated	tumour	cells	
ECM	 Extra	cellular	matrix	
EDTA	 Ethylenediaminetetraacetic	acid	
ELISA	 Enzyme-linked	immunosorbant	assays	
EOP	 End	of	procedure	
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ETI	 Etidronate	
GFP	 Green	fluorescent	protein	
GP	 Growth	plate	
H2O	 Water	
H2O2	 Hydrogen	peroxide	
HCl	 Hydrochloric	acid	
HGF	 Hepatocyte	growth	factor	
hr	 Hour	
HSCs	 Haematopoietic	stem	cells	
IBAN	 Ibandronate	
IGF-1	 Insulin-like	growth	factor	1	
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IICs	 Infiltrating	immune	cells		
Ils	 Interleukins	
lN2	 Liquid	nitrogen	
LOX	 Lysyl	oxidase	
M-CSF	 Macrophage	colony	stimulating	factor		
MDSCs	 Myeloid	derived	suppressor	cells	
MET	 Hepatocyte	growth	factor	receptor	
met	 Metaphysis	
min	 Minutes	
min	 Minute	
MIP-1α	 Macrophage	inflammatory	protein	
MMPs	 Matrix	metalloproteinases	
MSC	 Mesenchymal	stem	cells	
MSCs	 Mesenchymal	stem	cells	
NBP	 Nitrogen	containing	bisphosphonate	
NNBP	 Non-nitrogen	containing	bisphosphonate	
Ob	 Osteoblast	
Oc	 Osteoclast	
OPG		 Osteoprotegerin	
OPN	 Osteopontin	
PAM	 Pamidronate	
PBS	 Phosphate-buffered	saline	
PDGF	 Platelet-derived	growth	factor		
PFA	 Paraformaldehyde	
PINP	 Procollagen	type	I	N	propeptide	
PTH	 Parathyroid	hormone	
PTHrP	 Parathyroid	hormone-related	protein		
PVP	 Polyvinylpyrrolidone	
qRT-PCR	 Quantitative	Real	Time	Polymerase	Chain	
Reaction	
RANK	 Receptor	activator	of	nuclear	factor-kB		
RANK	 Receptor	activator	of	nuclear	factor	kappa-B	
RANKL	 Receptor	activator	of	nuclear	factor	kappa-B	
ligand	
RIS	 Risedronate	
RNA	 Ribonucleic	acid	
RT	 Room	temperature	
RTKs	 Receptor	Tyrosine	Kinases		
SDF-1	 Stromal	cell-derived	factor	1	
sec	 Second	
SREs	 Skeletal	related	events	
TAMs	 Tumour	associated	macrophages	
Tb	 Trabeuclar	bone	
TGF-β	 Transforming	growth	factor-β		
TME	 Tumour	microenvironment	
TNF-α	 Tumour	necrosis	factor	alpha		
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TRAP	 Tartrate-resistant	acid	phosphatase	
VEGF	 Vascular	endothelial	growth	factor	
VOI	 Volume	of	interest	
ZOL	 Zoledronic	acid	
µCT	 Micro-computed	tomography	
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1.1. Breast	cancer	and	breast	cancer	metastasis	to	bone	–	Statistics	
Breast	cancer	 is	one	of	the	most	common	cancers	 in	Europe	(464,000	cases;	13.5%	of	all	
cancer	 cases	 diagnosed	 in	 2012)	 [1].	 Steady	 improvements	 in	 screening	 methods	 and	
therapy,	 awareness	 and	 early	 detection	 have	 led	 to	 excellent	 prognosis	 for	 patients.	
Nevertheless,	it	remains	the	leading	cause	of	death	from	cancer	in	women.	Progress	in	the	
treatment	 of	 primary	 breast	 cancer	 has	 resulted	 in	 doubling	 of	 the	 10-year	 net	 survival	
rates,	 which	 is	 currently	 at	 nearly	 78%	 [2].	 The	 skeleton	 is	 the	 most	 favoured	 site	 of	
metastasis	in	breast	cancer	and	around	70%	of	patients	with	advanced	disease	will	develop	
bone	metastases	[3].	These	patients	experience	high	morbidity	caused	by	skeletal-related	
events	(SREs)	due	to	the	osteolytic	nature	of	the	disease	[3].	Survival	rates	at	this	stage	are	
poor,	 only	 15%	 of	 patients	 diagnosed	with	 stage	 IV	 breast	 cancer	 (metastatic	 spread	 to	
other	 organs	 of	 the	 body)	will	 survive	 their	 disease	 for	 up	 to	 five	 years	 [4].	 	 Given	 that	
advanced	disease	is	incurable,	and	the	lack	of	routine	markers	for	early	detection	of	bone	
metastases,	 emphasises	 the	 need	 for	 new	 treatment	 strategies	 and	 novel	 therapeutic	
approaches	to	improve	the	long-term	survival	of	patients	with	advanced	breast	cancer.	
1.2. The	tumour	microenvironment	(TME)	
Over	 the	 last	 decade,	 research	 has	 moved	 away	 from	 the	 hypothesis	 that	 cancer	 cells	
alone	 result	 in	 development	 and	 progression	 of	 the	 disease.	 The	 tumour	
microenvironment	(TME),	the	cellular	environment	in	which	the	cancer	exists,	 in	addition	
to	the	surrounding	matrix	and	signalling	molecules	is	widely	acknowledged	to	contribute	to	
disease	 progression;	 and	 offers	 a	 broad	 field	 for	 research	 investigation	 and	 treatment	
intervention.	A	number	of	aspects	of	the	contribution	of	the	TME	are	established	(e.g.	the	
role	of	endothelial	cells	in	tumour	angiogenesis	[5-7]),	whereas	others	including	the	impact	
of	 the	 TME	 in	 mediating	 response	 to	 anti-cancer	 therapy,	 activation	 of	 invasion	 and	
metastasis	 [8,	 9],	 remain	 under-researched	 and	 poorly	 defined.	 Understanding	 the	
complexity	of	how	components	of	the	TME	co-operate	with	cancer	cells	is	instrumental	to	
ultimately	establish	more	successful	anti-cancer	treatment.	
1.2.1 Composition	of	the	TME	and	contribution	to	disease	progression	
The	complexity	of	tumour–stroma	interactions	and	the	role	of	the	TME	has	been	actively	
researched	and	 reviewed	over	 the	 last	decades	 [10-12].	Therefore	only	a	 short	 summary	
will	 be	 provided	 here,	 with	 a	more	 detailed	 discussion	 concerning	 the	 role	 of	 the	 bone	
microenvironment	(BME)	in	breast	cancer	growth	in	the	next	sections.	On	a	cellular	level,	
the	TME	comprises	a	broad	 spectrum	of	 subpopulations.	 For	 simplification	Hanahan	and	
Coussens	have	grouped	these	into	three	compartments	including	(1)	Angiogenic	Vascular	
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Cells	(AVCs)	(2)	Infiltrating	Immune	Cells	(IICs,	 including	tumour	associated	macrophages,	
TAMs)	and	(3)	Cancer-Associated	Fibroblastic	cells	(CAFs)	[10].		
Briefly,	CAFS	are	suggested	to	be	the	most	prominent	compartment	of	the	TME	in	
breast	 cancer	 [13].	 Given	 the	 physiological	 role	 of	 fibroblasts	 in	 wound	 healing,	
inflammation	and	ECM	remodelling,	their	activated	presence	in	the	TME	is	predominant	as	
tumours	are	considered	“chronic,	non-healing	wounds”.	The	origin	of	CAFs	remains	unclear	
but	they	may	be	derived	from	resident	fibroblasts	[14],	bone	marrow	derived	cells	that	are	
actively	 recruited	 and/or	 cancer	 cells	 that	 under-go	 active	 epithelial-mesenchymal	
transition	(EMT)	[15].	There	is	currently	no	specific	set	of	markers	to	identify	CAFs	as	they	
are	 a	 heterogeneous	population,	 similar	 to	 the	 tumour	 itself.	 The	 role	of	 CAFs	 in	 cancer	
progression,	invasion	and	metastasis	has	been	extensively	reviewed	[13].	Briefly	these	cells	
produce	a	variety	of	soluble	factors	that	all	contribute	to	drive	the	disease	(e.g.	hepatocyte	
growth	factor	(HGF),	transforming	growth	factor-β	(TGF-β),	stromal	derived	factor-1	(SDF-
1),	vascular	endothelial	growth	factor	(VEGF),	interleukins	(IL-6)	etc.),	in	addition	to	matrix	
metalloproteinases	(MMPs),	thereby	affecting	several	hallmarks	of	cancer	[8,	9,	16].		
Macrophages	 derived	 from	 haematopoietic	 origins	 physiologically	 contribute	 to	
tissue	repair	and	defence	against	foreign	pathogens;	and	are	often	thought	to	be	the	first	
cells	 arriving	 at	 sites	 of	 infection	 and/or	 wounds.	 Macrophages	 are	 one	 of	 the	 most	
abundant	 cell	 populations	 at	 the	 tumour	 site	 (termed	 tumour	 associated	 macrophages,	
TAMs).	 They	 are	 generally	 not	 tumouricidal	 unless	 tumour-derived	 factors	 including	
interleukins	 (Ils)	 and	 TGF-β	 activate/promote	M2	macrophage	 polarisation	 (the	 tumour-
growth-promoting	subtype)	 [17].	TAMs	are	generally	associated	with	poor	prognosis	due	
to	 their	 ability	 to	 promote	 tumour	 angiogenesis	 (e.g.	 via	 epidermal	 growth	 factor	 (EGF),	
VEGF,	 platelet-derived	 growth	 factor	 (PDGF),	 tumour	necrosis	 factor	 alpha	 (TNFα),	 CCL2,	
CXCL8,	etc.)	 [18,	 19],	migration	 (e.g.	 EGF,	MMPs,	etc.),	metastatic	 spread	 (preparing	 the	
metastatic	 site	 through	 VEGFR1,	 CCR2,	 and	 CX3CR1)	 [20],	 and	 immunosuppression	 –	 all	
recently	reviewed	in	detail	[21].		
In	addition	to	macrophages	also	other	infiltrating	immune	cells	such	as	neutrophils	
and	 subsets	 of	 T-cells,	 can	 have	 both	 tumour	 promoting	 and	 inhibiting	 functions	 –	
processes	 mediated	 via	 microenvironmental	 factors	 including	 for	 example	 interferons	
(IFNs)	and	TGF-β.	As	a	key	component	in	inflammation	they	contribute	to	tumour	growth	
partially	via	the	secretion	of	pro-tumorigenic	factors	including	EGF,	TGF-β,	PDGF,	HGF	and	
VEGF	[22].	
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The	contribution	of	AVCs	including	pericytes,	endothelial	cells	and	smooth	muscle	
cells	has	been	extensively	characterised	in	tumour	development.	Briefly	they	contribute	to	
tumour	 growth	 via	 providing	 nutrients	 and	 oxygen,	 facilitate	 trafficking	 of	 growth	
promoting	 factors	 as	 well	 as	 cells	 to	 and	 from	 the	 tumour	 and	 allow	 cancer	 cell	
dissemination	 and	 metastasis.	 In	 turn,	 cancer	 cells	 induce	 the	 so-called	 ‘’angiogenic	
switch“.	 This	 involves	 the	 induction	 of	 tumour	 angiogenesis	 through	 detachment	 of	
perivascular	 cells	 and	 vessel	 dilation,	 followed	 by	 angiogenic	 sprouting,	 formation	 and	
maturation	of	new	vessels	to	provide	essential	nutrients	and	oxygen	[23,	24].	This	results	
in	 increased	 rate	 of	 tumour	 growth	 [6,	 7,	 25].	 In	 their	 extensive	 review	 Hanahan	 and	
Coussens	have	elegantly	summarised	and	illustrated	key	contributions	of	cells	of	the	TME	
to	cancer	growth	–	see	Figure1.	
Of	 relevance	 to	 breast	 cancer,	 the	 mammary	 stroma	 is	 comprised	 of	 following	
components:	adipocytes,	pre-adipocytes,	fibroblasts,	blood	vessels,	 inflammatory	cells,	as	
well	as	extracellular	matrix	[26].	Stromal	cells	in	the	developing	mammary	gland,	as	well	as	
growth	factors	and	cytokines	are	associated	with	breast	cancer	growth	and	progression	–	
reviewed	in	[26].	
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Figure	1	Contribution	of	the	tumour	microenvrionment	to	cancer	growth.		
A	 myriad	 of	 cell	 populations	 contribute	 to	 the	 „Hallmarks	 of	 Cancer“	 [9].	 „Reprinted	 from	
Accessories	to	the	Crime:	Functions	of	Cells	Recruited	to	the	Tumor	Microenvironment	
	D.	 Hanahan,	 L.M.	 Coussens,	 Accessories	 to	 the	 crime:	 functions	 of	 cells	 recruited	 to	 the	 tumor	
microenvironment,	 Cancer	 Cell	 21(3)	 (2012)	 309-22.	 Copyright	 ©	 2012	 Elsevier	 Inc.	 Terms	 and	
Conditions;	with	permission	from	Elsevier.	doi:10.1016/j.ccr.2012.02.022	
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1.2.1.1. Recruitment	of	bone	marrow-derived	cells	to	promote	tumour	growth	
Growing	attention	is	paid	to	bone	marrow-derived	cells	(BMDCs)	and	their	contribution	to	
breast	cancer	growth.	Many	of	the	stromal	cells	present	within	the	TME	are	mobilised	host	
cells	 from	 distant	 tissues	 including	 the	 bone	marrow	 and	 spleen,	 illustrated	 in	 Figure	 2.	
Recruitment	 of	 BMDCs	 involves	 the	 release	 of	 tumour-derived	 factors	 including	
granulocyte-colony	 stimulating	 factor	 (G-CSF),	 VEGF,	 TGF-β,	 osteopontin	 (OPN),	 lysyl	
oxidase	(LOX)	and	stromal	cell-derived	factor	1	(SDF-1)	[27-29].	SDF-1	is	a	key	regulator	of	
bone	 marrow	 retention	 and	 homing	 of	 haematopoietic	 stem	 and	 progenitor	 cell	
populations	 (HSCs,	 HSPCs)[30,	 31].	 G-CSF	 in	 contrast	 causes	 mobilisation	 of	 HSCs	 or	
prevents	 their	homing	 to	bone	marrow	niches	 [32].	Additionally	 the	bone	matrix	protein	
OPN	 is	 required	 for	 the	pro-tumorigenic	 function	of	BMDCs	 in	 tumour	 xenograft	models	
[27].	Studies	have	shown	that	BMDCs	contribute	to	vascularisation	and	growth	of	primary	
tumours.	Formation	of	a	complex	vascular	network	is	a	pre-requisite	of	tumour	growth	and	
in	 addition	 to	 the	 sprouting	 from	pre-existing	 vessels,	BMDCs	 including	haematopoietic-,	
endothelial	progenitor	cells	and	mesenchymal	stem	cells	are	recruited	to	promote	tumour	
angiogenesis	 and	 growth	 [33-35].	 It	 is	 also	 suggested	 that	 recruitment	 of	 BMDCs	 is	
detrimental	 for	 the	 early	 stages	 of	 tumour	 angiogenesis,	 whereas	 residual	 BMDCs	 may	
contribute	 to	 later	 tumour	 growth	 [33].	 In	 addition	 tumour-derived	 chemoattractants	
including	 VEGF,	 colony	 stimulating	 factor	 1	 (CSF-1)	 and	 CCL2	 (Chemokine	 (C-C	 Motif)	
Ligand	 2)	 drive	 the	 accumulation	 of	 TAMs	 derived	 from	 mononuclear	 bone	 marrow	
progenitor	 cells	 in	 the	 tumour	 stroma	 [36].	 TAMs	 produce	 angiogenic	 factors	 including	
VEGF	 and	 angiopoietin	 [37-40],	 which	 stimulates	 the	 recruitment	 of	 further	 BMDCs	
including	mast	cells,	neutrophils,	myeloid-derived	suppressor	cells	and	leukocytes	[36,	40,	
41].	The	role	of	BMDCs	in	mediating	primary	breast	cancer	(re)-growth	is	further	discussed	
in	Chapter	3;	and	illustrated	in	Figure	2	below.	However,	the	contribution	of	BMDCs	is	not	
limited	 to	 primary	 tumour	 growth,	 which	 became	 evident	 by	 studies	 reporting	 that	
VEGFR1+ve	bone	marrow-derived	haematopoietic	progenitor	cells	home	to	pre-metastatic	
sites	where	they	form	clusters	prior	to	the	arrival	of	tumour	cells	[28,	42].	Here	the	role	of	
BMDCs	 in	metastasis	 is	 stressed	by	 the	observation	 that	metastasis	 did	 not	 occur	 in	 the	
absence	of	BMDC	recruitment	[28].	
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Figure	2	Bone	marrow-derived	precursor	cells	(BMDCs)	-	contribution	to	primary	breast	cancer	
growth.	
Cancer	 cells	 secrete	 various	 growth	 factors,	 cytokines	 and	 chemokines,	 which	 results	 in	 the	
recruitment	 of	 bone	 marrow-resident	 precursor	 cells.	 These	 cells	 actively	 promote	 disease	
progression.	However,	whether	 these	cells	 get	activated	whilst	 still	 in	 the	bone	marrow	or	at	 the	
site	 of	 tumour	 growth	 is	 still	 unclear.	 The	 complex	 tumour-stroma	 crosstalk	 gives	 room	 for	
therapeutic	targeting.	
1.2.2 The	TME	-	Summary		
In	summary,	 the	composition	of	 the	TME	 is	complex	and	our	 increased	understanding	of	
the	tumour-stroma	crosstalk	resulted	in	the	development	of	therapeutic	agents	that	target	
not	only	the	tumour	cells	but	also	the	microenvironment.	This	includes	for	example	agents	
that	affect	the	tumour	vasculature	such	as	bevacizumab,	sunitinib,	sorafenib,	erlotinib	and	
gefitinib.	Other	approaches	are	to	enhance	tumour	immunity	by	targeting	myeloid	derived	
suppressor	cells,	T-,	and	B-cells.	Various	chemokines	that	recruit	BMDCs	including	TAMs,	as	
well	as	inflammatory	signalling	pathways	are	explored	as	therapeutic	targets.	Agents	that	
disrupting	 the	 interaction	 between	 tumour	 cells	 and	 the	 ECM	 as	 well	 as	 the	 bone	
microenvironment	are	 investigated	and/or	used	 in	 clinical	practice	 including	 for	example	
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integrin	 inhibitors	 and	 anti-resorptives	 such	 as	 bisphosphonates	 and	 Denosumab	
(discussed	in	section	1.5.1.	and	1.5.2.).	
1.3. The	bone	microenvironment		(BME)	
Besides	 lung,	 liver	 and	 brain,	 bone	 is	 the	 preferred	 site	 for	 breast	 cancer	 metastasis.	
Around	 70%	of	 patients	with	 advanced	 disease	will	 develop	 bone	metastases	 [3],	 hence	
indicating	the	potential	for	therapeutic	modification	of	the	bone	microenvironment	(BME).	
In	 addition,	 physiological	 interaction	 between	 breast	 and	 bone	 is	 apparent,	 especially	
during	the	process	of	childbearing	and	breastfeeding.	Lactation	as	well	as	suckling	requires	
the	 release	of	 large	amounts	of	 calcium	 (Ca2+)	 from	the	skeleton.	Both	processes	 involve	
alterations	 in	 parathyroid	 hormone	 (PTH),	 parathyroid	 hormone-related	 protein	 (PTHrP),	
calcium	 (Ca2+),	 RANK/RANKL	 signalling	 (Receptor	 activator	 of	 nuclear	 factor	 kappa-
B/ligand;	key	regulatory	pathway	of	osteoclastogenesis	and	drivers	of	bone	remodelling),	
calcitonin,	 vitamin	 D3,	 gonadotropin-releasing	 hormone,	 prolactin	 and	 estradiol	 [43-45].	
During	pregnancy	 and	breastfeeding	 this	 commonly	 results	 in	 increased	bone	 resorption	
and	bone	loss,	which	is	rapidly	reversible	after	weaning	[46].	A	key	regulator	of	serum	Ca2+	
levels	 is	 PTH	 through	 its’	 effects	 on	 bone	 (release	 of	 Ca2+/bone	 remodelling)	 and	 kidney	
(increase	 Ca2+	 resorption,	phosphate	excretion	 and	1,25	 dihydroxyvitamin	 D	formation).	
Decreased	Ca2+	 levels	result	 in	rapid,	 increased	secretion	of	PTH,	followed	by	osteoclastic	
bone	 resorption	 to	 release	 Ca2+	 stored	 in	 the	 skeleton,	 a	 tightly	 regulated	 feedback	
mechanism.	 However,	 PTH	 can	 have	 both	 anabolic	 (bone	 building)	 and	 catabolic	 (bone	
destroying)	functions,	depending	on	exposure	and	concentration	(intermittent	=	anabolic,	
continuous	=	catabolic	[47]).	
1.3.1. Bone	composition	and	function	
Bone	is	a	dynamic	organ	composed	of	a	mineral	phase	(hydroxyapatite),	an	organic	phase	
including	 lipids,	and	water.	The	organic	phase	can	be	divided	 into	 (1)	structural	 proteins	
including	 type	 I	 collagen,	 fibronectin, and	 (2)	 non-collagenous	 proteins	 such	 as	
proteoglycans,	 osteopontin,	 osteonectin,	 matrix	 metalloproteinases	 and	 phosphatases	
[48].	 These	 building	 blocks	 are	 produced	 by	 cells	 of	mesenchymal	 origin,	 including	 both	
osteoblasts	and	fibroblasts.	Two	structural	subtypes	of	bone	are	observed:	(1)	 trabecular	
(around	20%	of	the	skeleton,	high	metabolic	activity)	and	(2)	cortical	bone	(about	80%	of	
the	skeleton,	less	active,	provides	mechanical	strength)	[49].		
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1.3.1.1. Key	bone	cells	and	function	
Briefly,	 the	 bone	 marrow	 hosts	 two	 distinct	 stem	 cell	 populations,	 haematopoietic	 and	
mesenchymal	stem	cells	(HSCs	and	MSCs),	with	each	having	different	progenies.	HSCs	give	
rise	 to	 all	 lymphoid	 and	 myeloid	 linage	 cells	 finally	 differentiating	 into	 immune	 cells,	
megakaryocytes,	myeloid	cells	(monocytes/	macrophages/	granulocytes)	and	erythrocytes	
[50].	MSCs	in	contrast	differentiate	to	give	rise	to	adipocytes,	bone	and	connective	tissue-
forming	cells	including	chondrocytes,	osteoblasts	and	myoblasts	(Figure	3).	In	addition	the	
bone	marrow	 is	 comprised	of	 a	 dense,	 interconnected	 vascular	 system	 (endothelial	 cells	
arising	 from	 hemangioblasts	 similar	 to	 HSCs	 [30]),	 which	maintains	 haematopoiesis	 and	
osteogenesis	[51,	52].		
	
Figure	3	Origin	of	cells	of	the	bone	microenvironment.		
The	bone	marrow	hosts	two	distinct	stem	cell	populations,	haematopoietic	and	mesenchymal	stem	
cells	(HSCs	and	MSCs),	with	each	having	different	progenies.	
The	three	key	cells	responsible	for	maintaining	bone	structure	and	function	include	(1)	the	
bone	resorbing	osteoclast,	(2)	the	bone	forming	osteoblast	and	(3)	the	mechanosensory	
osteocyte,	the	most	abundant	cell	type	in	bone.		
Cells	of	the	osteoblast	family:		MSCs	differentiate	into	osteoblast	precursors	(so-called	
osteoprogenitors	characterised	by	expression	of	osterix	and	Runx2	[53,	54])	followed	by	
maturation	 into	 active,	 bone	 forming	 osteoblasts	 (characterised	 by	 expression	 of	
Osteocalcin).	Osteoblasts	 are	 generally	 round	 in	 shape,	 characterised	 by	 a	 large	 golgi	
complex,	abundant	endoplasmatic	reticulum	and	found	in	clusters	lining	bone	surfaces	
[55].	After	a	short	phase	of	active	bone	formation	the	terminal	fate	of	osteoblasts	is	to	
become	buried	in	bone,	upon	which	they	are	classified	as	osteocytes,	or	exist	quiescent	
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on	bone	surfaces	as	bone	lining	cells	characterised	by	a	flattened	morphology	with	few	
organelles	[56].	Being	embedded	within	the	bone	matrix	and	their	tight	connection	with	
neighbouring	 cells	 through	 various	 cell	 processes	 allows	 osteocytes	 to	 sense	
mechanically-induced	 matrix-strain	 and	 to	 consequently	 relay	 signals	 to	 surrounding	
cells	to	respond	to	mechanical	stimuli	[55,	57]	.			
Osteoclasts:	 Derived	 from	 haematopoietic	 cells	 of	 the	 myeloid	 lineage,	 osteoclast	
precursors	 differentiate	 into	 large,	 multinucleated	 osteoclasts	 (tartrate-resistant	 acid	
phosphatase	 TRAP+ve,	 cathepsin	 K+ve);	 a	 process	 controlled	 by	 receptor	 activator	 of	
nuclear	 factor-kB	 (RANK,	 or	 TNFSF11)	 and	macrophage	 colony	 stimulating	 factor	 (M-
CSF).		Osteoclasts	are	responsible	for	breaking	down	and	resorbing	mineralised	matrix.	
Only	 when	 in	 contact	 with	 mineralised	 bone	 surfaces,	 osteoclasts	 generate	 distinct	
membrane	domains	 including	the	ruffled	membrane,	bind	to	resorption	sites	via	αvβ3	
integrin	 molecules	 and	 create	 a	 unique,	 isolated	 microenvironment	 known	 as	 the	
sealing	zone.	Hydrogen	ions	are	pumped	into	this	sealing	zone	creating	a	low	pH	(4.5),	
which	 in	 combination	with	 collagenolytic	 enzymes	 (Cathepsin	K,	MMPs)	degrades	 the	
bone	matrix	[58].			
Connective	tissue	cells	–	Fibroblasts:	Another	mesenchymal-derived	cell	type	abundant	in	
the	BME	includes	fibroblasts.	Fibroblasts	synthesize	and	secrete	extracellular	matrix	(ECM)	
molecules	including	collagens,	fibronectin	and	proteoglycans	in	addition	to	ECM-degrading	
proteases,	 thereby	 contributing	 to	 connective	 tissue	 maintenance.	 Physiologically	
quiescent	or	resting	spindle-shaped	fibroblasts	are	found	embedded	within	the	ECM.	Next	
to	 their	 contribution	 of	 ECM	 synthesis	 and	 deposition,	 quiescent	 fibroblasts	 become	
activated	by	 tissue	 injury	or	associated	stimuli	 (e.g.	 transforming	growth	 factor-β	 (TGFβ),	
platelet-derived	growth	factor	(PDGF)	and	interleukin-6	(IL-6)),	thus	contributing	to	wound	
healing,	tissue	repair	and	regeneration	[59,	60].		During	bone	repair,	fibroblasts	start	to	lay	
down	 ECM	 to	 aid	 vascular	 ingrowth.	 Once	 vascular	 ingrowth	 is	 progressing	 a	 collagen	
matrix	 is	 laid	 down,	 osteoid	 secreted	 and	 finally	mineralised	 by	 osteoblasts.	 In	 addition	
they	 contribute	 to	haematopoiesis	 by	 secreting	 cytokines	 including	GM-CSF,	 IL-6	 and	M-
CSF,	macrophage	 inflammatory	protein	 (MIP-1α),	monocyte	chemotactic	protein-1	 (MCP-
1),	 interferon-γ	 [61-63].	 Fibroblasts	 also	 contribute	 to	 angiogenesis,	 in	 example	 through	
production	of	HGF,	basic	fibroblast	growth	factor	(bFGF)	and	thrombospondin	[64].		
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1.3.1.2. Physiological	bone	remodelling	
Cross-talk	between	osteoblasts	and	osteoclasts	 is	 regulated	 in	 time	and	space	during	the	
process	 of	 bone	 remodelling.	 Remodelling	 takes	 place	 in	 distinct	 sites	 termed	 basic	
multicellular	 units	 (BMUs).	 This	 ensures	maintenance	 of	 tissue	 turnover	 and	 is	 a	 tightly	
“coupled”	 process	 involving	 resorption	 of	 bone	 by	 osteoclasts	 followed	 by	 osteoblast-
mediated	bone	formation	[65].	The	hypothesis	of	communication	between	osteoblasts	and	
osteoclasts	 by	 Rodan	 and	 Martin	 [66]	 resulted	 in	 the	 discovery	 of	 the	 RANK/RANKL,	
osteoprotegerin	(OPG)	signalling	cascade,	and	its	importance	during	bone	remodelling	[67-
72].	
Briefly,	 the	 remodelling	 cycle	 consists	 of	 distinct	 phases	 including	 activation,	
resorption,	 reversal	 formation	 and	 finally	 termination	 of	 the	 cycle	 [65],	 schematically	
illustrated	in	Figure	4.		
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Figure	4	Schematic	representation	of	a	Bone	Mineral	Unit	(BMU)	and	the	associated	bone-
remodeling	process.	
The	remodelling	cycle	consists	of	distinct	phases	including	activation,	resorption,	reversal	formation	
and	 finally	 termination	 of	 the	 cycle.	 Each	 phase	 is	 tightly	 regulated	 by	 the	 interaction	 of	 various	
bone	 cells.	 „This	 research	 was	 originally	 published	 in	 The	 Journal	 of	 Biological	 Chemistry.	
L.J.Raggatt,	 N.C.	 Partridge.Cellular	 and	 molecular	 mechanisms	 of	 bone	 remodelling.J	 Biol	 Chem	
285(33)	 (2010)	25103-8.	©2010	by	 the	American	Society	 for	Biochemistry	and	Molecular	Biology,	
Inc;	 with	 permission	 from	 American	 Society	 for	 Biochemistry	 and	 Molecular	 Biology".	 doi:	
10.1074/jbc.R109.041087		
The	 remodelling	 cycle	 is	 activated	 through	 an	 initial	 stimulus	 including	 (1)	 mechanical	
stress	 sensed	 by	 osteocytes	 affecting	 IGF-I,	 a	 factor	 known	 to	 be	 required	 for	 MSC	
differentiation	[73];	(2)	PTH	as	an	endocrine	bone	remodelling	signal	or	(3)	reduced	TGF-β	
concentrations	 resulting	 from	 osteocyte	 apoptosis	 during	 tissue	 damage	 [74].	 Next	
osteoclast	precursors	are	recruited	to	the	resorption	site	followed	by	their	differentiation	
into	 mature,	 multinucleated	 osteoclasts.	 	 Completion	 of	 osteoclast	 precursor	
differentiation	 requires	 expression	of	macrophage	 colony	 stimulating	 factor	 (M-CSF)	 and	
RANKL	by	osteoblastic	stromal	cells	and	binding	to	the	corresponding	receptors	RANK	and	
c-fms	on	osteoclast	precursors	[67,	71,	75].	RANK/RANKL	mediated	osteoclast	maturation	
Schematic representation of a BMU and the associated bone-remodeling process. 
Liza J. Raggatt, and Nicola C. Partridge J. Biol. Chem. 
2010;285:25103-25108 
©2010 by American Society for Biochemistry and Molecular Biology 
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is	 inhibited	 by	 OPG,	 a	 decoy	 receptor	 for	 osteoblastic	 RANKL	 and	 negative	 regulator	 of	
bone	 resorption,	 which	 is	 also	 produced	 by	 osteoblasts	 (Figure	 4)	 [69].	 Signalling	
downstream	 the	 RANK/RANKL,	M-CSF/c-fms	 signalling	 axes	 result	 in	 activation	 of	NF-kB,	
NFATc1	and	c-fos	[68,	76]	leading	to	expression	of	osteoclast	specific	genes	including	TRAP,	
cathepsin	K	 and	b3	 integrins.	Osteoclastic	bone	 resorption	 is	 systemically	 regulated	by	4	
main	 hormones,	 PTH	 and	 1,25-dihydroxy	 vitamin	 D3	 stimulating	 and	 oestrogen	 and	
calcitonin	reducing	bone	resorption	directly	or	 indirectly.	PTH	and	1,25-dihydroxy	vitamin	
D3	are	key	regulators	of	calcium	homeostasis;	by	stimulating	osteoclastic	bone	resorption,	
both	are	 required	 to	maintain	 serum	Ca2+	 concentrations	 to	avoid	 clinical	manifestations	
including	 hypo-	 and	 hypercalcemia.	 The	 resorption	 site	 is	 isolated	 by	 a	 membrane	 ring	
known	 as	 the	 sealing	 zone	 and	 low	 pH	 in	 combination	 with	 collagenolytic	 enzymes	
ultimately	lead	to	degradation	of	the	bone	matrix	[58].	During	the	reversal	and	formation	
phase	an	equal	amount	of	previously	resorbed	bone	needs	to	be	removed	and	replaced	by	
new	 matrix;	 known	 as	 coupling	 [77].	 Reversal	 of	 bone	 resorption	 is	 proposed	 to	 be	
initiated	by	mononuclear	 cells	of	 still	 unknown	origin,	 called	 “reversal	 cells”	 [74].	During	
this	 phase,	 any	 remaining	 collagen	 is	 removed	 and	 the	bone	 surface	 is	 prepared	 for	 the	
subsequent	formation	of	new	matrix	by	osteoblasts	[56].	The	signals	that	couple	formation	
and	 resorption	 of	 bone	 remain	 a	 subject	 of	 debate,	 but	 are	 suggested	 to	 include	 bone	
matrix-derived	factors	 including	ILs,	TGF-β,	osteoclast-osteoblast-derived	signals	 including	
EphB4-ephrin-B2	 [78]	 and	 Sphingosine	 1-phosphate	 [79],	 or	 mechanical	 stimulation	 via	
osteocytes	[73,	74].	Mesenchymal-derived	osteoblast	precursors	differentiate	into	mature	
osteoblasts	 mediated	 via	 PTH,	 ILs,	 bone	 sialoprotein	 (BSP),	 osteocalcin	 and	 osteopontin	
[56].	 Osteoblastogenesis	 is	 further	 driven	 by	 bone	 morphogenic	 proteins	 (BMPs),	 wnt	
signalling,	 Notch	 signalling	 and	 the	 transcription	 factors	 Runx2	 and	 osterix.	 Once	 equal	
amounts	of	resorbed	bone	has	been	formed,	mature	osteoblasts	undergo	apoptosis,	revert	
to	bone	lining	cells	or	become	embedded	in	the	mineralised	matrix	as	osteocytes.	
In	 addition	 other	 cells	 present	 in	 the	 bone	marrow	 are	 suggested	 to	 contribute	 to	
bone	remodelling,	for	example	megakaryocytes.	Platelet-producing	megakaryocytes	reside	
in	the	bone	marrow	and	mice	deficient	in	the	transcription	factors	GATA-1	and	NF-E2	have	
increased	 megakaryocyte	 number	 accompanied	 by	 elevated	 osteoblast	 numbers	 and	
increased	bone	volume	[80].	In	vitro,	osteoblast	proliferation	is	increased	by	the	presence	
of	megakaryocytes	[80]	and	direct	cell-to	cell	contact	between	both	cell	types	is	suggested	
to	occur	via	gap	junctions	[81]	and/or	integrins	[82].	However,	further	studies	are	required	
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to	determine	 the	 role	of	megakaryocytes	 in	bone	 remodelling	 in	 vivo	 (discussed	 in	more	
detail	in	Chapter	4).	
1.4. The	TME	in	breast	cancer	bone	metastasis	
The	multi-step	 process	 of	metastasis	 development	 involves	 (1)	 colonisation	 of	 the	 bone	
marrow	 by	 circulating	 tumour	 cells	 (CTCs),	 (2)	 survival	 and/or	 dormancy	 in	 specialised	
microenvironments	 or	 “niches”,	 followed	 by	 (3)	 reactivation	 and	 development	 into	
actively	proliferating	micrometastases	[83].	The	metastatic	cascade	has	been	described	as	
less	efficient	than	growth	at	primary	sites,	mainly	due	to	the	obstacles	faced	upon	arrival	
at	 the	 distant	 organs;	 and	 only	 a	 small	 subset	 of	 cells	will	 eventually	 initiate	metastatic	
outgrowth	[84,	85].	For	example,	studies	using	B16F1	murine	melanoma	cells	in	a	C57Bl/6	
mouse	 model	 of	 liver	 metastasis	 showed	 that	 a	 total	 of	 about	 80%	 of	 injected	 cells	
survived	the	extravasation	into	the	secondary	organ	(data	from	90	minutes	and	3	days	post	
injection).	In	contrast,	13	days	post	injection	only	36.2%	of	injected	cells	were	still	present	
of	which	0.07%	were	present	as	micrometastases	(4-16	cells),	0.02%	as	macrometastases,	
with	the	remaining	cells	being	‘’solitary“/dormant	cells	(Ki67	–ve,	TUNEL	–ve)	[84].	Similar	
effects	were	observed	in	prostate	cancer	models,	DiD-labelled	tumour	cells	(dye	retaining	
cells	are	here	defined	as	quiescent)	could	be	detected	 in	tibiae	of	mice	24hrs	after	 intra-
cardiac	 injection,	which	 accumulated	 over	 the	 first	week	 and	 then	 rapidly	 declined	 over	
time.	 However,	 DiD-labelled,	 quiescent	 cells	 were	 still	 detected	 in	 bone	 6	 weeks	 post	
injection	showing	that	mitotic	quiescence	cells	persist	 in	bone	until	a	still	unknown	signal	
triggers	proliferation	[85].	
Beside	lung,	liver	and	brain,	breast	cancer	cells	(‘’seeds“)	preferentially	metastasise	
to	bone	(‘’soil“),	a	concept	based	on	Steven	Paget’s	seed	and	soil	theory	that	„when	a	plant	
goes	to	seed,	its	seeds	are	carried	in	all	directions;	but	they	can	only	live	and	grow	if	they	
fall	on	congenial	soil“	[86].	Bone	provides	such	a	‘’congenial	soil“	as	it	undergoes	constant	
remodelling	thereby	providing	an	ideal	microenvironment	for	disseminated	breast	cancer	
cells	 through	 a	 constant	 supply	 of	 soluble	 factors	 (e.g.	 RANKL,	 ILs,	 TGF-β	 and	 high	 Ca2+	
levels	[87-89]).	
1.4.1. The	concept	of	niches	
Based	 on	 Paget’s	 seed	 and	 soil	 theory	 [86]	 the	 concept	 that	 distinct	 supporting	
microenvironments	(“niches”)	promote	survival,	and/or	proliferation	of	metastatic	tumour	
cells	was	established	[86].	Circulating	breast	tumour	cells	have	a	high	affinity	for	bone,	in	
particular	areas	of	active	bone	remodelling	[90].	Not	only	the	complex	interplay	between	
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osteoblasts	and	osteoclasts,	but	also	the	presence	of	various	other	bone	marrow-derived	
(precursor)	 cell	 populations	 (BMDCs)	 and	 soluble	 factors	 (e.g.	 OPN,	 MMPs,	 etc.),	 make	
bone	an	attractive	site	(a	“metastatsis	niche“)	for	disseminated	tumour	cells	(DTCs).		
	 Within	 bone,	 the	 proposed	 metastasis	 niche	 is	 comprised	 of	 various	 individual	
entities	of	BMDCs	comprising	a	(1)	haematopoietic,	(2)	endosteal	and	(3)	(peri-)	vascular	
niche	 [31].	 Emerging	 data	 also	 implicate	 a	 role	 for	 the	 immune-	 and	 bone	 marrow	
adipocyte	 niche	 in	 bone	 metastasis	 [91,	 92].	 The	 interaction	 and	 overlap	 between	 the	
niches	 remain	 to	 be	 established.	 This	 has	 resulted	 in	 the	 generalised	 term	 of	 the	
“metastasis	niche”	 that	 is	 thought	 to	 regulate	homing,	 survival	and	dormancy	of	 tumour	
cells	 [31,	92-96].	The	 following	 sections	will	discuss	 the	 role	of	 the	BME	 in	 the	early	and	
late(r)	stages	of	bone	metastasis.	
1.4.2. Formation	of	pre-metastatic	niches	
Development	 of	 metastatic	 disease	 was	 previously	 considered	 the	 last	 step	 in	 disease	
progression	however,	in	about	30%	of	patients	with	early-stage	breast	cancer,	presence	of	
micro-metastases	 in	 the	 bone	marrow	 at	 the	 time	 of	 diagnosis	 has	 been	 reported	 [97];	
which	is	associated	with	poor	prognosis.		
Although	 exact	mechanisms	 that	 guide	 tumour	 cells	 towards	 the	metastatic	 site	
remain	 to	 be	 established,	 current	 thinking	 is	 that	 tumour	 cells	 themselves	 modify	 the	
distant	 microenvironment,	 for	 example	 through	 systemic	 factors,	 that	 make	 it	 more	
attractive	 for	 the	disseminated	 tumour	 cells	 (DTCs)	 [28,	 98,	 99]	 -	 Figure	5.	Consequently	
the	 formation	 of	 these	 supportive	 microenvironments	 (pre-metastatic	 niches)	 involves	
primary	 tumour-derived	 factors	 (e.g.	VEGF,	placental	growth	 factor	 (PIGF),	TNF-α,	TGF-β,	
LOX,	G-CSF,	miRNAs)	as	well	as	recruitment	of	BMDCs	including	macrophages	[18,	28,	42].		
Lysyl	 oxidase	 (LOX),	 an	 enzyme	 that	 plays	 a	 key	 role	 in	 extracellular	matrix	 and	
collagencrosslinking,	 for	 example	has	been	associated	with	breast	 cancer	metastasis	 and	
increased	risk	for	bone	relapse	 in	ER	-ve	breast	cancer	patients	[29].	Recent	studies	using	
the	 syngeneic	 4T1-BALB/c	 immunocompetent	 mouse	 model	 of	 spontaneous	 metastasis	
(LOXhigh)	 showed	 that	 the	 formation	 of	 osteolytic	 lesions	 preceded	 the	 arrival	 of	 tumour	
cells	 in	 bone.	 Similar	 results	 were	 observed	 when	 injecting	 recombinant	 LOX	 into	 both	
immunocompetent	 and	 immunocompromised	mice,	which	 resulted	 in	 formation	 of	 local	
osteolytic	 lesions	 and	 increased	 bone	 resorption	markers.	 These	 data	 suggest	 that	 high	
levels	 of	 LOX	 could	 drive	 the	 development	 of	 osteolytic	 lesions	 independent	 of	 the	
presence	of	tumour.	In	contrast,	formation	of	osteolytic	lesions	was	decreased	when	LOX	
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activity	was	silenced	using	either	4T1shLOX	tumours	(LOXlow)	or	a	specific	antibody	against	
LOX.	 In	 vitro	 addition	 of	 recombinant	 LOX	 stimulated	osteoclastogenesis	 independent	 of	
the	presence	of	RANKL,	decreased	proliferation	and	 increased	 terminal	differentiation	of	
primary	 calvarial	 mouse	 osteoblasts.	 Similar	 effects	 on	 differentiation	 of	 the	 human	
osteoblast	SaOS-2	cell	 line	was	observed	when	cultured	with	cancer-conditioned	medium	
from	LOXhigh	4T1	cells	when	compared	to	control.	In	summary,	LOX	shifted	the	balance	of	
bone	 remodelling	 towards	 osteoclastic	 bone	 resorption,	 confirmed	 by	 quantification	 of	
osteoblasts	 (reduced)	 and	 osteoclasts	 (increased)	 in	 bones	 of	 4T1scr	 bearing	mice	when	
compared	to	4T1shLOX	tumour	bearing	mice.	These	studies	also	suggested	the	formation	
of	 specialised	 niches	within	 the	 BME	 upon	 LOX-mediated	 pre-metastatic	 focal	 osteolytic	
lesion	 generation	 that	 supported	 colonisation	 of	 circulating	 tumour	 cells.	 Following	
intracardiac	 4T1	 injection	mice	were	 injected	with	 hypoxic	 4T1	 conditioned	medium	 +/-	
simultaneous	 treatment	with	 the	bisphosphonate	Zoledronic	acid.	Addition	of	Zoledronic	
acid	significantly	reduced	tumour	cell	colonisation	and	development	of	bone	metastases,	
suggesting	 beneficial	 effects	 of	 bisphosphonate	 treatment	 for	 patients	 with	 LOXhigh	
tumours	(e.g.	ER	-ve).	These	intriguing	findings	highlight	the	potential	for	novel	therapeutic	
intervention	 in	 the	 treatment	 of	 bone	metastases	 by	 targeting	 tumour-derived	 systemic	
factors	[29].	
In	 addition,	 by	 injecting	 different	 cell	 lines	 into	 the	 contralateral	 flanks	 of	mice,	
McAllister	and	colleagues	showed	that	‘’instigator’’	cell	lines	were	capable	of	inducing	the	
growth	of	‘’responder’’	cells	in	the	opposite	flank,	which	was	not	observed	after	injection	
of	matrigel	or	’’non-instigators“.	Growth	of	‘’responders“	was	mediated	by	mobilised	bone	
marrow	 cells	 and	 analysis	 of	 blood	 plasma	 suggested	 that	 tumour-instigation	 was	
mediated	by	osteopontin	(OPN).	 In	addition	 ‘’instigators“	also	 increased	the	frequency	of	
lung	 metastases,	 which	 was	 reduced	 by	 inhibition	 of	 OPN	 by	 shRNA	 [27].	 In	 addition,	
Kaplan	and	colleagues	demonstrated	 that	haematopoietic	VEGFR1+ve	bone	marrow	cells	
appear	 to	 home	 to	 bone	 marrow	 sites	 where	 they	 form	 clusters	 prior	 to	 the	 arrival	 of	
tumour	 cells	 [28,	 42].	 Recently	 it	 has	 also	 been	 shown	 that	 pancreatic	 ductal	
adenocarcinoma-derived	exosomes	are	selectively	uptaken	by	 liver	Kupfer	cells,	 resulting	
in	the	establishment	of	a	pro-inflammatory,	metastasis-supporting	environment	[98].		
However,	 besides	 these	 few	 studies	 there	 is	 minimal	 data	 demonstrating	 that	
systemic	factors	influence	bone	metastases,	whether	systemic	factors	released	from	DTCs	
are	also	released	from	distant	(primary	tumours)	to	 influence	the	BME	or	which	systemic	
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factors	are	necessary	to	create	a	favourable	microenvironment	for	DTCs;	critical	questions	
raised	in	a	recent	review	by	Ubellacker	and	McAllister	[100]	.	
	
	
Figure	5	The	pre-metastatic	niche	and	the	role	of	systemic	factors	in	bone	metastases.		
Studies	suggest	that	disease	progression	might	be	mediated	through	systemic	factors,	derived	from	
both	 the	 BME	 and	 the	 TME.	 However	 these	 remain	 relatively	 unexplored.	 Reprinted	 from	 J.M.	
Ubellacker,	 S.S.	McAllister,	 The	unresolved	 role	of	 systemic	 factors	 in	bone	metastasis,	 Journal	of	
Bone	 Oncology	 ©	 2016	 The	 Authors,	 Published	 by	 Elsevier	 GmbH,	 under	 Creative	 Commons	
Attribution-NonCommercial-No	 Derivatives	 License	 (CC	 BY	 NC	 ND),	
https://creativecommons.org/licenses/by-nc-nd/4.0/,	doi:10.1016/j.jbo.2016.03.009.	
1.4.3. The	role	of	the	BME	in	the	early	stages	of	breast	cancer	bone	metastasis		
Given	 that	 bone	 metastases	 are	 incurable	 once	 established	 in	 bone,	 increasing	 our	
knowledge	about	the	mechanisms	that	direct	tumour	cells	towards	bone	and	subsequent	
bone	marrow	colonisation	will	 facilitate	 the	design	of	drugs	 that	 could	 specifically	 target	
these	early	steps	of	metastatic	disease.	
Colonising	 tumour	 cells	 will	 be	 exposed	 to	 a	 heterogeneous	 BME	 upon	 arrival,	
which	 could	determine	whether	 they	will	 actively	proliferate,	 stay	quiescent/dormant	or	
die.	A	recent	review	suggested	that	long-term	dormancy	might	be	supported	when	tumour	
cells	 face	 quiescent/static	 microenvironments	 (e.g.	 endosteal	 surfaces	 covered	 by	 bone	
lining	 cells,	 stable	 vasculature	 [101]),	 whereas	 active,	 dynamic	 microenvironments	
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including	 areas	 of	 osteoclastic	 bone	 resorption	 and	 sprouting	 vasculature	 [101]	 support	
active	proliferation	and/or	reactivation	of	dormant	tumour	cells	[83].		
Bone	is	a	major	site	of	haematopoiesis	thereby	providing	a	reservoir	of	HSCs	(HSC	
niche).	BMDCs	suggested	to	comprise	the	endosteal	(osteoblasts,	osteoclasts,	adipocytes)	
and	 (peri-)	 vascular	 niche	 (vascular	 endothelial	 cells,	 pericytes)	 regulate	 self-renewal,	
differentiation	 and	 proliferation	 of	 HSCs	 [102-104]	 through	 production	 of	 cytokines	 and	
intracellular	signals	 in	addition	to	cell-to-cell	contact	 (integrins,	cadherins	etc.)	 [102,	103,	
105-107].	 Tumour	 cells	 are	 capable	 of	 responding	 to	 these	 niche	 signals	 and	 various	
chemokines	 and	 their	 receptors	 have	 shown	 to	 be	 involved	 in	 directing	 cancer	 cells	
towards	the	metastasis	niche,	with	the	best	studied	being	the	CXCL12/CXCR4	axis.	CXCL12	
or	stromal	cell-derived	factor-1	(SDF-1)	is	produced	and	secreted	by	bone	marrow	stromal	
cells,	primarily	the	osteoblast,	endothelial	and	epithelial	cells	 [108].	Signalling	takes	place	
through	 its	 cognate	 receptor	 CXCR4,	 expressed	 on	 haematopoietic,	 stromal	 and	
endothelial	cells;	and	 in	high	 levels	on	various	cancer	cell	 lines	(prostate:	PC3,	C42B	 [95],	
breast:	MDA-MB-231	[109]).	Homing	of	HSCs	to	the	marrow	niche	is	partially	regulated	by	
CXCR4/CXCL12	chemotactic	signalling	[110],	and	there	is	evidence	that	tumour	cell	homing	
to	 bone	 is	mediated	 similarly	 [95].	 For	 example,	 Shiozawa	 and	 colleagues	 demonstrated	
that	human	prostate	cancer	cells	compete	with	HSCs	for	niche	localisation	[95].	In	support	
of	this,	CXCR4	overexpression	in	MDA-MB-231	cells	increases	bone	metastasis	[111].	Very	
recently,	 it	 has	 been	 demonstrated	 that	 the	 CXCR4-antagonist	 AMD3100	 resulted	 in	
mobilisation	 of	 breast	 cancer	 cells	 from	 the	 bone	marrow	 into	 the	 circulation	 in	 female	
SCID	mice,	and	both	newly	and	established	metastases	were	anchored	in	the	bone	marrow	
by	 CXCR4/SDF-1	 interactions	 [112].	 Further	 niche	 signals	 are	 suggested	 to	 include	 OPN	
[27],	 vascular	 adhesion	molecule-1	 (VCAM-1),	 very	 late	 antigen-4	 (VLA-4,	 α4β1	 integrin),	
intercellular	 adhesion	 molecule-1	 (ICAM-1)	 and	 N-cadherin	 [94,	 96].	 Whether	
homing/colonising	tumour	cells	prefer	HSCs	and/or	other	progenitor	niches	has	yet	to	be	
determined,	 as	 all	 are	 closely	 associated	 with	 each	 other	 being	 located	 adjacent	 to	
endosteal	surfaces.	The	endosteal	niche	has	recently	risen	in	prominence	and	osteoblasts	
and	osteoclasts	are	considered	key	cells	in	the	early	events	of	metastasis	development	[85,	
90,	94].	Whether	osteoblasts	are	indeed	part	of	the	metastasis	niche	is	subject	to	debate	
[113],	and	is	discussed	in	Chapter	3.	
Based	on	 the	observation	 that	 adipokines,	 including	 leptin,	mediate	migration	of	
MDA-MB-231-fLuc-EGFP	breast	cancer	cells	 to	human	bone	tissue	 fragments	 in	vitro	also	
highlighted	the	importance	of	adipocytes,	one	of	the	most	abundant	stromal	components	
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in	 the	 BME,	 in	 breast	 cancer	 cell	 osteotropism	 and	 early	 colonisation	 [92].	 Direct	 cell	
contact	 between	 adipocytes	 and	 cancer	 cells	 of	 the	 bone	 marrow	 compartment	 was	
observed	when	co-cultured	with	human	bone	fragments	[92].	Another	level	of	complexity	
is	 added	given	 that	 the	 (peri)-vascular	niches	may	also	 support	DTCs	 to	establishment	 in	
bone	 not	 only	 by	 providing	 oxygen	 and	 nutrients	 but	 also	 through	 endothelial-derived	
angiocrine	 stimulation	 [114].	 It	 is	 also	 hypothesised	 that	 regulation	 of	 tumour	 cell	
dormancy	 in	 bone	 could	 partially	 be	 mediated	 through	 the	 (peri)-vascular	 niche	 [101];	
which	will	be	discussed	in	the	following	section.	
1.4.3.1. Tumour	cell	dormancy	-	microenvironmental	control		
The	 relapse	 of	 cancer	 patients	 with	 no	 clinical	 evidence	 of	 disease	 after	 their	 initial	
treatment	 is	 caused	 by	 DTCs	 that	 remain	 in	 a	 reversible,	 quiescent/dormant	 state	 upon	
dissemination	to	the	secondary	organ.	Elimination	of	DTCs	 is	currently	not	possible	given	
the	 resistance	 of	 dormant	 tumour	 cells	 to	 conventional	 therapy	 [115],	 and	 the	 lack	 of	
insight	into	the	mechanisms	of	this	stage.	Briefly	three	molecular	mechanisms	involved	in	
tumour	dormancy	have	been	suggested.	This	includes	cellular	dormancy	where	cells	arrest	
in	G0-G1	phase	of	the	cell	cycle	or	angiogenic	dormancy	where	tumour	cells	are	unable	to	
recruit	 new	 blood	 vessels	 required	 for	 the	 supply	 of	 oxygen	 and	 growth-supporting	
nutrients.	 	 By	 recognising	 foreign	 pathogens	 and	 transformed	 cells	 the	 body’s	 immune	
system	eliminates	most	cancer	cells	however	a	subset	persists	in	immunological	dormancy		
(immunosurveillance)	[116].	Various	microenvironmental-derived	factors	are	suggested	to	
be	 involved	 in	 tumour	 cell	 dormancy	 including	 thrombospondin	 [101],	 growth	 arrest	
specific	protein	6	(GAS6)	and	its	cognate	receptor	annexin	II	and	AXL	[96],	as	well	as	BMPs,	
wnt	 proteins	 and	 IL-6	 [83,	 91].	 A	 recent	 review	 by	 Quayle	 and	 colleagues	 discusses	
molecular	drivers	in	breast	and	prostate	cancer	cell	dormancy	in	greater	detail	[117].	With	
the	 lack	 of	 suitable	 experimental	 in	 vivo	 models	 our	 understanding	 of	 tumour	 cell	
dormancy	remains	limited,	especially	with	regards	to	mechanistic	regulation.		
Given	 the	 multi-step	 process	 of	 metastasis	 and	 that	 DTCs	 travel	 via	
haematogenous	 routes	 to	 the	 secondary	 organ,	 this	 raised	 the	 hypothesis	 that	 vascular	
endothelial	 cells	 and	 their	 surrounding	 basement	membrane	 could	 be	 key	 regulators	 of	
tumour	 cell	 dormancy.	 Specific	 factors	 released	by	 endothelial	 cells,	 so-called	 angiocrine	
factors,	 are	 thought	 to	 regulate	 tumour	 growth	 through	 the	 establishment	 of	 vascular	
niches.	 Angiocrine	 signals	 may	 include	 adhesion	 molecules	 including	 ICAM1,	 VCAM1,	 E-	
and	P-selectin,	chemokines	such	as	 ILs,	monocyte	chemotactic	protein	 (MCP1),	SDF1	and	
various	 growth	 factors	 including	 BMPs,	 TGF-β	 and	 VEGFA	 [94,	 114].	 Furthermore	
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angiocrine	signals	are	suggested	to	be	involved	in	recruitment	of	 inflammatory	cells,	thus	
contributing	to	immune	dormancy	[114].	VCAM-1	for	example	is	hypothesised	to	regulate	
activation	 of	 indolent/dormant	 micrometastases	 through	 the	 recruitment	 of	 integrin	
α4β1+ve	osteoclast	progenitors	and	promotion	of	osteclast	activity,	key	for	initiation	of	the	
vicious	cycle	[118].	Further	studies	in	a	mouse	model	showed	that	dormant	(defined	as	Ki-
67–ve)	 MDA-MB-231	 and	 T4-2	 breast	 cancer	 cells	 were	 observed	 residing	 directly	 on	
microvascular	endothelium	of	lung	and	bone	marrow,	confirmed	in	vitro	using	organotypic	
microvasculature	 cultures.	 Here	 thrombospondin	 (TSP-1)	 was	 defined	 as	 an	 endothelial-
derived	tumour	suppressor	based	on	the	finding	that	TSP-1	was	reduced	in	the	location	of	
sprouting	 neovasculature,	 an	 area	where	 tumour	 growth	was	 accelerated.	 This	was	 also	
due	to	the	high	presence	of	tumour-growth	promoting	factors	such	as	TGF-β	at	sprouting	
vasculature.	 In	 contrast	 quiescent/dormant	 tumour	 clusters	 were	 often	 associated	 with	
stable	vasculature	(data	from	in	vitro	cultures	and	zebra	fish	models)	[101].	In	summary,	in	
vascular	niches	dormancy	 is	 suggested	 to	be	 induced/maintained	 through	 the	balance	of	
pro-	 (VEGF,	 PDGF,	 FGF	 and	 angiopoietin)	 and	 anti-angiogenic	 factors	 (TSP-1,	 angiostatin)	
[101,	 119].	Given	 the	dormancy-regulating	 role	of	 TSP-1,	 other	 components	of	 the	BME,	
such	as	megakaryocytes	and	platelets	may	be	key	regulators	of	dormancy.	Absence	of	TSP-
1	from	circulating	platelets,	the	terminal	differentiation	state	of	megakaryocytes,	has	been	
shown	 to	 reduce	 the	 ability	 of	 platelets	 to	 inhibit	 tumour	 angiogenesis	 during	 the	 initial	
stages	of	tumour	growth	in	a	mouse	model	of	lewis	lung	carcinoma	[120].	
With	regards	to	immunological	dormancy,	dormant	tumour	cells	(breast	and	lung)	
showing	stem-like	characteristics	(e.g.	CD44high/CD24low)	were	able	to	enter	a	slow-cycling	
state	 by	 autocrine	overexpression	of	DKK1,	 thus	 silencing	 the	wnt	 signalling	 pathway.	 In	
addition	this	slow-cycling	state	allowed	the	cells	to	significantly	down-regulate	cell	surface	
natural	killer-cell-activators,	rendering	them	resistant	to	NK-cell-mediated	elimination	[91].	
This	suggests	a	potential	mechanism	by	which	quiescent/dormant	cells	are	protected	from	
immune	surveillance.	Depletion	of	NK-cells	resulted	in	metastatic	outgrowth,	showing	that	
these	 quiescent	 cells	 have	 the	 capacity	 to	 enter	 immune	 surveillance	whilst	maintaining	
the	 ability	 to	 re-initiate	 metastasis.	 The	 authors	 suggest	 that	 a	 decrease	 in	 NK	 cell	
cytotoxicity	could	be	used	as	a	marker	for	disease	relapse	in	cancer	patients	[91].	
Recent	 studies	also	 showed	 that	 in	model	 systems	of	multiple	myeloma,	 tumour	
cells	colonise	endosteal,	osteoblast-rich	niches	as	early	as	1-3	days	post	injection;	a	niche	
suggested	 to	 support	 tumour	 cell	 survival	 and	 dormancy	 [115].	 Using	 the	 lipophilic	
membrane	dye	DiD,	 that	 is	 lost	during	active	cell	proliferation	but	 retained	 in	“dormant”	
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cells,	 allowed	 detection	 of	 dormant	 cells	 in	 vivo,	 with	 differential	 gene	 expression	 (e.g.	
VCAM-1,	AXL)	compared	to	proliferating	(DiDlow/neg)	populations.	In	agreement	conditioned	
medium	 from	 osteoclastic	 cells	 stimulated	 myeloma	 cell	 proliferation	 in	 vitro.	 In	 vivo	
increased	 osteoclast	 activity	 reduced	 the	 presence	 of	 dormant	 myeloma	 cells	 in	 bone,	
suggesting	 re-activation	 of	 these	 cell	 populations	 based	 on	 osteoclast	 activity	 [115].	
However,	 whether	 dormancy	 mechanisms	 observed	 in	 multiple	 myeloma,	 a	
haematological	malignancy	of	 the	bone	marrow,	are	 relatable	 to	solid	breast	or	prostate	
bone	metastasis,	remains	to	be	established.		
1.4.4. Role	of	the	BME	during	late(r)	stages	of	bone	metastasis		
Once	 established	 in	 bone,	 tumour	 cells	 gradually	 take	 over	 control	 of	 the	
microenvironment,	 a	 process	 known	 as	 the	 vicious	 cycle	 [121].	 Herein	 the	 finely	 tuned	
balance	 of	 bone	 remodelling	 is	 disturbed	 resulting	 in	 osteolytic,	 osteoblastic	 or	 mixed	
lesions;	predominantly	osteolytic	in	breast	cancer.	
	 By	 inducing	 increased	 RANKL	 expression	 on	 osteoblasts	 and	 stromal	 cells	 [122],	
breast	 cancer	 cells	 stimulate	 osteoclastogenesis	 and	 bone	 resorption.	 This	 is	 especially	
prominent	 in	 patients	with	 severe	 osteolysis	 showing	 increased	 serum	RANKL/OPG	 ratio	
when	compared	to	healthy	individuals	[87].	In	a	murine	model,	PTHrP	overexpressing	MCF-
7	 breast	 cancer	 cells	 developed	 bone	 metastases	 earlier	 and	 to	 a	 greater	 extent	 when	
compared	 to	 parental	 cells,	 based	 on	 imbalanced	 RANKL/OPG	 ratio	 upon	 breast-cancer-
cell-mediated	PTHrP	secretion	 [122].	Briefly,	a	variety	of	other	osteolytic	 tumour	derived	
factors	including	ILs,	TNF-α,	GM-CSF,	MIP-1α,	MCP-1	and	VEGF	[23,	123,	124]	are	present	
during	 metastatic	 tumour	 growth	 in	 bone;	 (reviewed	 in	 [125]),	 and	 alterations	 in	 bone	
remodelling	induced	for	example	by	ovariectomy	are	known	to	accelerate	tumour	growth	
in	pre-clinical	models	 [126].	Additionally,	breast	cancer	cells	have	been	shown	to	secrete	
factors	 that	 affect	 osteoblast	 differentiation	 including	 for	 example	 DKK1	 [127,	 128].	
Besides	 the	cancer	 cell	directly	affecting	osteoblasts	and	osteoclasts,	 the	 increased	bone	
resorption	 in	 turn	 results	 in	 the	 release	of	 growth	 factors	 from	 the	bone	matrix	 such	 as	
TGF-β,	Ca2+	and	BMPs,	that	drive	tumour	growth.	Thereby	a	“vicious	cycle”	between	bone	
destruction	and	tumour	growth	is	established	[129,	130].	
1.5. Targeting	the	BME	in	breast	cancer	bone	metastasis	–	current	standard	of	care	
As	 discussed	 previously,	 homing	 of	 breast	 tumour	 cells	 to	 bone	 and	 establishment	 of	
osteolytic	 disease	 involves	 interaction	 with	 the	 BME,	 stimulating	 tumour	 growth	
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progression	 through	 the	 vicious	 cycle.	Given	 the	 clinical	 features	 of	 bone	metastases	 (in	
particular	 pain)	 treatment	 often	 involves	 anti-neoplastic	 therapy	 in	 addition	 to	 palliative	
regimens,	with	the	latter	including	analgesics,	radiotherapy	and	surgery	to	improve	quality	
of	 life.	 Therefore	 agents	 that	 target	 the	 osteoclast-osteoblast	 crosstalk	 have	 been	
developed,	 leading	 to	 the	 clinical	 use	 of	 osteoclast-targeted	 agents	 including	
bisphosphonates	 and	 the	 RANKL	 inhibitor	 Denosumab,	 the	 current	 standard	 of	 care.	 In	
addition	multiple	novel	anti-resorptive	agents	are	under	 investigation	 including	 inhibitors	
for	Cathepsin	K	(Odanacatib),	Src	(Dasatinib,	Saracatinib),	Activin	A	(Sotatercept)	or	mTOR	
(Everolimus).	However,	targeting	osteoclasts	is	not	sufficient	to	eliminate	cancer	growth	in	
bone	 and	 anti-resorptive	 agents	 are	 thus	 commonly	 combined	 with	 other	 anti-cancer	
drugs	including	chemotherapy	regimes	[3,	131-135].		
1.5.1. Bisphosphonates	
The	anti-resorptive	bisphosphonates	 (BPs)	are	 the	standard	of	 care	 for	 skeletal	disorders	
that	are	characterised	by	excessive	bone	resorption	including	osteoporosis,	Pagets	disease	
as	well	as	cancer-induced	bone	disease.	BPs	inhibit	bone	resorption	by	having	high	affinity	
for	bone	mineral	where	they	are	internalised	by	osteoclasts	during	active	bone	resorption	
and	interfere	with	various	biochemical	processes	that	will	be	discussed	below.	The	use	of	
BPs,	 in	 particular	 Zoledronic	 acid	 (ZOL)	 will	 be	 addressed	 in	 greater	 detail	 here,	 as	 this	
agent	was	used	in	two	of	the	Chapters	presented	in	this	thesis	(see	Chapter	3	+	5).	
1.5.1.1. Structure	and	mechanism	of	action	
Their	 high	 affinity	 to	 bone	 is	 mediated	 via	 the	 P-C-P	 motif,	 usually	 enhanced	 by	 the	
presence	 of	 a	 hydroxyl	 group	 in	 the	 R1	 side	 chain.	 The	 structure	 of	 the	 R2	 side	 chain	
determines	 the	anti-resorptive	potency,	marking	 the	 two	 classes	of	BPs:	 nitrogen	 (NBPs)	
and	non-nitrogen	containing	BPs	(NNBPs)	–	see	Table	1.	
Table	1	Classification	of	bisphosphonates	and	their	potency.	
Classification	 Structural	feature	of	R2	side	
chain	
Example	
		
Increased	potency	!
	
		
Non-nitrogen	containing	 Absence	of	amino	group	 Clodronate	(CLO)	
Etidronate	(ETI)	
Nitrogen	containing	 Presence	of	primary	amino	
group	
Pamidronate	(PAM)	
Alendronate	(AL)	
Nitrogen	containing	 Presence	of	secondary	or	
tertiary	amino	group	
Ibandronate	(IBAN)	
Risedronate	(RIS)	
Zoledronate	(ZOL)	
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Both	 classes	 of	 BPs	 induce	 apoptosis	 however,	 via	 different	mechanisms.	 Briefly,	 NNBPs	
are	metabolised	into	AppCp-type	metabolites,	cytotoxic	analogues	of	ATP	that	accumulate	
in	the	cytoplasm	and	induce	apoptosis	by	inhibiting	the	mitochondrial	adenine	nucleotide	
translocase	 (ANT)[136].	 NBPs	 in	 contrast	 induce	 apoptosis	 via	 inhibiting	 farnesyl	
pyrophosphate	synthase	(FPP)	a	key	enzyme	of	the	mevalonate	pathway.	Inhibition	of	FPP	
results	in	reduced	prenylation	of	small	GTPases	such	as	Ras,	Rab,	Rho	and	Rac	resulting	in	
loss	 of	 osteoclast	 function	 and	 consequently	 osteoclast	 apoptosis	 [137].	 NBPs	 can	 also	
induce	apoptosis	via	the	production	of	ApppI	(triphos-	phoric	acid	1-adenosin-50-yl	ester	3-
(3-methylbut-3-enyl)	 ester),	 an	 endogenous	 ATP	 analogue.	 Accumulation	 of	 isopentenyl	
pyrophosphate	 isomerase	 (IPP)	 results	 from	 the	 inhibition	 of	 FPP	 and	 is	 then	 converted	
into	 ApppI	 inducing	 osteoclast	 apoptosis	 via	 inhibiting	 ANT	 -	 Adenine	 nucleotide	
translocator,	also	known	as	the	ADP/ATP	translocator	[138].	Given	the	 importance	of	the	
mevalonate	pathway	and	GTPases	in	cell	physiology	BPs	can	theoretically	affect	every	cell	
type	 however,	 given	 their	 high	 affinity	 to	 bone,	 osteoclasts	were	 identified	 as	 the	main	
target	of	BPs.	
1.5.1.2. Anti-tumour	effects	of	BPs	
Extensive	pre-clinical	studies	have	reported	anti-tumour	effects	of	BPs,	in	addition	to	their	
bone-preserving	 activity,	 in	 vitro	 [139-142]	 and	 in	 vivo	 [143-146].	 Initial	 studies	
investigated	the	use	of	BPs	as	single	treatment	in	models	of	cancer-induced	bone	disease	
from	prostate,	breast	and	myeloma	cells.	In	agreement	reduced	osteolysis	was	observed	as	
a	 consequence	 of	 BP	 treatment	 (ZOL,	 IBAN,	 PAM,	RIS,	 ETI).	 Data	 on	BP	 effects	 on	 intra-
osseous	 tumour	 burden	 were	 conflicting,	 with	 some	 reporting	 no	 effects	 or	 increased	
tumour	burden.	However,	the	majority	of	studies	observed	a	reduction	of	tumour	burden	
in	bone,	especially	in	breast	cancer	models	(reviewed	in	detail	in	[147]).	
The	 majority	 of	 studies	 concluded	 that	 anti-tumour	 effects	 of	 BPs	 are	 bone-
mediated,	 predominantly	 via	 the	 inhibition	 of	 osteoclast-mediated	 bone	 resorption	 and	
disruption	of	the	vicious	cycle	of	bone	metastasis;	and	no	effects	at	peripheral	sites	being	
achieved	 unless	 high	 and/or	 repeated	 dosing	 is	 used.	 Studies	 comparing	 RIS	 with	
analgoues	exhibiting	a	lower	bone	mineral	affinity	and	a	lower	anti-resorptive	activity	[145,	
148]	 revealed	 that	 anti-tumour	 effects	 were	 irrespective	 of	 the	 bone	 sparing	 activities,	
however	 the	 RIS-analogue	 with	 300-fold	 lower	 anti-resorptive	 activity	 than	 the	 original	
compound	did	not	reduce	growth	of	B02	bone	metastases.	This	suggests	that	anti-tumour	
effects	of	BPs	are	mainly	mediated	via	their	anti-resorptive	activities.	In	contrast,	data	from	
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mice	lacking	functional	osteoclasts	showing	reduced	melanoma	burden	in	bone	upon	ZOL	
(pre)-treatment	 support	 osteoclast	 independent	 anti-tumour	 effects	 of	 ZOL	 [143].	
However,	 these	 studies	 did	 not	 determine	 effects	 of	 BPs	 on	 soft	 tissues,	 suggesting	 a	
microenvironmental-dependent	 anti-tumour	 effect.	 With	 regards	 to	 soft	 tissue	 tumour	
burden	there	are	reports	of	both	increased	[149]	and	reduced	tumour	burden	[150]	upon	
BP	treatment.	 It	still	 remains	unclear	whether	effects	of	BPs	on	cancer	cells	are	direct	or	
via	indirect	anti-tumour	effects,	yet	it	is	likely	that	a	combination	of	both	mechanisms	are	
involved	 in	 inhibition	 of	 bone	 metastases.	 This	 is	 supported	 by	 data	 from	 Gao	 et	 al.,	
showing	 reduced	osseous	 tumour	burden	and	decreased	 soft	 tissue	burden	 [150],	which	
suggests	 that	BPs	exert	direct	effects	on	cancer	cells,	but	not	necessarily	 independent	of	
the	BME.	
Indeed,	 BPs	 including	 ZOL	 have	 been	 shown	 to	 inhibit	 proliferation,	 migration,	
adhesion	and	 invasion	 in	 vitro	 [141,	 142,	 148].	However,	most	 in	 vitro	 studies	used	high	
doses	 and/or	 prolonged	 exposure	 consequently	 resulting	 in	 drug	 levels	 that	 are	 not	
achievable	 in	 vivo.	 Evaluation	of	 pharmacokinetics	 and	dynamics	 of	 ZOL	 in	 patients	with	
cancer	and	bone	metastases	showed	anti-resorptive	effects	24hrs	after	infusion	that	were	
maintained	over	28	days,	supporting	the	clinical	schedule	of	4mg	infusions	every	3-4	weeks	
[151].	Peak	plasma	concentrations	of	ZOL	(1-2µM)	decline	rapidly	to	1%	after	24hrs,	with	a	
short	 serum	 half-life	 of	 about	 1hr	 [151].	 However	 the	 drug	 remains	 bound	 to	 bone	 for	
years,	 exerting	 prolonged	 effects	 after	 a	 single	 administration	 [152],	 suggesting	 that	
release	 of	 stored	 BPs	 from	 bone	 mineral	 during	 osteoclast	 mediated	 bone	 resorption	
(reaching	peaks	up	to	1000µM	in	the	resorption	pits	[153])	could	expose	DTCs	to	cytotoxic	
BP	 concentrations	 in	 bone.	 However	 exact	 molecular	 mechanisms	 remain	 to	 be	
established,	 with	 the	 major	 difficulty	 remaining	 to	 separate	 between	 direct	 effects	 on	
cancer	cells	and	those	that	are	mediated	via	alterations	of	the	BME.	In	clinical	practice	the	
BP	ZOL	is	given	as	a	single,	intravenous	infusion	every	3-4-weeks	and	given	the	high	doses	
and	frequent	administrations	in	experimental	studies,	effects	on	cells	other	than	the	bone	
is	highly	unlikely	in	the	clinical	setting.	For	example,	only	weekly	and	daily	administration,	
not	a	single	dose,	of	ZOL	did	result	in	convincing	anti-tumour	effects	in	pre-clinical	models	
[146,	154].	
The	effects	of	NPBs	on	FPP	synthase	suggests	that	these	agents	have	potential	to	
affect	any	cell	type	as	long	as	sufficient	amounts	can	be	internalised.	Various	in	vitro	and	in	
vivo	studies	have	identified	osteoclasts	and	macrophages	as	the	key	targets	of	NBPs,	due	
to	their	high	endocytic	capacity	[38,	148,	155-157].	However,	emerging	data	are	indicating	
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further	 cell	 types	 in	 bone	 as	 potential	 targets	 of	 BPs,	 including	 the	 osteoblast	 [158]	 or	
vascular	 endothelial	 cells	 [159]	 with	 potential	 consequences	 on	 both,	 primary	 and	
metastatic	breast	cancer	growth.	Bone	 is	a	highly	vascularised	organ	 [51,	160];	however,	
surprisingly	few	studies	have	established	the	effects	of	ZOL	on	(vascular)	endothelial	cells	
within	 the	 bone	 although	 anti-tumour	 effects	 of	 ZOL	 are	 suggested	 to	 be	 partially	
mediated	via	its	anti-angiogenic	properties.	The	data	are	mainly	from	in	vitro	experiments	
[161-163],	with	a	notable	lack	of	studies	investigating	the	effects	of	BPs	on	vasculature	in	
vivo.	 Reduced	 vessel	 thickness	 and	 increased	 vessel	 numbers	 after	 long-term	 ZOL-
treatment	 (4	weeks)	 in	mice	 [159],	decreased	 levels	of	 circulating	endothelial	progenitor	
cells	(CD34+/133-/VEGFR2+)	in	ZOL-treated	patients	suffering	from	osteonecrosis	of	the	jaw	
[164],	 and	 reduced	 differentiation	 of	MSCs	 into	 endothelial	 cells	 after	 BP	 treatment	 (in	
vitro,	 ZOL,	 AL	 [165])	 	 suggest	 the	 ability	 of	 ZOL	 to	 affect	 the	 in	 vivo	 bone	 marrow	
vasculature.	 In	 agreement	 with	 this,	 cancer	 patients	 receiving	 BP	 treatment	 have	
decreased	 serum/plasma	 levels	 of	 VEGF,	 a	 potent	 angiogenic	 factor,	 as	 well	 as	 altered	
levels	of	γ-IFN,	IL-6	and	PDGF	[166,	167].	Similar	effects	of	ZOL	on	cytokine	and	chemokine	
levels	 have	 been	 observed	 in	 mice	 [37,	 168].	 Macrophages,	 especially	 TAMs,	 are	
considered	potent	targets	of	BP	treatment	[38,	155]	and	ZOL	increases	levels	of	apoptosis	
as	well	 as	accumulation	of	unprenylated	Rap1A	 in	 vitro	 and	 in	 vivo	 [38,	155].	Recently	 it	
has	also	been	demonstrated	that	ZOL	 impaired	prostate	cancer	 induced	M2	macrophage	
polarisation	 and	 prevented	 M2-mediated	 fibroblast	 activation,	 resulting	 in	 reduced	
subcutaneous	 tumour	 growth	 and	 lung	 metastasis	 in	 a	 murine	 prostate	 cancer	 model	
[169].	A	further	potential	target	of	BP	treatment	could	include	myeloid-derived	suppressor	
cells	(MDSCs),	a	cell	type	increased	in	the	bone	marrow,	blood	and	spleen	of	patients	with	
solid	tumours	[170].	Intra-tumoural	depletion	of	CD11b+/Gr-1+	MDSCs,	reduced	infiltration	
of	 CD-11b+/Gr-1+/F4/80+	 cells	 into	 the	 tumour	 stroma	 and	 decreased	 presence	 of	 these	
cells	 in	peripheral	blood	has	been	observed	after	ZOL	treatment	 [37,	170,	171].	Whether	
this	 was	 due	 to	 direct	 effects	 of	 ZOL	 on	MDSCs,	 or	mediated	 via	 ZOLs’	 effects	 on	 bone	
remains	unclear.	Melani	and	colleagues	 for	example	suggest	 that	reduced	 intra-tumoural	
presence	 of	 MDSCs	 could	 be	 mediated	 through	 impaired	 bone	 marrow	mobilisation	 by	
ZOL-induced	 reduction	 of	MMP-9,	 a	 factor	 required	 for	MDSC	 function	 and	mobilisation	
[37].	 In	addition,	ZOL	resulted	in	a	reduction	of	the	number	of	clonogenic	colony-forming	
progenitor	cells	present	in	bone	marrow	[37].	Injection	of	fluorescently	labelled	BPs	in	vivo	
allowed	identification	of	further	cellular	targets	of	these	drugs.	They	found	that	CD14+ve	
bone	 marrow	 monocytes	 internalised	 fluorescently	 labelled	 RIS-analogues	 in	 vivo	 and	
caused	an	accumulation	of	unprenlyated	Rap1a	(24hrs-7days	post	single	dose),	suggesting	
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potential	effects	of	BPs	on	bone	marrow	monocytes	[172].	However,	Wolf	and	colleagues	
did	not	observe	 increased	rates	of	apoptosis	or	necrosis,	nor	effects	on	differentiation	of	
CD14+ve	 monocytes	 from	 healthy	 individuals,	 when	 cultured	 under	 increasing	
concentrations	of	ZOL	 (24hr	 treatment	with	0.1-10	μM)[173].	Additionally,	effects	of	BPs	
including	ZOL	have	been	observed	on	γδ	T	cells,	fibroblasts	as	well	as	HSCs	[159,	162,	174].	
For	 example,	 IBAN,	 PAM	 and	 ZOL	 reduced	 viability	 of	 fibroblasts	 in	 vitro	 [162],	 and	
repeated	treatment	with	ZOL	has	shown	to	expand	HSCs	in	vivo	[159].	With	regards	to	γδ	T	
cells,	BPs	are	known	to	promote	Vg9Vd2Tcell	chemotaxis	and	cytotoxicity	in	vivo	[175].	
To	 summarise,	 BPs	 have	 the	 potential	 to	 affect	 a	wide	 variety	 of	 BMDCs,	 in	 addition	 to	
modifying	 levels	of	growth	 factors	and	cytokines	 involved	 in	 tumour	growth,	both	within	
and	outside	bone	 [38,	155,	156,	163,	166,	174,	176].	Potential	 anti-cancer	effects	of	BPs	
are	 illustrated	 in	 Figure	 6;	 however	 as	 discussed	 previously	 novel	 cellular	 as	 well	 as	
systemic	mediators	of	treatment	response	are	emerging.	The	role	of	the	BME	in	mediating	
peripheral,	 primary	 tumour	 (re)-growth	 in	 the	 presence	 and	 absence	 of	 BPs	 will	 be	
discussed	in	Chapter	5.	
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Figure	6	Potential	anticancer	effects	of	bisphosphonates	in	vivo.		
Various	 in	vitro	and	 in	vivo	studies	have	identified	osteoclasts	and	macrophages	as	the	key	targets	
of	 NBPs,	 due	 to	 their	 high	 endocytic	 capacity	 [38,	 148,	 155-157].	 However,	 emerging	 data	 are	
indicating	 further	 cell	 types	 in	 bone	 as	 potential	 targets	 of	 BPs. Reprinted	 by	 permission	 from	
Macmillan	Publishers	Ltd:	Bone	Key	Reports	P.	Clezardin,	Mechanisms	of	action	of	bisphosphonates	
in	oncology:	a	scientific	concept	evolving	from	antiresorptive	to	anticancer	activities,	BoneKEy	Rep	
2,	 Article	 number	 267	 (2013),	 Bone	 Key	 Reports,	 Copyright	 ©	 2013,	 Rights	 Managed	 by	 Nature	
Publishing	Group".		doi:10.1038/bonekey.2013.1	
1.5.1.3. BPs	in	the	clinical	setting	
The	clinical	benefits	of	BPs	are	well	established	in	metastatic	prostate	and	breast	cancer	as	
well	as	advanced	multiple	myeloma,	with	reduced	skeletal	morbidity	and	reduced	risk	of	
developing	skeletal	related	events	(SREs)	including	fractures,	spinal	cord	compression	and	
pain	being	reported	[134,	177].		
Initial	 clinical	 studies	 tested	 the	efficacy	of	BPs	 in	preventing	breast	 cancer	bone	
metastasis,	 reporting	survival	benefits	 including	 improved	disease-free	survival	 (DFS)	and	
prolonged	overall	survival	following	clodronate	treatment	in	patients	with	primary	stage	I-
III	breast	cancer	 [178,	179].	This	 led	 to	several	 subsequent	clinical	 trials	 investigating	 the	
potential	 of	 combining	 adjuvant	 ZOL	 with	 endocrine	 therapy,	 aromatase	 inhibitors	 and	
chemotherapy	in	breast	cancer	patients	[132,	133,	135,	180,	181];	 including	the	ZO-FAST,	
AZURE,	ANZAC	and	ABSCSG-12	trials.	Detailed	trial	informations	are	listed	in	Table	2.	
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Briefly,	 the	 ZO-FAST	 study	 in	 postmenopausal	 women	 with	 hormone	 receptor-
positive	 early	 breast	 cancer	 receiving	 adjuvant	 letrozole	 +/-	 ZOL,	 reported	 benefits	 in	
disease	free	survival	in	the	ZOL	cohort	[135,	181],	with	similar	results	being	observed	in	the	
Austrian	Breast	and	Colorectal	Cancer	Study	Group	trial-12	(ABCSG-12)	[180].	 In	contrast,	
the	adjuvant	use	of	ZOL	in	addition	to	standard	therapy	in	the	AZURE	trial	did	not	show	a	
difference	 in	 DFS	 in	 the	 overall	 study	 population.	 However,	 sub-group	 analysis	 showed	
substantial	benefits	for	postmenopausal	women	[133].	Following	the	completion	of	several	
clinical	 trials	with	differential	 inclusion/exclusion	 criteria,	 study	populations,	 trial	 designs	
and	conflicting	results,	menopausal	 status	has	emerged	as	 the	benefit-limiting	 factor	of	
adjuvant	ZOL	[133,	180].	This	became	evident	with	the	meta-analysis	from	the	Early	Breast	
Cancer	 Trials	 Collaborative	 Group	 (EBCTCG),	 summarising	 that	 for	 the	 entire	 population	
(18766	women	involved	in	26	randomised	trials)	BPs	had	little	effect	on	clinical	outcomes	
for	 the	 overall	 population	 (post-	 and	 premenopausal)	 [182].	 Benefits	 were	 often	 only	
borderline	significant,	whereas	prolonged	time	till	first	distant	recurrence	in	bone,	overall	
breast	cancer	recurrence,	distant	recurrence	at	any	site	and	breast	cancer	mortality	were	
improved	in	postmenopausal	women	receiving	ZOL.	It	is	therefore	concluded	that	adjuvant	
ZOL	is	beneficial	for	postmenopausal	women	only	[182].		In	agreement	with	this	subgroup	
analysis	the	importance	of	ZOLs	impact	on	the	BME	depending	on	menopausal	status	has	
also	been	demonstrated	in	experimental	studies	in	vivo	[183].		
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Table	2	Clinical	trials	of	adding	ZOL	in	the	adjuvant	setting.		
DFS	=	disease-free	survival,	IDFS	=	invasive	DFS,	ZOL	=	Zoledronic	acid	
	
Several	 studies	 using	 BPs	 in	 the	 adjuvant	 setting	 have	 also	 been	 performed	 in	
prostate	cancer	and	multiple	myeloma,	summarised	 in	[177].	 	Briefly,	 in	men	with	 locally	
advanced	 prostate	 cancer	 addition	 of	 ZOL	 to	 radiotherapy	 and	 androgen	 suppression	
(RADAR	trial)	decreased	prostate-specific	antigen	(PSA)	progression	and	reduced	the	need	
Study	 Patients	 Outcome	 Ref.	
ZOL	in	the	adjuvant	setting	
Adjuvant	
Zoledronic	Acid	
to	Reduce	
Recurrence	
(AZURE	trial)	
Open-label,	
international,	
multicentre,	
randomised,	
controlled,	
parallel-group	
phase	3	trial	
59/84	months	
follow	up	
• 3360	patients,	female	>18	
years	
• Stage	II	or	III	breast	cancer		
• Standard	adjuvant	
systemic	treatment	alone	
(control	group)	or	with	4	
mg	ZOL		
Overall	population	
• No	difference	DFS,	IDFS	overall	
survival	and	distant	recurrence	
• ZOL	reduced	the	development	of	
bone	metastases	
• ZOL	protected	against	fractures	
Patients	>5	years	post	menopause	
• Improved	IDFS	
• Reduction	in	risk	of	extraskeletal	
recurrence	
[132,	
133]	
Austrian	Breast	
and	Colorectal	
Cancer	Study	
Group	trial-12	
(ABCSG-12)	
Randomised,	
controlled,	open-
label,	two-by-two	
factorial,	
multicentre	trial	
62/94.4	months	
follow-up	
• 1803	patients,	female	
• Premenopausal	
• Endocrine-receptor-
positive	early-stage	(stage	
I-II)	breast	cancer	
receiving	goserelin	(to	
induce	menopause),	
anastrozole	or	tamoxifen	
with	or	without	ZOL	(4mg)	
• ZOL	improved	DFS	
• ZOL	reduced	the	relative	risk	of	
DFS	events	(disease	recurrence	
or	death)	
• No	effect	on	risk	of	death	
[180,	
184]	
Zoledronic	acid	
(zoledronate)	for	
postmenopausal	
women	with	
early	breast	
cancer	receiving	
adjuvant	
letrozole		
(ZO-FAST	study)	
Open-label,	
multicentre,	
randomised	study	
• 1065	patients,	female	
• Postmenopausal	
• Oestrogen-	and/or	
progesterone-receptor-
positive	[ER+/PR+]	stage	I,	
II,	or	IIIA	early	breast	
cancer	
• Adjuvant	letrozole	with	
immediate	ZOL	or	delayed	
(fractures,	low	T-score)	
	
Immediate	ZOL	vs.	delayed	ZOL	
• Immediate	ZOL	improved	lumbar	
spine	and	hip	bone	mineral	
density		
• Reduced	DFS	events	(disease	
recurrence	or	death)	vs.	delayed	
ZOL	
• Reduced	local	and	distant	
disease	recurrences	vs.	delayed	
ZOL	
• Bone	metastases	were	more	
common	in	the	delayed	ZOL	
group	
• Improved	DFS	vs	no	ZOL	
treatment	
[135]	
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for	 secondary	 therapeutic	 intervention,	 but	 this	 was	 limited	 to	 patients	 with	 a	 Gleason	
score	 of	 8–10	 (histopathological	 grading	 system,	 8-10=cells	 are	 poorly	 differentiated)	
[185].	 In	 the	 ZEUS	 study,	 standard	 prostate	 cancer	 therapy	 +/-	 ZOL	 in	 high	 risk	 localised	
prostate	cancer	patients,	addition	of	ZOL	was	not	effective	in	preventing	bone	metastases	
[186].	A	recent	meta-analysis	compared	several	randomised	controlled	trials	assessing	the	
use	of	standard	of	care	+/-	docetaxel	or	BPs	for	men	with	high-risk	localised	or	metastatic	
hormone-sensitive	prostate	 cancer.	Here	no	evidence	of	 improved	 survival	was	 reported	
when	BPs	were	added	to	standard	care	in	patients	with	locally	advanced	disease	[187].	In	
multiple	 myeloma,	 clodronate	 increased	 overall	 survival	 in	 patients	 without	 vertebral	
fracture	at	study	entry	when	compared	to	placebo	[188].	In	a	separate	trial	ZOL	improved	
progression-free	 and	 overall	 survival	 and	 reduced	 SREs	when	 compared	with	 clodronate	
[189,	190].	In	summary,	besides	reducing	SREs,	myeloma	and	prostate	cancer	patients	did	
not	benefit	from	prolonged	survival	when	BPs	were	administered	in	the	adjuvant	setting.	
Whereas	 BPs	 have	 been	 extensively	 explored	 in	 the	 adjuvant	 setting,	 little	 is	
known	 about	 their	 role	 in	 neoadjuvant	 therapy,	 given	 before	 surgical	 removal	 of	 the	
primary	tumour.	Recently,	addition	of	ZOL	to	neoadjuvant	chemotherapy	in	breast	cancer	
has	also	been	explored,	 showing	conflicting	 results,	but	again	with	 some	benefits	mainly	
for	postmenopausal	women	(see	Table	3,	further	discussed	in	Chapter	5)	[191-193].		
In	summary,	in	breast	cancer	survival	benefits	from	ZOL	depend	on	menopausal	status.	 If	
this	 is	adopted	 into	clinical	practice	as	adjuvant	 therapy,	 this	could	save	several	 lives	per	
year	 in	 the	UK	alone,	 given	 that	between	2011	and	2013	each	year	 almost	half	 (48%)	of	
patients	diagnosed	with	in	situ	breast	cancer	in	the	UK	were	over	the	age	of	60	[194].		
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Table	3	Clinical	trials	of	adding	ZOL	in	the	neoadjuvant	setting.		
DFS	=	disease-free	survival,	IDFS	=	invasive	DFS,	ZOL	=	Zoledronic	acid,	pCRb	=	pathological	complete	
response	in	the	breast,	pCR	=	pathological	complete	response	in	the	breast	and	lymph	nodes,	RITS	=	
Residual	Invasive	Tumour	Size	
Study	 Patients	 Outcome	 Ref.	
ZOL	in	the	neoadjuvant	setting	
Addition	of	
zoledronic	acid	to	
neoadjuvant	
chemotherapy	does	
not	enhance	tumor	
response	in	patients	
with	HER2-negative	
stage	II/III	breast	
cancer	
(NEOZOTAC	trial)	
National,	
multicenter,	
randomized	study	
• 250	patients,	female	>18	
years	
• Stage	II/III,	HER2-
negative	breast	cancer	
TAC	 (docetaxel,	
adriamycin	 and	
cyclophosphamide)	
chemotherapy	 +/-	 ZOL	 (4	
mg	 within	 24hrs	 after	
chemotherapy)	 followed	
by	 granulocyte	 colony-
stimulating	factor	on	day	2	
Overall	population	
• No	difference	in	pCR	in	breast	
• No	improved	objective	response	
rates		-	no	significant	difference	
in	decrease	of	the	sum	of	
diameters	of	tumor	lesions		(MRI)	
Postmenopausal	
• Numerical	benefit	in	favor	of	
treatment	with	ZOL,	but	did	not	
reach	statistical	significance	
• No	 improved	 objective	 response	
rates	(MRI)	
[195]	
Evaluation	of	
Chemotherapy	Prior	
to	Surgery	With	or	
Without	Zometa	for	
Women	with	Locally	
Advancer	Breast	
Cancer	
Open	 label,	 Phase	 2	
randomized	trial	
• 120	patients,	female	
• Post	and	premenopausal	
• Clinical	stage	II–III	newly	
diagnosed	breast	cancer	
4mg	 ZOL	 or	 no	 ZOL	
concomitant	 with	
neoadjuvant	 epirubicin	
plus	docetaxel		
• ZOL	reduced	presence	of	
disseminated	tumour	cells	in	
bone	marrow	at	3	months	follow	
up	
• ZOL	increased	bone	mineral	
density	
• No	difference	in	DFS	at	12	and	24	
months	
	
[191]	
Neoadjuvant	arm	of	
the	AZURE	trial	
• 205	patients,	female	
• Neoadjuvant	
chemotherapy	
(anthracyclin	or	taxane)	
+/-	ZOL	(4mg)	
• ZOL	reduced	RITS	
• No	difference	in	axillary	nodal	
involvement	
• ZOL	nearly	doubled	pCR	(6.9%	vs.	
11.7%)	
[192]	
A	meta-analysis	-	
Effects	of	
neoadjuvant	
chemotherapy	with	
or	without	
zoledronic	acid	on	
pathological	
response	
Individual	patient	data	
from	four	prospective	
randomised	clinical	trials	
neoadjuvant	
chemotherapy	+/-	ZOL;	
data	from	750	patients	
pooled	
Total	study	population	
• ZOL	did	not	affect	pCRb	and	pCR	
• No	benefits	in	
pre/perimenopausal	women	
Postmenopausal	women	
• ZOL	increased	pCRb	(significant)	
and	pCR	(7.8%	vs.14.6%,	p=0.076)	
[193]	
AdditioN	of	
Zoledronic	Acid	to	
Chemotherapy	
(ANZAC)	
• 40	patients	female		
• invasive	breast	cancer		
• >18	years		
• no	evidence	of	
metastatic	disease	
neoadjuvant	
chemotherapy	
(fluorouracil,	epirubicin,	
cyclophosphamide	every	3	
weeks	+/-	4mg	ZOL,	
followed	by	3	cycles	of	
docetaxel		
• no	evidence	of	a	direct	antitumor	
effect	
• addition	of	ZOL	to	chemotherapy	
in	postmenopausal	women	
decreases	serum	levels	of	the	
activin	inhibitor,	follistatin	
	
[196]	
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1.5.2. Denosumab	
RANKL	 plays	 a	 key	 role	 in	 bone	 remodelling	 and	 a	 further	 osteoclast-targeted	 agent	
currently	used	for	the	treatment	of	cancer-induced	bone	disease	is	Denosumab	(XGEVA®),	
a	 fully	 human	monoclonal	 IgG2	 antibody	 against	 RANKL,	 paralleling	 the	 role	 of	 OPG.	 By	
inhibiting	 RANK/RANKL	 signalling,	 Denosumab	 can	 inhibit	 survival,	 formation	 and	
activation	of	osteoclasts	resulting	in	decreased	bone	resorption	[197].		
Initial	studies	in	a	mouse	model	of	breast	cancer,	MDA-MB-231	breast	cancer	cells	
injected	 intracardially	 into	 athymic	 BALB/c-nu/nu	 mice,	 showed	 that	 recombinant	 OPG	
(25mg/kg,	3x	weekly	for	4	weeks)	prevented	osteolytic	lesions,	decreased	number	and	size	
of	 skeletal	 tumour	 nests	 per	mouse,	 consequently	 resulting	 in	 an	 80%	 decrease	 in	 total	
skeletal	 tumour	burden	when	compared	to	vehicle	control	 [198].	 In	a	separate	study	the	
potency	 of	 RANKL–inhibition	 with	 OPG	 to	 that	 of	 BPs	 in	 murine	 models	 of	 osteoclast-
mediated	hypercalcemia	using	C-26	colon	adenocarcinoma	cells	was	compared.	OPG	(0.2-
5mg/kg)	suppressed	hypercalcemia	at	longer	and	faster	rates	than	the	BP	ZOL	in	the	C-26	
tumour	model	 (OPG:	 25-96hrs	 vs.	 ZOL:	 48-96hrs)	 [199].	 In	 agreement	 with	 this	 a	 dose-
dependent,	 inhibitory	 effect	 on	 osteoclasts	 in	 femurs	 of	 rB6CSFe-da-CsfnP(op/op)	 mice,	
accompanied	by	remarked	reduction	in	tumour	size	of	2472	murine	sarcoma	cells	in	bone	
was	observed	after	OPG	 treatment	 (0.1,	0.5,	or	5.0	mg/kg,	daily)	when	compared	 to	 the	
vehicle	treated	cohort	[200].		
The	anti-resorptive	properties	of	Denosumab	have	been	reported	 in	clinical	 trials	
of	bone	metastasis	and	Denosumab	is	approved	at	a	dose	of	120mg	subcutaneously	every	
3-4	weeks	for	the	prevention	of	SREs	in	patients	with	bone	metastases	from	solid	tumours.	
Denosumab	appeared	to	be	superior	when	compared	to	ZOL	in	preventing	SREs	[201,	202],	
representing	 a	 novel	 alternative	 treatment	 option.	 However,	 overal	 survival,	 disease	
progression,	and	rates	of	adverse	events	 (AEs)	and	serious	AEs	were	similar	between	the	
ZOL	and	Denosumab	group	[201].		
With	regards	to	using	Denosumab	in	the	adjuvant	setting,	the	Austrian	Breast	and	
Colorectal	 Cancer	 Study	 Group	 Trial-18	 compared	 Denosumab	 vs.	 placebo	 in	
postmenopausal	 women	 receiving	 adjuvant	 aromatase	 inhibitors.	 Compared	 with	 the	
placebo	 group,	 patients	 receiving	 Denosumab	 had	 a	 significantly	 delayed	 time	 to	 first	
clinical	 fracture,	 indicating	 that	 adjuvant	 denosumab	 significantly	 reduces	 aromatase	
inhibitor-induced	fractures	 in	postmenopausal	patients	with	breast	cancer	[203].	Another	
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exciting	study	in	patients	with	high-risk	early	breast	cancer	is	currently	on-going	aiming	to	
establish	 if	 denosumab	 prevents	 disease	 recurrence	 and	 prevents	 survival	 benefits	
(ClinicalTrials.gov	 Identifier:	NCT01077154).	The	pharmacokinetic	and	dynamic	properties	
of	 Denosumab	 are	 quite	 different	 when	 compared	 to	 BPs,	 and	 inhibition	 of	 osteoclast	
resorption	by	Denosumab	is	reversible	when	treatment	is	terminated,	whereas	BPs	remain	
stored	in	bone	and	might	still	be	active	for	suppression	of	bone	remodelling.	
1.6. Further	approaches	to	target	the	TME/BME	in	breast	cancer	bone	metastasis		
Vascularisation	is	a	key	requirement	for	tumour	growth	and	is	regulated	by	pro-	and	anti-
angiogenic	 factors	produced	by	both	tumour	cells	as	well	as	stromal	cells.	Key	regulating	
factors	 include	 vascular-endothelial	 growth	 factor	 (VEGF),	 platelet-derived	 growth	 factor	
(PDGF),	 epidermal	 growth	 factor	 (EGF)	 and	 fibroblast	 growth	 factor	 (FGF),	 with	 their	
corresponding	receptors.	The	VEGFR	tyrosine	kinase	receptor	family	–	VEGFR-1,	-2,	and	-3	
–	 mediate	 angiogenesis	 and	 lymphangiogenesis	 by	 activating	 signalling	 cascades	 in	
endothelial	 cells.	 VEGFR-2	 is	 considered	 to	 be	 the	most	 prominent	 signalling	 receptor	 in	
tumour	 angiogenesis	 and	 formation	 of	 new	 blood	 vessels	 is	 required	 for	 tumours	 to	
progress	and	metastasise	as	 they	 supply	oxygen,	nutrients	and	 the	 “route”	 to	 secondary	
organs	[25].	
The	concept	of	targeting	angiogenesis	 in	cancer	therapy	was	initially	proposed	by	
Folkman	 [6,	 7,	 25].	One	 of	 the	 first	 agents	 showing	 proof-of	 principle	 that	 targeting	 the	
microenvironment	in	addition	to	cancer	cells	is	effective	was	bevacizumab,	a	recombinant	
humanised	 VEGF-neutralising	 monoclonal	 antibody	 (mAb).	 Pre-clinical	 models	 using	 the	
murine	bevacizumab-equivalent	A4.6.1	showed	reduced	tumour	growth	of	multiple	human	
cancer	cell	lines	in	mice	in	addition	to	inhibition	of	metastasis	development;	with	additive	
and	 synergistic	 effects	when	 combined	with	 chemotherapy	or	 radiotherapy	 (reviewed	 in	
[204]).	 In	 clinical	 practice	 combining	 bevacizumab	 with	 capecitabine	 was	 generally	 well	
tolerated	 and	 increased	 response	 rates	 in	 patients	 with	 metastatic	 breast	 cancer	
previously	treated	with	an	anthracycline	and	a	taxane.	However,	this	did	not	translate	into	
survival	 benefits	 [205].	 Combination	 of	 bevacizumab	 with	 sorafenib	 (a	 tyrosine	 kinase	
inhibitor	of	PDGFR	and	VEGFR)	 in	patients	with	confirmed	adenocarcinoma	of	 the	breast	
with	evidence	of	metastatic	disease	did	not	increase	survival,	with	minimal	effects	on	the	
previously	 treated	metastatic	disease	and	resulted	 in	substantial	 toxicity	 [206].	Effects	of	
bevacizumab	 in	the	metastatic	setting	are	modest.	Studies	have	revealed	 life-threatening	
side	 effects	 when	 using	 angiogenesis	 inhibitors	 in	 general	 leading	 to	 complications	 in	
physiological	 processes	 including	 wound	 healing,	 kidney	 and	 heart	 function	 as	 well	 as	
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reproduction,	 and/or	 other	 fatal	 adverse	 events	 including	 gastrointestinal	 tract	
perforation,	 neutropenia	 or	 haemorrhage.	 Further	 FDA	 approved	 anti-angiogenic	
compounds	 include	 sorafenib	 (targets	 RAF/MEK/ERK	 pathway	 and	 tyrosine	 kinases	
VEGFR/PDGFR)	 and	 sunitinib	 (VEGFR-1,	 VEGFR-2,	 fetal	 liver	 tyrosine	 kinase	 receptor	 3	
(FLT3),	KIT	(stem-cell	factor	receptor),	PDGFRα	and	β).	Although	early	clinical	benefits	have	
been	 documented	 in	 the	 treatment	 of	many	 cancer	 types,	 the	 effects	 of	 VEGF-targeted	
therapies	 are	 not	 long	 lasting.	 This	 shows	 that	 cancers	 have	 the	 ability	 to	 develop	
resistance	against	VEGF	therapy,	but	the	detailed	mechanisms	behind	this	remain	unclear	
[207].	 In	addition,	very	 little	 is	 known	about	 the	effects	of	anti-angiogenic	agents	on	 the	
BME	as	these	drugs	were	mainly	designed	to	target	the	tumour	vasculature.	
Given	the	concerning	safety	profile	of	anti-angiogenic	agents	and	minimal	effects	
on	prolonged	survival,	these	agents	are	not	routinely	used	in	the	treatment	of	metastatic	
breast	cancer.	
1.6.1. Targeting	 the	 VEGF/HGF	 axis	 in	 breast	 cancer	 (bone	 metastasis)	 with	
Cabozantinib	
Over	 recent	 years	 tyrosine	 kinase	 inhibitors	 (TKIs)	 have	 emerged	 as	 novel	 cancer-
microenvironment	 targeting	 agents,	 as	 they	 showed	 to	 have	 effects	 on	 cells	 of	 the	
osteoclast	and/or	osteoblast	lineage	[208].	This	is	likely	to	arise	from	the	target	receptors	
being	expressed	on	both	cancer	as	well	as	bone	cells	[208-215].	
Receptor	Tyrosine	Kinases	(RTKs)	consist	of	an	extra-cellular	N-terminal	domain,	a	
transmembrane	part	 and	a	C-terminal	 intra-cellular	domain	with	 tyrosine	kinase	activity;	
and	 are	 the	 second	 largest	 class	 of	 cell-surface	 receptors.	 There	 is	 an	 ATP	 binding	 cleft	
between	the	N-	and	C-termial	 lobes	[216,	217].	Ligand	binding	causes	dimerization	of	the	
receptor	 followed	 by	 stimulation	 of	 the	 intrinsic	 protein	 tyrosine	 kinase	 activity,	
subsequently	 resulting	 in	 signal-transduction	 cascades	 leading	 to	 alterations	 in	 cell	
physiology	 and/or	 gene	 expression.	 Tyrosine	 kinases	 are	 enzymes	 that	 transfer	 donor	
molecules	to	substrates,	resulting	in	protein	phosphorylation	(e.g.	ADP-ATP).		
Tyrosine	 kinases	 can	 be	 inhibited	 either	 by	 direct	 binding	 to	 the	 receptor	 ligand	
and	competing	with	ligand	binding,	both	of	which	occur	extracellularly.	Further	approaches	
include	 inhibiting	 the	 kinase	 activity	 thus	 inhibiting	 phosphorylation	 of	 the	 receptor	 and	
subsequent	downstream	signalling,	such	as	the	RAS-MAPK	and	PI3K-AKT	pathways,	NF-κB	
and	Wnt/GSK-3β/	β-Catenin.	Cabozantinib	 (XL184,	Exelixis,	San	Francisco,	herein	referred	
to	as	CBZ),	 is	a	potent	 inhibitor	of	VEGFR2	and	MET	 (the	 receptor	 for	HGF)	and	has	also	
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shown	 activity	 against	 various	 other	 kinases	 associated	 with	 tumour	 pathobiology	
including	KIT,	RET,	AXL,	TIE2,	and	Fms-like	tyrosine	kinase	3	[218].	The	mechanism	of	action	
of	CBZ	is	illustrated	in	Figure	7	below.	
	
	
Figure	7	MET	and	VEGFR2,	tyrosine	kinase	receptors	targeted	by	Cabozantinib.		
Extracellular	 MET	 is	 composed	 of	 three	 domains	 including	 a	 semaphorin	 (Sema)	 domain,	 a	 PSI	
domain	 (present	 in	 plexins,	 semaphorins	 and	 integrins)	 and	 4	 IPT	 (immunoglobulin-plexin-
transcription)	 domains.	 Tyrosine	 kinase	 activity	 is	 intracellular.	 Tyrosine	 kinase	 (Tyr)	 Y1234/5	
positively	 regulate	 enzyme	 activity,	 in	 contrast	 to	 TyrY1003.	 Signal	 transducers	 and	 adaptors	 are	
recruited	 to	 the	docking	site	upon	receptor	activation	 [219].	The	extracellular	domain	of	VEGFR-2	
includes	 7	 Ig-like	 domains,	 intracellular	 2	 tyrosine	 kinase	domains	with	 autophosphorylation	 sites	
are	present	 (TyrY1054/59	are	required	for	maximum	kinase	activity)[220].	Cabozantinib	 (CBZ),	 the	
small	molecule	multiple	tyrosine	kinase	inhibitor	targets	MET	and	VEGFR-2.	
	
Although	our	understanding	of	the	mechanisms	of	tumour	cell	resistance	to	anti-
VEGF	 therapy	 remains	 limited,	 one	 potential	mechanism	might	 include	 the	 induction	 of	
hypoxia	due	to	inhibition	of	the	VEGF	pathway,	consequently	resulting	in	up-regulation	of	
MET	expression	[221].	HGF	is	the	only	known	ligand	for	the	receptor	tyrosine	kinase	MET.		
MET/HGF	 signalling	 is	 instrumental	 in	 embryogenesis,	 cell	 proliferation,	 motility	 and	
survival	 in	 addition	 to	 angiogenesis	 and	wound	 healing	 [222-225].	 High	 levels	 of	MET	 in	
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cancer	 are	 associated	with	 poor	 prognosis	 and	 are	 known	 to	 promote	 tumour	 invasion,	
metastasis,	growth	and	survival	 [226].	Simultaneously	targeting	the	VEGFR/MET	axis	with	
the	small	molecule	tyrosine	kinase	inhibitor	CBZ	therefore	appears	a	promising	therapeutic	
approach.	 As	 a	 competitive	 ATP	 inhibitor	 [218,	 227]	 CBZ	 crosses	 the	 cell	 membrane,	
mimics	 ATP	 binding	 and	 thereby	 inhibits	 phosphorylation	 and	 subsequent	 downstream	
signalling	of	the	target	receptors	[218].	Studies	by	Yakes	and	colleagues	demonstrated	high	
affinity,	but	 reversible	binding	 for	MET	and	VEGFR-2	 [218]	and	metabolism	occurs	 in	 the	
liver	 via	 CYP3A4	 and	 CYP2C9.	 	 Peak	 plasma	 concentrations	 of	 CBZ	 have	 been	 found	 2-5	
hours	post	administration	and	the	predicted	effective	half-life	is	55	hours.	CBZ	is	therefore	
administered	daily	[228].		
CBZ	has	been	approved	for	the	treatment	of	metastatic	medullary	thyroid	cancer	
(MTC)	 by	 the	 US	 Food	 and	 Drug	 Administration	 in	 November	 2012.	 In	 a	 double-blind,	
phase	III	trial	comparing	CBZ	with	placebo	in	patients	with	metastatic	MTC,	CBZ	prolonged	
progression	 free	 survival	 (11.2	 vs.	 4	months)	 when	 compared	 to	 placebo	 [229].	 Various	
studies	 have	 investigated	 the	 effects	 of	 CBZ	 on	 tumour	 cells	 in	 vitro,	 reporting	 reduced	
viability,	proliferation,	migration	and	 invasion	of	breast,	 lung,	prostate	and	gastric	cancer	
cells	 [218,	 230].	 The	 majority	 of	 pre-clinical	 studies	 have	 been	 performed	 in	 prostate	
cancer	models	of	bone	metastasis	showing	reduced	tumour	growth,	not	only	in	bone	but	
also	 of	 subcutaneously	 transplanted	 tumours	 [230-233].	 Besides	 these	 promising	 results	
there	are	limited	numbers	of	studies	using	models	of	breast	cancer	to	my	knowledge	[218],	
which	are	discussed	in	Chapter	4.		However,	there	is	a	rational	for	studies	in	breast-cancer	
bone	metastasis	models	given	that	in	addition	to	RANK/RANKL	signalling	[69]	the	MET	and	
VEGF	signalling	pathways	regulate	the	tightly	balanced	coupling	between	osteoblasts	and	
osteoclasts	as	both	 cell	 types	express	 target	 receptors	 [209-212];	 and	 that	breast	 cancer	
cells	 express	 MET	 receptor,	 which	 is	 correlated	 with	 poor	 prognosis	 and	 increased	
aggressiveness	[226].		
CBZ	has	demonstrated	promising	results	in	a	phase	II	randomised	discontinuation	
trial	with	 castration-resistant	 prostate	 cancer	 (CRPC)	 patients	 including	 improvements	 in	
bone	scans	in	68%	of	patients,	with	12%	showing	complete	response.	This	correlated	with	
partial	response	of	tumour	lesions	and	pain	relief.	Soft	tissue	lesions	decreased	in	72%	of	
evaluable	patients	 and	progression-free	 survival	 after	 in	 the	CBZ	 cohort	was	23.9	 vs.	 5.9	
weeks	 in	 the	 placebo	 group.	 This	 study	 also	 reports	 a	 reduction	 in	 serum	 total	 alkaline	
phosphatase	and	plasma	cross-linked	C-terminal	telopeptide	I	collagen	[234].	Another	trial	
in	 patients	 with	 CRPC	who	 received	 chemotherapy	 prior	 to	 CBZ	 reported	 similar	 results	
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[235].	Given	 the	 rapid	and	complete	 resolution	of	disease	 in	bone	scans,	a	phenomenon	
hardly	ever	observed	among	therapies	with	proven	survival	benefits,	raises	the	possibility	
that	CBZ	might	 interfere	with	 imaging	of	 radionuclides	during	bone	 remodelling.	A	 study	
tested	 this	 hypothesis	 by	 surgically	 inducing	 bone	 remodelling	 in	 naïve	 mice	 and	
performed	 18F–sodium	 fluoride	 (18F-NaF)	 positron	 emission	 tomographic	 (PET)	 and	
technetium	 99m–methylene	 diphosphonate	 (99mTc-MDP)	 single-photon	 emission	
computed	 tomographic	 (SPECT)	 scans	 before	 and	 after	 CBZ	 or	 related	 inhibitor	
administration	 (axitinib	 for	VEGFR,	 crizotinib	 for	MET,	 single	or	 combined	 treatment).	 	 A	
remarked	 reduction	 in	 radiotracer	 uptake	 in	 the	 CBZ	 treated	 group	was	 observed	when	
compared	 to	 the	 control	 group,	 whereas	 this	 was	 not	 observed	 by	 inhibiting	 the	
VEGFR/MET	signalling	axis	with	axitinib	or	crizotinib.	These	studies	 therefore	provide	the	
first	 evidence	 that	 bone	 scan	 resolution	 after	 CBZ	 treatment	 could	 be	 a	 tumour-
independent	effect,	raising	the	need	to	carefully	 interpret	the	peviously	described	results	
[236].	 	 Nevertheless	 in	 all	 these	 studies	 CBZ	 was	 associated	 with	 reduced	 pain	 [237].	
However,	due	to	the	results	of	the	COMET-1	trial	-	a	Phase	III,	randomized	trial	comparing	
treatment	 with	 CBZ	 to	 treatment	 with	 prednisone	 among	 men	 who	 had	 already	
progressed	 after	 earlier	 treatment	 on	 standard	 of	 care	 therapy	 –	 failed	 to	 meet	 the	
primary	end	point	of	extending	overall	survival	in	men	with	metastatic	castration	resistant	
prostate	 cancer	 (CBZ	 arm:	 11.0	 vs.	 Prednisone	 arm:	 	 9.8months),	 ClinicalTrials.gov	
Identifier:	NCT01605227.	
This	 trial	 failure	explains	 the	 limited	clinical	 studies	of	CBZ	 in	breast	 cancer	bone	
metastasis	 however,	 Cabozantinib	 (60mg	 daily)	 mono-therapy	 has	 recently	 also	 shown	
evidence	of	antitumor	activity	in	a	phase	II	study	of	CBZ	in	metastatic	triple-negative	breast	
cancer	patients	[238]	(Clinical	trial	information:	NCT02260531).	Further	studies	for	the	use	
of	 CBZ	 in	 advanced	 breast	 cancer	 are	 recruiting.	 This	 includes	 	 “A	 Phase	 II	 Trial	 of	
Cabozantinib	 in	Women	With	Metastatic	Hormone-Receptor-Positive	Breast	Cancer	With	
Involvement	of	Bone“	(ClinicalTrials.gov	Identifier:	NCT01441947)	and	“A	Phase	II	Study	of	
Cabozantinib	Alone	 or	 in	 Combination	With	 Trastuzumab	 in	 Breast	 Cancer	Patients	With	
Brain	Metastases“	(ClinicalTrials.gov	Identifier:	NCT02260531).	
Recent	 news	 from	 the	 METEOR	 trial	 [239]	 shows	 significant	 benefits	 in	 overall	
survival	 and	 progression-free	 survival	 in	 patients	 with	 advanced	 renal	 cell	 carcinoma	
(http://www.exelixis.com/investors-media/press-releases).	 Patients	 with	 bone	metastasis	
at	 baseline	 showed	 median	 overall	 survival	 of	 20.1	 months	 	 (CBZ)	 versus	 12.1	 months	
(everolimus);	 ClinicalTrials.gov	 Identifier:	 NCT01865747.	 In	 addition	 CBZ	 has	 now	 been	
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FDA-approved	for	the	treatment	of	patients	with	advanced	renal	cell	carcinoma	(RCC)	who	
have	received	prior	anti-angiogenic	therapy	[240].		
In	 summary,	CBZ	 is	 showing	promise	against	 various	 types	of	 advanced	cancer	 in	 clinical	
trials,	 with	 potential	 to	 explore	 this	 agent	 further	 in	 patients	 with	 breast	 cancer	 bone	
metastasis.		
1.7. Summary,	conclusion	and	outstanding	questions	
In	summary,	the	TME	is	increasingly	recognised	as	a	key	component	of	tumourigenesis	and	
response	 to	 therapy.	 Breast	 cancer	 preferentially	metastasizes	 to	bone,	 hence	 indicating	
the	potential	for	therapeutic	modification	of	the	BME.		
To	 date	 very	 little	 is	 known	 on	 how	 the	 BME	 responds	 to	 anti-cancer	 therapy,	
which	is	detrimental	to	treatment	success	or	failure.	A	better	understanding	of	how	novel	
and	 existing	 anti-cancer	 agents	 mediate	 their	 effects	 is	 therefore	 crucial	 to	 improve	
treatment	 regimens	 and	 to	 elucidate	how	 this	 affects	 the	 interactions	between	 tumours	
and	their	microenvironment.	Detailed	characterisation	of	the	response	of	the	naïve	BME	is	
needed	to	elucidate	if	therapeutic	agents	exert	their	anti-cancer	activity	via	direct,	indirect,	
or	dual	mechanisms.		
Dissemination	of	tumour	cells	appears	to	occur	early	on	in	the	disease	and	in	about	
30%	of	patients	with	early-stage	breast	cancer,	presence	of	micro-metastases	in	the	bone	
marrow	 at	 the	 time	 of	 diagnosis	 has	 been	 reported	 [97].	 Once	 progressing	 in	 bone	 the	
disease	is	considered	incurable,	though	patients,	with	metastasis	found	in	bone	only,	may	
live	 for	 several	 years	 as	 long	 as	 the	 cancer-induced	 bone	 disease	 is	 controlled.	 To	
effectively	 treat	 and/or	 prevent	 the	 breast	 cancer	 bone	 metastasis,	 a	 deeper	
understanding	of	how	breast	cancer	cells	establish	themselves	in	bone	is	needed	and	it	is	
of	 great	 clinical	 relevance	 to	 characterise	 the	 early	 steps	 of	 the	 disease,	 including	 the	
homing	 of	 tumour	 cells	 to	 bone.	 The	 bone	 metastasis	 niche	 is	 suggested	 to	 regulate	
tumour	 cell	 homing,	 survival	 and	 progression	 in	 bone	 [31,	 42,	 92,	 94,	 101,	 105,	 112].	
However,	outstanding	questions	remain	concerning	the	precise	cellular	composition	of	the	
niche,	the	role	of	the	osteoblasts	during	the	early	stages	of	bone	metastasis	[94,	113],	how	
niche	components	interact	[51]	as	well	as	how	it	is	modified	during	treatment.	
Recent	 clinical	 data	 have	 shown	 the	 efficacy	 of	 BPs	 in	 the	 adjuvant	 setting	 [131,	
132,	 135,	 182].	 This	 will	 result	 in	 increasing	 use	 in	 patients	 without	 evidence	 of	 bone	
metastasis.	 Given	 that	 the	 microenvironment	 of	 primary	 breast	 tumours	 is	 partially	
composed	 of	 BMDCs,	 a	 key	 role	 of	 the	 BME	 in	mediating	 peripheral	 breast	 cancer	 (re)-
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growth	 is	 expected.	 BMDCs,	 as	well	 as	 their	 precursors,	may	 be	 affected	 by	 anti-cancer	
treatment	 and	 thereby	 directly	 or	 indirectly	 contribute	 to	 therapeutic	 response	 on	
peripheral	tumour	growth.	To	date	it	remains	unclear	how	therapeutic	modulation	of	the	
BME	affects	peripheral	tumour	(re)-growth.			 	
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1.8. Hypothesis,	aims	and	objectives	
Work	presented	in	this	thesis	aims	to	establish	the	role	of	the	tumour	microenvironment	
(TME)	 in	 breast	 cancer	 using	 a	 variety	 of	 in	 vivo	 models.	 To	 address	 these	 aims,	 the	
following	hypothesis	will	be	tested:	
	
The	bone	microenvironment	(BME)	mediates	response	to	anti-cancer	therapy	in	breast	
cancer.	
1.8.1. Aims	and	objectives	
To	test	the	above	hypothesis	this	thesis	aims	to	address	the	following:	
• Aim	1:	Establish	the	response	of	the	BME	to	anti-cancer	therapy	in	vivo.	
o Determine	the	early	effects	of	a	single,	clinically	relevant,	dose	of	the	anti-
resorptive	agent	Zoledronic	acid	(ZOL)	on	key	bone	cells.	
o Characterise	 the	 effects	 of	 short-term	 administration	 of	 Cabozantinib,	 a	
tyrosine	kinase	inhibitor	of	MET	and	VEGFR-2,	on	the	naïve	BME.		
o Determine	 if	 the	bone	metastasis	niche	 is	affected	by	ZOL	treatment	and	
potential	consequences	on	tumour	cell	homing	to	bone.	
	
• Aim	2:	Determine	the	role	of	the	BME	in	peripheral	breast	cancer	(re)-growth.	
o Establish	a	tumour	re-implantation	model	to	study	the	role	of	the	BME	in	
primary	breast	cancer	re-growth.	
o Assess	 whether	 reduced	 tumour	 growth	 after	 combination	 therapy	 is	
altered	when	tumours	are	transplanted	into	animals	with	a	modified	BME.	
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Chapter	2	–	Materials	and	
Methods	
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2.1. List	of	Materials	and	Equipment	
2.1.1. Laboratory	reagents	and	Kits	
Reagent	or	Kit	 Supplier	
10X	Casein	 Vector	Laboratories,	SP-5020	
1mg/mL	Geneticin	10131	 Gibco,	Life	technology	
30%	Hydrogen	Peroxide	 VWR	Chemicals	Prod23622.296	
30%	Hydrogenperoxide	 VWR	Chemicals,	23622.298	
ABC	 Vectastain,	PK-6100	
Acetic	acid	 AnalaR	VWR,	100001	CU	
Alizarin	Red	S	 SIGMA,	A5533		
Cabozantinib,	XL184	 Exelixis,	South	San	Francisco,	CA	
Calcein	 SIGMA,	C0875		
Chloroform	 Sigma-Aldrich,	C2432	
Citric	Acid	 AnalarR,	Prod.100813M	
Citric	acid	 AnalaR,	100813M	
Copper(II)sulfate,	0.1mol/l	 Fulka	Analytical,	35185	
DAB	 Vector	Laboratories,	SK-4100	
Dako	Target	Retrieval	Solution		 Dako,	S1699	
Dimethylformamide	 Fisher	Chemicals	
DMEM	culture	medium	 Gibco	61965-026	
Doxorubicin	hydrochloride	 2mg/mL,	 PL20075/0109,	
PA1390/022/001		
DPX	mountant	 VWR,	360294H	
EDTA	 SIGMA,	03620		
Eosin	 Atom	Scientific	LTD,	RRSP35-A	
Ethanol	 Fisher	Scientific,	E/0665DF/17	
Ethanol	 Sigma-Aldrich,	24103-1L-R	
Fast	green	FCF	 Sigma-Aldrich,	44715		
Gelatine	 SIGMA,	G1890	
Gill's	 haematoxylin	 solution	 modified	
according	to	Gill	II	
Merck,	HX249494		
High	Capacity	RNA-to-cDNATM	Kit		 Applied	Biosystems®	Cat.No.:	4387406	
Hydrochloric	acid	(HCl)	 	AnalaR	VWR,	10125	
Luciferin		 Perkin	Elmer	
Methanol	 AnalaR	NORMAPUR,	Prod.20847.307	
MouseTRAPTM	Assay	 Immunodiagnostic	systems,	SB-TR103	
Naphthol	AS-BI	phosphate	(sodium	salt)	 SIGMA,	N-2125		
Normal	Goat	Serum	 Vector	Laboratories,	S-1000	
O.C.T.	 compound,	 mounting	 media	 for	
cryotomy	
VWR,	361603E	
Pararosaline	 SIGMA,	P-3750		
PBS	for	in	vivo	studies	 Gibco	 by	 Life	 Technologies,	 pH7.4,	
100-10-015	
Paraformaldehyde	PFA	 SIGMA,	P6148	
Phosphate	Buffered	Saline	Tablets	 Oxoid,	BR0014G	
Pierce	BCA	Protein	Assay	Reagent	A		 Thermo	Scientific,	23223	
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Proto	Gel	Acrylamide	 Geneflow,	A2-0072	
Proto	Gel	Resolving	Buffer	 Geneflow,	B9-0012	
Proto	Gel	Stacking	buffer	 Geneflow,	B9-0014	
PVP	 Sigma-Aldrich,	PVP40		
Rat/Mouse	PINP	EIA	 Immunodiagnostic	systems,		AC-33F1	
RBC	lysis	buffer	 eBioscience	
RNA	Clean	&	Concentrator	Kit		 Zymo	Research	(ZEC174900)	
RNAlater	Tissue	Collection	Solution	 Ambion,	 Life	 Science	 Technologies,	
AM7021	
RPMI	culture	medium	 Gibco	61870-10	
Safranin	O	Solution	 SIGMA,	HT90432		
Safranin	O	Solution	 Sigma-Aldrich,	S2255	
Sodium	acetate	trihydrate	 SIGMA,	S-9513		
Sodium	Bicarbonate	(NaHCO3)	 SIGMA,	S5761		
Sodium	Hydroxide	pellets	(NaOH)	 Fisher	Scientific,	5/4920/53	
Sodium	tartrate	(dihydrate)	 SIGMA,	S-4797	
Taab	Medium	Grade	LR	White	Resin		 Taab	Laboratory	Equipment	Ltd,	L012	
Toluidine	Blue	O	 SIGMA,	T0394	
TRI	Reagent	 SIGMA,	T9424	
Triton-X	100	 Sigma-Aldrich,	X100-500ML	
Tween	20	 Fisher,	T14206160	
Tween	20R	 Fisher	Chemical,	T/4206/60	
VECTASHIELD®	Mounting	Media	with	DAPI	 Vector	Laboratories,	H1200	
Vibrant®	CM-DiI	Cell-Labeling	Solution	 Life	Technologies,		V-22888	
Vibrant®	DID	Cell-Labeling	Solution	 Life	Technologies,	V22887	
Zoledronic	acid	 Novartis	
	
2.1.2. Softwares	used	for	data	analysis	
Software	 Supplier	
CTAnalyser	software	 SkyScan,	Bruker	microCT,	CT-Analyser	version	
1.14.4.1	
Fiji	(ImageJ)	 ImageJ,	Version	2.0.0-rc-24/1.49m	
GraphPad	Prism	software	 Prism,	Version	6.0c	
LAS	AF		 Leica	Microsystems	CMS	GmbH,	Version	2.6.3	
build	8173	
Living	Image	4.0	software	 Caliper	Life	Sciences	
NIS-Elements-software		 Nikon	Instruments,	Version	4.30	
Nrecon	 SkyScan,	Bruker	microCT,	Version	1.6.9.9	
OsteoMeasure	 OsteoMetrics	
SDS	2.1	software	 Applied	Biosystems	7900HT	Fast	Real-Time	
PCR	System	
Tree	Star	FlowJo	 FlowJo,	vX.07		
Volocity	software	 Improvision,	Version	4.3.2	
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2.1.3. Antibodies	used	
Antibody	 Supplier	
Alexa	Fluor®	555,	goat	anti-rat	IgG	 LifeTechnologies,	A21434	
Alexa	Fluor®	647,	goat	anti-rat	IgG	 LifeTechnologies,	A21247	
Anti-CD31	(Ms)	from	Rat		 DIA-310,	Dianova	
Anti-Mouse	CD11b	Alexa	Fluor®	488	 eBioscience,	Clone	M1-70,	Cat.No.:53-
0112-80	
Anti-Mouse	CD41	PE		 eBioscience,	Clone:	eBioMWReg30,	Cat.	
No:	12-0411-81	
Anti-Mouse	TER-119	APC		 Anti-Mouse	TER-119	APC	(eBioscience,	
Clone:	TER-119,	Cat.	No:	17-5921-81)	
Biotinylated	anti	Mouse	IgG	(H+L),	made	in	
horse	
Vector	BA-2000	
Biotinylated	Goat-anti-Rat	IgG	 Vector	BA-9401	
Brilliant	Violet	421™	anti-mouse	CD45	
Antibody		
BioLegend,	Clone	30-F11,	Cat.No:	
103133	
c-Met	[pY1230/34/35]	Rb	recombinant	
monoclonal	
Invitrogen,	Clone	5H27L59	
Endomucin	V.7C7,	rat	monoclonal	 Santa	Cruz,	sc-65495	
goat-anti-rat	IgG	FITC	conjugated	 ZyMax	81-951	
Monoclonal	Mouse	Anti-Human	Ki67	 DAKO,	Clone	MIB-1	
Met	Antibody	(C-28)	 sc-161,	Santa	Cruz	
Pe-Cy7	anti-mouse	Ly-6G/Ly-6C	(Gr-1)	 Clone	RB6-8C5,	Cat.No.:108415	
Polyclonal	Goat	Anti-Mouse	Iggs	HRP,		 Dako,	P0447	
Rat	anti-mouse	CD34	 MCA1825GA,	AbD	Serotec	
	
2.1.4. TaqMan	Real-Time	PCR-Assays	
Gene	 Taq	Man	ID	
B2M	 Mm00437762_m1,	Thermo	Fisher	Scientific	
HPRT	 Mm00446968_m1,	Thermo	Fisher	Scientific	
Abl1	 Mm00802029_m1,	Thermo	Fisher	Scientific	
RANKL	 Mm00441906_m1,	Thermo	Fisher	Scientific	
RANK	 Mm00437135_m1;	 Mm00437132_m1,	
Thermo	Fisher	Scientific	
OPG	 Mm00435451_m1,	Thermo	Fisher	Scientific	
Vegfa	 Mm01281449_m1,	Thermo	Fisher	Scientific	
Sox9	 Mm00448840_m1,	Thermo	Fisher	Scientific	
	
2.1.5. Machines	used	
Machine	 Supplier	
2200	TapeStation	Instrument	 Agilent	Technologies	
ABI	PRISM	7900HT	Sequence	Detection	System		 Applied	Biosystems	
Agilent	RNA	ScreenTape	assay		 Agilent	Technologies	
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Benchtop	Centrifuges	 MSE	 Mistral	 2000;	 Heraeus	
FRESCO21;	 5810R,	 Eppendorf;	
Eppendorf	 Centrifuge	 5810;	
Beckman	 Microfuge	 Lite;	 Beckman	
GPR 
Confocal	Microscope	 Nikon	A1	inverted	
Cryostat	 5030	Microtome,	Bright	
Cryostat	 MICROM	HM560	
Desktop	X-ray	microtomograph	 SkyScan	1172,	Bruker	microCT	
Dry	Heating	bath	 Labnet	International	
FACSCalibur		 Becton	Dickinson	
Glass	bottomed	Dish	12mm	 Thermo	Scientific,	150680	
Gradient	Thermo	Cycler	 MJ	Research,	PT-200		
Inverted	widefield	fluorescence	microscope		 Leica	DMI	4000B,	Leica	AF6000LX		
IVIS®	Lumina	II	 Perkin	Elmer	
Leica	AF6000LX	inverted		 Leica	
Leica	DM1000	 Leica	
Leica	DMRB	upright	microscope	 Leica	
LSRII	 BD	BioSciences	
Multiphoton	Confocal	Microscope	 Zeiss	LSM510	NLO	Inverted	
Nanodrop	2000	 Thermo	Scientific	
Nanodrop	ND-1000	Spectrophotometer		 Nanodrop	Wilmington,	DE	
Olympus	BX53	microscope		 Olympus	BX53		
Superfrost	®	Plus	Slides	 Thermo	Scientific,	J1800AMNZ	
Thermomoxer	Comfort	 Eppendorf	
Vortexer	 Rotamixer,	Hook&Tucker	
Instruments	
Water	bath		 Grant	JB	Series	
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2.2. Methods		
In	vitro	work	
2.2.1. Cell	lines	
For	experiments	establishing	 the	role	of	 the	BME	 in	peripheral	breast	cancer	growth,	Dr.	
Penelope	Ottewell	 (University	of	Sheffield,	UK)	kindly	provided	the	GFP	expressing	MDA-
G8	cell	 line.	This	 cell	 line	has	been	originally	derived	 from	MDA-MB-436	 (triple	negative)	
breast	cancer	cells	[241].	Tumour	cell	homing	to	bone	was	established	using	the	MDA-MB-
231-NW1-luc2	cell	 line,	transfected	with	 luciferase	and	kindly	provided	by	Dr.	Ning	Wang	
(University	of	Sheffield,	UK).	This	cell	line	was	derived	from	the	MDA-MB-231	ATCC	breast	
cancer	cell	line.	
2.2.2. Thawing	and	freezing	of	cells	
For	 long-term	storage	 cell	 lines	were	kept	 in	 liquid	nitrogen	 (lN2).	 For	 culture,	 cells	were	
removed	 from	 lN2	and	 rapidly	 thawed	 in	a	37°C	water	bath.	9mL	corresponding	medium	
containing	10%	foetal	bovine	serum	(FBS)	was	added	followed	by	centrifugation	at	800rpm	
for	5min.	The	cell	pellet	was	re-suspended	 in	10mL	fresh	medium	and	cells	plated	 into	a	
T75	 flask.	 For	 freezing,	 cells	were	washed	 in	 PBS	 (2x),	 dislodged	 using	 trypsin/EDTA,	 re-
suspended	in	medium	and	centrifuged	for	5min	at	800rpm	(Beckman	GPR	fitted	with	rotor	
GH3.7;	 ≈160xg).	 Cell	 number	 was	 determined	 and	 1x106	 cells/mL	 aliquoted	 in	 their	
corresponding	 growth	medium	 supplemented	with	 10%	DMSO.	 Cells	were	 frozen	 in	Mr.	
FrostyTM	 Freezing	 Container	 (Thermo	 Scientific;	 achieves	 a	 cooling	 rate	 of	 -1°C/minute	
which	is	optimal	for	cells)	at	-80°C	prior	to	long-term	storage	in	lN2.	
2.2.3. Cell	culture	
Cultures	 were	 maintained	 and	 grown	 in	 T75	 or	 T125	 flasks	 containing	 the	 appropriate	
medium	for	each	cell	 type	at	37°C,	5%	CO2.	Sub-culturing	was	performed	 in	sterile	tissue	
culture	 hoods	 and	 took	 place	 depending	 on	 confluence	 (about	 70-80%	 prior	 to	 sub-
culture).	To	sub-culture	cells	were	washed	 twice	with	5mL	sterile	PBS,	1mL	 trypsin/EDTA	
added	 followed	by	 incubation	at	 37°C	 for	2-5min	 to	detach	adherent	 cells.	 To	neutralise	
the	 trypsin/EDTA	 cells	 were	 re-suspended	 in	 fresh	 medium	 (if	 required	 cell	 number	
determined)	followed	by	centrifugation	at	800rpm	(Beckman	GPR	fitted	with	rotor	GH3.7;	
≈160xg)	 for	5min.	The	cell	pellet	was	re-suspended	 in	10mL	fresh	medium	and	a	 ratio	of	
cells	 (commonly	 1:10)	 plated	 into	 a	 T75	 flask	 containing	 fresh	 growth	medium.	 	 DMEM	
supplemented	with	 10%	 FBS	was	 used	 for	MDA-231-NW1-luc2	 and	 RPMI	 supplemented	
with	10%	FBS	for	MDA-G8	cells. 
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2.2.4. Determination	of	cell	number	
Cell	number	was	determined	using	a	haemocytometer	and	where	applicable	a	viable	cell	
count	was	performed	using	trypan	blue	exclusion	principle.	Briefly,	a	single	cell	suspension	
was	 prepared	 and	 an	 aliquot	 (10µL)	 transferred	 into	 the	 haemocytometer	 followed	 by	
counting	 the	 total	 cell	 number	 of	 all	 4	sets	 of	 16	 corner	 squares	 (according	 to	 standard	
operating	procedures).	To	determine	the	total	number	of	cells	the	average	of	all	4	sets	was	
calculated	and	multiplied	by	1x104	and	the	volume	from	which	the	original	cell	sample	was	
obtained.		For	trypan	blue	staining	cells	were	mixed	1:2	with	trypan	blue	prior	to	transferal	
into	the	haemocytometer	and	the	dilution	factor	 incorporated	when	estimating	total	cell	
number.	
2.2.5. Labelling	cells	with	lipophilic	dyes	–	DiD	and	CM-DiI	
Dialkylcarbocyanines	 such	 as	DiD	 and	 CM-DiI	 are	 lipophilic	 tracers	 that	 are	 incorporated	
into	 cell	 membranes,	 thereby	 staining	 the	 entire	 cells	 and	 allowing	 their	 detection	 by	
fluorescence.	Here	 the	 lipophilic	membrane	dyes	DiD	 and	CM-DiI	were	used	 to	map	 the	
location	of	cancer	cells	in	bone	by	immunofluorescence	and	two-photon	microscopy.	
Labelling	of	cells	with	the	dyes	was	performed	to	manufacturers	 instructions.	Briefly,	
cells	were	trypsinised	and	dislodged	as	described	before	and	suspensions	of	1x106	cells/mL	
prepared	 in	serum	free	medium	(for	DiD)	or	HBSS/D-PBS	 (for	CM-DiI).	5µL	dye	per	1x106	
cells/mL	were	added	to	the	suspension.	For	DiD	staining	cells	were	incubated	for	20min	at	
37°C	 in	 the	 dark.	 	 For	 CM-DiI	 labelling	 suspensions	 were	 incubated	 for	 5min	 at	 37°C	
followed	 by	 15min	 on	 ice.	 Following	 incubation	 with	 the	 dye	 cells	 were	 centrifuged	
(800rpm,	5min),	re-suspended	and	washed	2	times	in	sterile	PBS	prior	to	injection.		
In	vivo	work	
2.2.6. Ethics	
For	 all	 experiments	 animals	were	housed	 in	 the	University	of	 Sheffield	Biological	 Service	
Unit	to	the	required	guidelines.	All	experiments	were	performed	in	compliance	with	the	UK	
Animals	 (Scientific	 Procedures)	 Act	 1986	 and	 were	 reviewed	 and	 approved	 by	 the	 local	
Research	 Ethics	 Committee	 of	 the	 University	 of	 Sheffield	 (Sheffield,	 UK).	 Studies	 were	
performed	under	Home	Office	Project	Licence	40/3531	 (PPL,	Prof.	NJ	Brown)	or	40/2972	
(Prof.	C	Eaton).	Until	my	UK	Home	Office	personal	 license	(PIL40/10913,	December	2013)	
was	 granted,	 in	 vivo	 work	 was	 kindly	 performed	 by	 Dr.	 Hannah	 Brown,	 University	 of	
Sheffield	as	indicated	in	Chapter	3.	
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2.2.7. Animals	
Male	 and	 female	 immunocompromised	 BALB/c	 nude	 mice	 were	 ordered	 form	 Charles	
River	(UK)	or	Harlan	(UK)	as	 indicated	for	each	study	respectively.	Genetically	engineered	
mice	 expressing	GFP	 +ve	 cells	 of	 the	 osteoblastic	 lineage	 (pOBCol2.3GFPemd	 crossed	 to	
BALB/c	nude)	were	kindly	provided	 from	Leeds	 Institute	 for	Molecular	Medicine	 (UK).	By	
expressing	 GFPemd	 in	 cells	 of	 the	 osteoblast	 lineage	 this	 immunocompromised	 mouse	
model	 (BALB/c	 nude	 background	 as	 described	 in	 detail	 in	 [158])	 allowed	 a	 detailed	
investigation	 of	 the	 effects	 of	 anti-cancer	 therapies	 on	 osteoblastic	 cells	 and	 the	 link	
between	disseminated	cancer	cells	and	 resident	osteoblasts.	With	aging	 the	composition	
of	the	BME	changes,	including	the	presence	of	myeloid	and	lymphoid	lineages	in	the	bone	
marrow	 in	 addition	 to	 alterations	 in	 intrinsic	 HSC	 properties	 such	 as	 proliferation	 and	
differentiation.	 In	 addition,	 mesenchymal	 stem	 cells	 change	 their	 proliferation	 and	
differentiation	 capacity	 during	 aging,	 which	 is	 potentially	 associated	 with	 the	 increased	
bone	 loss	 in	 adulthood	 [242].	 Young	 mice	 (6-8-weeks	 old)	 with	 high	 bone	
turnover/immature	 skeleton	 and	 older	 mice	 (9-17-weeks	 old)	 with	 a	 mature	 skeleton	
enabled	 to	 assess	 effects	 of	 anti-cancer	 therapeutics	 in	 different	 BMEs	 were	 therefore	
used	 in	my	experiments.	 In	addition	I	also	 incorporated	male	mice	 in	a	subset	of	studies.	
For	 collaborative	 studies	with	 the	McAllister	 Laboratory,	Boston,	USA	6-week	old	 female	
immonocompromised	NCr-Nu	(nude),	CrTac:NCr-Foxn1nu		mice	(herein	referred	to	as	NCr-
Nu	(nude);	Taconic	Laboratories	(Hudson,	NY))	were	used.	These	mice	are	derived	from	an	
original	cross	between	the	BALB/c	inbred	nude	and	NIH(S)	outbred	nude	mice.	
 
2.2.8. Preparation	of	injectables	and	drug	administration		
2.2.8.1. Luciferin	
Luciferin	 (D-	 Luciferin	potassium	salt)	was	prepared	and	kindly	provided	by	Anne	Fowles	
(University	 of	 Sheffield,	 UK),	 and	 administered	 intraperitoneally	 at	 a	 concentration	 of	
30mg/kg.	
2.2.8.2. Intracardiac	injection	of	breast	cancer	cells	
Briefly,	 MDA-MB-231	 breast	 cancer	 cells	 were	 harvested	 and	 DiD	 or	 DiI	 labelled	 as	
described	 previously.	 To	 prevent	 clump	 formation,	 cells	 were	 passed	 through	 a	 100µm	
nylon	 mesh	 prior	 to	 injection.	 Mice	 were	 anaesthetised	 using	 isoflurane	 and	 complete	
anaesthesia	was	confirmed	by	the	pinch	reflex.	Correct	position	of	the	needle	was	assessed	
by	the	bright	red	colour	of	oxygenated	blood	drawn	into	the	syringe	prior	to	slow	injection	
of	 the	 cell	 suspension	 (containing	 1x105	 cells)	 into	 the	 left	 ventricle.	 Injection	 was	
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performed	 using	 1mL	 insulin	 syringes	 with	 27-gauge	 needles.	 Following	 intracardiac	
injection	 mice	 were	 put	 into	 an	 incubator	 to	 recover	 and	 closely	 monitored.	 For	
experiments	presented	in	Chapter	3,	intracardiac	injections	were	performed	by	Dr.	Hannah	
Brown,	University	of	Sheffield,	UK	or	Jessalyn	Ubellacker,	Boston,	USA.	
2.2.8.3. Subcutaneous	injection	of	MDA-436	cells	
Cell	 number	 was	 determined	 as	 described	 previously	 and	 100µL	 (5x105	 cells)	 injected	
subcutaneously	into	the	right	flank	using	1mL	syringes,	25-gauge	needle.		
2.2.8.4. Intravenous	injection	of	Doxorubicin	
Clinical	 grade	 Doxorubicin	 was	 kindly	 provided	 from	 Weston	 Park	 Cancer	 Hospital	
(2mg/mL).	 A	 drug	 suspension	with	 2mg/kg	 Doxorubicin	was	 prepared	 in	 PBS	 and	 sterile	
filtered	prior	to	intravenous	injection.	The	drug	was	prepared	fresh	for	each	day.	To	dilate	
tail	veins	animals	were	placed	in	an	incubator	at	35°C	for	at	least	15min.	For	injection	mice	
were	placed	in	a	bench	top	restrainer	fitted	onto	a	heating	pad	and	100µL	drug	suspension	
were	slowly	injected	into	the	tail	vein	using	insulin	syringes	(27-gauge	needle).	
2.2.8.5. Zoledronic	acid	
Zoledronic	acid	was	provided	as	 the	hydrated	disodium	salt	 ([1-hydroxy-2-1H-imidazol-1-
yl)ethylene]bisphosphonic	acid	(Novartis).	A	10mg/mL	stock	solution	was	prepared	by	Ms.	
A	Evans	in	PBS	and	stored	in	aliquots	at	-20°C.		A	100µg/kg	suspension	in	PBS	was	prepared	
fresh	 prior	 to	 injection,	 sterile	 filtered	 and	 100µL	 injected	 intraperitoneally	 using	 1mL	
syringes	(25-gauge	needle).	
2.2.8.6. Cabozantinib	
Cabozantinib	(XL184),	kindly	provided	by	Exelixis	Inc.	(South	San	Francisco,	California,	USA)	
was	 prepared	 in	 sterile	 filtered	 dH2O.	 To	 aid	 dissolution	 of	 the	 drug	 5µL	 1N	 HCl	 per	
3mg/mL	CBZ	were	added	according	 to	 company	 recommendations.	 The	drug	 suspension	
was	prepared	fresh	on	the	day	of	administration	and	given	within	1hr	of	preparation	in	a	
dose	volume	of	200µL	by	oral	gavage.	
2.2.8.7. Phosphate	buffered	saline	-	PBS	
PBS	 served	 as	 a	 vehicle	 control	 for	 all	 in	 vivo	 experiments	 as	 not	 otherwise	 specified.	
Sterile	filtration	was	performed	prior	to	injection	and	100µL	injected	using	the	same	route	
as	for	the	respective	experimental	drug.		
2.2.9. In	vivo	imaging		
The	 Illumatool	 Lightning	 System	was	used	 to	 image	 the	presence	of	GFP+ve	 cells	 in	 vivo	
using	a	Retiga	EX-B	camera	with	QCapture	software	 (Version	2.70.0).	Prior	 to	 in	vivo	 live	
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imaging	 using	 IVIS	 Lumina	 II	 system	 mice	 were	 anaesthetised	 using	 isoflurane.	 Briefly,	
anaesthetised	mice	were	placed	 into	a	dark	box	 imaging	chamber	with	a	12.5cm	field	of	
view	and	 focus	on	 subject	height.	Grey	 scale	 images	were	 taken	and	animals	 imaged	 for	
luciferase	 signal.	 Relative	 fluorescence	 was	 visualised	 and	 overlaid	 with	 the	 grey	 scale	
images	using	pseudo	colours	and	Living	Image	software.	Auto	Settings	were	used	for	image	
acquisition.		
Ex	vivo	analysis	
2.2.10. Sample	collection	and	processing	
2.2.10.1. Blood	samples	
Blood	 was	 collected	 at	 experimental	 endpoints.	 Animals	 were	 intraperitoneally	 injected	
with	50µL	pentobarbiturate,	deep	anaesthesia	confirmed	using	the	pinch	reflex.	Blood	was	
retrieved	 from	 the	 heart	 using	 a	 1mL	 syringe,	 25-gauge	 needle	 and	 placed	 in	 1.5mL	
Eppendorf	tubes	after	removal	of	the	needle.	To	obtain	serum,	blood	was	allowed	to	clot	
at	 ambient	 temperature	 followed	 by	 10min	 centrifugation	 at	 10,000rpm	 (Beckman	
Microfuge	 Lite	 with	 rotor	 F1802B;	 ≈7150xg),	 4°C.	 The	 clear	 supernatant	 (serum)	 was	
removed	and	pipetted	into	fresh	Eppendorf	tubes.	Serum	samples	were	stored	at	-80°C	for	
later	analysis.	For	flow	cytometric	analysis	of	whole	blood	samples,	blood	was	collected	as	
described	 before	 but	 the	 collection	 syringe	 and	 needle	 were	 pre-wetted	 with	 Heparin	
(50µL).	 
2.2.10.2. Fixation	of	soft	tissue	samples	for	histological	analysis	
Soft	 tissues	were	 fixed	 in	4%	paraformaldehyde	 (PFA,	prepared	 in	PBS,	pH	7.4)	 for	48hrs	
and	 subsequently	 transferred	 into	 70%	ethanol,	 processed	by	 the	University	 of	 Sheffield	
Bone	Biology	Lab	and	embedded	in	paraffin.	For	staining	sections	with	a	thickness	of	3µm	
were	cut	by	Alyson	Evans,	University	of	Sheffield.	
2.2.10.3. Fixation	of	bone	samples	for	histological	analysis	
For	paraffin	embedding	long	bones	were	fixed	in	ice	cold	4%	PFA	(prepared	in	PBS,	pH	7.4)	
for	48-72hrs	and	decalcified	in	0.5M	EDTA/0.5%	PFA	(prepared	in	PBS,	pH8)	for	2	weeks	at	
4°C,	constant	shaking.	Tissues	were	then	embedded	in	paraffin	and	sections	of	2	non-serial	
levels	with	a	thickness	of	3µm	were	cut	by	Mark	Kinch	and	Alyson	Evans,	both	University	of	
Sheffield.	
For	 frozen	 sections	 embedded	 in	 gelatine	 a	 protocol	 kindly	 provided	 by	 Dr.	 Anjaly	
Kusumbe,	Max	Plank	Institute,	Munich	was	followed.	On	day	of	cull,	tibiae	were	fixed	in	ice	
cold	4%	PFA	 (pH	7.4,	 in	PBS)	 for	4hrs	at	4°C.	Next	 samples	were	washed	3x5min	 in	PBS,	
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decalcified	in	0.5M	EDTA	(pH	8,	in	PBS)	for	at	least	24hrs.	Once	decalcified,	samples	were	
washed	 3x5min	 in	 PBS	 and	 subsequently	 transferred	 into	 a	 20%	 sucrose/2%	
Polyvinylpyrrolidone	(PVP)	solution	(prepared	 in	PBS)	and	 incubated	overnight	at	4°C.	On	
the	following	day	bones	were	incubated	in	a	water	bath	at	60°C	in	a	solution	containing	8%	
gelatine/	20%	sucrose/	2%	PVP	for	45min	prior	to	transferal	 into	cryomolds.	The	gelatine	
solution	was	allowed	 to	 solidify	 for	 at	 least	 30min	 followed	by	 transferal	 of	 the	 samples	
into	the	-80°C	freezer	for	long-term	storage.	Sections	of	30µm	thickness	were	cut	using	a	
cryostat	(MICROM	HM560).	
For	 calcein	 analysis	 a	 protocol	 provided	 and	optimized	by	Orla	Gallagher,	 Bone	Analysis	
Laboratory	Sheffield	was	followed.	Dissected	spines	were	fixed	in	70%	ethanol	for	at	least	
48hrs,	lumbar	vertebra	4	isolated	and	stored	in	the	dark	until	further	processing.	Vertebrae	
were	 infiltrated	with	 alcohol	 (2x	 80%	 IMS,	 2x	 90%	 IMS,	 2x	 100%	pure	 ethanol	 for	 48hrs	
each	at	ambient	temperature)	prior	to	transferal	into	Taab	Medium	Grade	LR	White	Resin	
(Taab	 Laboratory	 Equipment	 Ltd;	 3	 changes	 for	 48hrs	 each)	 at	 4°C.	 	 Next	 samples	were	
placed	 in	plastic	moulds	and	the	LR	White	Resin	allowed	to	polymerise	at	55°C	overnight	
for	up	to	24hrs.	Sections	for	histomorphometric	analysis	were	then	cut	by	Orla	Gallagher,	
Bone	Analysis	Laboratory	Sheffield.	
2.2.10.4. Micro	computed	tomography	(µCT)	analysis	
For	 µCT	 analysis	 bones	 were	 either	 scanned	 within	 the	 48-72hr	 time	 frame	 of	 4%	 PFA	
fixation	 or	 whilst	 in	 10%	 Formalin	 solution.	 To	 determine	 effects	 of	 anti-cancer	
therapeutics	 on	 bone,	 trabecular	 bone	 volume	 (depicted	 as	 bone	 volume	 per	 tissue	
volume,	 BV/TV	 in	%),	 trabecular	 number	 (Tb.N.	 in	mm-1),	 trabecular	 thickness	 (Tb.Th.	 in	
mm)	and	cortical	bone	volume	(BV	in	mm-3)	were	analysed	using	a	SkyScan	1172	or	1272	
(SkyScan).	Tibiae	were	scanned	using	a	currency	of	200mA,	51kV,	a	0.5mm	aluminium	filter	
and	a	medium	camera	resolution	of	2000x1024	or	2016x1344	respectively.	Pixel	size	for	all	
scans	 was	 set	 to	 4.3µm.	 For	 each	 sample	 images	 were	 reconstructed	 using	 NRecon	
software.	A	bone	volume	of	interest	(VOI)	was	determined	by	interactively	drawing	on	the	
obtained	 two-dimensional	 images.	 Analysis	 was	 started	 from	 a	 fixed	 offset	 (0.5mm	 for	
trabecular	bone	and	1.2mm	for	cortical	bone	analysis)	after	a	reference	line	was	set	at	the	
lower	 part	 of	 the	 growth	 plate	 (Figure	 8).	 Analysis	 was	 performed	 covering	 a	 length	 of	
1.0mm	for	each	bone.	Obtained	grey	scale	 images	of	the	VOI	were	converted	into	binary	
images	 (thresholds	 were	 consistent	 within	 one	 study)	 and	 bone	 parameters	 calculated	
using	CTAn	software.	
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Figure	8	Schematic	workflow	of	µCT	analysis.		
(A)	A	point	of	reference	was	set	at	the	growth	plate	(“growth	plate	bridge”,	indicated	by	red	arrow	
heads	in	A).	Analysis	was	started	from	a	fixed	offset	(B)	after	this	reference	point	covering	an	area	of	
1.0mm	 for	 each	bone	 (C).	 It	was	 interactively	drawn	around	 the	 volume	of	 interest	 (VOI)	 (C)	 and	
binary	images	created	(D).		
Reference	line	
A	 Reference	point	
Reference	line	
B	 Analysis	start	0.5mm	away	
from	reference	point	
Reference	line	
C	 Create	ROI	
Create	binary	
image	
D	
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2.2.10.5. Immunohistochemistry	
A	range	of	 staining	procedures	were	applied	 to	 identify	cells	on	histological	bone	and/or	
soft	tissue	sections.		
2.2.10.5.1. Haematoxylin	and	Eosin	(H&E)	staining	
H&E	 staining	 can	 be	 used	 to	 visualise	 numerous	 different	 tissue	 structures	 as	 nuclei	 are	
stained	 in	 blue	 by	 haematoxylin,	 whereas	 cytoplasm	 and	 connective	 tissue	 appears	 in	
various	 intensities	 of	 pink.	 	 H&E	 staining	 of	 paraffin	 embedded	 tissue	 sections	 was	
performed	 according	 to	 standard	 operating	 procedures	 developed	 by	 the	 Bone	 Analysis	
Laboratory,	 University	 of	 Sheffield.	 	 Briefly,	 3µm	 sections	 of	 paraffin	 embedded	 tissue	
sections	were	dewaxed	in	xylene	(2x5min),	rehydrated	through	decreasing	concentrations	
of	 alcohol	 (99%,	 99%,	 95%	 and	 70%,	 1min	 each)	 to	 distilled	 water.	 Samples	 were	 then	
incubated	in	Gill’s	Haematoxylin	solution	for	2	minutes	followed	by	“bluing”	in	running	tap	
water	for	5	min,	5min	incubation	in	1%	eosin	solution	and	another	washing	step	in	running	
tap	water	until	completely	clear.	Slides	were	dehydrated	through	alcohols	(70%,	95%,	99%,	
99%),	cleared	in	xylene	and	mounted	and	cover	slipped	using	DPX	[(distyrene),	plasticizer	
(tricresyl	phosphate)	and	xylene]	mounting	medium.	
2.2.10.5.2. Tartrate-resistant	acid	phosphatase	(TRAP)	staining	
Bone	 resorbing	 osteoclasts	 express	 TRAP.	 To	 analyse	 number,	 size	 and	 presence	 of	
osteoclasts	 in	 bone,	 histological	 samples	 were	 stained	 for	 TRAP	 according	 to	 standard	
operating	procedures	developed	by	the	Bone	Analysis	Laboratory,	University	of	Sheffield.	
Sections	were	dewaxed	and	rehydrated	to	dH2O	as	described	previously	followed	by	5min	
incubation	in	pre-warmed	acetate-tartrate	buffer	at	37°C.	Sections	were	then	immersed	in	
naphtol	AS-BI	phosphate/dimethylformamide	solution	in	acetate	tartrate	buffer	for	30min	
at	37°C	–	the	optimal	temperature	for	this	enzyme.	Consequently	sections	were	incubated	
in	sodium	nitrite/	pararosaniline/	acetate-tartrate	buffer	containing	solution	for	15min	at	
37°C.	 Counterstaining	 was	 performed	 using	 Gill’s	 Haematoxilin	 prior	 to	 dehydration	
through	alcohol	and	xylene,	mounting	and	cover	slipping.	Table	4	shows	the	composition	
of	 buffer	 solutions	 for	 TRAP	 staining	 and	 gives	 quantities	 of	 reagents	 to	 stain	 10	
histological	samples.	
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Table	4	Composition	of	buffers	for	TRAP	staining	
BUFFER	SOLUTION	 PRE	WARM	 SOLUTION	A	 SOLUTION	B	
N
o.	of	Slides	
Sodium
	Acetate	(g)	
H
2 O
	(m
l)	
Acetic	Acid	(m
l)	
Total	Acetate-TartrateBuffer	
Volum
e	(m
ls)	
Sodium
	Tartrate	(g)	
Prew
arm
	Slides	Acetate-Tartrate	
Buffer	(m
l)	
N
aphthol	AS-BI	phosphate	(g)	
D
im
ethyl	form
am
ide	(m
l)	
Solution	A	Acetate-Tartrate	
Buffer	(m
l)	
Sodium
	N
itrite	(g)	
H
2 O
	(m
l)	
Para	Rosaniline	(m
l)	
Total	Volum
e	of	Para	Rosaniline-
N
itrite	(m
l)	
Solution	B	Para	Rosaniline-
N
itrite	Volum
e	Required	(m
l)	
Solution	B	Acetate-Tartrate	
Buffer	(m
l)	
10	 5.44	 200	 50	 250	 4.6	 50	 0.02	 1	 50	 0.08	 2	 2	 4	 2.5	 50	
	
2.2.10.5.3. Visualisation	of	proteoglycan	using	Safranin-O	and	Toluidine	Blue	staining	
The	cationic	dyes	Safranin-O	and	Toluidine	blue	were	used	to	visualise	acidic	proteoglycan	
in	growth	plate	cartilage	on	histological	sections	of	tibiae.		
Safranin-O	staining	was	used	to	stain	cartilage/proteoglycan.	Cartilage	and	mucin	
are	stained	in	red,	nuclei	in	black	and	background	(bone)	in	green.	Briefly,	rehydrated	and	
dewaxed	sections	were	incubated	in	Weigert’s	iron	hematoxylin	working	solution	(solution	
A:	Hematoxilin/95%	alcohol,	Solution	B:	29%	Ferric	chloride	in	dH2O/concentrated	HCl;	1:1)	
for	 5	min,	washed	 in	dH2O	 followed	by	de-staining	 in	 acid	 ethanol	 prior	 to	 staining	with	
Fast	Green	 solution	 (Sigma-Aldrich)	 for	 5	min	 at	 ambient	 temperature.	 Slides	were	 then	
rinsed	with	1%	acetic	acid	and	immersed	in	0.1%	Safranin	–	O	solution	for	5min	followed	
by	mounting	with	DPX.		
Toluidine	 blue,	 a	 metachromasia	 dye,	 stains	 acidic	 proteoglycan	 and	 was	 next	 to	
Safranin	O	 staining	 used	 to	 visualise	 alterations	 in	 growth	 plate	 cartilage.	 Bone	 sections	
were	dewaxed	and	hydrated	as	described	and	immersed	in	Toluidine	blue	working	solution		
(Toluidine	 Blue	 O,	 Sigma	 Aldrich;	 1%	 NaCL	 pH	 =	 2.3)	 at	 ambient	 temperature	 for	 3min,	
followed	by	clearing	in	running	dH2O,	dehydration	through	alcohols	and	cover	slipping.		
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2.2.10.6. Immunofluorescence	
2.2.10.6.1. Visualisation	of	GFP+ve	osteoblastic	cells	
To	 visualise	 the	 presence	 of	GFP+ve	 osteoblastic	 cells	 in	 bone,	 paraffin	 embedded	 bone	
sections	were	dewaxed	as	described	previously,	followed	by	mounting	with	VECTASHIELD®	
Mounting	Media	with	DAPI.	Images	were	acquired	using	a	Leica	DMI4000B	microscope	and	
LAS	AF	Lite	software.	
2.2.10.6.2. Visualisation	of	the	bone	marrow	vasculature	
To	 visualise	 effects	 of	 anti-cancer	 drugs	 on	 the	 bone	 marrow	 vasculature,	
immunofluorescence	staining	against	the	vascular	endothelial	cell	marker	Endomucin	and	
CD31	was	 performed	 on	 either	 paraffin	 embedded	 bone	 sections	 or	 gelatine	 embedded	
sections	(1:100,	Endomucin	V.7C7,	rat	monoclonal,	Santa	Cruz,	sc-65495)	and	CD31	(1:100,	
DIA-310:	 Anti-CD31	 (Ms)	 from	 Rat	 (Clone:	 SZ31)).	 Endomucin	 is	 expressed	 in	 venous	
endothelium	and	as	well	as	capillaries,	whereas	 it	 is	not	present	on	arterial	endothelium.	
CD31	 (or	 platelet	 endothelial	 cell	 adhesion	 molecule-1,	 PECAM-1)	 is	 expressed	 on	 cell	
surfaces	of	platelets,	neutrophils,	embryonic	and	mature	endothelial	cells;	and	involved	in	
cell-to-cell	adhesion.	
With	 a	 recommended	 working	 concentration	 of	 1:50-1:500	 for	
immunohistochemistry	 the	 1:100	 working	 solution	 of	 the	 Endomucin	 Antibody	 has	
previously	been	optimised	in	our	laboratory	group	and	was	based	on	previously	published	
experiments	 by	 Kusumbe	 and	 colleagues	 [51].	 Dianova	 recommended	 a	 starting	
concentration	of	1:20	for	immunohistochemistry,	the	CD31	antibody	was	initially	tested	at	
a	concentration	of	1:50	and	1:100.	Vascular	staining	was	observed	at	both	concentrations	
with	1:100	being	ultimately	used	for	all	further	experiments.	Appropriate	negative	controls	
where	 incorporated	 by	 emitting	 the	 primary	 antibody.	 No	 fluorescence	 signal	 was	
observed	on	these	samples.		
2.2.10.6.2.1. Visualisation	 of	 the	 bone	 marrow	 vasculature	 on	 paraffin	 embedded	
sections	
The	protocol	for	paraffin	embedded	bone	sections	was	optimised	with	kind	advice	from	Dr.	
Russell	Hughes,	University	of	Sheffield	 (UK).	Histological	 sections	of	 tibiae	were	dewaxed	
and	 rehydrated	 prior	 to	 antigen	 retrieval	 in	 Tris-buffer	 (pH9)	 for	 15min	 at	 95°C	 in	 a	
waterbath.	Heated	slides	were	allowed	to	stand	at	ambient	temperature	for	10min	prior	to	
washing	in	Tris	buffered	saline	(TBS),	blocking	in	5%	normal	goat	serum/3%	bovine	serum	
albumine	 (BSA)	 followed	by	overnight	 incubation	 in	primary	antibody	 (1:100,	Endomucin	
V.7C7,	 rat	monoclonal,	Santa	Cruz,	 sc-65495)	at	4°C.	After	washing	 in	TBS,	 sections	were	
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incubated	 in	 secondary	 antibody	 (1:200,	 Alexa	 fluor	 555,	 goat	 anti-rat	 Igg,	
LifeTechnologies,	A21434)	at	ambient	temperature	for	1hr	followed	by	washing	in	TBS	and	
mounted	with	 VECTASHIELD®	Mounting	Media	with	 DAPI.	 Images	were	 acquired	 using	 a	
Leica	 DMI4000B	 microscope	 and	 LAS	 AF	 Lite	 software	 (20x	 objective)	 or	 a	 Nikon	 A1	
confocal	microscope	with	NIS	Elements	software	(40x	objective).	Visualisation	of	the	bone	
marrow	vasculature	on	gelatine	embedded	sections	
To	 visualise	 effects	 of	 anti-cancer	 agents	 on	 the	 bone	 marrow	 vasculature	 I	 was	 kindly	
provided	 with	 a	 protocol	 from	 Dr.	 A	 Kusumbe,	Max	 Plank	 Institute,	Munich	 (Germany).	
Briefly,	 immunofluorescence	 staining	 against	 the	 vascular	 endothelial	 cell	 marker	
Endomucin	 (1:100,	 Endomucin	 V.7C7,	 rat	 monoclonal,	 Santa	 Cruz,	 sc-65495)	 and	 CD31	
(1:100,	DIA-310:	Anti-CD31	(Ms)	from	Rat	(Clone:	SZ31))	was	performed.	30µm	thick	frozen	
sections	of	 tibiae	were	 left	 to	defrost	at	ambient	 temperature	 for	20min	 followed	by	 re-
hydrating	the	tissue	with	PBS	and	20min	incubation	in	0.3%	Triton	X-100.	Slides	were	then	
rinsed	3	times	in	PBS	followed	by	incubation	in	5%	goat	serum	(in	PBS,	blocking	solution)	
for	30min	at	ambient	 temperature.	Primary	antibody	 (prepared	 in	blocking	solution)	was	
applied	to	incubate	for	2hrs	at	ambient	temperature	or	4°C	over	night.	This	was	followed	
by	3	rinses	in	PBS	to	remove	unbound	antibody	and	samples	were	incubated	in	secondary	
antibody	 (1:200,	Alexa	 fluor	555,	goat	anti-rat	 Igg,	LifeTechnologies,	A21434,	prepared	 in	
PBS)	 for	 1hr	 at	 room	 temperature	 followed	 by	 3	 rinses	 in	 PBS	 and	 mounting	 with	
VECTASHIELD®	Mounting	Media	with	 DAPI.	 DAPI	was	 left	 to	 settle	 for	 5min	 followed	 by	
sealing	the	coverslips	with	nail	polish.	Slides	were	stored	at	4°C	until	image	acquisition.	
Images	 were	 acquired	 using	 the	 Nikon	 A1	 Confocal	 microscope	 (NIS-Elements-
software	Version	4.30,	CFI	Plan	Fluor	20x	MI	 (NA	0.75),	403nm	and	562nm	 laser)	or	 	 the	
Nikon	 inverted	 Ti	 eclipse	microscope	 (NIS-Elements	 software	Version	4.30,	 Plan	Apo	20x	
(NA	 0.75)).	 For	 a	 subset	 of	 samples	 Z-stacks	 of	 20µm	 depth	 (0.9µm	 intervals,	 23	 steps)	
were	 acquired	 and	 3D	 projections	 reconstructed	 using	 Fiji	 (ImageJ,	 Version	 2.0.0-rc-
24/1.49m,	Image>Stacks>3D	projections).		For	others	tile	scans	(6x6	or	8x8)	were	aquired.	
Appropriate	negative	controls	were	included	(omitting	the	primary	antibody).	
2.2.10.7. Assessing	histological	slides	
As	 not	 indicated	 separately	 all	 histological	 analysis	 of	 bone	 samples	 was	 performed	 on	
3µm	thick	sections	of	two	non-serial	sections	(20µm	apart).	
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2.2.10.7.1. Osteoblasts	and	osteoclasts	
Osteoblast	 quantification	 was	 performed	 on	 H&E	 or	 TRAP	 stained	 sections,	 osteoclasts	
were	 quantified	 on	 TRAP-stained	 bone	 sections	 according	 to	 standard	 operating	
procedures	 developed	 by	 the	 Bone	 Analysis	 Laboratory,	 University	 of	 Sheffield.	
Histopathological	support	was	kindly	provided	by	Dr.	K	Hunter	(University	of	Sheffield,	UK).	
Briefly,	osteoblasts	were	identified	by	their	characteristic	cuboidal	shape,	a	distinct	
single	nucleus,	large	golgi	complex	and	violet	appearance	after	H&E	staining.		Osteoblasts	
function	as	an	entity	of	bone	forming	cells	and	were	therefore	found	in	groups	of	at	least	3	
cells	 lining	 the	bone	surfaces.	 (Fig.9).	Osteoclasts	were	 identified	by	 their	multiple	nuclei	
and	bright	pink	appearance	after	TRAP	staining	as	illustrated	in	Figure	9.	Bone	cell	number	
(here	represented	as	osteoblast	and	osteoclast	number/mm	trabecular	bone	surface)	and	
size	 was	 determined.	 Using	 OsteoMeasure	 software	 (OsteoMetrics),	 it	 was	 interactively	
drawn	around	areas	of	interest	including:	osteoblast	surface	(the	surface	covered	by	bone	
forming	osteoblasts),	 osteoclast	 surface	 (the	 surface	 resorbed	by	osteoclasts),	 osteoclast	
volume	 (depicted	 as	 osteoclast	 size	 in	mm2)	 and	 trabecular	 bone	 surfaces.	 A	 schematic	
illustration	and	an	example	screenshot	using	OsteoMeasure	can	be	seen	in	Figure	10.	
A	list	of	parameters	used	for	analysis	can	be	seen	in	Figure	10).	Osteoblast	and	osteoclast	
number/mm	 trabecular	 bone	 surface	 was	 started	 125µm	 from	 the	 last	 hypertrophic	
chondrocyte	 stack	 away	 covering	 all	 trabecular	 bone	 surfaces,	 using	 a	 10x	 objective.	
Cortical	bone	was	excluded	for	analysis.	For	a	subset	of	studies	presented	in	Chapter	3	an	
offset	 of	 200µm	was	 used	 and	 a	 20x	 objective	 due	 to	 an	 upgrade	 of	 the	OsteoMeasure	
system	and	provision	of	a	new	camera	and	microscope	(Olympus	BX53	microscope).	This	is	
indicated	separately	under	the	corresponding	data	sets	(Chapter	3).	
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Figure	9	Identification	parameters	for	osteoblasts	and	osteoclasts	on	histological	sections.		
	
	
	
	
Figure	10	llustration	of	bone	cell	quantification	using	OsteoMeasure	software.		
Osteoblasts	(black	arrow	head)	and	osteoclasts	(asterisk)	lining	all	trabecular	bone	surfaces	(green)	
were	identified	and	quantified	by	interactively	drawing	around	the	parameters	of	interest.		
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2.2.10.8. Serum	measurments	by	ELISA	
2.2.10.8.1. TRAP	
Tartrate-resistant	 acid	 phosphatase	 (TRAP)	 is	 expressed	 by	 osteoclasts	 when	 actively	
resorbing	bone	and	this	enzymatic	assay	was	therefore	used	to	measure	osteoclast	activity	
in	serum	samples.	MouseTRAPTM	Assay	from	Immuno	Diagnostic	Systems	(SB-TR103)	was	
used	to	determine	osteoclast-derived	tartrate-resistant	acid	phosphatase	form	5b	(TRACP	
5b).	 The	 assay	 was	 performed	 according	 to	 manufacturer’s	 guidelines.	 Anti-mouseTRAP	
Antibody	 (100µL)	 was	 added	 to	 the	 96-well	 plate,	 incubated	 for	 60min	 at	 room	
temperature	 (RT)	on	a	micro	plate	 shaker,	prior	 to	washing	wells	with	Washing	 solution.	
Calibrator	and	Control	solutions	(100µL/well)	were	added	to	assigned	wells	 in	duplicates.	
0.9%	 NaCl	 (75µL/well)	 followed	 by	 serum	 samples	 (25µL/well)	 were	 pipetted	 into	 the	
remaining	 wells	 in	 duplicate.	 Releasing	 Reagent	 (25µL/well)	 was	 added	 using	 a	
multichannel	 pipette	 and	 the	 plate	 was	 incubated	 at	 RT	 for	 60min	 with	 shaking.	 The	
previously	 mentioned	 washing	 step	 was	 repeated	 followed	 by	 a	 2hr	 incubation	 with	
Substrate	 Solution	 (100µL/well)	 at	 37°C.	 Finally	 Stop	 Solution	 (NaOH,	 25µL/well)	 was	
added	and	absorbance	was	read	within	30	min	of	adding	the	Stop	Solution	at	405nm	using	
a	MRXII	Dynex	Technologies	plate	reader.	Standard	curves	were	generated,	experimental	
sample	concentrations	calculated	and	expressed	in	U/L.	
2.2.10.8.2. Rat/Mouse	PINP	Enzyme	immunoassay	
The	 bone	 matrix	 consists	 partly	 of	 Type	 I	 collagen.	 Bone	 forming	 osteoclasts	 release	
precursor	type	I	procollagen	which	can	be	used	as	a	marker	to	determine	bone	formation.		
Rat/Mouse	 PINP	 Enzyme	 immunoassay	 for	 the	 quantitative	 determination	 of	 N-terminal	
propeptide	 of	 type	 I	 procollagen	 (PINP)	 (Immunodiagnosticsystems	 (AC-33F1)	 was	
therefore	 used	 to	 monitor	 osteoblast	 activity	 in	 serum	 samples.	 	 Briefly,	 Control	 and	
Calibrator	 (50µL/well)	 were	 added	 to	 the	 assigned	wells	 of	 the	 antibody	 coated	 96-well	
plate	 in	duplicates.	 	 Samples	 (5µL/well)	 and	Sample	diluent	 (45µL/well)	were	pipetted	 in	
duplicate	 to	 the	 appropriate	wells	 before	 PINP	Biotin	 (50µL/well)	was	 added	 to	 all	wells	
and	 the	 plate	 was	 incubated	 for	 1hr	 at	 RT	 on	 a	 microplate	 shaker.	 After	 washing	 with	
Washing	buffer,	Enzyme	Conjugate	 (150µL/well)	was	added	and	 the	plate	was	 incubated	
for	 30min	 at	 RT.	Washing	of	wells	was	 repeated	 and	 the	plate	was	 incubated	with	 TMB	
substrate	(150µL/well)	for	30	min	at	RT.	Last	Stop	Solution	(HCl,	50µL/well)	was	added	and	
absorbance	at	450nm	was	measured	using	a	Spectra	Max	plate	reader	(Molecular	Devices).	
Standard	 curves	 were	 generated,	 experimental	 sample	 concentrations	 calculated	 and	
expressed	in	ng/mL.	
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2.2.10.9. Gene	expression	analysis	using	long	bones	
A	representative	workflow	can	be	seen	in	Figure	11	below	and	is	described	in	the	following	
section.	
On	day	of	 sacrifice,	 tibia	and	 femur	were	 isolated	and	all	muscle	 tissue	 removed	
using	scissors	and	scalpel.	Bones	were	immediately	preserved	in	RNAlater	Tissue	Collection	
Solution	 (Ambion,	 Life	 Science	 Technologies),	 followed	 by	 splitting	 into	 halves	 and	
manually	scraping	out	the	bone	marrow	using	scalpels	and	razor	blades.	Bones	were	then	
snap	frozen	in	lN2	prior	to	storage	at	-80°C	for	further	analysis.		
	
	
Figure	11	Schematic	workflow	of	gene	expression	studies.		
RNA	 from	 long	 bones	 was	 extracted	 using	 TRIZol	 and	 RNA	 Clean&	 Concentrator	 Kit,	
quantitiy	and	quality	assessed	followed	by	cDNA	synthesis,	and	loading	the	samples	into	a	
384-well	plate	for	qRT-PCR	analysis.		
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2.2.10.9.1. RNA	extraction	
For	 RNA	 extraction	 snap	 frozen	 bones	 were	 pulverised	 using	 mortar	 and	 pestle	 under	
constant	addition	of	lN2.	Tibia	and	femur	from	one	leg	of	each	mouse	were	pooled	for	RNA	
extraction	 to	ensure	 sufficient	 concentration	of	 extracted	RNA.	RNA	was	extracted	using	
standard	phenol-chloroform	TRIzol	RNA	extraction	 in	 combination	with	 the	RNA	Clean	&	
Concentrator	 Kit	 from	 Zymo	 Research	 (ZEC174900).	 	 Briefly,	 1mL	 TRIzol®	 (Sigma)	 was	
added	per	100mg	pulverised	bone	tissue.	Samples	were	incubated	at	ambient	temperature	
for	 10min	 followed	 by	 centrifugation	 at	 12,000rpm	 (Beckman	Microfuge	 Lite	 with	 rotor	
F1802B;	≈10300xg)	for	10min	at	4°C	to	pellet	 insoluble	high	fat	content.	The	supernatant	
was	 transferred	 to	 a	 fresh	 Eppendorf	 tube	 and	 100µL	 chloroform/millilitre	 TRIzol®	were	
added.	 Samples	 were	 incubated	 for	 15min	 at	 ambient	 temperature	 followed	 by	
centrifugation	 at	 12,000rpm	 (Beckman	Microfuge	 Lite	 with	 rotor	 F1802B;	 ≈10300xg)	 for	
15min	at	4°C.	The	aqueous	RNA	phase	was	transferred	into	a	fresh	Eppendorf	tube	and	an	
equal	volume	of	100%	ethanol	was	added	prior	to	transferral	into	a	Zymo-Spin	IC	column.	
RNA	 Clean	&	 Concentrator	 Kit	 from	 Zymo	 Research	 (ZEC174900)	was	 used	 according	 to	
manufacturers	 guidelines.	 Briefly,	 the	 sample	 was	 centrifuged	 for	 30sec,	 followed	 by	
addition	of	400µL	RNA	Prep	Buffer.	After	centrifugation	RNA	was	washed	twice	using	RNA	
Wash	Buffer	and	eluted	in	a	final	volume	of	20µL	of	DNAse/RNAse	free	H2O.	 
2.2.10.9.2. Assessment	of	RNA	quality	and	quantity	
RNA	 was	 quantified	 using	 a	 Nanodrop	 ND-1000	 Spectrophotometer	 (Nanodrop	
Wilmington,	DE).	An	A260/280	ratio	of	1.8-2.2	and	an	A260/230	of	2.0-2.2	was	accepted	
for	pure	RNA	[243],	and	only	these	samples	were	used	for	cDNA	synthesis.	
RNA	integrity	was	analysed	using	Agilent	RNA	ScreenTape	assay	(Agilent	Technologies)	and	
2200	 Tape	 Station	 Instrument	 (Agilent	 Technologies).	 The	 RNA	 integrity	 number	 (RIN)	
algorithm	was	used	to	analyse	the	entire	electrophoretic	 trace	of	an	RNA	sample	 for	 the	
presence	of	degradation	products.	The	resulting	RIN	number	ranges	from	1	to	10,	with	1	
being	 the	 most	 degraded	 and	 10	 being	 the	 most	 intact	 RNA.	 RIN	 number	 takes	 into	
account	the	ratio	between	the	ribosomal	peaks	at	28S	and	18S	in	mammalian	samples.	In	
my	experiments	RIN	numbers	ranged	from	8.3	to	10.		
2.2.10.9.3. cDNA	synthesis	
2µg	of	RNA	was	reverse	transcribed	in	a	total	volume	of	20µL	using	High	Capacity	RNA-to-
cDNATM	 Kit	 (Applied	 Biosystems®)	 according	 to	 manufacturers	 instructions	 (See	 Table	 5	
below).	 For	 each	 sample	 a	 “Reverse	 transcription	 (Enzyme	 Mix)	 negative	 control“	 was	
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loaded,	 	 therefore	 each	 sample	was	 prepared	 in	 two	 replicate	 tubes.	 In	 addition	 a	 tube	
containing	“DNAse/RNAse	free	water“	only	was	also	prepared	to	ensure	no	contamination	
in	the	reagents	(see	Table	5).The	reaction	was	performed	using	a	thermal	cycler	at	37°C	for	
60min,	95°C	for	5min	and	held	at	4°C,	followed	by	long-term	storage	at	-20°C.	The	resulting	
first-strand	 complementary	DNA	 (cDNA)	worked	as	 a	 template	 for	 real-time	quantitative	
polymerase	chain	reaction	(qRT-PCR)	–	composition	of	the	reaction	mix	is	seen	in	Table	6	
below.	 Species-specific	 TaqMan®	 assays	 (Life	 Technologies)	 were	 used	 to	 analyse	 the	
expression	of	selected	genes	of	interest	(GOI).			
	
Table	5	Reagents	used	for	cDNA	synthesis	
	
 
Table	6	Composition	of	the	PCR	reaction	mix 
	
	
2.2.10.9.4. Selection	of	house	keeping	gene	
During	relative	quantitation	of	a	qRT-PCR	experiment	the	expression	of	a	gene	of	interest	
(GOI)	in	one	sample	(e.g.	control	group)	is	compared	to	the	expression	of	the	same	GOI	in	
another	sample	(e.g.	treatment	group).	To	correct	for	sample-to-sample	variation	data	are	
normalised	 to	 an	 invariant,	 stable	 endogenous	 control,	 a	 so-called	 housekeeping	 gene	
Volume	(µL)	
Reagent	 Sample	
Negative	sample	
control	(no	reverse	
transcriptase)	
Negative	(no	
RNA)	control	
2X	RT	Buffer	 10	 10	 10	
20	X	Enzyme	Mix	 1	 -	 1	
RNA	
Up	to	9µL	
(concentration	of	
1µg)	
Up	to	9µL	
(concentration	of	
1µg)	
-	
DNAse/RNAse	
free	H2O	
Filled	up	to	a	final	
volume	of	20µL	
Filled	up	to	a	final	
volume	of	20µL	 9	
Total	reaction	
volume	 20	 20	 20	
Reagent	 Volume	(µL)	
2X	TaqMan®	Universal	PCR	Master	Mix	(Applied	Biosystems)	 5	
RNAse/DNAse	free	H2O	 2.5	
20X	TaqMan®	Gene	Expression	Assay	(Applied	Biosystems)	 0.5	
cDNA	 2	
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(HKG).	 The	 quality	 of	 normalised	 expression	 data	 can	 therefore	 only	 be	 as	 good	 as	 the	
quality	of	the	HKG	itself.	Any	variation	of	the	HKG	will	result	 in	artifactual	changes	[244],	
and	 therefore	 HKG	 have	 to	 be	 selected	 carefully	 for	 each	 experiment.	 Here,	 expression	
levels	 of	 B2M,	 HPRT1	 and	 Abl1	 were	 assessed	 but	 only	 B2M	was	 stable	 expressed	 and	
therefore	used	as	 a	HKG	 for	 all	 experiments	described	 in	Chapter	4	 (HKG	validation	was	
performed	according	to	guidelines	obtained	from	[245]).	In	addition	efficiency	of	both	HKG	
and	 GOI	 were	 assessed	 using	 a	 standard	 curve	 of	 serially	 diluted	 cDNA	 (1,	 1:10,	 1:100,	
1:1000)	was	 performed	 for	 each	 housekeeper	 and	GOI.	 Results	were	 plotted	with	 input	
nucleic	acid	quantity	(log	of	dilution)	on	the	X-axis	and	Ct-value	on	the	Y-axis	(see	Fig.12).	
The	 efficiency	 was	 calculated	 using	 following	 formula:	 Efficiency=10(-1/-slope)-1	 where	 the	
slope	 of	 the	 standard	 curve	 indicates	 the	 PCR	 efficiency.	 PCR	 efficiency	 ranged	between	
90-110%,	the	accepted	range	for	TaqMan	assays	[246].	
	
						
	Figure	12	Representative	graph	showing	House	Keeping	Gene	efficiency.		
	
2.2.10.9.5. Quantitative	Real	Time	Polymerase	Chain	Reaction	(qRT-PCR)	
qRT-PCR	was	performed	using	the	ABI	PRISM	7900HT	Sequence	Detection	System	(Applied	
Biosystems)	and	SDS	2.1	 software.	The	PCR	program	consisted	of	an	 initial	hold	50°C	 for	
2min,	 an	 activation	 step	 at	 95°C	 for	 10min	 and	 40	 cycles	 at	 95°C	 for	 15sec	 followed	 by	
annealing	for	1min	at	60°C.	A	FAM	non-fluorescence	detector	and	a	passive	ROX	reference	
signal	were	 used.	 A	 baseline	 (the	 initial	 steps	 of	 the	 PCR	where	 there	 is	 little	 change	 in	
fluorescence	 signal)	 of	 cycles	 3-15	 and	 a	 threshold	 (the	 level	 of	 signal	 that	 represents	 a	
significant	increase	over	the	calculated	baseline	signal)	of	0.2	were	used.	This	allowed	the	
determination	of	the	threshold	cycle	(Ct),	the	cycle	number	at	which	the	fluorescent	signal	
0 -1 -2
0
10
20
30
RANK
Dilution (log)
C
t v
al
ue
 
Slope: -3..442
R2:0.999
Efficiency: 95.21% 
	 83	
of	 the	 reaction	 crosses	 the	 threshold.	 Ct	 values	 are	 inversely	 proportional	 to	 the	
expression	 of	 the	 target	 meaning	 that	 decreased	 amount	 of	 template	 =	 higher	 cycle	
number.	Ct	values	≥34	were	excluded	from	analysis.	
2.2.10.9.6. Analysis	–	Relative	quantification	
Relative	 quantification	 shows	 the	 expression	 of	 the	 GOI	 relative	 to	 a	 HKG.	Obtained	 Ct-
values	are	expressed	as	a	fold	change	in	expression	of	the	„treated	samples“	relative	to	the	
„control	samples“.	Briefly,	the	ΔCt	value	was	calculated	from	obtained	Ct-values	of	the	GOI	
by	normalising	 to	 the	Ct-value	oft	 he	HKG	using	 the	 formula	ΔCt=Ct(GOI)-Ct(HKG).	Next,	
the	 ΔΔCt	 was	 calculated	 as	 follows:	 ΔΔCt=ΔCt(GOI)-ΔC(HKG).	 This	 is	 followed	 by	
determination	of		2-ΔΔCt,	the	fold	change.	
2.2.11. Statistical	Analysis	
Statistical	 analysis	 was	 performed	 using	 GraphPad	 Prism	 Version	 6.0.	 To	 determine	
whether	 the	 effects	 of	 anti-cancer	 therapeutics	 on	 bone	 and	 key	 bone	 cells	 were	
statistically	 significant	unpaired	 Student’s	 t-test	or	 2-way	ANOVA	with	Bonferroni’s	 post-
test	was	used.	T-test	 is	usually	applied	when	 the	 test	 samples	 follow	a	normal,	Gaussian	
distribution.	 In	my	studies	 I	used	small	n-numbers	 (n=3-5),	and	most	statistical	normality	
tests	require	higher	n-numbers	to	test	for	normal	distribution	of	the	samples	(e.g.	Shapiro-
Wilk	test	requires	n≥7	or	D'Agostino	&	Pearson	omnibus	test	n≥8).	I	decided	to	use	t-test	
when	 analysing	 bone	 parameters	 including	 bone	 volume,	 bone	 cell	 number	 and	 serum	
levels	of	bone	resorption/formation	markers	given	the	following:		
• Tight	 error	 bars	 and	 small	 sample-to-sample	 variation	 were	 obtained	 when	
analysing	 bone	 parameters	 in	 previous	 experiments	 in	 our	 laboratory	 and	 by	
myself	[154,	158,	247].	
• In	 Chapter	 4	 I	 obtained	 samples	 from	 collaborative	 experiments	 to	 assess	
treatment	 effects	 of	 the	 tyrosine	 kinase	 inhibitor	 CBZ	 on	 growth	 plate	
chondrocytes	(n=9-10).	These	n-numbers	allowed	me	to	assess	normal	distribution	
of	 values	 obtained	 for	 the	 hypertrophic	 and	 resting/proliferating	 chondrocyte	
zone.	 Using	 the	 D'Agostino	 &	 Pearson	 omnibus	 test,	 which	 tests	 the	 null-
hypothesis	that	“all	the	values	are	sampled	from	a	Gaussian	distribution“,	showed	
that	both	parameters	were	normally	distributed.	
• In	 addition	 one	 can	 assume	 that	 when	 a	 distribution	 is	 normal,	 the	 mean	 and	
median	will	 be	 equal.	 Mean	 and	 median	 of	 analysed	 parameters	 were	 in	 most	
analyses	nearly	identical.	For	example	effects	of	a	single	dose	of	ZOL	on	trabecular	
	 84	
bone	 volume	 3	 days	 after	 PBS	 or	 ZOL	 treatment	 (n=3-4):	 PBS:	Mean:	 2.25	%	 vs.	
Median:	2.14%;	ZOL:	Mean:	3.66%	vs.	Median:	3.62%.	
• When	analysing	data	sets	using	Mann-Whitney	test	(assuming	that	samples	are	not	
from	 a	 normally	 distributed	 population),	 statistics	 were	 similar	 to	 that	 obtained	
from	t-test.	
Given	 the	 high	 variance	 in	 tumour	 growth,	 tumour	 size,	 microvascular	 density,	 necrotic	
core	area	and	proliferation	data	were	assessed	using	Mann-Whitney	test.		 	
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the	Creative	 Commons	 Attribution-NonCommercial-ShareAlike	 License	 (CC	 BY	 NC	 SA).	
(http://creativecommons.org/licenses/by-nc-sa/3.0/),	DOI:	10.1016/j.bone.2014.06.023	
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3.1. Summary	
Bone	 metastasis	 is	 the	 most	 common	 complication	 of	 advanced	 breast	 cancer.	 The	
majority	 of	 cancer	 patients	 die	 because	 of	 metastatic	 disease,	 not	 from	 their	 primary	
tumour.	 Once	 the	 cancer	 has	 spread	 to	 bone	 treatment	 remains	 restricted	 to	 palliative	
care.	The	cancer-induced	bone	disease	is	often	treated	with	bone-sparing	agents	including	
the	bisphosphonate	Zoledronic	acid	(ZOL).	Importantly,	the	lack	of	effective	anti-metastatic	
therapy	 reflects	 the	 gap	 in	 our	 understanding	 of	 the	 underlying	 biology	 of	 tumour	 cell	
spread	 to	bone.	 In	clinical	 trials	ZOL	has	 shown	 to	 reduce	 recurrence	of	breast	 cancer	 in	
bone,	which	is	suggested	to	be	partially	mediated	by	modification	of	the	BME	surrounding	
the	disseminated	tumour	cells.	However,	the	exact	mechanisms	behind	this	effect	remain	
unknown.	
The	hypothesis	 to	be	 tested	 in	 this	chapter	 is	 that	 ZOL	modifies	 key	 components	 of	 the	
bone	 metastasis	 niche	 including	 osteoblasts	 and	 osteoclasts	 in	 vivo,	 with	 potential	
consequences	on	tumour	cell	homing	to	bone	and	metastatic	outgrowth.	
Briefly,	this	chapter	presents	a	detailed	characterisation	of	the	early	effects	of	ZOL	on	key	
cells	of	the	bone	metastasis	niche	in	vivo	and	will	discuss	how	therapeutic	modification	of	
the	 niche	 affects	 breast	 cancer	 cell	 homing	 to	 bone.	 A	 single	 injection	 of	 ZOL	 rapidly	
altered	the	cellular	(osteoblast	and	osteoclast	number	as	well	as	activity)	and	extra-cellular	
(bone	structure,	extracellular	matrix)	composition	of	the	bone	metastasis	niche	in	6-week	
old,	naïve	mice	as	early	as	3	days	post	treatment.	 In	addition	alterations	in	the	structural	
organisation	 of	 the	 bone	marrow	 vasculature	 were	 observed	 3	 days	 after	 ZOL	 injection	
when	compared	 to	 control.	 Injection	of	MDA-MB-231	breast	 cancer	 cells	 at	day	5,	when	
ZOL	 induced	effects	 reached	their	peak,	demonstrated	that	breast	cancer	cells	appear	 to	
preferentially	home	to	osteoblast-rich	trabecular	bone	areas,	which	could	be	altered	when	
they	arrive	in	a	ZOL-modified	microenvironment	
In	conclusion,	a	single	dose	of	ZOL	caused	significant	changes	in	the	bone	area	suggested	
to	 contain	 the	 metastasis	 niche.	 Osteoblasts	 may	 be	 key	 components	 of	 the	 bone	
metastasis	niche	and	therefore	a	potential	therapeutic	target	in	breast	cancer.	
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3.2. Introduction	
The	skeleton	is	the	most	favoured	site	of	metastasis	in	patients	with	advanced	breast	and	
prostate	cancer.	Both	are	likely	to	account	for	nearly	80%	of	all	cases	of	metastatic	disease	
and	show	the	highest	morbidity	caused	by	skeletal	related	events	(SREs)	due	to	osteolytic	
and/or	 osteoblastic	 bone	 lesions	 [3].	 Currently	 there	 is	 a	 lack	 of	 biological	markers	 that	
could	 be	 used	 for	 routine	 diagnosis	 and	 bone	 metastases	 are	 usually	 detected	
radiologically	once	bone	lesions	are	established.	At	this	stage	treatment	remains	palliative	
and	 often	 includes	 agents	 that	 prevent	 bone	 resorption	 by	 inhibiting	 osteoclast	
differentiation	 and/or	 apoptosis.	 The	 cancer-associated	 bone	 disease	 is	 therefore	 often	
targeted	 by	 Denosumab,	 the	monoclonal	 antibody	 to	 RANKL,	 or	 bisphosphonates	 (BPs),	
with	ZOL	being	 the	most	potent	one	 [248].	Both	 compounds	primarily	 target	osteoclasts	
but	 have	 also	 shown	 to	 affect	 other	 cell	 types	 in	 bone	 including	osteoblasts	 [249],	HSCs	
and	vascular	endothelial	cells	[159].	
Briefly,	 the	 nitrogen-containing	 BP	 ZOL	 inhibits	 key	 enzymes	 of	 the	 intracellular	
mevalonate	 pathway	 by	 targeting	 the	 enzyme	 farnesyl	 pyrophosphate	 synthase	 (FPP	
synthase).	 Inhibition	 of	 FPP	 results	 in	 a	 lack	 of	 prenylation	 of	 downstream	 signalling	
proteins	 resulting	 in	 loss	 of	 osteoclast	 function	 and	 consequently	 osteoclast	 apoptosis	
[138,	250].		
The	 progression	 from	 primary	 to	 secondary	 or	 metastatic	 tumour	 is	 a	 highly	 controlled	
process	 including	 detachment	 of	 tumour	 cells	 from	 the	 ECM,	 intravasation	 into	
surrounding	tissue,	lymph	and/or	blood	vessels,	circulation,	attachment	to	the	vessel	wall	
and	 extravasation	 into	 the	 secondary	 organ	 [251].	 The	 extent	 and	 aggressiveness	 of	
primary	tumours	has	long	been	thought	to	be	the	main	risk	factor	for	the	development	of	
secondary	disease.	However,	it	became	clear	that	also	small	primary	tumours	could	cause	
metastatic	 relapse,	 often	 at	much	 later	 time	 points.	 This	 suggests	 that	 dissemination	 of	
malignant	cells	(DTCs)	to	bone	is	an	early	event	and	tumour	cells	may	reside	in	a	dormant	
state	within	the	bone	for	many	years	[252,	253].	With	treatment	remaining	palliative	once	
the	 tumour	cells	proliferate	 in	bone,	a	potent	 therapeutic	approach	 is	 to	prevent	and/or	
target	 the	 early	 steps	 of	 bone	 metastasis	 including	 the	 homing	 of	 tumour	 cells	 to	
secondary	 sites.	 Increasing	 our	 understanding	 about	 the	 metastatic	 spread	 is	 therefore	
detrimental	for	developing	effective	therapies.		
As	 discussed	 previously	 Steven	 Paget	 almost	 100	 years	 ago	 already	 proposed	 that	
therapies	to	modify	the	microenvironment	that	supports	tumour	growth	might	be	of	equal	
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importance	as	therapies	targeted	against	cancer	cells	themselves	[86].	General	consensus	
is	 that	 bone	 marrow-derived	 cells	 (BMDCs)	 make	 up	 a	 “metastasis	 niche”,	 a	 tumour	
growth-promoting	milieu	within	 the	 bone,	which	 regulates	 tumour	 cell	 homing,	 survival	
and	 dormancy.	 The	 niche	 is	 suggested	 to	 be	 comprised	 of	 various	 entities	 of	 BMDCs	
including	 (1)	 a	 hematopoietic	 stem	 cell	 niche,	 (2)	 an	 endosteal	 niche	 (osteoblasts,	
osteoclasts,	 mesenchymal	 stem	 cells,	 adipocytes)	 and	 (3)	 a	 (peri)-vascular	 niche	 [101],	
discussed	in	greater	detail	in	Chapter	1,	Section	1.4.		
Recent	 work	 has	 highlighted	 that	 the	microenvironment	 comprising	microscopic	
bone	lesions	is	primarily	comprised	of	osteoblastic	cells	[94]	and	suggests	that	OCs	are	not	
critical	 in	 the	 earliest	 stages	 of	 bone	 metastases	 but	 rather	 at	 later	 stages	 of	 disease	
progression	[93].	DTCs	are	suggested	to	take	advantage	of	similar	molecular	mechanisms	
that	regulate	HSC	homing	and	retention	including	the	CXCL12/CXCR4	signalling	axis	which	
might	 involve	 the	 osteoblast	 as	 a	 key	 mediator	 [103].	 In	 vitro	 CXCL12	 (or	 SDF-1)	 is	
expressed	on	a	variety	of	cells	of	the	BME	including	osteoblasts	and	endothelial	cells	[254,	
255].	In	addition	CXCR4,	the	receptor	for	CXCL12,	is	expressed	on	a	variety	of	cancer	cells	
including	 breast	 and	 prostate	 [255,	 256].	 Using	 prostate	 cancer	 models	 Shiozawa	 and	
colleagues	 have	 shown	 that	 tumour	 cells	 compete	 with	 HSCs	 for	 the	 occupancy	 of	 the	
haematopoietic	 niche	 [95].	 This	 suggests	 that	 cancer	 cells	might	 use	 the	 CXCL12/CXCR4	
pathway	whilst	homing	to	the	osteoblastic	niche	 in	bone.	This	 is	supported	by	data	 from	
Price	 and	 colleagues	who	 have	 recently	 demonstrated	 that	 both,	 newly	 and	 established	
metastases	are	anchored	in	the	bone	marrow	by	CXCR4/SDF-1	interactions	[112];	a	factor	
highly	 expressed	 by	 osteoblastic	 cells.	 Whether	 osteoblasts	 are	 indeed	 part	 of	 the	
metastasis	niche	 is	subject	to	debate	[113]	and	was	experimentally	addressed	within	this	
chapter.		
Several	clinical	trials	support	beneficial	effects	of	ZOL	for	breast	cancer	patients	in	
the	adjuvant	setting	[132,	179,	180,	182].	The	AZURE	(BIG	01/04)	clinical	trial	reported	that	
increased	 risk	 of	 bone	 metastasis	 seemed	 to	 be	 associated	 with	 high	 serum	 PINP	
(osteoblast	activity)	 levels	at	baseline	 (study	entry)	when	compared	 to	patients	with	 low	
PINP.	Although	 this	was	not	 relevant	 for	overall	 distant	disease	 recurrence,	 it	 suggests	 a	
potential	role	of	osteoblasts	in	breast	cancer	recurrence	in	bone,	and	a	novel	therapeutic	
target.	 Importantly,	 there	 was	 also	 a	 reduced	 incidence	 of	 bone	 metastases	 in	 women	
(post-menopausal)	receiving	ZOL	in	addition	to	standard	adjuvant	therapy	[132].		
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In	agreement	several	 in	vivo	studies	have	reported	a	reduction	 in	cancer-induced	
bone	disease	when	osteoclastic	bone	 resorption	was	 inhibited	by	early	administration	of	
BPs	 (BP	 pre-treatment	 prior	 to	 tumour	 cell	 injection)	 in	 the	 development	 of	 bone	
metastasis.	 In	addition,	preventative	schedules	appear	to	slow	down	disease	progression.	
Initiating	 ibandronate	 treatment	 (10µg/kg/day)	 upon	 appearance	 of	 osteolytic	 lesions	 in	
femurs	 of	 rats	 reduced	 progression	 of	 these	 lesions	 however,	 tumour	 growth	 was	 not	
eliminated	 [144].	 In	 contrast,	 when	 ibandronate	 treatment	 was	 started	 3	 days	 prior	 to	
tumour	cell	injection,	the	development	of	osteolytic	lesions	was	inhibited	and	expansion	of	
osteolytic	areas	slowed	down	[144].	In	agreement	with	this,	a	study	by	van	der	Pluijm	et	al.	
showed	that	pre-treatment	(2	days	prior	to	injection	of	MDA-231-B/luc+)	with	olpadronate	
(1.6µmol/kg/day),	 delayed	 the	 progression	 and	 decreased	 the	 development	 of	 bone	
metastases	 in	 addition	 to	 reducing	 the	 establishment	 of	 osteolytic	 lesions	 [257].	 The	
authors	 suggest	 that	 preventative	 schedules	 reduce	 tumour	 growth	 by	 inhibiting	 the	
release	 of	 tumour	 growth	 factors	 by	 osteoclastic	 bone	 resorption,	 a	 mechanism	 well	
known	for	driving	progression	of	cancer-induced	bone	disease	[257].	Additionally	BPs	have	
shown	 to	 inhibit	 invasion,	 a	pre-requisite	 for	 the	establishment	of	metastatic	disease,	of	
PC-3	 and	MDA-MB-231	 prostate	 and	 breast	 cancer	 cells	 in	 in	 a	 dose	 dependent	 fashion	
with	ZOL	being	the	most	potent	agent	[142].		
Taken	together	 these	data	suggest	 that	 the	bone	metastasis	niche	generates	a	beneficial	
microenvironment	 for	 disseminated	 tumour	 cells	 in	 bone	 and	 that	 osteoblasts	might	 be	
one	of	the	key	components	of	this	niche.	 	
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3.3. Hypotheses	
• A	 single	 dose	 of	 ZOL	 rapidly	 alters	 the	 cellular	 and	 extracellular	 composition	 of	 the	
bone	metastasis	niche.	
• ZOL-induced	modification	of	 the	bone	metastasis	niche	alters	 tumour	 cell	 homing	 to	
bone	and	metastatic	outgrowth	in	vivo.		
3.4. Aims	and	Objectives	
• Establish	 the	 early	 effects	 (Day	 3-10)	 of	 a	 single,	 clinically	 relevant	 dose	 of	 ZOL	
(100µg/kg)	on	the	bone	metastasis	niche	in	vivo	by	assessing	alterations	in		
o Osteoblast	number	and	activity	
o Osteoclast	number	and	activity	
o Extracellular	matrix	composition	
o Bone	marrow	vasculature	
• Determine	 if	 the	presence	of	 tumour	 cells	 in	bone	 is	altered	when	 they	encounter	a	
ZOL-modified	microenvironment.	
o Do	tumour	cells	home	to	specific	areas	in	bone?	
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3.5. Material	and	methods	
Methods	not	described	below	can	be	found	in	the	general	methods	section,	Chapter	2.		A	
summary	of	methods	applied	is	listed	in	Table	7	below.	
Table	7	Summary	of	methods	applied	in	Chapter	3	
Method	 Parameters	analysed	 Equipment	
Microcomputed	
tomography		
-Trabecular	bone	volume	
(BV/TV	in	%)	
-Trabecular	number		
(TB.N.	in	mm-1)	
-Trabecular	thickness	
(Tb.Th.	in	mm)	
-SkyScan	1172/1272	scanner	(SkyScan)	
-NRecon	software	
-CTAn	software	
Histological	assessment	
Tartrate-resistant	
acid	phosphatase	
staining	(TRAP)	
-Osteoclast	number	per	mm	
of	trabecular	bone	surface	
-Osteoclast	size	(in	mm2)	
-OsteoMeasure	software	(OsteoMetrics)	
-Leica	DMRB	upright	microscope	
Haematoxylin	and	
Eosin	staining	
(H&E)	
-Osteoblast	number	per	mm	
trabecular	bone	surface	
-OsteoMeasure	software	(OsteoMetrics)	
-Leica	DMRB	upright	microscope	
-Olympus	BX53	microscope	
Toluidine	blue	
staining	
-Alterations	in	growth	plate	
area	
-Visualise	proteoglycan	
-Quantification	of	growth	
late	area	per	tissue	area	
-OsteoMeasure	software	(OsteoMetrics)	
-Leica	DMRB	upright	microscope	
Immunofluoresce
nce/confocal	
microscopy	
-Visualisation	of	Endomucin	
positive	vascular	endothelial	
cells		
	
-Leica	DMI4000B	microscope	(20x	objective)		
-Leica	AF6000LX	inverted	microscope	(20x	
objective)		
-	LAS	AF	Lite	software	
-Nikon	A1	confocal	microscope	with	NIS	
Elements	software	(40x	objective)	
-Nikon	inverted	Ti	eclipse,	NIS-Elements	
software	Version	4.30,	Plan	Apo	20x	(NA	0.75)	
-Cryostat	(MICROM	HM560)	
Tumour	cell	homing	to	bone	
Two-photon	
microscopy	
-Presence	of	tumour	cells	in	
bone	
-Bright	 OTF	 Cryostat	with	 a	 3020	microtome	
(Bright	Instrument	Co.	Ltd,	Huntingdon,	UK)	
-Zeiss	 LSM510	 NLO	 upright	
multiphoton/confocal	 microscope	 (Carl	 Zeiss	
Inl,	Cambridge,	UK).	A	20x/0.8	lens	
-LMS	software	version	4.2	(Zeiss)	
-Volocity	 3D	 Image	 Analysis	 software	 6.01	
(PerkinElmer,	Cambridge,	UK)	
Flow	cytometry	 -	Presence	of	tumour	cells	in	
bone	marrow	and	blood	
-FACS	Calibur	
Enzymatic	analysis	
MouseTRAPTM	
Assay	
-Osteoclast	activity	 -MouseTRAPTM	Assay	from	immunodiagnostic	
systems	(SB-TR103)	
	
Rat/Mouse	PINP	
Enzyme	
immunoassay	
-Osteoblast	activity	 -Rat/Mouse	PINP	Enzyme	immunoassay	for	
the	quantitative	determination	of	N-terminal	
propeptide	of	type	I	procollagen	from	
immunodiagnostic	systems	
Statistical	analysis	
Statistical	analysis	 -Experimental	datasets	 -Prism	GraphPad	
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3.5.1. Cell	lines		
The	 triple	 negative	 MDA-MB-231-NW1-luc2	 cell	 line	 was	 kindly	 provided	 by	 Dr.	 Wang,	
University	of	Sheffield,	UK.	For	collaborative	experiments	with	Dr.	McAllister,	Boston	USA	
the	MDA-MB-231-GFP-IV	cells,	stably	transfected	with	e-GFP	by	Dr.	Ottewell,	University	of	
Sheffield,	was	used.	The	here	used	MDA-MB231-GFP-IV	cell	line	is	derived	from	MDA-MB-
231	cells	that	underwent	repeated	passaging	in	vivo,	however	does	not	have	the	full	bone-
homing	phenotype	described	in	[258].	The	MDA-MB231-B02-FII	was	kindly	provided	by	J.	
Ubellacker,	Harvard	School	of	Medicine,	USA.	Cell	cultures	were	maintained	as	described	in	
Chapter	2,	Section	2.2.3.		
3.5.2. Substance	preparation	
3.5.2.1. Zoledronic	acid	
Zoledronic	 acid	 (ZOL)	 was	 supplied	 as	 the	 hydrated	 disodium	 salt	 ([1-hydroxy-2-1H-
imidazol-1-yl)ethylene]bisphosphonic	 acid	 	 from	 Novartis.	 The	 drug	 suspension	 at	 a	
concentration	of	100µg/kg	was	prepared	 fresh	on	 the	day	of	 injection	 in	PBS	and	 sterile	
filtered	 (45µm	 filter)	 prior	 to	 intraperitoneal	 injection	 (100µL)	 using	 1mL	 syringes,	 25-
gauge	needle.	
3.5.3. Experimental	design		
Intracardiac	 tumour	 cell	 injections	 in	 this	 chapter	 have	 been	 performed	 by	 Dr.	 Hannah	
Brown,	University	of	 Sheffield.	Until	 the	 receipt	of	my	Home	Office	Personal	 License	 she	
kindly	performed	the	ZOL	or	PBS	treatments.	For	collaborative	experiments,	 in	vivo	work	
was	performed	by	Jessalyn	Ubellacker,	Boston,	USA.	
3.5.3.1. Establishing	short-term	effects	of	ZOL	on	the	bone	microenvironment	in	vivo	
The	early	effects	of	a	single	dose	of	ZOL	on	osteoblasts	and	osteoclasts	were	elaborated	in	
6-week	 old	 immunocompromised	 BALB/c	 nude	mice	 (n=3-4/group;	 BALB/c-Nude[Foxn1-
Crl],	Charles	River,	UK).	Collaborative	experiments	with	Dr.	Sandra	McAllisters	group	were	
performed	 using	 6-week	 old	 female	 NCr-Nu	 (nude),	 CrTac:NCr-Foxn1nu	 	 mice	 (herein	
referred	 to	 as	 NCr-Nu	 (nude).	 In	 these	 experiments	 1X	 Hank’s	 Balanced	 Buffer	 Solution	
(HBSS)	was	used	as	a	vehicle	control.	
Experimentally	animals	were	randomised	into	two	groups	and	received	a	single	dose	of	(1)	
Zoledronic	 acid	 (100µg/kg,	 100µL,	 i.p.,	 equivalent	 to	 the	 4mg	 infusion	 used	 in	 the	
treatment	of	cancer-induced	bone	disease	[241])	or	(2)	sterile	vehicle	control	(100µL,	i.p.)	
on	day	0.	Previous	studies	 in	 immunocompromised	and/or	 immunocompetent	mice	have	
shown	 no	 effect	 of	 ZOL	 on	 bone	 and	 bone	 cells	 24hrs	 after	 a	 single	 dose,	 but	 reduced	
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osteoblast	and	osteoclast	numbers	on	day	15	post	 treatment	when	compared	 to	control	
[154,	158].	To	determine	how	quickly	ZOL	affects	the	BME,	mice	were	culled	3,	5,	8	and	10	
days	after	treatment	–	See	Fig.13.	
	
	
Figure	13	Experimental	outline	–	Establish	early	effects	of	Zoledronic	acid	on	the	in	vivo	bone	
microenvironment.		
To	 determine	 the	 early	 effects	 of	 Zoledronic	 acid	 (ZOL)	 on	 the	 in	 vivo	 BME	 6-week	 old	 female	
BALB/c	nude	 (n=3-4/group)	 or	NCr-Nu	 (nude),	 CrTac:NCr-Foxn1nu	mice	 	 (n=5/group)	were	 treated	
with	a	single,	clinically	relevant	dose	of	ZOL	(100µg/kg,	100µL,	 i.p.)	or	vehicle	control	(100µL,	 i.p.).	
Samples	(indicated	by	green	and	red	arrow	head)	were	collected	3,	5,	8	and	10	days	post	injection.	
	
3.5.3.2. Establishing	 if	 therapeutic	modification	of	 the	bone	microenvironment	with	
ZOL	alters	tumour	cell	homing	to	bone	
To	establish	if	therapeutic	modification	of	the	BME	with	ZOL	affects	tumour	cell	homing	to	
bone	 and	whether	 osteoblasts	 are	 key	 components	 of	 the	 bone	metastasis	 niche	 8–13-
week	 old	 female	 immunocompromised	mice	 expressing	 GFP+ve	 cells	 of	 the	 osteoblastic	
lineage	 were	 used	 (homozygote	 and	 heterozygote	 nude,	 BALB/cAnNCrl.Cg-Tg(Col1a1-
GFP)Row	Foxn1nu/nu,	described	in	greater	detail	in	[158],	referred	to	as	GFP-Ob+,	n=4/group	
for	 2	 independent	 experiments).	Mice	were	 randomised	 and	 received	 either	 (1)	 a	 single	
dose	 of	 ZOL	 (100µg/kg,	 100µL,	 i.p.)	 or	 (2)	 sterile	 PBS	 control	 (100µL,	 i.p.)	 on	 day	 0.	 To	
assess	 if	 tumour	 cell	 homing	 to	 bone	 is	 altered	when	 the	 cells	 arrive	 in	 a	 ZOL-modified	
BME,	animals	were	injected	intracardiac	with	1x105	DiD	labelled	MDA-MB-231-NW1	(luc2	
positive)	breast	cancer	cells	on	day	5,	 the	 time	point	where	ZOL-induced	modification	of	
the	BME	reached	its’	peak.	Samples	were	collected	on	day	10	–	see	Fig.14.	
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Figure	14	Experimental	outline	to	establish	the	effects	of	Zoledronic	acid	pre-treatment	on	
tumour	cell	homing	to	bone.		
Effects	of	ZOL	pre-treatment	were	established	in	8-13-week	old	female	mice	expressing	GFP+	cells	
of	the	osteoblastic	lineage	(n=4/group	for	two	individual	experiments,	GFP-Ob+).	Mice	were	treated	
with	a	single	dose	of	Zoledronic	acid	(100µg/kg,	100µL,	i.p.,	ZOL)	or	PBS	control	(100µL,	i.p.).	5	days	
post	 injection	 1x105	 DiD	 labelled	 MDA-MB-231-NW1-luc2	 breast	 cancer	 cells	 were	 injected	
intracardiac.	
	
To	further	characterise	the	effects	of	ZOL	on	tumour	cell	homing	to	bone	I	collected	bone	
samples	 from	 collaborative	 experiments	 performed	 in	 Dr.	 Sandra	McAllisters	 laboratory,	
Brigham	and	Women’s	hospital,	Boston,	USA.	In	these	experiments	6-week	old	female	NCr-
Nu	 (nude),	 CrTac:NCr-Foxn1nu	 	mice	 	were	 injected	with	 a	 single	dose	of	 ZOL	 (100µg/kg,	
100µL,	 i.p.)	 or	 HBSS	 (100µL,	 i.p.)	 on	 day	 0.	 Three	 days	 post	 treatment	 both	 control	 and	
treated	mice	were	randomly	assigned	 into	 two	groups	 receiving	 (1)	1x105	cM-DiI	 labelled	
MDA-MB-231-B02-FII	or	(2)	1x105	CM-DiI	labelled	MDA-MB-231-GFP-IV	cells	(i.c.).	Samples	
were	 collected	 5	 days	 post	 cancer	 cell	 inoculation	 (day	 8)	 –	 See	 Fig.15.	 McAllister	 and	
colleagues	were	most	interested	in	assessing	the	effects	of	a	single	dose	of	ZOL	on	HSCs	in	
vivo,	 with	 potential	 to	 further	 establish	 consequences	 on	 tumour	 cell	 homing	 and	
metastatic	outgrowth	in	bone.	These	studies	have	shown	rapid	effects	on	HSCs	72hrs	post	
ZOL	 treatment	 in	 the	NCr-Nu	 (nude)	mice,	 hence	 the	 intracardiac	 inoculation	 of	 tumour	
cells	72hrs	post	pre-treatment.	
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MDA"MB231"NW1"luc2&breast&cancer&cells&were&injected&intra&cardiac&and&eﬀects&on&tumour&cell&homing&
to&bone&assessed&on&day&10.&
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Figure	15	Experimental	outline	–	Collaborative	experiments	
In	collaborative	experiments	the	effects	of	ZOL	pre-treatment	on	tumour	cell	homing	to	bone	were	
established	in	6-week	old	female	NCr-Nu	(nude),	CrTac:NCr-Foxn1nu	mice	(n=5/group).	Animals	were	
treated	with	a	single	dose	of	ZOL	 (100µg/kg,	100µL,	 i.p.)	or	HBSS	control	 (100µL,	 i.p.).	Three	days	
post	 injection	 1x105	 cM-DiI-	 labelled	MDA-MB-231-GFP-IV	 or	MDA-MB-231-B02-FII	 breast	 cancer	
cells	were	 injected	 intracardiac	 and	 effects	 on	 tumour	 cell	 homing	 to	 bone	 assessed	 on	 day	 8	 (5	
days	 post	 i.c.	 injection).	 Here	 I	 collected	 bone	 samples	 to	 visualise	 tumour	 cells	 in	 proximity	 to	
vascular	endothelial	cells.	
3.5.3.3. Pilot	 experiment	 to	 establish	 if	 pre-treatment	 with	 a	 single	 dose	 of	 ZOL	
affects	the	development	of	bone	metastasis	
To	 establish	 the	 consequences	 of	 ZOL	 pre-treatment	 on	 the	 development	 of	 bone	
metastasis,	immunocompromised	6-week	old	female	GFP	Ob+	mice	received	a	single	dose	
of	ZOL	(100µg/kg,	100µL,	i.p.)	or	PBS	(100µL)	on	day	0	followed	by	intracardiac	injection	of	
1x105	MDA-MB-231-NW1-luc2	 cells	 (performed	by	Dr.	HK	Brown,	University	of	 Sheffield)	
on	 day	 5	 as	 described	 in	 Chapter	 2,	 section	 2.2.8.2	 (n=6/group).	 Development	 of	 bone	
metastases	was	monitored	2x	weekly	using	bioluminescence	signalling	and	visualised	using	
the	IVIS	system	as	described	in	Chapter	2,	section	2.2.9.	This	experiment	was	performed	in	
2	“batches”	(6	days	apart	between	experiment	start)	due	to	a	subset	of	mice	having	lower	
body	weight	 thus	potentially	complicating	recovery	 from	 intracardiac	 injections.	Data	are	
represented	as	mean	tumour	number	per	mouse	and	corresponding	time	points	for	each	
“batch”	pooled	(e.g.	tumour	growth	on	day	11	post	i.c.	injection	from	experiment	1	pooled	
with	day	12	post	 i.c.	 injection	 from	experiment	2).	The	experiment	was	terminated	upon	
observation	of	first	signs	of	morbidity	(Day	32	and	36	respectively).	
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3.5.4. Sample	collection	and	analysis	
3.5.4.1. Bone	cell	quantification	on	histological	sections	
Osteoblasts	 and	 osteoclasts/mm	 trabecular	 bone	 surfaces	 were	 scored	 on	 2	 non-serial	
histological	 sections	 (3µm,	 H&E	 or	 TRAP-stained)	 using	 OsteoMeasure	 as	 described	 in	
Chapter	2,	Section	2.2.10.7.1.	
3.5.4.2. Quantification	of	the	proteoglycan-rich	area		
Toluidine	 blue	 staining	 to	 visualise	 ZOL-induced	 alterations	 to	 extracellular	 matrix	
composition	 was	 performed	 as	 described	 in	 Chapter	 2,	 Section	 2.2.10.5.3.	 The	
proteoglycan-rich	 area	 in	 the	 bone	 (in	 particular	 in	 the	 epiphysis)	 was	 quantified	 using	
OsteoMeasure	 software	 (OsteoMetrics),	 Leica	 DMRB	 upright	 microscope	 and	 a	 2.5x	
objective.	 It	was	 interactively	 drawn	around	 the	 area	of	 interest	 (AOI),	which	 comprised	
the	 proteoglycan-rich	 growth	 plate	 and	 all	 trabecular	 bone	 surfaces	 (with	 dark	 purple	
staining)	 directly	 connected	 to	 the	 epiphysis	 (see	 Fig.16	 for	 schematic	 illustration).	 All	
cortical	bone	surfaces	were	excluded	from	analysis	as	well	as	trabecular	bone	surfaces	not	
directly	connected	to	the	dense	network	of	trabeculi	at	the	epiphysis	–	see	Figure	16.	
3.5.4.3. Bone	cell	activity	
Serum	was	collected	as	described	in	Section	2.2.10.1,	Chapter	2	and	PINP	levels	(osteoblast	
activity)	 or	 TRAP	 levels	 (osteoclasts)	 measured	 using	 ELISA	 according	 to	 manufacturers	
instructions	(Section	2.2.10.8.1/2,	Chapter	2).	For	collaborative	experiments	the	PINP	ELISA	
was	 performed	 in	 conjunction	with	 J.	 Ubellacker,	 using	 plasma	 samples	 of	mice	 treated	
with	ZOL	or	PBS.	 In	 these	experiments	 the	Mouse	procollagen	 I	N-terminal	peptide,	PINP	
ELISA	Kit	(MyBioSource		MBS703389)	was	used.		
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Figure	16	Quantification	of	extracellular	matrix	(ECM)/	proteoglycan	rich	area	in	bone.		
Using	OsteoMeasure	 software	 it	was	 interactively	 drawn	around	 the	 area	of	 interest	 (AOI)	which	
covered	 the	proteoglycan-rich	epiphysis	 and	all	 trabecular	bone	 surfaces	directly	 connected	 to	 it.	
Bone	 disconnected	 from	 the	 trabeculi	 extending	 the	 epiphysis	 were	 excluded	 from	 analysis	 (red	
circle).	OsteoMeasure	software	was	used,	using	an	Leica	DMRB	upright	microscope,	2.5x	objective.	
Proteoglycan-rich	matrix	 area	 (in	mm2)	was	 quantified	 for	 a	 total	 region	 of	 interest	 of	 1mm2	 for	
each	 sample.	 All	 cortical	 bone	 surfaces	 were	 excluded	 from	 analysis.	 Toluidine	 blue	 stained	
histological	sections	of	tibiae	were	used	for	quantification	(3µm	thick,	paraffin	embedded)	
3.5.4.4. Bone	samples	for	µCT	analysis	
µCT	 analysis	 for	 6-week	 old	 female	 BALB/c	 nude	 mice	 was	 performed	 as	 described	 in	
Section	2.2.10.4,	Chapter	2.	For	NCr-Nu	 (nude)	mice	a	SkyScan	1272	 (SkyScan)	was	used.	
Femurs	 were	 scanned	 using	 200mA,	 51kV,	 a	 0.5mm	 aluminium	 filter,	 medium	 camera	
resolution	 of	 2016x1344	 and	 pixel	 size	 set	 to	 4.3µm.	 Images	 were	 reconstructed	 using	
NRecon	 software	 and	 a	 bone	 volume	 of	 interest	 (VOI)	 was	 determined	 by	 interactively	
drawing	on	 the	 two-dimensional	 images.	Analysis	was	 started	 from	a	 fixed	offset	0.7mm	
away	from	the	lower	part	of	the	growth	plate	covering	a	length	of	1.5mm.	Obtained	grey	
scale	 images	of	 the	VOI	were	converted	 into	binary	 images	 (threshold	95-225)	and	bone	
parameters	calculated	using	CTAn	software.	
AOI$
Excluded$from$analysis,$not$connected$to$
trabecular$bone$surfaces$extending$from$
the$epiphysis$
Area$of$1mmx1mm$
Extracellular$matrix$rich$area$in$metaphysis$!$
Area$of$Interest$(AOI)$
Quan?ﬁca?on$of$extracellular$matrix$(ECM)/$proteoglycan$rich$area$in$bone.$Using&
s eomeasure&so.w re&it&was&interac1vely&drawn&around&the&area&of&interest&(AOI)&
which&covered&the&proteoglycan>rich&epiphysis&and&all&&trabecular&bone&surfaces&
directly&connected&to&it.&Bone&disconnected&from&the&trabeculii&extending&the&
epiphysis&were&excluded&from&analysis&(red&circle).&Osteomeasure&so.ware&was&used,&
using&an&Leica&RMRB&upright&microscope,&2.5x&objec1ve.&Proteoglycan>rich&matrix&area&
(in&mm2)&was&quan1ﬁed&for&a&total&region&of&1mm2&for&each&sample.&All&cor1cal&bone&
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3.5.4.5. Bone	samples	for	two-photon	microscopy	
To	 visualise	 presence	 of	 single	 tumour	 cells	 in	 bone	 using	 two-photon	 microscopy	
dissected	bones	were	wrapped	in	foil	on	day	of	sacrifice,	snap	frozen	in	lN2	and	stored	at	-
80°C.	 One	 day	 before	 analysis	 bones	 were	 embedded	 in	 Optimal	 Cutting	 Temperature	
(OCT)	 medium	 (VWR,	 361603E)	 in	 plastic	 moulds	 and	 left	 to	 settle	 at	 -80°C.	 On	 day	 of	
analysis	the	growth	plate	was	exposed	using	a	Bright	OTF	Cryostat	with	a	3020	microtome	
(Bright	 Instrument	Co.	 Ltd,	Huntingdon,	UK).	 For	 imaging	 the	 tibia	was	placed	on	a	glass	
bottom	dish	with	the	exposed	growth	plate	facing	downwards,	covered	by	aluminium	foil	
and	immediately	taken	to	the	Zeiss	LSM510	NLO	upright	multiphoton/confocal	microscope	
(Carl	Zeiss	 Inl,	Cambridge,	UK).	A	20x/0.8	 lens	and	visual	 light	were	used	 to	 focus	on	 the	
edge	 of	 the	 growth	 plate	 prior	 to	 visualisation	 of	 bone	 and	 tumour	 cells	 using	
corresponding	lasers.	LMS	software	version	4.2	(Zeiss)	was	used,	MTS	files	and	temporary	
databases	 were	 generated	 for	 each	 individual	 sample	 and	 a	 stack	 area	 of	 2104μm	 x	
2525μm	with	70μm	depth	captured.	Presence	of	CM-DiI	and	DiD	labelled	tumour	cells	was	
visualised	 using	 a	 543nm	 and	 633nm	 laser	 respectively.	 	 Bone	 was	 visualised	 using	 the	
900nm	laser	(Coherent,	Santa	Clara,	CA.).	Quantification	of	DiD+ve	events	within	selected	
regions	 of	 interest	 was	 analysed	 using	 the	 Volocity	 3D	 Image	 Analysis	 software	 6.01	
(PerkinElmer,	 Cambridge,	 UK).	 Two-photon	 microscopy	 and	 analysis	 to	 quantify	 the	
presence	 of	 DiD+ve	 tumour	 cells	 was	 kindly	 performed	 by	 Dr.	 HK	 Brown,	 University	 of	
Sheffield	UK	(Fig.32).	Once	trained	on	the	two-photon	microscope	I	indeed	performed	the	
two-photon	 scans	 for	 a	 subset	 of	 samples	 from	 collaborative	 experiments	 described	 in	
Fig.17,	 to	 visualise	 the	 presence	 of	 CM-DiI+ve	 MDA-MB-231-B02-FII	 cells	 in	 bone	 (see	
Figure	33/34).	
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Figure	17	Experimental	setup	for	two-photon	analysis.		
(A&B)	 shows	 the	 set	 up	 of	 the	 bone	 sample	 for	 two-photon	 analysis,	 (C)	 representative	 laser	
settings	 (top)	 and	 tile	 scan	 settings	 (bottom)	 for	 the	 detection	 of	 CM-DiI	 positive	 tumour	 cells	 in	
bone	for	collaborative	experiments.	Multi	Time	Series	(MTS)	settings	are	illustrated	in	(D).	
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3.5.4.6. Flow	cytometry	
Presence	of	DiD+ve	 tumour	cells	 in	 the	bone	marrow	and	circulation	was	assessed	using	
flow	cytometry.	Briefly,	whole	blood	was	collected	in	syringes	pre-wetted	with	heparin	and	
total	blood	volume	retrieved	from	each	mouse	recorded.	Red	blood	cells	were	lysed	using	
the	Whole	blood	erythrocyte	 lysing	kit	(R&D)	according	to	manufacturers	 instructions.	To	
collect	bone	marrow,	hind	 legs	were	dissected	and	 the	end	bit	 of	 the	bones	 cut	off	 and	
bone	marrow	flushed	by	inserting	a	25G	needle	attached	to	a	10mL	syringe	filled	with	PBS.	
Flushing	was	repeated	until	the	bones	appeared	translucent	and	samples	pooled	for	each	
treatment	group.	Bone	marrow	 flushes	were	centrifuged	at	1500rpm	(MSE	mistral	2000;	
≈403xg)	 for	 3min	 at	 ambient	 temperature,	 the	 supernatant	 discarded	 and	 cell	 pellets	
resuspended	 in	 1X	 Whole	 blood	 erythrocyte	 lysing	 kit	 (R&D).	 Red	 blood	 cell	 lysis	 was	
performed	according	to	manufacturers	guidelines.	Samples	were	passed	through	a	70µm	
nylon	cell	 strainer	prior	 to	analysis	 in	PBS	containing	10%	FBS.	The	number	of	circulating	
DiD+ve	events	was	assessed	by	flow	cytometry	using	the	Red	633nm	laser	on	the	LSRII	flow	
cytometer	(BD	Biosciences).	Flow	cytometry	samples	were	run	by	the	Flow	Cytometry	Core	
Facility,	 University	 of	 Sheffield.	 Bone	 marrow	 and	 blood	 samples	 were	 pooled	 for	 each	
treatment	group	respectively,	and	experiments	repeated	twice.	 
3.5.4.7. Visualise	presence	of	tumours	cells	at	experimental	endpoint		
To	 visualise	 presence	 of	 established	 tumours	 in	 organs	 and	 bones	 at	 experimental	
endpoint,	organs	and	bones	were	excised	and	bioluminescence	signal	was	visualised	using	
the	IVIS	system.	
3.5.4.8. Ex	vivo	organ	cultures	
To	establish	whether	ZOL	treatment	causes	tumour	cells	to	home	to	other	(non	bone)	sites	
ex	 vivo	 organ	 cultures	 of	 lung,	 liver,	 brain,	 spleen,	 remaining	 bone	 marrow	 and	 blood	
suspensions	were	prepared.	Briefly,	organs	were	mechanically	disrupted	using	scissors	and	
scalpels,	 passed	 through	 a	 100µm	 cell	 strainer	 and	 plated	 into	 6-well	 plates	 containing	
DMEM	+	GlutaMAX	+	Pyruvate	supplemented	with	10%FCS,	5%	Pen	Strep,	5%	fungizone.	
After	48hrs	growth	media	was	additionally	supplemented	with	1	mg/mL	G418	to	select	for	
MDA-MB-231-NW1-luc2	 breast	 cancer	 cells	 using	 antibiotic	 pressure.	 Medium	 was	
changed	every	other	day	and	cells	 left	 to	grow	for	2	weeks	at	37°C,	5%	CO2.	Tumour	cell	
growth	was	then	visualised	by	bioluminescence	using	IVIS.	
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3.5.4.9. Visualisation	of	ZOL-induced	alterations	to	the	bone	marrow	vasculature		
Immunofluorescence	 staining	 against	 the	 vascular	 endothelial	 cell	 marker	 Endomucin	
(1:100,	 Endomucin	 V.7C7,	 rat	 monoclonal,	 Santa	 Cruz,	 sc-65495)	 and	 CD31	 (1:100,	 DIA-
310:	 Anti-CD31	 (Ms)	 from	 Rat	 (Clone:	 SZ31))	 was	 performed	 to	 visualise	 ZOL-induced	
effects	 on	 bone	 marrow	 vasculature	 as	 described	 previously	 in	 Chapter	 2,	 Section	
2.2.10.6.2.2.			
3.5.4.10. Statistical	Analysis	
Statistical	 analysis	was	 performed	 using	 GraphPad	 Prism	 Version	 6.0.	 Analysis	was	 done	
using	 unpaired	 Student’s	 t-test	 or	 2-way	 ANOVA	 with	 Bonferroni’s	 post-test.	 Statistical	
tests	 applied	 are	 specified	 underneath	 the	 corresponding	 figures	 or	 if	 no	 graphs	 are	
presented	next	to	the	raw	data.	
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3.6. Results	
I	first	established	the	effects	of	a	single,	clinically	relevant,	dose	of	ZOL	(100µg/kg,	i.p.)	on	
bone	and	key	bone	cells	in	6-week	old	female	BALB/c	nude	mice,	the	xenograft	model	later	
used	in	all	tumour	studies.	Establishing	the	duration	of	the	effects	of	a	single	dose	of	ZOL	in	
this	 animal	model	was	 of	 great	 importance	 as	 the	majority	 of	 studies	 published	 to	 date	
have	used	 repeated	and/or	clinically	 irrelevant	dosing	 schedules	 [38,	159,	183,	241,	247,	
259,	260].	This	enabled	the	design	of	later	experiments	so	that	the	arrival	of	tumour	cells	
in	 bone	 coincided	 with	 the	 time	 point	 when	 ZOL-induced	 alterations	 to	 the	 BME	 had	
reached	their	peak.	
3.6.1. A	single	dose	of	ZOL	rapidly	affects	bone	volume	and	structure	
The	early	effects	of	ZOL	(100µg/kg)	on	trabecular	and	cortical	bone	volume	of	tibiae	were	
established	3,	5	and	10	days	post	treatment	using	µCT	analysis.		
As	 early	 as	 3	 days	 after	 a	 single	 dose	 of	 ZOL	 trabecular	 bone	 volume	 (bone	
volume/tissue	 volume	 in	 %)	 of	 tibiae	 was	 nearly	 doubled	 when	 compared	 to	 control	
(p≤0.01,	Fig.18A,	Table	8).	The	increase	in	trabecular	bone	volume	was	maintained	10	days	
after	 injection	 (p≤0.01,	 Fig.18A,	 Table	 8).	 Similarly,	 ZOL	 increased	 trabecular	 number	 on	
day	3	(p≤0.05;	≈63%	increase)	and	10	(p≤0.01;	≈71%	increase)	when	compared	to	control	
(Fig.18B,	Table	8).	Trabecular	thickness	was	significantly	elevated	3	days	(p≤0.05,	Fig.18C,	
≈16%	increase,	Table	8)	post	ZOL	treatment	whereas	a	reduction	was	determined	on	day	
10	 (p≤0.05,	 Fig.18C,	 Table	 8,	 ≈12.5%	 decrease).	 Representative	 µCT	 cross	 sections	 are	
shown	in	Fig.18E&F.	
Table	8	Effects	of	a	single	dose	of	Zoledronic	acid	(ZOL,	100µg/kg)	on	bone.			
Trabecular	 bone	 volume	 (BV/TV	 in	%),	 trabecular	 thickness	 (Tb.Th.	 in	mm)	 and	 number	 (Tb.N.	 in	
mm-1)	was	assessed	3,	5	and	10	days	post	treatment.	ns	is	non-significant,	*	is	p≤0.05,	**	is	p≤0.01;	
2-way	ANOVA	with	Bonferroni	post-test,	data	show	Mean±SEM,	n=3	PBS,	n=4	ZOL.	
	 BV/TV	(%)	 Tb.Th.	(mm)	 Tb.N.	(mm-1)	
Day	 PBS	 ZOL	 p	 PBS	 ZOL	 p	 PBS	 ZOL	 p	
3	 7.21	±	
1.39	
13.40	±	
1.18	
**	 0.032	±	
0.001	
0.037	±	
0.001	
*	 2.25	±	
0.36	
3.66	±	
0.28	
*	
5	 12.60	±	
1.20	
15.28	±	
1.20	
ns	 0.036	±	
0.001	
0.036	±	
0.001	
ns	 3.52	±	
0.37	
4.27	±	
0.42	
ns	
10	 11.25	±	
1.30	
17.01	±	
0.95	
*	 0.040	±	
0.001	
0.035	±	
0.001	
*	 2.80	±	
0.23	
4.81	±	
0.22	
**	
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Figure	18	Effects	of	a	single	dose	of	Zoledronic	acid	on	bone	volume	and	structure	of	tibiae.		
6-week	old	female	BALB/c	nude	mice	received	a	single	dose	of	Zoledronic	acid	(ZOL,	100µg/kg,	i.p.)	
or	sterile	PBS	control	on	day	0.	(A)	Effects	on	trabecular	bone	volume	(in	%	),	(B)	number	(in	mm-1)	
and	(C)	thickness	(in	mm)	were	determined	using	µCT	analysis.	Effects	on	cortical	bone	volume	(in	
mm3)	are	shown	in	(D).	n=3	for	PBS,	n=4	for	ZOL,	*	is	p≤0.05,	**	is	p≤0.01,	ns	is	non-significant,	Two-
way	 ANOVA	 with	 Bonferroni	 post-test,	 data	 show	 Mean±SEM.	 (E)	 shows	 representative	 cross	
sections	 from	 tibiae	 10	 days	 after	 (PBS)	 and	 (F)	 100µg/kg	 ZOL	 injection,	 0.5mm	 away	 from	 the	
epiphyseal	growth	plate.	
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I	 could	not	detect	a	 significant	 increase	 in	 trabecular	bone	volume	 (HBSS:	8.13	±	
1.09%	vs.	ZOL:	10.56	±	1.06%)	and	number	(HBSS:	2.37	±	0.24mm-1	vs.	ZOL:	3.23	±	0.29mm-
1)	 3	days	post	 ZOL	 treatment	 relative	 to	 the	 control	 cohort	when	analysing	 femurs	of	 6-
week	 old	 NCr-Nu	 (nude),	 CrTac:NCr-Foxn1nu	 mice,	 probably	 due	 to	 the	 small	 sample	
number	and/or	the	early	time	point	post	ZOL	treatment.	
In	 6-week	 old	 female	 BALB/c	 nude	 mice	 cortical	 bone	 volume	 of	 tibiae	 was	
significantly	increased	3	days	after	a	single	dose	of	ZOL	(PBS:	0.51	±	0.05mm3	vs.	ZOL:	0.69	
±	0.04mm3,	p≤0.05,	 Fig.18D).	 The	difference	 in	 cortical	 bone	 volume	5	 and	10	days	post	
injection	did	however	not	reach	statistical	significance	(Day	5:	PBS:	0.65	±	0.06mm3	vs.	ZOL:	
0.76	±	0.02mm3,	Day	10:		PBS:	0.63	±	0.04	vs.	ZOL:	0.74	±	0.04,	Fig.18D).		
To	summarise,	both	trabecular	and	cortical	bone	volume	are	rapidly	increased	following	a	
single	 dose	 of	 ZOL,	 indicating	 substantial	 and	 quick	 response	 of	 bone	 to	 anti-cancer	
therapy	in	this	model	system	(young	mice	with	rapid	bone	turnover).	
3.6.2. A	single	dose	of	ZOL	rapidly	modifies	the	cellular	composition	of	the	BME	
I	 aimed	 to	 provide	 a	 detailed	 characterisation	 of	 the	 effects	 of	 ZOL	 on	 key	 bone	 cells,	
including	 osteoblasts	 and	 osteoclasts.	 In	 addition	 I	 wanted	 to	 determine	 the	 time	 point	
when	ZOL-induced	effects	on	the	BME	had	reached	their	maximum	as	well	as	the	duration	
of	 the	effect(s).	 Therefore	 the	number	of	osteoblasts	and	osteoclasts	per	mm	trabecular	
bone	 surface	 was	 determined	 3,	 5,	 8	 and	 10	 days	 after	 one	 dose	 of	 ZOL	 (100µg/kg)	 or	
control	 on	H&E	 and	 TRAP	 stained	 histological	 sections	 of	 tibiae	 (3µm	 thick,	 2	 non-serial	
levels).	
3.6.2.1. A	single	dose	of	ZOL	rapidly	alters	osteoclasts		
Bisphosphonates	are	potent	 inhibitors	of	osteoclastic	bone	resorption	 inducing	apoptosis	
via	interfering	with	the	mevalonate	pathway	[261].	This	experiment	aimed	to	establish	the	
acute	(Day	3-10)	effects	of	a	single	dose	of	ZOL	on	osteoclast	number,	activity	and	size.		
There	was	a	rapid	and	significant	drop	in	osteoclast	number	3	days	post	 injection	
onwards	 (Day	 3:	 p≤0.0001,	 ≈94%	 reduction;	 Day	 5:	 p≤0.0001,	 ≈89%	 decrease,	 Table	 9,	
Fig.19A).	The	osteoclast	number	 in	ZOL	treated	mice	remained	significantly	decreased	10	
days	post	injection	(Day	10:	p≤0.001,	Table	9,	≈70%	decrease,	Fig.19A)	when	compared	to	
control,	 however	 a	 slight	 increase	 compared	 to	 the	 earlier	 time	 points	 was	 observed.	
Histological	TRAP-stained	sections	illustrating	the	effects	of	ZOL	on	osteoclasts	are	shown	
in	Fig.23	below.	
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Table	9	Effects	of	a	single	dose	of	Zoledronic	acid	on	osteoclast	number.		
Effects	of	a	single	dose	of	Zoledronic	acid	(100µg/kg)	on	osteoclasts	in	6-week	old	BALB/c	nude	mice	
was	 assessed	 on	 two	 non-serial	 histological	 sections	 of	 TRAP	 stained	 tibiae	 3,5	 and	 10	 days	 post	
treatment.	 	***	 is	p≤0.001,	****	 is	p≤0.0001;	2-way	ANOVA	with	Bonferroni	post-test,	data	show	
Mean±SEM,	n=3	PBS,	n=4	ZOL.	
Osteoclast	number/mm	trabecular	bone	surface	
Day	 PBS	 ZOL	 p	
3	 7.30	±	0.50	 0.46	±	0.050	 ****	
5	 8.33	±	1.25	 0.91	±	0.16	 ****	
10	 7.88	±	0.74	 2.40	±	0.60	 ***	
	
Collaborative	 experiments	 with	 Dr.	 McAllisters	 laboratory	 group	 in	 Boston,	 USA	
allowed	me	 to	analyse	 the	effects	of	a	 single	dose	of	ZOL	 (100µg/kg)	on	osteoclasts	 in	a	
different	mouse	model.	 I	was	kindly	provided	with	bone	samples	of	 tibiae	of	6-week	old	
female	 NCr-Nu	 (nude)	 mice.	 In	 agreement	 with	 my	 previous	 experiments,	 a	 significant	
reduction	 in	 osteoclast	 number/mm	 trabecular	 bone	 surface	 compared	 to	 control	 was	
detected	 3	 days	 after	 ZOL	 treatment	 (HBSS:	 	3.51±0.19	 vs.	 ZOL:	 0.30±0.06,	 p≤0.0001,	
Fig.20A),	 slowly	 starting	 to	 return	 to	 control	 levels	 by	 day	 8	 (HBSS:	 3.51±0.56	 vs.	 ZOL:	
1.83±0.22,	p≤0.05,	Fig.20A).		
Morphology	of	the	remaining	osteoclasts	after	ZOL	treatment	appeared	altered	in	
both	 6	 week	 old	 female	 BALB/c	 nude	 and	 NCr-Nu	 (nude)	 however	 this	 did	 not	 reach	
statistical	 significance	 (BALB/c	 nude:	 Day	 3:	 PBS:	 1.05x10-4	 ±	 4.10x10-6mm2	 vs.	 ZOL:	
1.59x10-4	 ±	 3.35x10-5mm2;	 Day	 5:	 PBS:	 9.70x10-5	 ±	 4.16x10-6mm2	 vs.	 ZOL:	 1.67x10-4	 ±	
1.44x10-5mm2;	 Day	 10:	 PBS:	 9.83x10-5	±	 6.69x10-6mm2	vs.	 ZOL:	 1.42x10-4	±	 1.69x10-5mm2,	
Fig.19C,	 NCr-Nu	 (nude):	 (Day	 3:	 HBSS:	 1.99x10-4	 ±	 3.14x10-5	 mm2	 vs.	 ZOL:	 1.21x10-4	 ±	
1.71x10-5	mm2;	Day	8:	HBSS:	1.06x10-4	±	2.14x10-5	mm2	vs.	ZOL:	1.25x10-4	±	1.24x10-5	mm2,	
Fig.20B).	
The	 reduction	 in	 osteoclast	 number	 lining	 trabecular	 bone	 surfaces	 was	 mirrored	 by	 a	
rapid	 and	 significant	 reduction	 in	 serum	 TRAP	 levels	 (used	 as	 a	 measure	 of	 osteoclast	
activity)	 three	 (PBS:	 7.18	 ±	 1.94	U/L	 vs.	 ZOL:	 2.46	 ±	 0.28	U/L,	 p≤0.001,	 Fig.19B)	 and	 five	
(PBS:	5.69	±	0.52	U/L	vs.	 ZOL:	1.97	±	0.08	U/L,	p≤0.01)	days	after	administration	of	ZOL.	
Serum	TRAP	 levels	reached	that	of	control	mice	on	day	10	(PBS:	3.88	±	0.33	U/L	vs.	ZOL:	
2.61	±	0.37	U/L,	Fig.19B)	reflecting	the	osteoclast	quantification	data.		
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Figure	19	Effects	of	a	single	dose	of	zoledronic	acid	on	osteoclasts	in	6-week	old	female	BALB/c	
nude	mice.		
6-week	old	female	BALB/c	nude	mice	received	a	single	dose	of	Zoledronic	acid	(ZOL,	100µg/kg,	i.p.)	
or	sterile	PBS	control	on	day	0.	Effects	on	(A)	osteoclast	number/mm	trabecular	bone	surface,	 (B)	
osteoclast	activity	 (serum	TRAP	 levels)	and	 (C)	osteoclast	 size	was	assessed	3,	5	and	10	days	post	
injection.	n=3	for	PBS,	n=4	for	ZOL,	Day	5:	n=4/group	for	TRAP,	**	is	p≤0.01,***	is	p≤0.001,****	is	
p≤0.0001,	Two-way	ANOVA	with	Bonferroni	post-test,	data	show	Mean±SEM.		
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Figure	20	Effects	of	a	single	dose	of	zoledronic	acid	on	osteoclasts	in	6-week	old	female	NCr-Nu	
(nude)	mice.		
6-week	old	 female	NCr-Nu	 (nude)	mice	 received	 a	 single	 dose	of	 Zoledronic	 acid	 (ZOL,	 100µg/kg,	
i.p.)	 or	 HBSS	 control.	 Effects	 on	 (A)	 osteoclast	 number/mm	 trabecular	 bone	 surface	 and	 (B)	
osteoclast	size	was	assessed	3	and	8	days	post	injection	Day	3:	n=4/group,	Day	8:	n=5	for	PBS,	n=4	
for	ZOL,	****	is	p≤0.0001,	*	is	p≤0.05,	ns	is	non-significant.	Student’s	t-test,	data	show	Mean±SEM.	
	
In	 summary,	 a	 single	 and	 clinically	 relevant	 dose	 of	 ZOL	 rapidly	 affects	 the	 number	 and	
activity	of	osteoclasts	in	vivo.		ZOL-induced	effects	on	osteoclasts	reached	their	peak	3	days	
after	the	single	injection	and	started	to	return	to	control	levels	from	day	10	onwards.	
3.6.2.2. Effects	on	osteoblasts	
To	 establish	 if	 the	 increased	 bone	 volume	 following	 ZOL	 administration	 is	 a	 result	 of	
increased	osteoblast-mediated	bone	formation	the	number	of	osteoblasts	lining	trabecular	
bone	surface	and	their	activity	(measured	by	serum	PINP	levels)	was	determined.		
Interestingly,	osteoblast	number/mm	trabecular	bone	surface	in	ZOL	treated	mice	
decreased	significantly	from	day	5	onwards	when	compared	to	control	(PBS:	14.73	±	1.79	
vs.	 ZOL:	 6.62	 ±	 0.88,	 p≤0.05,	 Fig.22A).	 The	 drop	 in	 the	 number	 of	 osteoblasts	 lining	
trabecular	bone	surfaces	was	even	more	prominent	by	day	10	(PBS:	15.65	±	3.06,	vs.	ZOL:	
5.66	±	0.85,	p≤0.01,	Fig.22A).		Histological	TRAP-stained	sections	illustrating	the	effects	of	
ZOL	on	osteoclasts	are	illustrated	in	Fig.23	below.	The	reduction	in	osteoblast	number	was	
reflected	 by	 a	 drop	 in	 serum	 PINP	 levels	 (used	 as	 a	 measure	 for	 osteoblast	 activity).	
Osteoblast	activity	was	 reduced	 from	day	3	onwards	 (Day	3:	PBS:	281.0	±	76.70	vs.	 ZOL:	
65.62	±	4.69ng/mL,	p≤0.01;	Day	5:	PBS:	157.1	±	55.43ng/mL	vs.	ZOL:	63.00	±	6.03ng/mL;	
Day	10:	PBS:	91.05	±	12.56ng/mL	vs.	ZOL:	78.22	±	12.98ng/mL,	Fig.22B).	
In	 addition	 a	 significantly	 higher	 osteoblast	 per	 osteoclast	 ratio	 compared	 to	
control	mice	(PBS:	2.13	±	0.39%	vs.	ZOL:	21.39	±	3.67%,	p≤0.0001,	Fig.22C)	was	observed	3	
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days	after	the	single	dose	of	ZOL	normalised	to	control	levels	on	day	10	(PBS:	2.48	±	0.69%	
vs.	ZOL:	2.93	±	0.79%	Fig.22C).		
Similar	 effects	were	observed	when	analysing	bone	and	plasma	 samples	 from	6-
week	 old	 female	NCr-Nu	 (nude)	mice	 that	 had	 received	 a	 single	 dose	 of	 ZOL	 (100µg/kg,	
i.p.).	 In	 agreement	with	 the	 effects	 of	 ZOL	 observed	 in	 6-week	 old	 female	 BALB/c	 nude	
mice,	 osteoblast	 number/mm	 trabecular	 bone	 surface	 (Day	 3:	 HBSS:	 9.92±1.64	 vs.	 ZOL:	
2.88±0.68,	p≤0.01;	Day	8:	HBSS:	10.87±1.35	vs.	ZOL:	1.05±0.51,	p≤0.001,	Fig.21A)	and	PINP	
plasma	levels	(Day	3:	PBS:	198.2	±	38.91	pg/mL,	vs.	ZOL:	79.02	±	3.803	pg/mL,	p≤0.05;	Day	
8:	 PBS:	 268.9	 ±	 11.11	 pg/mL	 vs.	 ZOL:	 132.9	 ±	 32.29	 pg/mL,	 p≤0.01,	 Fig.21B)	 were	
significantly	reduced	3	and	8	days	after	the	single	dose	of	ZOL.	
	
	
Figure	21	Effects	of	a	single	dose	of	Zoledronic	acid	on	osteoblasts	in	6-week	old	female	NCr-Nu	
(nude)	mice.		
6-week	old	 female	NCr-Nu	 (nude)	mice	 received	 a	 single	 dose	of	 Zoledronic	 acid	 (ZOL,	 100µg/kg,	
i.p.)	or	sterile	HBSS	control	on	day	0.	Effects	on	(A)	osteoblast	number/mm	trabecular	bone	surface	
and	 (B)	 osteoblast	 activity	 (serum	 PINP	 levels)	 was	 assessed	 3	 and	 8	 days	 post	 injection	 Day	 3:	
n=4/group,	 Day	 8:	 n=5	 for	 PBS,	 n=4	 for	 ZOL,	 ***	 is	 p≤0.001,	 **	 is	 p≤0.01,*	 is	 p≤0.05,	 ns	 is	 non-
significant.	Student’s	t-test,	data	show	Mean±SEM.	
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Figure	22	Effects	of	a	single	dose	of	Zoledronic	acid	on	osteoblasts	in	6-week	old	female	BALB/c	
nude	mice.		
6-week	old	female	BALB/c	nude	mice	received	a	single	dose	of	Zoledronic	acid	(ZOL,	100µg/kg,	i.p.)	
or	sterile	PBS	control	on	day	0.	Effects	on	(A)	osteoblast	number/mm	trabecular	bone	surface,	(B)	
osteoblast	activity	(serum	PINP	levels)	and	(C)	osteoblast/osteoclast	ratio	was	assessed	3,	5	and	10	
days	 post	 injection.	 n=3	 for	 PBS,	 n=4	 for	 ZOL,	 Day	 5:	 n=4/group	 for	 PINP,	 *	 is	 p≤0.05,**	 is	
p≤0.01,****	is	p≤0.0001,	Two-way	ANOVA	with	Bonferroni	post-test,	data	show	Mean±SEM.	
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Figure	23	Histological	TRAP	stained	sections	illustrating	the	effects	of	a	single	dose	of	Zoledronic	
acid	on	osteoblasts	and	osteoclasts	in	vivo.		
6-week	old	female	BALB/c	nude	mice	received	a	single	dose	of	Zoledronic	acid	(ZOL,	100µg/kg,	i.p.)	
or	sterile	PBS	control	on	day	0.	Effects	on	osteoblasts	and	osteoclasts	were	assessed	3,5	and	10	days	
post	injection.	Representative	TRAP	stained	sections	of	tibiae	from	(left	panel)	PBS	and	(right	panel)	
ZOL	treated	mice	are	illustrated.	Black	arrowheads	point	out	osteoblasts,	osteoclasts	are	indicated	
with	black	asterisk.	Tb=	trabecular	bone.	Scale	bar	is	20µm,	40x	objective,	Olympus	BX53.		
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Taken	 together,	 these	 data	 support	 that	 ZOL	 does	 not	 only	 affect	 bone	 resorbing	
osteoclasts	but	also	rapidly	decreased	activity	and	number/mm	trabecular	bone	surface	of	
bone	forming	osteoblasts	in	these	experiments.	
3.6.2.3. Effects	of	Zoledronic	on	extracellular	matrix	composition	
Osteoclasts	 are	 responsible	 for	 initiating	 the	 remodelling	 of	 calcified	 cartilage	 into	
cancellous	 bone.	 At	 the	 edge	 of	 the	 growth	 plate	 newly	 formed	 cartilage	 (either	 from	
chondrocytes	 or	 osteoblasts)	 gets	 resorbed	 by	 osteoclasts.	 To	 determine	 if	 the	 rapid	
reduction	 in	 osteoclast	 number	 and	 activity	 after	 the	 single	 dose	 of	 ZOL	 affects	 the	
presence	of	proteoglycan-rich	extra	cellular	matrix	(ECM)	ZOL-induced	modification	of	the	
proteoglycan	 rich	 ECM	was	 visualised	 using	 toluidine	 blue	 staining	 and	 quantified	 using	
OsteoMeasure.	
The	single	injection	of	ZOL	significantly	increased	the	proteoglycan-rich	matrix	area	
in	the	metaphysis	which	stretched	deeper	into	the	extending	front	of	the	growth	plate	in	
ZOL	 treated	mice	 when	 compared	 to	 control	 from	 day	 5	 onwards	 (Day	 5:	 PBS:	 0.321	 ±	
0.015mm2	 vs.	 ZOL:	 0.449	 ±	 0.023mm2,	 p≤0.05,	 Fig.24A&C).	 The	 proteoglycan	 rich	 area	
extended	 even	 further	 down	 the	metaphysis	 10	 days	 after	 ZOL	 treatment	 (Day	 10:	 PBS:	
0.313	 ±	 0.021mm2	 vs.	 ZOL:	 0.480	 ±	 0.028mm2,	 p≤0.01,	 Fig.24A&C).	 The	 ZOL-induced	
increase	in	bone	volume	may	therefore	be	a	result	of	elevated	endochondral	ossification,	
as	this	excess	matrix	is	normally	resorbed	by	osteoclasts.	Similar	results	were	observed	in	
female	NCr-Nu	 (nude)	mice	 (Day	3:	HBSS:	0.371	±	0.021mm2	vs.	ZOL:	0.473	±	0.022mm2,	
p≤0.05;	Day	8:	0.347	±	0.012mm2	vs.	ZOL:	0.539	±	0.0190	mm2,	p≤0.01,	Fig.24B).	 
To	 summarise,	 a	 single	 dose	 of	 ZOL	 does	 not	 only	 affect	 the	 cellular	 but	 also	 the	 extra-
cellular	composition	of	the	bone	metastasis	niche.	
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Figure	24	Visualisation	of	ZOL-induced	effects	on	extracellular	matrix	composition.		
Alterations	 in	 proteoglycan/extracellular	 matrix	 composition	 of	 the	 epiphysis	 and	 metaphysis	 of	
tibiae	were	visualised	by	Toluidine	blue	staining	on	3µm	sections	of	tibiae	from	6-week	old	female	
BALB/c	nude	mice.	OsteoMeasure	software	was	used	to	quantify	the	proteoglycan-rich	area	(white	
dashed	line,	shown	in	C)	3,	5	and	10	days	after	a	single	dose	of	ZOL	(100µg/kg,	bottom	panel)	or	PBS	
control	 (top	 panel).	 n=3/group	 and	 time	 point,	 only	 one	 histological	 level	 was	 quantified.	 2-way	
ANOVA	with	Bonferroni’s	post-test.	**	is	p≤0.01,	*	is	p≤0.05.).	Scale	bar	is	100µm.	(B)	quantification	
data	 for	 6-week	 old	 NCr-Nu	 (nude)	 mice	 Day	 3:	 n=4	 for	 PBS,	 n=3	 for	 ZOL,	 Day	 8:	 n=3/group.	
Student’s	t-test.	Data	show	Mean±SEM.	
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3.6.3. Effects	of	Zoledronic	acid	on	the	bone	marrow	vasculature	
By	using	 fluorescent	markers	 against	 endothelial	 cells	work	published	by	Kusumbe	et	 al.		
provided	detailed	information	about	the	organisation,	functional	specialisation	and	precise	
function	 of	 the	 skeletal	 vasculature	 in	 mice	 [51].	 Vasculature	 in	 the	 methaphysis	 is	
described	as	straight	columns	being	interconnected	by	vessel	loops	or	arches.	Vasculature	
in	 the	 diaphysis	 in	 contrast	 was	 highly	 branched.	 Additionally	 both	 metaphyseal	 and	
diaphyseal	vasculature	were	interconnected	forming	one	vascular	bed	[51].	As	ZOL	induced	
rapid	modification	 in	 the	 cellular	 es	well	 as	 extracellular	 BME	 I	 aimed	 to	 visualise	 if	 the	
single	 dose	 of	 ZOL	 also	 alters	 the	 bone	 marrow	 vasculature.	 Therefore	 I	 performed	
immunofluorescence	 staining	 against	 the	 vascular	 endothelial	 cell	marker	 Endomucin	 on	
30µm	 sections	 of	 tibiae	 from	mice	 treated	 with	 100µg/kg	 ZOL	 or	 PBS	 control	 (samples	
were	collected	3	days	post	injection	from	collaborative	experiments,	NCr-Nu	nude	mice).	
In	the	control	cohort	(2	out	of	3)	I	observed	distinct	connection	and	organisation	of	
Endomucin	+ve	vasculature	in	the	metaphysis	and	diaphysis	as	described	in	[51],	with	long,	
branched	 tubular	 vessels	 occupying	 the	metaphysis	 and	 a	more	 sinusoidal	 patterning	 in	
the	diaphysis	(representative	images	shown	in	Fig.25A-D,	26A-L).	
The	 organisation	 and	 interconnection	 between	 the	 metaphyseal	 and	 diaphyseal	
vasculature	appeared	to	be	affected	by	ZOL	treatment	(3	out	of	3).	There	appeared	to	be	
increased	numbers	 of	 small,	 dilated	 and	 rounded	 vessels	 in	 the	diaphysis	 72	hours	 after	
the	 single	 injection	 of	 ZOL	 (2	 out	 of	 3,	 qualitative	 data).	 The	 third	 biological	 replicate	
showed	small	vessels,	but	these	were	not	rounded	or	dilated,	Fig.25&26.	The	presence	of	
endothelial	 vascular	 cells	 is	 detrimental	 for	 endochondral	 ossification	 at	 the	 epiphysis.	
Given	the	observed	alteration	to	the	structural	organisation	of	the	epiphysis	and	increased	
trabecular	bone	volume,	 I	 assessed	potential	 alterations	 in	CD31+ve	vascular	endothelial	
cells	 adjacent	 to	 the	 epiphysis.	 However,	 no	 apparent	 difference	 in	 organisation	 and	
structure	of	the	CD31+ve	bone	marrow	vasculature	was	observed	3	days	after	treatment	in	
the	ZOL-treated	cohort	when	compared	to	the	control	cohort	(Fig.27).	
To	 summarise,	 a	 single	 dose	 of	 ZOL	 appears	 to	 alter	 structural	 organisation	 of	 the	 bone	
marrow	vasculature	3	days	after	injection.	
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Figure	25	Effects	of	a	single	dose	of	Zoledronic	acid	(ZOL)	on	bone	marrow	vasculature.		
3	days	after	a	single	dose	of	(A&C)	HBSS	(100µL,	i.p.)	or	(B&D)	100µg/kg	ZOL	(100µL,	i.p.)	right	tibiae	
of	6-week	old	NCr-Nu	(nude),	CrTac:NCr-Foxn1nu	mice	were	collected.	Treatment	effects	on	on	bone	
marrow	 vasculature	 was	 visualised	 using	 immunofluorescence	 staining	 against	 the	 vascular	
endothelial	cell	marker	Endomucin	on	30µm	thick	sections	of	gelatine	embedded	tibiae.	(A-D)	8x8	
tile	 scans	 captured	 with	 20x	 objective	 using	 the	 Nikon	 Eclipse	 Ti,	 NIS-Elements-software	 Version	
4.30,	CFI	Plan	Fluor	20x	MI	(NA	0.75),	Endomucin+ve	vascular	endothelial	cells	=	green	(Alexa555)	
Ep	is	epiphysis,	met	is	metaphysis,	dia	is	diaphysis.	Scale	bar	is	250µm.	
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Figure	26	Visualisation	of	the	effects	of	a	single	dose	of	Zoledronic	acid	(ZOL)	on	bone	marrow	
vasculature.		
3	days	after	a	single	dose	of	(A-C,G-I)	HBSS	(100µL,	i.p.)	or	(D-F,J-L)	100µg/kg	ZOL	(100µL,	i.p.)	right	
tibiae	of	6-week	old	NCr-Nu	 (nude),	CrTac:NCr-Foxn1nu	mice	were	collected.	Treatment	effects	on	
bone	 marrow	 vasculature	 in	 the	 metaphysis	 (A-F)	 and	 (G-L)	 diaphysis	 were	 visualised	 using	
immunofluorescence	staining	against	the	vascular	endothelial	cell	marker	Endomucin	on	30µm	thick	
sections	 of	 gelatine	 embedded	 tibiae.	 (A-F)	 Z-stacks	 with	 a	 depth	 of	 20µm	 and	 (G-L)	 confocal	
images,	both	aquired	with	Nikon	A1	Confocal	microscope,	NIS-Elements-software	Version	4.30,	CFI	
Plan	Fluor	20x	MI	 (NA	0.75),	Endomucin+ve	vascular	endothelial	cells	=	green	(Alexa555),	nuclei	=	
blue	(DAPI).	Scale	bar	is	100µm.	n=3/group.	
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Figure	27	Effects	of	a	single	dose	of	Zoledronic	acid	(ZOL)	on	CD31+ve	bone	marrow	vasculature.	
3	days	after	a	single	dose	of	(A-C)	HBSS	(100µL,	i.p.)	or	(D-F)	100µg/kg	ZOL	(100µL,	i.p.)	right	tibiae	
of	 6-week	old	NCr-Nu	 (nude),	 CrTac:NCr-Foxn1nu	mice	were	 collected.	 Effects	 of	 ZOL	on	CD31+ve	
bone	 marrow	 vasculature	 in	 the	 metaphysis	 was	 visualised	 using	 immunofluorescence	 staining	
against	 the	 vascular	 endothelial	 cell	 marker	 CD31	 on	 30µm	 thick	 sections	 of	 gelatine	 embedded	
tibiae.	Z-stacks	with	a	depth	of	20µm	were	aquired	using	the	Nikon	A1	Confocal	microscope,	NIS-
Elements-software	Version	4.30,	CFI	Plan	Fluor	20x	MI	(NA	0.75),	CD31+ve	vascular	endothelial	cells	
=	yellow	(Alexa555),	nuclei	=	blue	(DAPI).	n=3/group.	
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3.6.4. Effects	of	ZOL	pre-treatment	on	tumour	cell	homing		
Two	 independent	 experiments	 using	 mature	 (8-13-week	 old)	 female	 BALB/c	 mice	
(heterozygote	or	homozygote	nude,	n=4/group	 in	each	experiment)	with	GFP	expressing	
cells	of	the	osteoblastic	lineage	were	performed	to	assess	if	the	ZOL-induced	alterations	to	
the	BME	affect	tumour	cell	homing	to	bone	in	vivo.	Briefly,	mice	were	injected	with	a	single	
dose	 of	 ZOL	 (100µg/kg,	 i.p.)	 or	 PBS	 on	 day	 0	 followed	 by	 intracardiac	 injection	 of	 DiD	
labelled	 MDA-MB-231-NW1	 (luciferase+ve)	 tumour	 cells	 on	 day	 5,	 when	 the	 previous	
experiments	had	shown	that	ZOL	effects	on	the	BME	were	most	prominent.	Samples	were	
collected	5	days	after	tumour	cell	injection	and	the	presence	and	location	of	tumour	cells	
in	circulation,	soft	tissue	and	bone	assessed.	
	 To	confirm	the	therapeutic	effects	of	ZOL	in	these	experiments	one	mouse/group	
was	sacrificed	5	days	after	the	single	dose	of	ZOL	and	trabecular	bone	volume	determined	
using	 µCT.	 As	 expected,	 trabecular	 bone	 volume	was	 higher	 after	 administration	 of	 ZOL	
when	compared	to	control	(PBS:	14.81%	vs.	ZOL:	16.72%,	Fig.28A)	and	histological	slides	of	
tibiae	additionally	demonstrated	the	expected	reduction	in	osteoblast	number	at	this	time	
point	(Fig.28B).		
	
Figure	28	Confirmation	of	ZOL-induced	effect	on	the	BME	in	the	bone	metastasis	studies.		
(A)	Trabecular	bone	volume	of	 tibiae	of	8-13-week	old	 female	GFP-Ob+	mice	5	days	after	a	 single	
dose	of	ZOL,	the	time	point	of	tumour	cell	injection	was	determined	using	µCT	analysis	(n=1/group).	
The	reduction	in	the	number	of	osteoblasts	(indicated	by	black	arrow	heads)	is	illustrated	in	(B)	on	
TRAP-stained	histological	sections	of	tibiae.	Tb	=	Trabecular	bone,	Bm	=	bone	marrow.	
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3.6.4.1. Circulating	tumour	cells	
Circulating	 tumour	 cells	 are	 often	 associated	 with	 poor	 prognosis	 and	 suggested	 to	 be	
early	 predictors	 of	 metastases	 in	 breast	 cancer	 patients.	 Flow	 cytometry	 was	 used	 to	
quantify	 the	 number	 of	 circulating	 DiD+ve	 tumour	 cells	 in	 blood	 10	 days	 after	 ZOL	
treatment	 (5	 days	 post	 i.c.	 injection	 of	 breast	 cancer	 cells)	 to	 assessed	 if	 pre-treatment	
with	the	bisphosphonate	affects	the	number	of	circulating	breast	cancer	cells.		
Both	 of	 the	 independent	 experiments	 suggested	 a	 reduction	 in	 the	 number	 of	
circulating	 tumour	 cells	 per	millilitre	 of	 blood	 (Experiment	 1:	 PBS:	 183.27	 events/mL	 vs.	
ZOL:	 2.55	 events/mL,	 Fig.	 30A;	 Experiment	 2:	 PBS:	 295.33	 events/mL	 vs.	 ZOL:	 31.43	
events/mmL,	 Fig.30C).	 To	 confirm	 the	 reduction	of	 tumour	 cells	 in	 the	 circulation,	 blood	
was	collected	on	day	of	sacrifice,	pooled	for	all	animals	per	treatment	group	and	an	aliquot	
of	 50µL	 plated	 in	 6-well	 plates	 and	 cultures	 maintained	 for	 2	 weeks.	 Using	 selective	
pressure	 in	 vitro	 (DMEM	 +	 GlutaMAX	 +	 Pyruvate	 supplemented	 with	 10%FCS,	 5%	 Pen	
Strep,	5%	fungizone,	and	1	mg/mL	G418)	the	decrease	of	tumour	cells	 in	blood	following	
ZOL	 treatment	 was	 confirmed	 by	 bioluminescence	 signal	 of	 luc2	 positive	MDA-MB-231-
NW1	 cells	 (Fig.29).	 These	 findings	 suggest	 that	 ZOL	 reduces	 the	 number	 of	 circulating	
tumour	cells	in	blood.	
	
	
	
	
	
	
	
	
Figure	29	Presence	of	tumour	cells	in	ex	vivo	blood	and	bone	marrow	cultures.		
Blood	 and	 bone	marrow	was	 collected	 on	 day	 of	 sacrifice,	 pooled	 for	 all	 animals	 per	 treatment	
group	 and	 an	 aliquot	 of	 50µL	 plated	 in	 6-well	 plates	 and	 cultures	 maintained	 for	 2	 weeks.	 The	
decrease	of	tumour	cells	in	blood	following	ZOL	treatment	was	confirmed	by	bioluminescence	signal	
of	 luc2	 positive	MDA-MB-231-NW1	 cells.	 These	 findings	 suggest	 that	 ZOL	 reduces	 the	 number	 of	
circulating	tumour	cells	in	blood.	
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Figure	30	Presence	of	tumour	cells	in	circulation	and	bone	marrow	after	Zoledronic	acid	pre-
treatment.	
5	days	post	intra-cardiac	injection	of	1x105	DiD	labelled	MDA-MB-231-NW1	(luc+)	breast	cancer	cells	
the	presence	of	 circulating	 tumour	 cells	 in	blood	 (A&C)	was	assessed	using	 flow	cytometry.	Bone	
marrow	(B&D)	was	flushed	and	analysed	for	the	presence	of	DID+	events	in	the	gated	population.	2	
independent	 experiments	 (n=4/group	 in	 each	 experiment)	 were	 performed	 and	 each	 time	 bone	
marrow	and	blood	samples	of	all	mice/group	were	pooled	for	analysis.	
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3.6.4.2. Presence	of	tumour	cells	in	soft	tissues	
To	 determine	 if	 tumour	 cells	 home	 to	 sites	 other	 than	 bone	 ex	 vivo	 cultures	 of	 organs	
collected	at	experimental	endpoint	were	performed	and	 selected	 for	MDA-MB-231-NW1	
cells	using	antibiotic	pressure.	No	tumour	cells	were	detected	 in	these	cultures	except	 in	
the	lung	culture	of	one	out	of	4	mice	of	the	ZOL	group.		
3.6.4.3. Presence	of	tumour	cells	in	bone		
To	 assess	 if	 ZOL	 pre-treatment	 affects	 the	 number	 of	 tumour	 cells	 homing	 to	 bone	 the	
presence	of	DiD+ve	tumour	cells	in	bone	marrow	flushes	of	mice	was	analysed	using	flow	
cytometry.	 The	 percentage	 of	 tumour	 cells	 in	 bone	 was	 not	 greatly	 affected	 by	 pre-
treatment	 with	 ZOL	 (Experiment	 1:	 PBS:	 0.018%	 vs.	 ZOL:	 0.028%;	 Experiment	 2:	 PBS:	
0.005%	vs.	ZOL:	0.007%,	Fig.	30B&D)	suggesting	that	ZOL	pre-treatment	does	not	affect	the	
actual	 number	 of	 tumour	 cells	 homing	 to	 bone.	 However,	 tumour	 cells	 could	 not	 be	
detected	when	culturing	a	suspension	of	bone	marrow	cells	collected	at	the	experimental	
endpoint	under	antibiotic	pressure	in	vitro.		
In	 previous	 experiments	 performed	 during	 a	 research	 internship	 [158]	 I	
determined	that	ZOL	treatment	primarily	affects	osteoblasts	on	trabecular	bone	surfaces,	
but	osteoblasts	were	still	visible	in	the	dense	growth	plate	area.	To	assess	if	the	presence	
or	 absence	 of	 osteoblasts	 and	 the	 ZOL	 induced	 alteration	 in	 ECM	 in	 this	 area	 of	 bone	
affects	 tumour	 cell	 location	 within	 bone,	 their	 presence	 was	mapped	 using	 two-photon	
microscopy	and	immunofluorescence.	
By	 using	 two-photon	 microscopy	 three	 different	 regions	 of	 interest	 (ROI)	 were	
analysed	 including	 the	 growth	 plate	 (ROI-2,	 osteoblast-rich	 in	 both	 treatment	 groups),	
trabecular	 bone	 (ROI-3,	 osteoblast	 rich	 in	 PBS	 vs.	 osteoblast-depleted	 in	 ZOL	 treated	
group)	and	 the	 total	 analysed	area	 (ROI-1	=	ROI-2	+	ROI-3,	 Fig.31A-C).	Cortical	bone	was	
excluded	 for	 analysis	 and	 data	 from	 the	 two	 separate	 experiments	were	 combined	 (n	 =	
6/treatment	group).		
In	 agreement	 with	 data	 obtained	 from	 the	 flow	 cytometry	 experiments,	 analysing	 the	
presence	of	DiD+ve	events	between	 the	 treatment	groups	 revealed	 that	a	 single	dose	of	
ZOL	did	not	affect	the	overall	number	of	tumour	cells	homing	to	bone	(data	represented	as	
DiD+ve	events,	ROI	1:	PBS:	504.7	±	135.2	vs.	ZOL:	501.1	±	28.49,	Fig.32	A&B).	No	difference	
in	 tumour	 cell	 number	 between	 the	 groups	 was	 observed	 when	 analysing	 the	 different	
areas	(ROI	2:	PBS:	113.7	±	46.38	vs.	ZOL:	208.7	±	30.49;	ROI	3:	PBS:	391.0	±	117.2	vs.	ZOL:	
292.4	±	45.32,	Fig.32A&B).	
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Figure	31	Effects	of	Zoledronic	acid	pre-treatment	on	tumour	cell	homing	between	treatment	
groups	for	three	different	areas	in	bone.		
8-13-week	 old	 female	 BALB/c	 nude	mice	 were	 pre-treated	 with	 a	 single	 dose	 of	 Zoledronic	 acid	
(ZOL,	100µg/kg,	i.p.,	100µL)	or	PBS	control	(i.p.,	100µL)	on	day	0.	Five	days	later	1x105	DiD	labelled	
MDA-MB-231-luc2-NW1	 cells	 were	 injected	 intracardiac	 and	 the	 number	 of	 tumour	 cells	 (DiD	
positive	events/mm3	bone	marrow)	was	determined	for	three	different	areas	in	bone	including	(A)	
total	bone	(ROI-1),	 (B)	the	growth	plate	area	(ROI-2)	and	(C)	trabecular	bone	areas	(ROI-3)	on	day	
10.	ROI	=	region	of	interest.	
	
However,	 in	 the	PBS	 treated	mice	more	DiD+ve	events	were	detected	 in	 the	osteoblast-
rich	trabecular	bone	area	(ROI-3)	compared	to	the	growth	plate	(ROI-2)	(ROI-2:	113.65	vs.	
ROI-3:	 391.03,	 p=0.0625,	 Fig.32A)	 although	 this	 did	 not	 reach	 statistical	 significance.	 In	
contrast,	 pre-treatment	with	 ZOL	 appeared	 to	 blunt	 this	 preferential	 distribution	 (ROI-2:	
208.67	vs.	ROI-3:	292.44,	p	=0.2959,	Fig.32B)	towards	the	osteoblast-	and	ECM-rich	growth	
plate	area.		
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Figure	32	Analysis	of	location	of	tumour	cells	in	three	different	areas	of	bone	by	two-photon	
microscopy.		
8-13-week	 old	 female	 BALB/c	 nude	mice	 were	 pre-treated	 with	 a	 single	 dose	 of	 Zoledronic	 acid	
(ZOL,	100µg/kg,	i.p.,	100µL)	or	PBS	control	(i.p.,	100µL)	on	day	0.	Five	days	later	1x105	DiD	labelled	
MDA-MB-231-luc2-NW1	cells	were	 injected	 intracardiac.	Data	 from	two	 independent	experiments	
(n=4/group	in	each	experiment)	were	pooled	for	analysis	(n=6/group).	To	determine	if	tumour	cells	
preferentially	 home	 to	 specific	 areas	 in	 bone	 presence	 of	 DiD	 positive	 tumour	 cells	 (in	 red)	 was	
analysed	for	total	bone	(ROI-1),	the	growth	plate	area	(ROI-2)	and	trabecular	bone	areas	(ROI-3)	on	
day	10.	(A)	shows	data	for	PBS	and	(B)	for	ZOL	pre-treated	mice.	Representative	two-photon	scans	
are	shown	in	(C)	for	PBS	and	(D)	for	ZOL.	Data	show	Mean±SEM,	Student’s	t-test	
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These	data	 suggest	 that	breast	 cancer	 cells	 appear	 to	preferentially	home	 to	bone	areas	
that	are	rich	in	osteoblasts	as	well	as	extracellular	matrix	and	that	the	location	of	tumour	
cells	in	bone	can	be	altered	when	they	arrive	in	a	modified	microenvironment.	
Using	 bones	 from	 collaborative	 studies	 I	 aimed	 to	 assess	 whether	 ZOL	 pre-
treatment	 affects	 the	 homing	 of	 two	 sub-clones	 of	 MDA-MB-231	 (CM-DiI+ve)	 breast	
cancer	cells	using	two-photon	microscopy.	Due	to	limited	amounts	of	samples	I	could	not	
perform	quantitative	 analysis,	 however,	 CM-DiI+ve	 events	were	 observed	 irrespective	 of	
HBSS	or	ZOL	pre-treatment	in	both	cell	lines	–	see	Figure	33.	
To	visualise	whether	tumour	cells	home	close	to	endothelial	cells	and/or	whether	
they	get	trapped	in	the	bone	marrow	microvasculature,	I	performed	immunofluorescence	
staining	 against	 vascular	 endothelial	 cells	 using	 the	endothelial	 cell	marker	 Endomucin.	 I	
was	 kindly	 provided	 with	 gelatine	 embedded	 bone	 samples	 from	 collaborative	
experiments	performed	at	Dr.	McAllister’s	laboratory.	In	these	experiments	mice	were	pre-
treated	with	a	 single	dose	of	 ZOL	 (100µg/kg)	or	 control	 and	1x105	cM-DiI	 labelled	breast	
cancer	 cells	 (MDA-MB-231-GFP-IV	 or	 MDA-MB-231-B02-FII)	 injected	 3	 days	 post	
treatment.	Samples	were	collected	5	days	post	tumour	cell	injection	(Fig.34).	I	was	able	to	
detect	 single	 tumour	 cells	 by	 using	 fluorescence	microscopy	 (2	 animals/group	 assessed).	
The	majority	of	tumour	cells	appeared	to	be	in	close	proximity	to	trabecular	bone	surfaces	
or	vascular	endothelial	cells	or	even	both.	This	suggests	that	tumour	cells	localise	to	areas	
that	are	 rich	 in	vascular	cells	and	adjacent	 to	bone	surfaces,	but	 this	needs	confirmation	
and	quantification	in	separate	studies.	
	
	
	
	
	
	
	
	
	
	 124	
	
	
Figure	33	Effects	of	Zoledronic	acid	pre-treatment	on	homing	of	two	MDA-MB-231	breast	cancer	
sub-clones	to	bone.	
6-week	old	 female	NCr-Nu	 (nude)	mice	were	 injected	with	 a	 single	dose	of	 (A,C)	HBSS	 control	 or	
(B&D)	 100µg/kg	 Zoledronic	 acid	 (ZOL)	 on	 day	 0	 followed	 72hrs	 later	 by	 intracardiac	 injection	 of	
1x105	cM-DiI	labelled	(A&B)	MDA-MB-231	B02-FII	cells	or	(C&D)	MDA-MB-231-	IV	cells.	Presence	of	
tumour	 cells	 (red,	 cM-DiI	 positive	 events)	 in	 bone	 (white)	 was	 mapped	 using	 two-photon	
microscopy.		
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Figure	34	Detection	of	tumour	cells	in	bone	by	two-photon	and	fluorescence/confocal	
microscopy.		
CM-DiI+ve	 MDA-MB-231-B02	 or	 MDA-MB-231-IV	 tumour	 cells	 (in	 red)	 were	 detected	 in	 bone	
(white)	by	two-photon	microscopy	(A&B)	and	fluorescence/confocal	microscopy	(C-F).	(C&D)	shows	
single	 tumour	 cells	 (red)	 in	 great	proximity	 to	 trabecular	bone	 (Tb)	 and	within	 the	bone	marrow,	
nuclei	 stained	 in	 blue	 with	 DAPI.	 (E&F)	 shows	 presence	 of	 tumour	 cells	 in	 great	 proximity	 to	
trabecular	bone	 surfaces	 (Tb)	 and	 vascular	 endothelial	 cells	 (green)	within	mouse	 tibiae.	 Samples	
are	 representative	 images	 from	 6-week	 old	 female	 NCr-Nu	 (nude)	mice	 8	 days	 after	 intracardiac	
injection	of	1x105	MDA-MB-231-BO2FII	cells.		
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3.6.5. Effects	of	ZOL	pre-treatment	on	breast	cancer	progression	in	bone	
To	 establish	 if	 pre-treatment	with	 ZOL	 affects	 breast	 cancer	 growth	 in	 bone	 6-week	 old	
female	nude	GFP-Ob+	mice	received	a	single	injection	of	ZOL	(100µg/kg,	100µL,	i.p.)	or	PBS	
(100µL,	 i.p.)	 on	 day	 0	 followed	by	 intra-cardiac	 injection	of	 1x105	DID	 labelled	MDA-MB-
231-NW1-luc2	breast	cancer	cells	on	day	5.	Tumour	growth	was	monitored	2x	weekly	using	
IVIS	imaging.		
At	 the	 experimental	 endpoint	 (day	 33-35)	 there	 was	 no	 difference	 in	 the	mean	
number	of	 tumours	established	per	mouse	between	the	two	groups	 (PBS:	1	vs.	ZOL:	0.8)	
suggesting	that	a	single	pre-treatment	with	ZOL	is	not	sufficient	to	affect	metastatic	breast	
cancer	growth	(Fig.35).	When	imaging	excised	limbs	and	organs	on	day	of	sacrifice,	tumour	
cells	 (bioluminescence	 signal)	 were	 detected	 in	 the	 lung	 (PBS:	 2	 vs.	 ZOL:	 1),	 long	 bones	
(PBS:	2	vs.	ZOL:	0)	and	the	ribs	(PBS:	1	vs.	ZOL:	0)	(n=5/group).		
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	Figure	35	Effects	of	Zoledronic	acid	(ZOL)	pre-treatment	on	the	development	of	bone	metastases.		
Potential	 differences	 in	 the	development	of	 bone	metastases	 after	 a	 single	 injection	of	 100µg/kg	
ZOL	 or	 PBS	 control	was	 assessed	 in	 6-8-week	 old	 female	 BALB/c	 nude	mice.	 1x105	MDA-MB-231-
luc2-NW1	 cells	 were	 injected	 5	 days	 post	 ZOL	 pre-treatment	 and	 development	 of	 tumours	
monitored	by	bioluminescence	signal	using	 IVIS.	Dorsal	and	ventral	representative	 IVIS	 images	are	
shown	in	(A)	for	PBS	and	(B)	for	ZOL	pre-treatment	group	(n=5/group),	day	29/30	post	injection.	(C)	
shows	mean	tumour	number/mouse	over	time	(Mean	±	SEM).		
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3.7. Discussion	
This	 study	 investigated	how	a	 single,	 clinically	 relevant	dose	of	 the	 anti-resorptive	 agent	
ZOL	 affects	 bone	 cells,	 suggested	 to	 be	 key	 components	 of	 the	 bone	 metastasis	 niche.	
Osteoclasts	 and	 osteoblasts	 are	 in	 part	 driving	 the	 vicious	 cycle	 in	 late	 stage	 bone	
metastasis	 however,	 their	 role	 in	 the	 early	 events	 of	 metastasis	 development	 including	
tumour	cell	homing	 to	bone	and/or	 triggering	subsequent	metastatic	outgrowth	 remains	
to	be	elucidated.	This	chapter	presents	the	first	detailed	characterisation	of	the	short-term	
effects	of	ZOL	on	both,	osteoblasts	and	osteoclasts	in	vivo	and	discusses	if	modification	of	
the	BME	with	ZOL	affects	tumour	cell	homing	to	bone.		
3.7.1. Effects	on	bone	volume	and	structure	
Bisphosphonates	are	standard	of	care	for	pathological	conditions	characterised	by	excess	
osteoclast-mediated	 bone	 resorption	 including	 osteoporosis	 and	 Paget’s	 disease.	 In	
addition	 patients	 with	 advanced	 breast	 cancer	 often	 receive	 BPs	 in	 combination	 with	
chemotherapy	to	prevent	the	cancer-induced	bone	loss.	It	is	well	established	that	repeated	
treatment	with	 the	bisphosphonate	ZOL	 increases	bone	volume.	Pozzi	et	al.	 for	example	
report	 increased	trabecular	bone	volume	and	number	 in	5-week	old	female	C57BL6	mice	
after	weekly	treatment	with	ZOL	(0.05-1mg	ZOL)	for	3	weeks	[262].	In	agreement	with	this,	
Ottewell	 and	colleagues	determined	 increased	 trabecular	and	cortical	bone	volume	 in	6-
week-old-female	MF1	nu/nu	mice	bearing	 subcutaneous	MDA-436	 tumours	 after	weekly	
administration	of	100µg/kg	ZOL	for	6	weeks	[241].			
Importantly,	 these	 studies	 used	 administration	 schedules	 or	 doses	 that	 are	 not	
comparative	 to	 that	 in	 clinical	 use.	 Patients	 with	 cancer-induced	 bone	 disease	 receive	 a	
single,	 intravenous	 infusion	 of	 4mg	 ZOL	 every	 3-4	 weeks.	 In	 my	 experiments	 I	 have	
investigated	the	early	effects	of	a	clinically	relevant	dose	of	ZOL	(100µg/kg	in	mice	=	4mg	in	
humans	[241])	on	the	naïve,	 in	vivo	BME.	Interestingly	trabecular	bone	volume	in	6-week	
old	 female	 BALB/c	 nude	 mice	 was	 rapidly	 increased	 as	 early	 as	 3	 days	 after	 the	 single	
injection	 indicating	 rapid	 effects	 of	 ZOL	 on	 bone.	 This	 is	 in	 agreement	 with	 findings	 by	
Brown	 et.	 al	 reporting	 increased	 trabecular	 bone	 volume	 15	 and	 23	 days	 after	 a	 single	
injection	of	ZOL	in	6-week	old	female	BALB/c	nu/nu	mice	[154],	suggesting	that	repeated	
treatment	with	 ZOL	 is	 not	 required	 to	 initiate	 ZOL-induced	 bone	 effects	 in	 these	model	
systems.	
3.7.2. Effects	on	bone	cells	
Effects	of	BPs	on	osteocytes	which	 comprise	more	 than	90%	of	 all	 cells	within	 the	bone	
matrix	 are	 reported.	 Plotkin	 and	 colleagues	 for	 example	 report	 that	 the	 BPs	 etidronate,	
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pamidronate,	 olpadronate	 and	 alendronate	 at	 doses	 of	 (10-9M	 –	 10-8M)	 inhibited	
dexamethasone	induced	apoptosis	of	murine	MLO-Y4	osteocytic	cells.	These	effects	were	
lost	at	higher	doses	[263].	 In	my	experiments	I	did	not	assess	the	acute	effects	of	ZOL	on	
osteocytes.	
3.7.2.1. Effects	on	osteoclasts	
However,	 there	 is	 general	 consensus	 that	 osteoclasts	 are	 the	 main	 targets	 of	 BPs.	 The	
compounds	 high	 affinity	 for	 bone	 brings	 them	 into	 close	 contact	 with	 bone	 resorbing	
osteoclasts	where	 they	 are	 embedded	 into	 the	 bone	matrix	 until	 released	 during	 active	
bone	 resorption.	 	 BPs	 affect	 osteoclasts	 in	 various	 ways	 including	 their	 recruitment,	
differentiation,	activity	and	viability	[261].	Long-term	and	repeated	treatment	with	BPs	 is	
known	to	reduce	osteoclast	activity	and	number	in	vivo	[241,	262].	Pozzi	et	al.	report	that	
ZOL	 (0.05-1mg/kg	 ZOL	 weekly	 for	 3	 weeks)	 reduces	 osteoclast	 activity	 (assessed	 by	
TRACP5b	 serum	 levels)	 in	 5-week	 old	 female	 C57BL6	 mice	 [262].	 In	 these	 experiments	
osteoclast	 number	 per	 bone	 perimeter	was	 slightly	 reduced	 however	 this	 did	 not	 reach	
statistical	significance.	Furthermore,	weekly	doses	of	ZOL	(100µg/kg)	for	6	weeks	caused	a	
significant	reduction	in	the	percentage	of	cortical	bone	surface	in	contact	with	osteoclasts	
[241].		
Cortical	bone	has	a	lower	bone	turnover	rate	when	compared	to	trabecular	bone	
and	recent	studies	demonstrated	 that	 the	 tibial	metaphysis	 is	preferentially	colonised	by	
breast	cancer	cells	in	bone	metastasis	models	[90,	264].	In	my	experiments	I	therefore	only	
investigated	 effects	 of	 ZOL	 on	 osteoclasts	 lining	 trabecular	 bone	 surfaces.	 To	 my	
knowledge	 acute	 effects	 (3-5	 days	 post	 injection)	 of	 a	 clinically	 relevant	 dose	 of	 ZOL	 on	
osteoclasts	 in	vivo	have	not	been	established	 in	great	detail	 and	effectiveness	of	 various	
dosing	 schedules	 (high	 dose	 with	 reduced	 treatment	 intervals	 vs.	 lower	 doses	 with	
increased	treatment	intervals)	are	subject	to	debate	[265].	I	determined	that	a	single	dose	
of	ZOL	rapidly	reduced	the	number	of	osteoclasts	on	trabecular	bone	surfaces	of	tibiae	of	
6-week	old	female	BALB/c	nude	mice	as	early	as	3	days	post	treatment	when	compared	to	
control.	A	drop	 in	osteoclast	activity	 (measured	by	serum	TRAP	 levels)	by	day	3	mirrored	
this	 finding.	 Analysing	 osteoclast	 numbers	 in	 tibiae	 of	 6-week	 old	 female	NCr-Nu	 (nude)	
mice	 support	 the	 rapid	 effect	 of	 ZOL	 on	 osteoclasts	 and	 similar	 effects	 were	 previously	
observed	 in	 immunocompetent	 BALB/c	 mice	 [158].	 These	 findings	 suggest	 that	 a	 single	
dose	of	ZOL	is	sufficient	to	initiate	rapid	therapeutic	effects	on	osteoclasts	irrespective	of	
the	 immune	 status	 of	 the	 animal	 model	 used.	 Importantly,	 effects	 on	 osteoclasts	 were	
transient	and	 returned	 to	control	 levels	by	day	8	and	10	 respectively.	This	highlights	 the	
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importance	 of	 determining	 the	 acute	 effects	 of	 therapeutic	 agents	 on	 bone	 cells	 over	
various	time	points.	In	contrast,	Fisher	et	al.	reported	increased	osteoclast	numbers	48hrs	
after	 a	 single	 dose	 of	 alendronate	 (5µg/kg)	 and	 ibandronate	 (150µg/kg	 and	 1.25µg/kg),	
whereas	 no	 alteration	 of	 total	 osteoclast	 number	 in	 tibiae	 of	 rats	 48hrs	 after	
administration	 of	 ZOL	 (333µg/kg)	 was	 observed	 [265].	 However,	 in	 agreement	 with	 my	
findings	Brown	et	al.	reported	that	a	single	administration	of	ZOL	does	not	only	decrease	
osteoclast	numbers/mm	trabecular	bone	surface	but	also	results	 in	significant	alterations	
in	 osteoclast	 morphology	 and	 increased	 osteoclast	 size	 15	 and	 23	 days	 after	 the	 single	
dose	[154].	Repeated	treatment	with	BPs	causes	the	presence	of	“giant”	osteoclasts	[157,	
266]	 and	 Fisher	 and	 colleagues	 proposed	 that	 higher	 doses	 of	 BPs	 are	 associated	 with	
changed	osteoclast	morphology	 (rounded),	whereas	 flat	 osteoclasts	were	observed	 after	
low	 dose	 [265].	 Importantly,	 they	 describe	 osteoclasts	 of	 ZOL	 treated	 rats	 as	 taller,	
rounded-up	and	plump	with	a	34%	increased	average	height	48hrs	after	administration	of	
a	 single	 (333µg/kg)	dose	of	 ZOL	 to	male	 Sprague-Daley	 rats	 [265].	 In	 addition,	 increased	
osteoclast	apoptosis	48hrs	after	administration	was	observed	 [265].	Electronmicrographs	
of	bones	from	adult	rats	 injected	twice	with	0.4mg/kg	of	the	BP	alendronate	followed	by	
infusion	with	PTHrP	to	stimulate	bone	resorption	resulted	in	a	lack	of	ruffled	borders	and	
fewer	 vacuoles	 of	 osteoclasts	 attached	 to	 bone	 surfaces	 when	 compared	 to	 control	
suggesting	that	BPs	partially	inhibit	osteoclastic	bone	resorption	by	interfering	with	ruffled	
boarder	formation	[153].	However,	comparing	 in	vivo	experiments	performed	in	rats	with	
those	 performed	 in	 mice	 might	 not	 be	 appropriate.	 I	 have	 previously	 determined	 a	
significant	increase	in	osteoclast	size	3	days	post	ZOL	administration	in	immunocompetent	
mice	[158],	however,	I	did	not	find	any	significant	alterations	in	osteoclast	morphology	or	
osteoclast	 apoptosis	 in	 either	 6-week	old	 female	BALB/c	nude	or	NCr-Nu	 (nude)	mice	 at	
analysed	time	points.		
3.7.2.2. Effects	on	osteoblasts	
Although	therapeutic	effects	of	BPs	might	be	dependent	on	their	anti-resorptive	properties	
there	is	increasing	evidence	that	they	also	affect	other	cells	of	the	BME	[249,	262,	267].		
Data	 on	 effects	 of	 BPs	 on	 osteoblasts	 are	 conflicting	 and	 vary	 depending	 on	 the	
experimental	 model,	 BP	 and	 dose	 used	 (reviewed	 in	 [268],	 however	 mainly	 focused	 on	
beneficial	 effects	 of	 BPs).	 Some	 report	 increased	 differentiation,	 proliferation	 and	
inhibition	of	apoptosis	[249]	whereas	others	report	opposite	effects.	Briefly,	 low	doses	of	
BPs	 appear	 to	 have	 pro-osteoblastogenic	 effects	 whereas	 higher	 doses	 were	 found	 to	
exhibit	 inhibitory	 effects.	 For	 example	 Im	 et	 al.	 studied	 the	 effects	 of	 aledronate	 and	
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risedronate	on	primary	 human	 trabecular	 bone	 cells	 and	MG-63	 (osteoblast-like)	 cells	 in	
vitro.	 At	 high	 dose	 (10-4M)	 both	 drugs	 inhibited	 proliferation	 of	 MG-63	 cells	 whereas	
proliferation	 was	 stimulated	 at	 lower	 doses	 (10-7M	 –	 10-9M;	 peak	 effects	 reached	 after	
72hr	 treatment).	Aledronate	and	risedronate	also	 increased	alkaline	phosphatase	activity	
of	MG-63	cells	after	24hr	treatment.	Similarly	aledronate	(10-8M)	increased	proliferation	of	
human	trabecular	bone	cells	 [249].	 In	addition,	others	report	 that	both,	 ibandronate	and	
ZOL	stimulated	proliferation	of	human	osteoblasts	after	72hrs	(10-8M	to	10-5M)	[269].		
The	 significance	of	 in	 vitro	 studies	 investigating	 the	effects	of	BPs	on	osteoblasts	
however	 needs	 to	 be	 assessed.	 	 This	 is	 due	 to	 the	 rapid	 incorporation	 of	 BPs	 into	 bone	
causing	 only	 short	 exposure	 times	 of	 other	 cell	 types	 including	 osteoblasts	 to	 these	
compounds	 in	vivo.	There	is	only	a	limited	number	of	published	studies	describing	effects	
of	BPs	on	osteoblasts	 in	vivo	 [154].	Here	I	assessed	the	acute	effects	of	a	single,	clinically	
relevant,	 dose	 of	 ZOL	 and	 showed	 that	 osteoblast	 number/mm	 trabecular	 bone	 surface	
and	 activity	 (measured	 by	 serum	 PINP	 levels)	 is	 rapidly	 decreased	 in	 6-week	 old	 female	
BALB/c	 nude	 mice	 from	 day	 5	 post	 injection	 onwards.	 Similar	 results	 were	 obtained	 in	
immunocompetent	mice,	with	significant	effects	on	osteoblasts	being	observed	from	day	3	
post	treatment	onwards	and	maximum	reduction	in	osteoblast	number	reached	on	day	5	
[158].	 These	 observations	 were	 confirmed	 when	 analysing	 samples	 from	 independent	
experiments	 using	NCr-Nu	 (nude)	mice.	 In	 agreement	 others	 report	 reduced	 osteocalcin	
levels	 after	 0.05-1mg/kg	 ZOL	 weekly	 for	 3	 weeks	 in	 female	 C57BL6	 mice,	 suggesting	
reduced	 osteoblast	 activity	 [262].	 A	 recent	 study	 by	 Brown	 et.	 al	 also	 found	 reduced	
osteoblast	number	and	activity	15	days	after	a	single	administration	of	ZOL	[154].	
It	is	difficult	to	establish	whether	effects	of	ZOL	on	osteoblasts	were	due	to	a	direct	
effect	on	these	cells	or	indirectly	via	osteoclast	coupling.	Treatment	of	human	osteoblasts	
for	 72hrs	 with	 ZOL	 or	 pamidronate	 resulted	 in	 increased	 levels	 of	 OPG	mRNA	 and	 OPG	
protein	 expression	 (measured	 by	 ELISA)	 with	 most	 potent	 effects	 at	 10-8	 to	 10-6M,	
respectively	 [270].	 This	 suggests	 that	 anti-resorptive	 effects	 of	 ZOL	 could	 be	 mediated	
through	 interference	 with	 the	 pro-differentiation	 and	 survival	 of	 osteoclasts	 by	 the	
RANK/RANKL/OPG	 axis	 mediated	 via	 osteoblasts.	 Considering	 the	 important	 role	 of	
osteoblasts	 in	 osteoclast	 differentiation,	 potential	 effects	 of	 BPs	 on	 osteoblasts	 might	
contribute	 to	 the	 observed	 reduction	 in	 osteoclast	 formation	 and	 activity	 following	 BP	
treatment.		
To	summarise	I,	have	shown	that	a	single	dose	of	ZOL	rapidly	affects	both	osteoblast	and	
osteoclasts	 in	 vivo	 demonstrating	 that	 repeated	 treatment	 cycles	 are	 not	 required	 for	
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initiation	 of	 bone	 effects.	 Effects	 on	 bone	 cells	 were	 transient	 for	 some	 parameters,	
highlighting	the	importance	of	measuring	both	cell	number	and	activity	over	time.	
3.7.3. Effects	on	growth	plate	cartilage	
Next	to	the	rapid	alterations	in	bone	volume	and	bone	cell	number	ZOL	treatment	resulted	
in	 a	 significant	 accumulation	 of	 proteoglycan-rich	 extracellular	 matrix	 around	 the	
epiphyseal	growth	plate,	thereby	changing	the	physical	environment	in	this	area	of	bone.	
Skeletal	 growth	 of	 long	 bones	 is	 achieved	 during	 endochondral	 ossification,	 a	 process	
mediated	 by	 chondrocyte	 proliferation,	 secretion	 of	 ECM,	 hypertrophy,	 terminal	
differentiation	 and	 ultimately	 chondrocyte	 death.	 ECM	 secreted	 by	 chondrocytes	 is	
composed	 of	 aggrecan,	 hyaluronan,	 collagen,	 proteoglycans	 and	 other	 non-collageneous	
proteins.	 In	 addition	 these	 cells	 secrete	 various	 growth	 factors	 to	 regulate	 their	
proliferation	and	hypertrophy	 including	BMPs,	 IGFs	and	VEGF	 (briefly	 reviewed	 in	 [271]).	
This	 in	 turn	 regulates	 the	 recruitment	 and	 invasion	 of	 cells	 to	 the	 ossification	 front	 to	
degrade	 and	 replace	 the	 cartilage	 matrix	 by	 ossified	 bone	 [53].	 Both	 osteoclasts,	
osteoblasts	and	endothelial	cells	are	required	at	the	ossification	front	to	maintain	normal	
growth	 plate	 physiology.	 In	 the	 absence	 of	 osteoclastic	 activity	 (induced	 by	 the	 BP	
clodronate)	 trabecular	bone	of	mice	was	elongated	due	 to	 the	 inability	of	 osteoclasts	 to	
invade	the	ossification	centre	[272].	However,	vascular	endothelial	cells	appear	to	be	the	
first	 cells	 to	 invade	 the	 growth	 plate	 potentially	 independent	 of	 the	 presence	 of	
osteoclastic	 activity	 and	 BP	 treatment	 [272].	 In	 addition	 osteoblasts	 are	 found	 at	 the	
ossification	 front	 where	 they	 deposit	 the	 bone	 matrix	 leading	 to	 the	 formation	 of	
trabecular	 bone	 surfaces.	 The	 increase	 in	 proteoglycan-rich	 ECM	 observed	 after	 ZOL	
treatment	might	therefore	be	a	consequence	of	altered	osteoblast	and	osteoclast	number	
and	activity.	
3.7.4. Effects	on	the	bone	marrow	vasculature	
To	visualise	potential	effects	of	ZOL	on	the	BME	I	performed	immunofluorescence	staining	
for	the	endothelial	cell	marker	Endomucin	on	gelatine	embedded	bone	samples	obtained	
during	collaborative	experiments	in	Boston,	USA.	
Any	 alteration	 in	 bone	 marrow	 vasculature	 prior	 to	 tumour	 cell	 dissemination	
could	affect	the	accessibility	and	therefore	colonisation	of	tumour	cells	 in	bone.	A	recent	
study	by	Ghajar	et	 al.	 has	 elegantly	 demonstrated	 the	 role	of	 the	 (peri)vascular	 niche	 in	
regulating	 tumour	 cell	 dormancy	 in	 vivo	 (mouse	 and	 zebra	 fish)	 and	 organotypic	
microvascular	 niches	 composed	 of	 human	 cells	 [101].	 The	 authors	 conclude	 that	 stable	
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microvasculature	 contains	 a	 dormant	 niche,	 whereas	 metastatic	 outgrowth	 happens	 at	
sprouting	 neovasculature,	 a	 process	 mediated	 by	 thrombospondin-1.	 Furthermore	 in	
breast	 cancer	 patients	 actively	 proliferating	 macro-metastases	 were	 found	 in	 great	
proximity	to	endosteal	surfaces	whereas	dormant	breast	cancer	cells	were	predominantly	
located	 adjacent	 to	 perisinusoidal	 niches	 [112].	 Whether	 the	 proposed	 endosteal	 niche	
overlaps	 with	 the	 vascular	 niche	 remains	 to	 be	 established	 however	 close	 interaction	
between	 those	 two	 is	 apparent:	 During	 bone	 formation	 osteoblasts	 are	 often	 detected	
adjacent	 to	vascular	endothelial	 cells,	 suggesting	 that	entry	of	osteoblast	precursors	 into	
developing	 bone	 is	 coupled	 to/directed	 by	 the	 invasion	 of	 blood	 vessels	 [53];	 data	
supported	by	Kusumbe	and	colleagues	demonstrating	that	osteogenesis	and	angiogenesis	
are	 closely	 coupled	 [51].	 In	 vitro	 ZOL	 has	 shown	 to	 inhibit	 proliferation	 of	 HUVECs	
suggesting	anti-angiogenic	properties	and	potential	of	the	drug	to	affect	the	 in	vivo	bone	
marrow	 vasculature.	 Using	 MicrofilTM	 perfusion	 followed	 by	 µCT	 analysis,	 Soki	 et	 al.	
showed	that	4-week	old	male	mice	treated	with	ZOL	for	4	weeks	(200µg/kg,	2x/week)	had	
reduced	vessel	thickness	and	increased	vessel	numbers	whereas	the	overall	vessel	volume	
fraction	was	not	affected	[159].	The	physiological	process	of	new	blood	vessel	formation	is	
a	very	rare	event	in	the	normal,	healthy	adult.	In	agreement	with	this	no	effects	of	ZOL	on	
bone	 marrow	 vasculature	 was	 determined	 in	 4-months	 old	 mice	 after	 4	 weeks	 of	 ZOL	
treatment	[159].	In	my	experiments	I	observed	alterations	in	the	vascular	architecture	in	6-
week	 old	 mice	 3	 days	 after	 a	 single	 dose	 of	 ZOL	 (100µg/kg).	 However	 this	 requires	
confirmation	by	quantitative	analysis	and	multiple	sections/samples.	Also	it	remains	to	be	
elucidated	whether	 the	observed	changes	 in	 structural	organisation	of	 the	bone	marrow	
vasculature	after	ZOL	treatment	is	due	to	direct	effects	of	the	drug	on	endothelial	cells	or	
due	to	the	altered	bone	structure.	
3.7.5. Effects	of	ZOL	pre-treatment	on	the	bone	metastasis	niche	
Targeting	 the	 BME	 with	 anti-resorptive	 agents	 including	 bisphosphonates	 has	 been	
standard	of	care	for	patients	with	cancer-induced	bone	disease	and	these	agents	are	also	
proposed	to	exhibit	direct	and/or	indirect	anti-tumour	effects	in	vivo	[147,	273].	
The	 AZURE	 (BIG	 01/04)	 trial	 enrolled	 3360	 women	 with	 stage	 II	 and	 III	 breast	
cancer	who	 received	 standard	 adjuvant	 therapy	 alone	 or	 in	 combination	with	 4mg	 ZOL.	
This	 study	 revealed	 reduced	 incidence	 of	 bone	 metastases	 in	 women	 receiving	 ZOL	
demonstrating	 beneficial	 effects	 of	 early	 ZOL-treatment	 [132].	 Although	 the	 underlying	
mechanisms	remain	to	be	established,	these	may	include	a	reduction	in	the	survival	and/or	
progression	of	 disseminated	 tumour	 cells	 in	 bone.	 This	 is	 supported	by	data	obtained	 in	
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model	systems,	showing	that	preventive	regimens	(e.g.	administration	of	BPs	prior	to	or	at	
the	 time	 of	 tumour	 cell	 injection)	 appear	 more	 effective	 compared	 to	 therapeutic	
treatment	 of	 established	 tumours	 [147].	 However,	 the	 focus	 of	most	 preventive	 in	 vivo	
studies	has	been	on	reduction	of	tumour	burden	and	the	associated	bone	disease	without	
assessing	the	effects	that	alterations	to	the	BME	may	have	on	tumour	cell	homing	to	bone.	
In	addition	the	AZURE	trial	suggested	that	patients	with	high	PINP	serum	levels	(a	marker	
for	osteoblast	activity)	at	study	entry	had	a	higher	risk	of	bone	metastasis	when	compared	
to	 patients	 with	 low	 PINP	 [132].	 However,	 potential	 consequences	 of	 BP	 treatment	 on	
osteoblasts	and	subsequent	tumour	cell	homing	to	bone	have	not	been	investigated	in	this	
context.	
Here	I	determined	if	ZOL	pre-treatment	and	the	therapeutic	induced	alterations	to	
the	 BME	 affect	 tumour	 cell	 homing	 to	 bone	 in	 vivo.	 The	 significant	 alterations	 in	
osteoclasts	and	osteoblasts	in	addition	to	the	accumulation	of	ECM	in	the	growth	plate	3-
10	days	post	ZOL,	raised	the	hypothesis	that	this	could	cause	alterations	to	the	location	of	
the	bone	metastatic	niche	and	subsequently	affect	tumour	cell	homing.	Injecting	MDA-MB-
231	breast	cancer	cells	5	days	post	ZOL	treatment	–	the	time	point	when	osteoblasts	were	
depleted	 form	 trabecular	bone	 surfaces	 -	 therefore	allowed	establishment	of	 the	 role	of	
osteoblasts	 in	 mediating	 tumour	 cell	 homing	 to	 bone.	 Additionally	 using	 two-photon	
microscopy	and	 immunofluorescence	enabled	analysis	of	 the	presence	of	 tumour	cells	 in	
different	areas	of	the	metaphysis	and	whether	this	is	modified	by	ZOL	pre-treatment.			
When	tumour	cells	arrived	in	mice	where	the	proposed	bone	metastasis	niche	area	
was	modified	by	ZOL	pre-treatment,	their	location	and	distribution	appeared	to	be	altered	
when	compared	to	control.	A	trend	towards	enrichment	of	tumour	cells	in	the	same	region	
of	the	metaphysis	where	ZOL	had	induced	accumulation	of	ECM	and	where	the	remaining	
osteoblasts	after	treatment	were	located	was	observed.		These	findings	need	validation	in	
independent	experiments	but	suggest	the	presence	of	particular	‘preferred’	osteoblast-rich	
niche	areas	 in	bone.	 In	 support	of	 this	are	 findings	 reported	by	Sasaki	and	colleagues.	 In	
these	 experiments	 the	 authors	 pre-treated	 3	 week	 old	 nude	mice	 daily	 for	 7	 days	 with	
risedronate	(4µg/mouse,	s.c.)	prior	to	 intracardiac	 injection	of	1x105	MDA-MB-231	breast	
cancer	 cells.	Upon	 cancer	 cell	 injection	 risedronate	 treatment	was	discontinued	 in	 these	
experiments.	At	experimental	endpoint	(day	28)	they	report	lower	numbers	of	osteoclasts	
and	that	metastatic	 invasion	of	breast	cancer	cells	was	restricted	to	the	area	adjacent	to	
the	epiphyseal	growth	plate	where	new	bone	would	have	been	formed	after	cessation	of	
risedronate	 treatment	 (observations	 made	 by	 histology)	 [149].	 Furthermore,	 a	 study	 by	
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Wang	and	colleagues	reports	abundant	expression	of	alkaline	phosphatase	and	collagen-I,	
both	 markers	 for	 osteoblastic	 lineage	 cells,	 in	 cells	 comprising	 “the	 microenvironment	
niche	of	microscopic	bone	lesions”.	Using	breast	cancer	models	(MCF-7,	4T1	or	MDA-MB-
361)	they	found	that	about	80%	of	cells	 in	the	niche	were	positive	for	ALP,	40-65%	were	
positive	 for	Col-I	and	only	20%	were	CTSK+	 (marker	 for	osteoclastic	cells)	 suggesting	 that	
the	niche	 in	early	bone	colonisation	 is	primarily	composed	of	osteoblastic	cells	 [94].	Also	
niche	cells	expressed	markers	of	osteognesis	including	RUNX2	and	Osterix	[94].	In	addition	
tumour	 cells	 are	 thought	 to	 harvest	 resources	 such	 as	 growth	 factors	 including	 TGFb,	
BMPs,	IGFs,	FGFs,	PDGFs	that	are	stored	in	bone	and	released	during	osteoclast	mediated	
bone	 remodelling	 [274]	 and	 osteoblast	 derived	 signals	 (in	 part	 required	 for	 HSC	
maintenance)	 including	 osteopontin,	 BMPs	 and	 RANKL,	 Notch	 signalling	 and	 PTH/PTHrP	
[102,	103].	Osteoblast	derived	adhesion	molecules	including	osteopontin	are	suggested	to	
be	 involved	 in	 tumour	 cell	 homing	 to	bone.	OPN	 for	 example	 interacts	with	 the	 integrin	
receptor	 αvβ3	 expressed	 on	 breast	 cancer	 cells	 and	 intravenous	 injection	 of	 αvβ3	 over-
expressing	breast	cancer	cells	has	been	associated	with	higher	metastatic	incidence	in	vivo	
[275].	 These	 studies	 demonstrated	 that	 inhibition	 of	 αvβ3	with	 a	 nonpeptide	 antagonist	
(PSK1404)	resulted	in	inhibition	of	osteoclast-mediated	bone	resorption	in	animal	models	
of	 bone	 metastasis	 and	 blocked	 colonisation	 of	 αvβ3-expressing	 cancer	 cells	 [275].	
Importantly,	 the	mapping	of	 individual	 tumour	cells	 in	bone	still	 remains	challenging	and	
whether	 modification	 of	 other	 elements	 that	 influence	 tumour	 cell	 homing	 (e.g.	 the	
vascular	niche,	the	HSC	niche)	are	modified	by	ZOL	remains	to	be	established.		
Additionally	these	data	show	that	pre-treatment	with	a	single	dose	of	ZOL	did	not	
affect	 the	 overall	 number	 of	 tumour	 cells	 homing	 to	 bone	 assessed	 by	 both,	 flow	
cytometry	 and	 two-photon	 microscopy.	 Others	 investigated	 the	 effects	 of	 ZOL	 pre-
treatment	on	B02	 (a	bone	 seeking	derivative	of	 the	MDA-MB231	 cell	 line)	breast	 cancer	
cell	 homing	 to	 bone	 (assessed	 by	 luciferase	 activity)	 in	 4-week	 old	 female	 BALB/c	 nude	
mice	 [146].	 In	 agreement	 I	 did	 not	 observe	 any	 differences	 in	 development	 of	 bone	
metastases	when	comparing	tumour	burden	in	mice	pre-treated	with	a	single	dose	of	ZOL	
or	control.	These	findings	suggest	that	repeated	treatment	with	BPs	is	needed	to	induce	a	
continuous	 inhibition	of	 bone	 resorption	 thereby	 allowing	 reduction	 and/or	 inhibition	of	
skeletal	 tumour	burden.	 In	 agreement	with	 this	 hypothesis	Neudert	et	 al.	 [144]	 and	 van	
der	Pluijm	[257]	report	beneficial	effects	of	the	BPs	(ibandronate	and	olpadronate)	on	the	
development	 and	 progression	 of	 bone	 metastases	 when	 continuous	 treatment	 was	
initiated	 prior	 to	 injection	 of	 MDA-MB231	 breast	 cancer	 cells	 in	 vivo.	 In	 support	 of	 my	
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findings	a	single	dose	of	ZOL	(100µg/kg)	1	day	prior	to	intravenous	injection	of	B02	breast	
cancer	cells	did	not	affect	luciferase	activity	(a	measure	of	skeletal	tumour	burden)	14	days	
post	injection,	or	reduce	the	area	of	bone	lesions	by	day	32	[146].	When	weekly	and	daily	
treatment	was	initiated	1	day	prior	to	tumour	cell	injection	reduced	luciferase	activity	was	
observed	suggesting	that	the	need	of	repeated	dosing	with	ZOL	to	successfully	reduce	the	
establishment	of	metastatic	disease	in	bone	[146].		In	agreement,	repeated	treatment	with	
ZOL	 is	shown	to	 increase	elimination	of	disseminated	breast	cancer	cells	 in	breast	cancer	
patients	 [191].	 Importantly	 reduced	 osteoclast	 activity	 is	 supposed	 to	 be	 the	 major	
mechanism	 behind	 the	 anti-tumour	 capacity	 of	 BP.	 However,	 also	 mice	 with	 defective	
osteoclasts	 receiving	ZOL	or	 control	10	and	3	days	prior	 to	 intra-arterial	 injection	of	B16	
melanoma	 cells	 showed	 an	 88%	decrease	 in	 tumour	 growth	 in	 bone	when	 compared	 to	
control.	 This	 study	 suggests	 a	 potential	 osteoclast	 –	 independent	 effect	 of	 N-BPs	 in	 the	
treatment	of	bone	metastasis	[143].		
3.8. Summary	and	Conclusion	
In	summary,	this	study	presents	novel	evidence	that	a	single,	clinically	relevant	dose	of	ZOL	
rapidly	induces	significant	alterations	to	both	the	cellular	component	and	the	extracellular	
matrix	of	the	metaphysis,	the	area	of	bone	comprising	the	metastatic	niche.	Although	the	
total	 number	 of	 breast	 cancer	 cells	 in	 bone	was	 not	 altered,	 there	was	 a	 trend	 towards	
accumulation	 of	 tumour	 cells	 in	 osteoblast-	 and	 proteoglycan-rich	 areas	 after	 ZOL	 pre-
treatment.	 In	addition	these	data	are	the	first	 to	show	that	breast	cancer	cells	appear	to	
preferentially	 localise	 to	 specific	 regions	 in	 the	metaphysis,	 but	 that	 they	may	 home	 to	
other	areas	if	challenged	by	an	altered	microenvironment.	These	findings	also	support	that	
osteoblasts	are	a	key	component	of	the	metastasis	niche.	
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4.1. Summary	
Cabozantinib	 (CBZ)	 is	 targeted	 against	 multiple	 receptor	 tyrosine	 kinases	 involved	 in	
tumour	 pathobiology,	 including	 hepatocyte	 growth	 factor	 receptor	 (MET)	 and	 vascular	
endothelial	 growth	 factor	 receptor	 2	 (VEGFR-2).	 CBZ	 demonstrated	 promising	 results	 in	
patients	with	 advanced	prostate	 cancer	with	 resolution	 of	 lesions	 visible	 on	 bone	 scans,	
implicating	 a	 potential	 role	 of	 the	 bone	microenvironment	 (BME)	 as	 a	 mediator	 of	 CBZ	
effects.		
I	performed	the	first	detailed	characterisation	of	the	effects	of	short-term	administration	
of	CBZ	(30mg/kg,	5	and	8	doses)	on	the	in	vivo	BME	in	the	absence	of	tumour.	Studies	were	
performed	 in	 a	 variety	 of	 animal	models	 of	 different	 age,	 sex	 and	 strain	 allowing	me	 to	
establish	the	therapeutic	response	to	CBZ	in	different	microenvironments.			
8	administrations	of	CBZ	resulted	in	increased	trabecular	thickness	and	further	significant	
effects	 on	 the	 BME	 were	 observed	 including	 a	 decrease	 in	 osteoclast	 and	 increase	 in	
osteoblast	numbers/mm	trabecular	bone	surface	compared	to	control	mice.	Irrespective	of	
administration	schedule	or	animal	model,	administration	of	CBZ	resulted	in	an	elongation	
of	the	growth	plate,	in	particular	the	hypertrophic	chondrocyte	zone.	In	addition	male	and	
female	 BALB/c	 nude	 mice	 had	 increased	 numbers	 of	 megakaryocytes	 and	 altered	 bone	
marrow	vasculature	following	CBZ	treatment.	Importantly,	effects	of	CBZ	on	the	BME	were	
transient	and	rapidly	lost	upon	treatment	termination.	
These	data	 reveal	 that	 short-term	administration	of	CBZ	 induces	 rapid,	 reversible	effects	
on	the	BME,	highlighting	a	potential	role	in	mediating	therapeutic	response	to	CBZ.		
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4.2. Introduction	
Effective	suppression	of	bone	metastasis	requires	therapeutic	targeting	of	both	the	tumour	
and	 the	 BME,	 hence	 use	 of	 agents	with	multiple	 targets	may	 provide	 an	 opportunity	 to	
improve	 outcome	 for	 patients	 with	 skeletal	 metastases.	 Cabozantinib	 (CBZ)	 targets	
multiple	 receptor	 tyrosine	 kinases	 (RTK)	 including	 hepatocyte	 growth	 factor	 receptor	
(MET)	and	vascular	endothelial	growth	factor	receptor	2	(VEGFR-2)	and	has	potential	as	an	
anti-tumour	agent	for	use	in	patients	with	bone	metastasis.		
Bone	metastasis	involves	complex	crosstalk	between	tumour	cells	and	cells	of	the	
BME	 including	 osteoclasts,	 osteoblasts,	 haematopoietic	 and	 vascular	 cells.	 Despite	
expression	on	 tumour	 cells,	CBZ	 target	 receptors	are	also	expressed	by	a	number	of	 cell	
types	 in	 bone	 including	 osteoblasts	 and	 osteoclasts	 [209-212,	 218].	 In	 addition	 to	
RANK/RANKL	 signalling,	 the	 MET	 and	 VEGF	 signalling	 pathways	 regulate	 the	 tightly	
balanced	coupling	between	osteoblasts	and	osteoclasts,	as	both	cell	 types	express	 target	
receptors	 [209-212]	 and	 are	 therefore	 potentially	 affected	 by	 CBZ.	 CBZ	 further	 inhibits	
phosphorylation	of	 KIT,	 RET,	AXL,	 TIE2,	 and	 FLT3	 [218]	 all	 of	which	might	 be	 involved	 in	
bone	remodelling	as	well	as	bone	cell	biology	[208,	213-215].	In	this	study	I	have	focused	
on	 exploring	 the	 potential	 role	 of	MET	 and	 VEGFR	 in	 the	 bone	 effects	 of	 CBZ	 although	
other	kinases	might	also	contribute	to	the	observed	effects.		
Clinical	 studies	 including	 a	 phase	 II	 randomised	 discontinuation	 trial	 of	 CBZ	 in	
patients	with	advanced	prostate	cancer	demonstrated	clinical	activity,	including	increased	
resolution	in	bone	scans,	reduction	in	serum	marker	levels	of	bone	remodelling,	in	addition	
to	pain	 relief	 in	more	than	60%	of	evaluable	patients	 [234,	235,	237].	Pre-clinical	 studies	
using	 in	 vivo	 models	 of	 prostate	 cancer	 bone	metastasis	 showed	 a	 decrease	 in	 tumour	
volume,	 tumour	 necrosis,	 suppression	 of	 tumour	 growth	 in	 addition	 to	 altered	 bone	
remodelling	 following	 long-term	 CBZ	 treatment,	 suggesting	 tumour	 cells	 [218,	 230]	 (see	
Table	10-12,	Figure	36)	as	well	as	cells	of	the	BME	as	potential	cellular	targets	of	CBZ	[231,	
233].		
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Figure	36	Schematic	representation	of	the	involvement	of	VEGF	and	HGF	signalling	in	bone	
remodelling	and	tumour	development.		
Target	 receptors	 of	 Cabozantinib	 (CBZ)	 including	VEGFR	 and	MET,	 both	 are	 expressed	on	 tumour	
cells	as	well	as	on	cells	of	the	BME	and	involved	in	regulating	their	proliferation,	differentiation	and	
survival.	Cells	of	the	BME	are	therefore	representing	potential	therapeutic	targets	of	CBZ.		
	
Effects	of	CBZ	on	tumour	cells	 in	vitro	and	 in	vivo	are	well	established	[218,	230,	
231,	235].	Briefly,	CBZ	resulted	in	decreased	viability,	proliferation,	migration	and	invasion	
of	 breast,	 lung,	 prostate	 and	 gastric	 cancer	 cells	 in	 vitro	 [218,	 230],	 in	 addition	 to	
decreased	prostate	 cancer	 growth	 in	 bone	 [230-233].	 In	 breast	 cancer	 xenograft	models	
CBZ	resulted	in	dose	dependent	inhibition	of	primary	MDA-MB-231	breast	tumour	growth	
(in	the	mammary	fat	pad)	and/or	stable	disease	(3-60mg/kg,	daily	for	14	days).	CBZ	did	not	
promote	 the	 formation	 of	 lung	 metastasis	 in	 these	 experiments	 (see	 Table	 10)	 [218].	
Importantly,	despite	the	frequent	diagnosis	of	bone	metastasis	 in	patients	with	advanced	
breast	cancer,	effects	of	CBZ	in	this	setting	have	not	been	established	yet.	
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Table	10	Effects	of	CBZ	on	breast	cancer	growth	in	vivo.		
Data	summarised	from	results	published	by	Yakes	et	al.	[218].	Note	that	these	experiments	did	not	
involve	 experiments	 assessing	 the	 role	 of	 CBZ	 in	 prevention	 and/or	 treatment	 of	 breast	 cancer-
induced	bone	disease.	
	
	
	
Importantly,	 these	 pre-clinical	 and	 clinical	 data	 strengthen	 the	 hypothesis	 that	 observed	
treatment	response	might	be	partially	mediated	by	cells	of	the	BME.	However	previously	
mentioned	studies	did	not	assess	 the	direct	effects	of	CBZ	on	the	BME	 in	great	detail.	 In	
vitro	assays	determining	the	impact	of	CBZ	treatment	on	bone	cells	showed	effects	of	the	
therapeutic	 agent	on	both	osteoblasts	 and	osteoclasts	 –	 summarised	 in	 greater	detail	 in	
Table	11.	CBZ	inhibited	differentiation,	proliferation	and	overall	resorptive	activity	in	RAW	
Animal	model	 Dose	of	CBZ	 Treatment	duration	 Effects	on	tumour	
Female	nu/nu	
mice,	1x106	
MDA-MB-231	
breast	cancer	
cells	injected	
subcutaneously	
into	the	
mammary	fat	
pad	
1,3,10,30,60	
mg/kg	
Daily	oral	
administration	for	14	
days	once	tumours	
reached	100,500	or	
1000mg	
Dose-dependent	inhibition	at	
3	and	10-mg/kg	doses	
Stable	disease	at	30-	and	
60mg/kg	
Female	nu/nu	
mice,	intra-
venous	injection	
of		1x106	MDA-
MB-231	breast	
cancer	cells	to	
assess	lung	
metastasis	
formation	
60mg/kg	
Daily	oral	
administration	for	28	
days	
No	promotion	of	lung	
metastasis	when	compared	to	
control	mice	
Female	nu/nu	
mice,	1x106	
MDA-MB-231	
breast	cancer	
cells	injected	sub	
cutaneously	into	
the	mammary	
fat	pad	
100mg/kg	
Daily	oral	
administration	for	4	
days	once	tumours	
reached	100mg	
Tumors	were	resected	at	4	
and	8	hours	after	the	first	
dose	and	4	hours	after	
consecutive	doses	
	
Early	effects:	
Increased	tumor	hypoxia	at	8	
and	4	hours	after	the	first	and	
second	dose	
	
Later	effects:	
Elevated	levels	of	apoptotic	
(78-fold)	and	hypoxic	(85-fold)	
cells	after	the	third	dose	
Reduction	in	Ki67	(55%)	and	
MECA-32	(75%)	
	
	 142	
264.7	pre-osteoclastic	cells	 in	two	independent	studies	[230,	276].	However,	 in	vitro	data	
on	osteoblastic	cells	are	contradictory,	with	some	reporting	 increased	mineralisation	and	
alkaline	 phosphatase	 (ALP)	 activity	 [231],	 whereas	 others	 found	 no	 effects	 of	 CBZ	 on	
mineralisation	[230]	and	biphasic	effects	on	ALP	[230,	276].		
The	 few	 studies	 investigating	 and	 reporting	 effects	 of	 CBZ	 on	 bone	 cells	 in	 vivo	
were	 all	 performed	 in	 models	 of	 prostate	 cancer-induced	 bone	 disease	 [230,	 231,	 233,	
235].	Indeed,	initial	observations	of	these	experiments	on	tumour-free	bone	in	mice	[230,	
231]	 indicate	that	CBZ	may	have	direct	effects	on	the	BME.	The	authors	report	 inhibitory	
effects	of	CBZ	on	osteoclasts	[230,	233]	and	stimulatory	effects	on	osteoblasts	[230,	232],	
summarised	 in	 greater	 detail	 in	 Table	 12	 below.	 However,	 the	 extensive	 loss	 of	 bone,	
combined	 with	 the	 profound	 effects	 of	 increasing	 tumour	 burden	 in	 this	 setting,	 could	
mask	the	effects	of	therapies	on	the	BME.	
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Table	11	Effects	of	CBZ	on	bone	cells	in	vitro	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Study	 Bone	cell	line	 Dose	 Effects	on	bone	cells	
Nguyen	
et	 al.	
[231]	
MC3T3	
	
0.01-3µM	 • Increased	mineralisation		
• Increased	alkaline	phosphatase	activity		
• Decreased	proliferation		
Stern	et	
al.		
[276]	
RAW	 264.7	
preosteoclas
t	cells	
	
MC3T3-E1	
osteoblastic	
1-10µM	 Osteoblasts	
• Decreased	RANKL	expression		
• Alkaline	phosphatase	–	biphasic	effects	
• Decreased	proliferation		
• Reduced	viability		
Osteoclasts	
• No	effect	on	expression	of	RANK,	cathepsin	
K,	integrin	αV,	integrin	β3,	TRAP	or	NFATc1	
after	24hr	culture		
• after	RANKL	induced	osteoclastogenesis		-	
reduction	in	activity	after	5	day	culture		
• Decreased	proliferation		
• Reduced	viability			
Dai	 et	
al.	
[230]	
Murine	
MC3T3	E1		
	
ST-2	 mouse	
bone	
marrow	
stromal	cells,	
	
RAW	 264.7	
mouse	
macrophage
/monocytes	
0.01-
5µmol/L		
Osteoblasts	
• Decreased	viability		
• Alkaline	phosphatase	–	biphasic	effects	
• Decreased	osteocalcin	expression		
• No	effect	on	mineralisation			
• Inhibited	phosphorylation	of	VEGFR2		
	
Osteoclasts	
• Inhibited	differentiation		
• Inhibition	of	overall	resorptive	activity		
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Table	12	Reported	effects	of	CBZ	on	tumour	and	bone	cells	in	vivo.	
Oc	is	Osteoclast,	Ob	is	osteoclast,	tb	is	tumoured	bone,	i.t.	is	intra	tibial,	s.c.	is	subcutaneously.	Note	
the	lack	of	studies	investigating	the	effects	of	CBZ	on	the	tumour	free	bone	microenvironment.	n.a.	
=	not	assessed	
	
Study	 Tumour	model	 Tumour	growth	
Effects	on	
bone	volume	
(tumour	
bearing	bone)	
Oc	 Ob	
Nguyen	
et.	 al	
[231]	
Prostate	
cancer	
	
LnCaP	 23.1	 (i.t.)	 (androgen-
sensitive,elict	 osteoblastic	
reaction)	
Decreased	
(i.b.)	
	
Decreased		
n.a.	 n.a	
C4-2B	 cells	 (i.t.)	 (castration	
resistant,	 elict	 mixed	
osteoblastic/osteolytic	
response)	
Decreased	
(i.b.)	
Increased		
	
C4-2B	 cells	 (s.c.)	 (androgen	
independednt,	 castration	
resistant,	 elict	 mixed	
osteoblastic/osteolytic	
response)	
Decreased	 n.a.	
BV/TV,	Tb.N.	increased,		Tb.Sp.	decreased	in	tumour-free	bone	
Dai		et.	al		
[230]		
Prostate	
cancer	
	
LnCaP	 35	 (s.c.)	 (androgen	
dependent	 Decreased	 n.a.	
De
cr
ea
se
d	
In
cr
ea
se
d	
Ace1luc	cells	(i.t.)	(osteoblastic)	 Decreased	(i.b.)	 Decreased	
C4-2Bluc	(i.t.)	(mixed)	 Decreased	(i.b.)	 Increased	
PC-3luc	(i.t.)(osteolytic)	 No	impact	 No	impact	
PC-3luc	(s.c.)	 Decreased	 n.a.	
No	affect	on	bone	mineral	content	in	tumour-free	bone	
Graham	
et.	 al		
[233]		
Prostate	
cancer	
VCaP	 BM1/cr-luc	 cells	
(castration	 resistant,	 androgen	
dependent,	osteoblastic)	(i.t.)	
	
Decreased	(i.b.)	
	
Increase	 in	
tumor-bearing	
to	 non-tumor-
bearing	
limb/bone	
volume	ratio		
Decreased	
exterior	 bone	
growth	
	
De
cr
ea
se
d	
n.a.	
Schimmo
ller	 et	 al.	
[232]	
Prostate	
cancer	
CRPC	 ARCaPM	
(osteoblastic/osteolytic)	(i.t.)	 Decreased	
Preserves	
bone	 volume	
and	 mineral	
content	
(tumour	
bearing	bone)	
N
o	
ef
fe
ct
s(t
b)
	
In
cr
ea
se
d(
tb
) 	
	 145	
In	summary,	both	clinical	and	preclinical	 studies	have	highlighted	 the	potential	of	CBZ	 to	
partially	mediate	its	treatment	response	by	modifying	cells	of	the	BME.		Therefore	I	have	
chosen	to	elucidate	the	effects	of	CBZ	on	bone	in	the	absence	of	tumour.	 	
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4.3. Hypotheses	
The	overall	hypothesis	in	this	chapter	is	to	test	whether	CBZ	partially	mediates	treatment	
effects	by	targeting	the	BME.	The	following	was	hypothesised:	
• Cabozantinib	 mediates	 treatment	 response	 in	 patients	 with	 bone	 metastasis	 by	
altering	bone	remodelling;	thus	disrupting	the	vicious	cycle.	
o Cabozantinib	 reduces	 osteoclast	 activity	 and	 number	 in	 the	 absence	 of	
tumour.	
o Cabozantinib	 increases	 bone	 volume	 by	 reducing	 bone	 resorption	 and/or	
increasing	osteoblast	activity.	
• Cabozantinib	 affects	 the	 bone	 marrow	 vasculature,	 which	 contributes	 to	 reduced	
tumour	growth	in	bone.	
• Further	 cell	 types	 of	 the	 BME	 (e.g.	 megakaryocytes,	 chondrocytes)	 express	 target	
receptors	 of	 Cabozantinib,	 hence	 effects	 of	 CBZ	 on	 these	 cell	 types	 contribute	 to	
therapeutic	response.		
4.4. Aims	and	objectives	
Within	the	aim	of	this	chapter	was	to	determine:	
• What	is	the	effect	of	Cabozantinib	on	osteoblasts	(number,	activity)?	
• What	are	the	effects	of	Cabozantinib	on	osteoclasts	(number,	activity)?	
• What	are	the	effects	of	Cabozantinib	on	bone	structure	and	volume?	
• Does	Cabozantinib	affect	other	cell	types	in	bone	(vascular	cells,	megakaryocytes,	
bone	marrow	cells	etc.)?	
• Does	 Cabozantinib	 modify	 the	 expression	 levels	 of	 genes	 associated	 with	 bone	
remodelling?	 	
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4.5. Material	and	methods	
A	summary	of	methods	and	analysis	used	can	be	seen	in	Table	13	below.	
Table	13	Summary	of	methods,	parameters	analysed	and	equipment	used	in	Chapter	4.	
Method	 Parameters	analysed	 Equipment	
Microcomputed	
tomography		
Bone	integrity	of	tibia:	
-Trabecular	bone	volume	(BV/TV	in	%)	
-Trabecular	number	(TB.N.	in	mm-1)	
-Trabecular	thickness	(Tb.Th.	in	mm)	
-SkyScan	1172	scanner	(SkyScan)	
-NRecon	software	
-CTAn	software	
Histological	assessment	
Tartrate-resistant	
acid	 phosphatase	
staining	(TRAP)		
-Osteoclast	 number	 per	 mm	 of	
trabecular	bone	surface	
-Osteoclast	size	(in	mm2)	
-OsteoMeasure	 software	
(OsteoMetrics)	
-Leica	DMRB	upright	microscope	
Haematoxylin	and	
Eosin	 staining	
(H&E)	
-Osteoblast	 number	 per	 mm	
trabecular	bone	surface	
-Quantification	of	growth	late	area	per	
tissue	area	
-Quantification	of	Megakaryocytes	per	
mm2	tissue	area	
-OsteoMeasure	 software	
(OsteoMetrics)	
-Leica	DMRB	upright	microscope	
Safranin-O	
staining	
-Alterations	in	growth	plate	area	
-Visualise	proteoglycan	
-OsteoMeasure	 software	
(OsteoMetrics)	
-Leica	DMRB	upright	microscope	
Immunofluoresce
nce	-	microscopy	
-Visualisation	 of	 Endomucin	 positive	
vascular	endothelial	cells		
-Alterations	in	bone	formation		
-Bone	formation	rate	
-Mineral	apposition	rate	
-Mineralising	surface	(%)	
-Leica	DMI4000B	microscope	and	
LAS	 AF	 Lite	 software	 (20x	
objective)		
-Nikon	 A1	 confocal	 microscope	
with	 NIS	 Elements	 software	 (40x	
objective)	
-OsteoMeasure	 software	
(OsteoMetrics)	
-Leica	DMRB	upright	microscope	
Enzymatic	analysis	
MouseTRAPTM	
Assay	
-Osteoclast	activity	 -MouseTRAPTM	 Assay	 from	
immunodiagnostic	 systems	 (SB-
TR103)	
Rat/Mouse	 PINP	
Enzyme	
immunoassay	
-Osteoblast	activity	 -Rat/Mouse	 PINP	 Enzyme	
immunoassay	for	the	quantitative	
determination	 of	 N-terminal	
propeptide	 of	 type	 I	 procollagen	
from	immunodiagnostic	systems	
Gene	expression	level	
Real	 time	 PCR	 –	
gene	expression	
-Expression	 of	 genes	 associated	 with	
bone	remodelling		
-TRIzol	 RNA	 extraction	 in	
combination	with	 the	 RNA	 Clean	
&	 Concentrator	 Kit	 	 (Zymo	
Research)		
-High	Capacity	RNA-to-cDNATM	Kit	
(Applied	Biosystems®)	
-ABI	 PRISM	 7900HT	 Sequence	
Detection	 System	 (Applied	
Biosystems)		
-SDS	2.1	software	
-TaqMan	 ®	 Gene	 expression	
assays	(Life	Technologies)	
Bone	marrow	cellularity	
Flow	cytometry	 -Percentage	of	haematopoietic	cells	 in	
bone	marrow	
-LSRII	(BD	Bioscience)	
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Protein	expression	
Western	blot	 -Met	receptor	phosphorylation	 -(c-Met	 [pY1230/34/35]	 Rb	
recombinant	 monoclonal	 Ab,	
Invitrogen,	 Clone	 5H27L59,	
1:1500;	Met	 Antibody	 (C-28),	 sc-
161,	Santa	Cruz)	
Statistical	analysis	
Statistical	analysis	 -Experimental	datasets	 -Prism	GraphPad	
Methods	not	described	below	can	be	found	in	the	general	methods	section	in	Chapter	2.	
4.5.1. Substance	preparation	
4.5.1.1. Preparation	and	administration	of	Cabozantinib	
Cabozantinib	 (XL184,	 CBZ),	 a	 kind	 gift	 from	 Exelixis	 Inc.,	 South	 San	 Francisco,	 California,	
USA)	 was	 prepared	 in	 sterile	 filtered	 dH2O	 according	 to	 company	 recommendations.	
Briefly,	CBZ	at	a	concentration	of	30mg/kg	was	dissolved	in	sterile	filtered	dH2O.	The	drug	
suspension	was	 placed	 in	 an	 ultrasonic	water	 bath	 for	 1min	 followed	 by	 brief	 vortexing	
(cycle	repeated	4	times).	To	aid	dissolution	and	ensure	better	tolerability	5μL	1N	HCl	per	
3mg/mL	 CBZ	 were	 added	 to	 the	 drug	 suspension	 as	 advised	 by	 Exelixis.	 The	 drug	 was	
administered	 via	 oral	 gavage	 needles	 attached	 to	 a	 1mL	 syringe,	 immediately	 after	
preparation	and	suspensions	prepared	fresh	every	day.	
4.5.1.2. Preparation	and	administration	of	Calcein		
Calcein	 intercorporates	 into	newly	calcified	bone	and	was	 therefore	used	 to	monitor	 the	
rate	of	new	bone	formation	following	CBZ	treatment.	Calcein	was	prepared	in	0.2%	sodium	
bicarbonate	and	injected	intraperitoneal	at	a	concentration	of	30mg/kg,	6	and	2	days	pre	
cull.		
4.5.2. Experimental	design	
As	breast	and	prostate	cancer	preferentially	metastasise	to	bone	I	incorporated	male	and	
female	 animals	 in	 my	 experiments.	 Using	 animals	 of	 different	 sex,	 age	 and	 strain	
additionally	 allowed	me	 to	 establish	 the	effects	 of	 CBZ	 in	 a	 range	of	microenvironments	
and	to	determine	the	degree	of	variability	between	these.	Animal	models	included	in	these	
experiments	are	as	 follows:	1)	6-week	old	male	BALB/c	nude	mice,	2)	6-week	old	 female	
BALB/c	 nude	 mice	 (BALB/c-Nude[Foxn1-Crl]; both	 Charles	 River,	 UK),	 3)	 8–9-week	 old	
female	genetically	engineered	mice	expressing	GFP+ve	cells	of	the	osteoblastic	lineage	on	
a	BALB/c	nude	background	((BALB/cAnNCrl.Cg-Tg(Col1a1-GFP)Row	Foxn1nu/nu,	described	
in	[158],	heterozygous,	referred	to	as	GFP	Ob+	mice)	and	4)	17-week	old	female	genetically	
engineered	 GFP	 Ob+	 mice	 (both	 Leeds	 Institute	 for	 Molecular	 Medicine,	 UK).	 As	 bone	
remodelling	is	reduced	with	increasing	age	using	two	cohorts	of	mice,	8-9-week	old	female	
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GFP	 Ob+	 (n=4/group)	 with	 a	 high	 bone	 turnover	 and	 17-week	 old	 female	 GFP	 Ob+	
(n=4/group)	mice	with	a	more	mature	skeleton	allowed	me	to	elaborate	the	effects	of	CBZ	
in	these	different	BMEs.	Breast	cancer	preferentially	metastasises	to	bone	hence	indicating	
the	potential	of	CBZ	as	a	potential	treatment	for	late	stage	disease.	Therefore	the	majority	
of	experiments	were	performed	in	female	animal	models.	
4.5.2.1. Treatment	schedules		
Previous	 studies	 give	evidence	 to	hypothesise	 rapid	effects	of	CBZ	on	bone	and/or	bone	
cells.	 In	 a	 model	 of	 prostate	 cancer	 bone	 metastasis	 Graham	 and	 colleagues	 observed	
reduced	 number	 of	 osteoclasts	 in	 tibiae	 of	 both	 tumour-bearing	 and	 tumour-free	 mice	
after	15	days	of	treatment	with	CBZ	(30mg/kg,	daily)	[233].	Additional	studies	by	Doran	et	
al.	observed	reduced	radiotracer	accumulation	at	the	site	of	bone	remodelling	in	mice	with	
surgically	 (fracture)-induced	 bone	 remodelling	 after	 7	 administrations	 of	 30mg/kg	 CBZ	
[236].	I	therefore	aimed	to	establish	the	short-term	effects	of	5	and	8	doses	of	CBZ	on	the	
naïve		in	vivo	BME.	
Animals	were	randomised	in	two	groups	receiving	(1)	30mg/kg	CBZ	(200μL)	or	(2)	
sterile	 H2O	 control	 (200μL).	 8-9-,	 and	 17-week	 old	 GFP-Ob+	 mice	 (n=4/group)	 received	
30mg/kg	CBZ	or	 sterile	H2O	control	5x	weekly	 for	5	days	 (cumulative	dose	of	150mg/kg)	
and	 were	 culled	 24hrs	 after	 the	 last	 treatment	 (Fig.	 37A).	 6-week	 old	male	 and	 female	
BALB/c	nude	(n=4-5/group)	as	well	as	female	9-week	old	GFP	Ob+	mice	(n=4/group)	were	
administered	30mg/kg	CBZ	or	sterile	H2O	control	5x	weekly	for	10	days	(8	administrations	
in	 total,	 cumulative	 dose	 of	 240mg/kg	 CBZ).	 Animals	 were	 culled	 6hrs	 after	 the	 last	
treatment.	 To	monitor	 the	 rate	 of	 bone	 formation	 Calcein	 (30mg/kg,	 100μL,	 i.p.,	 Sigma-
Aldrich)	was	injected	6	and	2	days	pre	cull	(for	the	10	day	treatment	schedule)	and	4	and	2	
days	pre	cull	(for	the	5	day	treatment	course,	8-9-week	old	mice)	respectively.	Additional	
animals	were	culled	on	day	15	and	22	to	assess	the	reversibility	of	effects	5	and	12	days	
after	the	last	administration	of	CBZ,	respectively	(Fig.	37B).	
An	 additional	 pilot	 experiment	 using	 10-week	 old	 male	 C57BL/6J	 mice	 (n=3/4	
group)	 receiving	 the	 previously	 described	 treatment	 schedule	 was	 performed	 for	 future	
method	establishment.	1	animal	per	group	was	culled	3.5hrs	post	treatment	termination,	
the	remaining	animals	24hrs	after	the	last	dose.		
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Figure	37	Schematic	outline	of	the		in	vivo	studies	investigating	the	effects	of	CBZ	on	the	bone	
microenvironment.		
(A)	8-9-	and	17-week	old	female	GFP	Ob+	mice	(n=4/group)	received	30mg/kg	Cabozantinib	(CBZ)	or	
sterile	H2O	control	(CTRL)	5x	weekly	for	5	days	via	oral	gavage.	Animals	were	killed	24hrs	after	the	
last	treatment	administration.	(B)	Male	and	female	6-week	old	BALB/c	nude	as	well	as	9-week	old	
female	GFP	Ob+	mice	(n=4-5/group)	received	8	doses	of	30mg/kg	CBZ	or	sterile	H2O	control	(CTRL).	
Animals	were	killed	6hrs	after	the	last	administration.	To	monitor	if	treatment	effects	of	CBZ	were	
maintained	once	treatment	was	terminated	additional	female	BALB/c	nude	mice	were	culled	5	(Day	
15)	and	12	days	(Day	22)	after	treatment	termination.	
	
To	determine	longer-term	effects	of	CBZ	on	the	BME	I	obtained	paraffin	embedded	
bone	 samples	 from	 collaborative	 experiments	 [231,	 233].	 	 These	 samples	 included	
contralateral,	 non-tumour	 bearing	 tibiae	 from	 castrated	 adult	 male	 NOD/SCID	 mice	
(injected	intratibially	with	VCaP	BM1/cr-luc	prostate	cancer	cells,	30mg/kg	CBZ	daily	for	15	
days	(n=6-7/group)	[233],	as	well	as	tibiae	from	6-week	old	castrated	male	beige	SCID	mice	
(injected	intratibially	with	C4-2B	prostate	cancer	cells,	60mg/kg	CBZ	5x	weekly	for	6-weeks	
(n=9-10/group)	[231].	
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4.5.3. Effects	of	CBZ	on	osteoblasts	and	osteoclasts	
Number	and	activity	of	osteoblast	and	osteoclast	was	assessed	as	described	in	Chapter	2,	
Section	2.2.10.7.		
4.5.4. CBZ-induced	alterations	in	growth	plate	composition	
To	determine	 the	effects	of	CBZ	on	growth	plate	chondrocytes,	an	area	of	 interest	 (AOI)	
was	 interactively	drawn	around	the	total	growth	plate	area,	 the	resting/proliferating	and	
hypertrophic	 chondrocyte	 zones	 using	 OsteoMeasure	 software	 (Fig.38A-C),	 4x	 objective	
and	a	Leica	DMRB	upright	microscope.	Both	growth	plate	areas	of	interest	(AOIs,	in	mm2)	
were	then	normalised	to	total	epiphyseal	growth	plate	area	(mm2)	(Fig.38A-C)	and	data	are	
presented	as	AOI	(mm2)/	total	growth	plate	area	(in	mm2).	The	total	length	of	the	growth	
plate	 was	 assessed	 usually	 covering	 3-4	 fields	 of	 view	 with	 each	 having	 a	 total	 area	 of	
625µm	x	625µm.	Growth	plate	area/total	tissue	area	for	each	sample	was	then	calculated	
for	 2	 non-serial	 levels.	 	 Analysis	 was	 performed	 on	 H&E	 stained	 sections	 using	 a	 4x	
objective.	
	
	
	 152	
	
Figure	38	Analysis	of	Cabozantinib	effects	on	the	growth	plate	chondrocytes.		
To	determine	effects	of	Cabozantinib	treatment	on	growth	plate	chondrocytes	 it	was	 interactively	
drawn	 around	 the	 total	 growth	 plate	 (GP)	 area	 (blue),	 the	 resting/proliferating	 (green)	 and	
hypertrophic	 (pink)	 chondrocyte	 area	 using	OsteoMeasure,	OsteoMetrics	 software,	 black	 squares	
represent	fields	of	view	with	an	area	of	625x625µm.	(A)	Analysis	was	performed	using	a	Leica	DMRB	
microscope,	4x	objective.	(B)	shows	parameter	specifications	used	for	drawing	around	the	separate	
zones.	 (C)	 shows	 representative	 data	 obtained	 from	 one	 field	 of	 view.	 For	 data	 representation	
individual	 growth	 plate	 zones	 (in	 mm2)	 were	 normalised	 to	 total	 growth	 plate	 area	 (in	 mm2),	
thereby	representing	the	proportion	of	the	individual	zones	per	total	growth	plate	area.		
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4.5.5. Quantification	of	bone	marrow	megakaryocytes	
To	assess	alterations	in	bone	marrow	cellularity	the	number	of	megakaryocytes	on	2	non-
serial	 H&E	 stained	 histological	 sections	 was	 scored	 using	 OsteoMeasure	 software	
(OsteoMetrics)	 and	 a	 Leica	 DMRB	 upright	 microscope	 (10x	 objective).	 Megakaryocytes	
were	 identified	by	 their	 characteristic	 shape	and	 large	 lobulated	nucleus	 (see	Fig.39).	All	
megakaryocytes	 per	 mm2	 tissue	 area	 were	 scored	 commencing	 125µm	 away	 from	 the	
growth	plate.	An	area	with	the	 length	of	1250µm	(5	fields	of	view	with	250µm	in	 length,	
measured	 on	 the	medial	 side	 of	 the	 tibia)	was	 assessed.	 Scored	megakaryocyte	 number	
was	then	normalised	to	the	total	tissue	area	scored	(see	Fig.	39)	and	data	are	represented	
as	megakaryocyte	numbers/mm2	tissue	area.	
	
	
	
Figure	39	Assessing	efects	of	CBZ	on	megakaryocytes.		
Number	of	megakaryocytes	was	scored	for	a	total	tissue	area	with	the	length	of	1250µm	(measured	
on	the	medial	side	of	the	tibia).	Number	of	megakaryocytes	was	then	normalised	to	the	total	tissue	
area	 assessed.	 Each	 square	 represents	 a	 field	 of	 view	 with	 250µm	 x	 250µm.	 OsteoMeasure	
software,	OsteoMetrics,	Leica	DMRB	microscope	and	a	10x	objective	were	used.		
	
	
	
M
ed
ia
l'
La
te
ra
l'
1250µm'
Megakaryocyte'scoring'
*'
*'
*'
Number'of'megakaryocyteswas'scored'for'a'total'4ssue'area'with'the'length'of'
1250µm'(measured'on'the'medial'side'of'the'4bia).'Number'of'megakaryocytes'was'
then'norm lised' o'the'total'4ssue' rea'assess d.'E ch'square'represents'a'ﬁeld'of'
vi w'with'250µm'x'250µm.'Oste measure'soGware,'O teoMetrics,'Leica'XXX'
microscope'and'a'10x'objec4ve'were'used.''
	 154	
4.5.6. Visualisation	of	bone	marrow	endothelial	vascular	cells		
To	visualise	effects	of	CBZ	on	the	bone	marrow	vasculature	immunofluorescence	staining	
against	the	endothelial	cell	marker	Endomucin	was	performed	on	3µm	histological	sections	
of	 paraffin	 embedded	 tibiae	 as	 described	 in	 Chapter	 2,	 Section	 2.2.10.6.2.	 Images	 were	
acquired	using	a	Leica	DMI4000B	microscope	and	LAS	AF	Lite	software	(20x	objective)	and	
a	Nikon	A1	confocal	microscope	with	NIS	Elements	software	(40x	objective).	
4.5.7. Assessment	of	bone	formation	rates	using	calcein	double-labelling	
Calcein	 intercorporates	 into	 newly	 formed	 bone	 and	 was	 therefore	 used	 to	 establish	
effects	 of	 CBZ	 on	 bone	 formation	 rate.	 Calcein	 analysis	 was	 performed	 on	 histological	
sections	of	lumbar	vertebra	4	from	6-week	old	female	BALB/c	nude	mice	(n=4/group)	that	
received	 10-day	 treatment	 of	 30mg/kg	 Cabozantinib	 (8	 administrations)	 or	 H2O	 control,	
respectively.		
Darren	 Lath,	 University	 of	 Sheffield,	 UK,	 kindly	 provided	 a	 protocol	 for	 Calcein	
analysis	of	 long	bones,	which	 I	adapted	 for	 the	analysis	of	vertebrae	 for	my	experiments	
(see	Figure	40).	 	Analysis	was	performed	using	OsteoMeasure	software	(OsteoMetrics),	a	
Leica	 DMRB	 upright	 microscope	 with	 a	 10x	 objective.	 The	 following	 parameters	 were	
determined	by	manually	 drawing	 around	 the	 bone	 surfaces/calcein	 labels.	 The	 following	
table	explains	analysed	parameters	and	data	analysis:	
Table	14	Parameters	analysed	during	assessment	of	calcein	labelling	
Parameter	 Abbreviations	 Definition	
Mineralisation	Surface	
(MS,%)	=	
((dL+0.5sL)/BPm.)x100	
	
dL:	double	label	perimeter	
sL:	single	label	perimeter	
BPm.:	bone	perimeter	
	
Extent	of	actively	mineralising	
bone	surface	
Mineral	apposition	rate	
(MAR,	µm/day)	=	
IL.W/number	of	days	
between	injections	
	
IL.W:	inter-label	width,	distance	
between	double	labels	
	
	
Distance	between	the	labels	
divided	by	the	time	between	
labelling;	rate	at	which	
osteoblasts	are	producing	
new	matrix	!	measures	Ob	
activity	
Bone	formation	rate	(BFR,	
mm2	x10-3/mm/day)	=	
(MARx(dL+0.5sL))/BPm	
	
See	above	
Multiplies	the	MAR	by	the	
fraction	of	bone	surface	that	
is	labelled	!	takes	into	
account	how	much	of	the	
bone	surface	is	actively	
mineralising		
Information	obtained	from	[277].	
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For	vertebrae,	analysis	was	started	250µm	away	from	the	growth	plate	and	250µm	away	
from	the	cortical	bone	surface.	All	 cortical	bone	surfaces	were	excluded	 from	analysis.	A	
total	 area	 comprising	 9	 squares	 of	 interest	 (each	 accounting	 for	 250µmx250µm)	 was	
analysed.	 It	 was	 manually	 drawn	 around	 trabecular	 bone	 surfaces,	 single	 and	 double	
calcein	 labels	 using	 a	 10x	 objective	 and	 OsteoMeasure	 software	 (Fig.40).	 Only	 one	
histological	level	per	sample	was	assessed.		
	
Figure	40	Assessing	effects	of	CBZ	on	bone	formation	using	Calcein	double-labelling.		
Analysis	was	started	250µm	away	from	the	growth	plate	and	250µm	away	from	the	cortical	bone	
surface.	All	cortical	bone	surfaces	were	excluded	from	analysis.	A	total	area	comprising	9	squares	of	
interest	 (each	 accounting	 for	 250µmx250µm)	 was	 analysed.	 It	 was	 manually	 drawn	 around	
trabecular	bone	surfaces,	single	and	double	calcein	labels	using	a	10x	objective	and	OsteoMeasure	
software.	Only	one	histological	level	per	sample	was	assessed.		
4.5.8. Gene	expression	analysis	
On	day	of	cull,	bones	were	 immediately	preserved	 in	RNAlater	Tissue	Collection	Solution	
(Ambion,	 Life	 Science	 Technologies),	 followed	 by	 dividing	 into	 halves	 and	 manually	
scraping	out	bone	marrow	using	scalpels	and	razor	blades.	Samples	where	then	processed,	
RNA	extracted	and	cDNA	synthesised	as	described	in	Chapter	2,	Section	2.2.10.9.	Tibia	and	
femur	from	each	mouse	were	pooled	to	ensure	sufficient	concentration	of	extracted	RNA.	
Alterations	 in	 genes	 associated	 with	 bone	 remodelling	 was	 assessed	 using	 qRT-
PCR.	 Genes	 of	 interest	 included	 OPG	 (Mm00435451_m1),	 RANKL	 (Mm00441906_m1),	
RANK	 (Mm00437135_m1;	 Mm00437132_m1),	 Vegf	 (Mm01281449_m1)	 and	 Sox9	
(Mm00448840_m1).	Data	were	normalised	 to	B2M	(Mm00437762_m1)	expression	 levels	
(see	Table	15	below).	
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Table	15	Summary	of	genes	analysed	following	Cabozantinib	administration	
Gene	 Function	
OPG	(Osteoprotegerin)	 Decoy	receptor	for	RANKL;	inhibits	osteoclast	differentiation,	fusion,	and	activation;	negative	regulator	of	bone	remodeling	
RANK	(Receptor	Activator	of	
NF-κB)	 Essential	for	osteoclastogenesis	
RANKL	(Receptor	Activator	of	
Nuclear	Factor	NF-κB	Ligand)	
Required	for	osteoclastogenesis	and	osteoclastic	bone	
resorption	
Vegf		(Vascular	Endothelial	
Growth	Factor)	 Angiogenesis	
Sox	9	 Transcription	factor		for	chondrogenesis		
4.5.9. Flow	cytometric	evaluation	of	effects	of	CBZ	on	bone	marrow	cellularity	–	a	pilot	
study	
The	effects	of	CBZ	on	bone	marrow	composition	were	 confirmed	by	histopathologist	Dr.	
Keith	Hunter.	I	aimed	to	detect	alterations	in	bone	marrow	cellularity	after	CBZ	(30mg/kg,	
o.g.)	 or	 sterile	 H2O	 control	 in	 10-week	 old	male	 C57BL/6J	mice	 receiving	 the	 previously	
described	 10-day	 administration	 regimen	 using	 flow	 cytometry.	 Animals	 were	 sacrificed	
3.5hrs	 post	 administration	 (n=1/group)	 and	24hrs	 post	 administration	 (n=3	 for	 CTRL	 and	
n=2	for	CBZ).	
Right	 hind	 legs	 were	 dissected	 and	 soft	 tissue	 removed.	 Tibia	 and	 femur	 were	
separated,	proximal	 end	 removed	using	a	 scalpel	 and	 the	bone	marrow	was	 flushed	out	
with	1mL	FACS	buffer	(1%FBS	in	PBS	(w/o	Mg2+,	Ca2+))	by	inserting	a	25G	needle.	Flushing	
was	repeated	3	times	or	until	the	bone	appeared	translucent.	Bone	marrow	aspirates	from	
the	right	tibia	and	femur	were	pooled	for	each	mouse	and	filtered	through	a	100-µm	cell	
strainer	(BD	Falcon).	
		 The	 2mL	 cell	 aspirate	was	 centrifuged	 at	 2500rpm	 (MSE	Mistral	 2000;	 ≈1121xg)	
and	resuspended	in	1mL	FACS	buffer	prior	to	aliquoting	into	individual	tubes	for	analysis	as	
outlined	below.	For	each	animal	fluorescence	minus	one	(FMO)	controls	were	included	as	
outlined	 in	Table	16.	Cell	 suspensions	were	 centrifuged	at	2500rpm	 (Heraeus	FRESCO21;	
≈600xg)	at	4°C	for	5	minutes	and	redissolved	in	200µL	FACS	buffer	containing	appropriate	
antibodies	(1µL	of	Ab	per	200µL	FACS	buffer).	Samples	were	stained	for	30min	in	the	dark	
using	Anti-Mouse	 CD41	 PE	 (eBioscience,	 Clone:	 eBioMWReg30	 (MWReg30),	 Cat.	No:	 12-
0411-81),	 Anti-Mouse	 TER-119	 APC	 (eBioscience,	 Clone:	 TER-119,	 Cat.	 No:	 17-5921-81),	
Brilliant	Violet	421™	anti-mouse	CD45	Antibody	(BioLegend,	Clone	30-F11,	Cat.No:	103133)	
and	LIVE/DEAD®	Fixable	Near-IR	Dead	Cell	Stain	(Life	technologies,	Cat.No.:	L10119).	 
	 157	
	
Table	16	Sample	preparation	for	flow	cytometric	analysis	including	relevant	controls	
(Fluorescence	Minus	One)	 				
Next	 samples	were	washed	2	 times	 in	 FACS	buffer	 (400µL,	 at	 2500rpm,	Heraeus	
FRESCO21,	 ≈600xg	 at	 4°C)	 prior	 to	 immediate	 analysis	 using	 flow	 cytometry	 (LSRII,	 BD	
Bioscience).	600000	events	were	recorded	 for	each	sample,	medium	flow	rate	was	used.	
Samples	 were	 run	 and	 gates	 set	 by	 the	 Flow	 Cytometry	 Core	 Facility,	 University	 of	
Sheffield,	UK.		
Table	17	Laser	settings	for	flow	cytometric	analysis	and	corresponding	dyes	
Emission/Filter	 VOLTAGE	 DYE	
Red	780	 555	 Near	infrared	
Violet	450	 570	 Brilliant	violet	421	
Blue	575	 712	 PE	
Red	660	 692	 APC		
4.5.10. Western	blot	analysis	for	phosphorylated	MET		
To	 determine	 phosphorylation	 of	 MET	 snap	 frozen	 liver	 samples	 of	 10-week	 old	 male	
C57BL/6J	 mice	 receiving	 the	 previously	 described	 10-day	 administration	 course	 of	 CBZ	
were	 analysed	 for	 protein	 expression	 of	 MET	 and	 phosphorylated	 MET	 (24hrs	 post	
administration	n=2	for	CBZ	and	n=3	for	CTRL;	n=1/group	3.5hrs	post	administration).	Liver	
samples	 were	 lysed	 using	 the	 Mammalian	 Cell	 Lysis	 Kit	 (Sigma	 Aldrich,	 MCL1-1K)	 with	
added	HaltTM	Protease	&	Phosphatase	 Inhibitor	Cocktail	 (Thermo	Scientific,	Prod#78440).	
Protein	 concentration	 of	 lysates	 was	 assessed	 using	 the	 BCA	 assay	 and	 50ng	 for	 each	
sample	run	on	10%	gels.	Gels	were	run	at	200V	for	1hr,	 transferred/blotted	for	70min	at	
70V.	 Membranes	 were	 blocked	 in	 5%	 BSA,	 incubated	 in	 primary	 antibody	 (c-Met	
[pY1230/34/35]	Rb	recombinant	monoclonal	Ab,	 Invitrogen,	Clone	5H27L59,	1:1500;	Met	
Antibody	 (C-28),	 sc-161,	 Santa	 Cruz),	 1:100	 as	 recommended	 by	 manufacturers	
instructions)	overnight.	Within	the	recommended	dilution	range	of	1:100-1:1000	the	Met	
antibody	was	tested	at	a	concentration	of	1:100-1:200;	no	expression	was	determined	at	a	
For	each	mouse	
Bone	marrow	flush	(µL)	 Labelling	
150	 All-Ter119	
150	 All-Viability	
150	 All	-	(Ter119+Viability)	
200	 All	Abs	
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concentration	 of	 1:200,	 with	 clear	 bands	 obtained	 at	 a	 concentration	 of	 1:100;	 the	
concentration	 used	 for	 further	 experiments.	 The	 c-Met	 [pY1230/34/35]	 antibody	 was	
tested	at	a	concentration	of	1:1000	and	1:1500;	slight	background	was	observed	at	1:1000,	
which	was	 eliminated	 by	 reducing	 the	 antibody	 concentration	 to	 1:1500.	 The	 Secondary	
antibody	was	Anti-Rabbit	IgG	(Dako	P0488,	1:30000).	After	membrane	stripping	(RestoreTM	
Western	 Blot	 Stripping	 Buffer,	 Thermo	 Scientific)	 GAPDH	 (Ms	 mAB	 to	 GAPDH	 [6C5],	
Abcam,	ab8245,	1:40000	 (working	concentration	previously	optimised	 in	our	 laboratory))	
was	used	as	a	loading	control	(secondary	antibody:	Polyclonal	Goat	Anti-Mouse	Iggs	HRP,	
Dako,	 P0447).	 Western	 blot	 optimisation	 was	 kindly	 assisted	 by	 Diane	 Lefley,	 Resarch	
Technician,	University	of	Sheffield.	
4.5.11. Statistical	Analysis	
Statistical	 analysis	was	 performed	 using	 GraphPad	 Prism	 Version	 6.0.	 Analysis	was	 done	
using	 unpaired	 Student’s	 t-test	 or	 2-way	 ANOVA	 with	 Bonferroni’s	 post-test.	 Statistical	
tests	 applied	 are	 specified	 underneath	 the	 corresponding	 figures	 or	 if	 no	 graphs	 are	
presented	next	to	the	raw	data.	 	
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4.6. Results	
4.6.1. The	BME	is	modified	following	5-days	of	Cabozantinib	administration	
This	 study	aimed	 to	establish	whether	 short-term	 treatment	with	CBZ	affects	 the	BME.	 I	
therefore	initially	administered	30mg/kg/day	CBZ	for	5	days	(cumulative	dose	=	150mg/kg)	
and	 assessed	 osteoblast	 and	 osteoclast	 number	 per	 mm	 trabecular	 bone	 surface,	 in	
addition	to	bone	volume	and	structure,	as	compared	to	H2O	control.	Two	cohorts	of	mice	
were	 used;	 8-9-week	 old	 female	 animals	 with	 a	 high	 bone	 turnover	 and	 17-week	 old	
female	animals	with	a	more	mature	skeleton,	allowing	comparison	of	the	effects	of	CBZ	in	
these	different	bone	BMEs	(Fig.37A).		
4.6.1.1. CBZ	effects	on	osteoblasts	
Osteoblasts	 were	 identified	 based	 on	 their	 characteristic	morphology	 and	 quantified	 on	
H&E-stained	tissue	sections.	In	addition,	I	used	genetically	engineered	mice	expressing	GFP	
in	 cells	 of	 the	 osteoblastic	 lineage	 to	 confirm	 the	 effects	 of	 CBZ	 on	 osteoblasts	 by	
immunofluorescence	(hereafter	called	GFP	Ob+,	Fig.41	A&B).	After	5	daily	administrations	
of	 30mg/kg	 CBZ,	 there	 were	 significantly	 increased	 numbers	 of	 osteoblasts	 lining	 the	
trabecular	bone	surfaces	in	17-week	old	GFP	Ob+	mice	(CTRL:	17.92	±	2.11	vs.	CBZ:	44.02	±	
3.63,	p≤0.001,	Fig.41C).	This	effect,	was	also	seen	in	8-9-week	old	GFP	Ob+	mice,	although	
less	prominent	(CTRL:	20.60	±	2.46	vs.	CBZ:	31.96	±	2.21,	p≤0.05,	Fig.41A&B,E).	Despite	the	
increase	 in	 osteoblast	 number,	 there	 was	 no	 significant	 difference	 in	 osteoblast	 activity	
(serum	PINP	 levels)	between	 the	 treatment	groups	 (17-week	old	GFP	Ob+:	CTRL:	33.17	±	
2.74ng/mL	 vs.	 CBZ:	 39.90	 ±	 3.64ng/mL,	 Fig.41D;	 8-9-week	 old	 GFP	 Ob+:	 CTRL:	 81.35	 ±	
6.97ng/mL	vs.	CBZ:	86.87	±	22.52	ng/mL;	Fig.41F).	
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Figure	41	Effects	of	5-day	treatment	with	Cabozantinib	on	osteoblasts.		
8-9	week	old	 	and	17-week	old	GFP	Ob+	mice	 received	5	doses	of	30mg/kg	Cabozantinib	 (CBZ)	or	
sterile	 H2O	 control	 (CTRL).	 (A)	 Representative	 histological	 sections	 of	 tibiae	 showing	 GFP+ve	
osteoblastic	 cells	 lining	 trabecular	 bone	 surfaces	 by	 immunofluorescence,	 20x	 objective.	 GFP+ve	
osteoblasts	are	shown	 in	green.	 (C&E)	Osteoblast	number/mm	trabecular	bone	surface	and	(D&F)	
osteoblast	 activity	 (measured	 by	 serum	 PINP	 levels),	 respectively	 after	 5-day	 administration	 of	
Cabozantinib	 (CBZ,	 30mg/kg)	 or	 H2O	 control	 (CTRL).	 (C&D)	 represents	 results	 for	 17-week	 old	
(n=4/group)	 and	 (E&F)	 for	 8-9-week	 old	 GFP	 Ob+	 mice	 (n=4/group).	 Osteoblast	 number/mm	
trabecular	bone	 surface	was	 scored	on	2	non-serial	histological	H&E	 stained	 sections	per	 sample.	
Student’s	 t-test,	 ns	 is	 non	 significant,*	 is	 p≤0.05,	 ***	 is	 p≤0.001.	All	 data	 show	Mean±SEM.	 Tb	 =	
trabecular	bone,	osteoblast	are	indicated	with	white	arrowheads.		
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4.6.1.2. Effects	on	osteoclasts	
The	number	of	osteoclasts/mm	trabecular	bone	surface	was	determined	on	TRAP-stained	
histological	 sections.	 Five	daily	 administrations	of	CBZ	 induced	a	 substantial	 reduction	 in	
osteoclast	number/mm	trabecular	bone	surfaces	in	8-9-week	old	GFP	Ob+	mice	compared	
to	CTRL	(CTRL:	6.91	±	0.39	vs.	CBZ:	3.95	±	0.24,	p≤0.001,	Fig.42A&B,	Fig.43A).	In	contrast,	
osteoclast	number	was	not	altered	in	older	(17-week	old)	GFP	Ob+	mice	(CTRL:	3.65	±	0.37	
vs.	 CBZ:	 2.93	 ±	 0.43,	 Fig.43B),	 probably	 reflecting	 the	 age-related	 reduction	 in	 bone	
remodelling.	 Osteoclast	 activity	 (TRAP)	was	 not	 affected	 by	 CBZ	 administration	 in	 either	
model	(8-9-week	old	GFP	Ob+:	CTRL:	7.82	±	0.75	U/L	vs.	CBZ:	9.16	±	1.50	U/L;	17-week	old	
GFP	Ob+:	CTRL:	11.14	±	1.75	U/L	vs.	CBZ:	15.20	±	1.50	U/L,	Fig.43B,D).	Osteoclast	size	was	
not	altered	in	both	mouse	models	following	CBZ	treatment	when	compared	to	control	(8-
9-week	 old	 GFP	 Ob+:	 CTRL:	 7.47x10-5	±	 4.94x10-6mm2	vs.	 CBZ:	 7.15x10-5	±	 2.04x10-6mm2,	
Fig.43E;	17-week	old	 female	GFP	Ob+	mice:	CTRL:	6.69x10-5	±	7.11x10-6mm2	vs.	CBZ:	8.14±	
3.49x10-6mm2,	Fig.43F).	
	
Figure	42	Illustration	of	the	effects	of	5	doses	of	Cabozantinib	on	osteoclasts	and	osteoblasts	in	
vivo.	
(A)	 Representative	 TRAP-stained	 histological	 bone	 tissue	 sections	 from	 8-9	 week	 old	 mice	
illustrating	the	decrease	in	osteoclast	numbers	following	5	doses	of	30mg/kg	Cabozantinib	(CBZ)	or	
(B)	control	(CTRL).	Osteoclasts	are	highlighted	with	black	asterisk,	osteoblasts	with	black	arrowhead,	
20x	objective,	scale	bar	is	50µm,	Bm=Bone	marrow,	Tb=Trabecular	bone.	
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Figure	43	Effects	of	5-day	treatment	with	Cabozantinib	on	osteoclasts.		
(A,C,E)	8-9	week	old	GFP	Ob+	and	(B,D,F)	17-week	old	 	GFP	Ob+mice	received	5	doses	of	30mg/kg	
Cabozantinib	 (CBZ)	 or	 control	 (CTRL)	 daily	 (n=4/group).	 (A&B)	 osteoclast	 number/mm	 trabecular	
bone	surface	(C&D)	osteoclast	activity	(serum	TRAP	levels)	and	(E&F)	osteoclast	size	(in	mm2)	were	
determined	Student’s	t-test:	ns	is	non	significant,	***	is	p≤0.001.	All	data	show	Mean±SEM.	
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4.6.1.3. Effects	on	bone	volume	and	structure	following	5	administrations	of	CBZ	
To	determine	 if	 the	effects	on	osteoblasts	and	osteoclasts	resulted	 in	alterations	of	bone	
structure	and	volume,	µCT	analysis	of	proximal	tibiae	after	administration	of	30mg/kg	CBZ	
or	 CTRL	 for	 5-days	 was	 performed.	 There	 was	 significantly	 increased	 trabecular	 bone	
volume	 in	 17-week	 old	 GFP	 Ob+	 mice	 (p≤0.01,	 Fig.44A,	 Table	 18),	 whereas	 all	 other	
analysed	 bone	 parameters,	 including	 trabecular	 thickness	 and	 number	 remained	
unaffected.	No	CBZ-induced	alterations	in	bone	structure	were	determined	in	8-9-week	old	
animals	(Fig.	44B,	Table	18).	Following	CBZ	treatment	cortical	bone	volume	was	not	altered	
in	both	animal	models	when	compared	to	control	receiving	mice	(Table	19).	
Taken	together,	these	data	demonstrate	that	a	5-day	course	of	CBZ	treatment	is	sufficient	
to	 induce	 modifications	 of	 osteoblasts	 and	 osteoclasts,	 although	 longer-term	
administration	 of	 CBZ	 is	 likely	 to	 be	 required	 to	 cause	 significant	 alterations	 to	 bone	
structure.		
	
	
	
	
Figure	44	Effects	of	5-day	treatment	with	Cabozantinib	on	trabecular	bone	volume.		
Trabecular	bone	volume	(BV/TV	in	%)	was	analysed	after	5	administrations	of	30mg/kg	Cabozantinib	
(CBZ)	or	control	(CTRL)	for	(A)	17-week	old	GFP	Ob+	mice	(n=4/group)	and	(B)	8-9-week	old	GFP	Ob+	
mice	(n=4/group).	Student’s	t-test:	ns	is	non	significant,	**	is	p≤0.01.	All	data	show	Mean±SEM.	
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4.6.2. A	 10-day	 course	 of	 Cabozantinib	 alters	 bone	 structure	 and	modifies	 key	 bone	
cells	
The	 5-day	 administration	 of	 30mg/kg	 CBZ	 (cumulative	 dose:	 150mg/kg)	 rapidly	modified	
osteoblast	and	osteoclast	number	with	only	modest	effects	on	bone	volume,	therefore	the	
dosing	 regimen	 was	 increased	 to	 a	 total	 of	 8	 administrations	 of	 CBZ	 over	 10	 days	
(cumulative	dose:	240mg/kg,	Fig.	37B).	
4.6.2.1. Effects	on	osteoblasts	
8	doses	of	CBZ	resulted	in	significantly	 increased	osteoblast	number/mm	trabecular	bone	
surface	in	6-week	old	male	BALB/c	nude	mice,	compared	to	control	(CTRL:	10.54	±	1.23	vs.	
CBZ:	15.01	±	1.12,	p≤0.05,	Fig.45A).	However,	there	was	no	effect	on	osteoblast	number	in	
the	 other	 experimental	 animal	 models	 receiving	 this	 treatment	 regimen	 (6-week	 old	
female	BALB/c	nude:	CTRL:	16.01	±	1.48	vs.	CBZ:	17.12	±	0.97,	Fig.45C;	9-week	old	GFP	Ob+:	
CTRL:	9.53	±	0.66	vs.	CBZ:	8.64	±	1.33,	Fig.45E).	Similar	to	5	doses	of	CBZ,	administration	of	
8	 doses	 did	 not	 alter	 serum	PINP	 levels	 in	 6-week	old	male	BALB/c	 nude	 (CTRL:	 332.0	 ±	
63.88ng/mL	vs.	CBZ:	431.6	±	36.24ng/mL,	Fig.45B),	6-week	old	female	BALB/c	nude	(CTRL:	
184.2	±	31.33	ng/mL	vs.	CBZ:	151.2	±	28.67ng/mL,	Fig.45D)	or	9-week	old	female	GFP-Ob+	
(CTRL:	46.30	±	1.81ng/mL	vs.	CBZ:	43.49	±	7.18ng/mL,	Fig.45F).	In	addition	at	day	5	and	12	
after	treatment	termination	no	change	in	osteoblast	number	(Day	15:	CTRL:	16.19	±	1.86	
vs.	 CBZ:	 15.49	 ±	 1.08;	 Day	 22:	 CTRL:	 17.37	 ±	 2.34	 vs.	 CBZ:	 15.90	 ±	 0.88;	 2-way	 ANOVA,	
Fig.49D)	was	observed.	However,	osteoblast	activity	was	lower	in	CBZ	treated	mice	when	
compared	to	control	(Day	15:	CTRL:	226.1	±	27.75ng/mL	vs.	131.3	±	17.12	ng/mL,	p≤0.05;	
Day	22:	CTRL:	186.1	±	32.59	ng/mL	vs.	CBZ:	94.11	±	11.79ng/mL;	2-way	ANOVA,	Fig.49B).	
Representative	TRAP-stained	histological	slides	from	6-week	old	female	BALB/c	nude	mice	
are	shown	in	Fig.46A&B.	
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Figure	45	Effects	of	8	administrations	of	CBZ	on	osteoblasts	in	vivo.	
Osteoblast	 number/mm	 trabecular	 bone	 surface	 (A,C,E)	 and	 activity	 (measured	 by	 serum	 PINP	
levels)	 (B,D,F)	were	 determined	 after	 8	 doses	 of	 30mg/kg	 CBZ	 or	 sterile	 H2O	 control	 (CTRL)	 in	 6-
week	old	male	BALB/c	nude	mice	 (n=4/group,	A&B),	6-week	old	 female	BALB/c	nude	 (n=5/group,	
C&D)	and	9-week	old	female	GFP	Ob+	mice	(n=4/group,	E&F).	Student’s	t-test:	ns	is	non-significant,	
*	is	p≤0.05.	All	data	show	Mean±SEM.	
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4.6.2.2. Effects	on	osteoclasts	
When	compared	to	control,	8	doses	of	CBZ	did	not	alter	osteoclast	number	in	6-week	old	
male	BALB/c	nude	mice	 (CTRL:	 5.63	 ±	 0.16	 vs.	 CBZ:	 6.56	 ±	 0.59,	 Fig.47A)	 but	 resulted	 in	
significantly	 increased	osteoclast	size	(CTRL:	7.10x10-5	±	4.74x10-6	mm2	vs.	CBZ:	9.72x10-5±	
6.53x10-6	mm2,	 p≤0.05,	 Fig.48A),	which	may	 indicate	 a	 loss	 of	 activity.	 In	 contrast,	 there	
was	a	 significant	decrease	 in	osteoclast	number	both	 in	6-week	old	 female	BALB/c	nude	
(CTRL:	 8.29	 ±	 0.39	 vs.	 CBZ:	 6.78	 ±	 0.48,	 p≤0.05,	 Fig.46,	 Fig47C)	 and	9-week	old	GFP	Ob+	
(CTRL:	 5.99	 ±	 0.46	 vs.	 CBZ:	 4.15	 ±	 0.30,	 p≤0.05,	 Fig.47E)	 treated	 with	 CBZ.	 Osteoclast	
activity	was	not	significantly	altered	in	6-week	old	female	BALB/c	nude	mice	(CTRL:	15.99	±	
0.75	U/L	vs.	CBZ:	13.81	±	2.99	U/L,	Fig.47D)	and	9-week	old	GFP	Ob+	mice	(CTRL:	11.64	±	
1.21	vs.	CBZ:	12.97	±	1.23	U/L,	Fig.47F).	However,	 increased	osteoclast	activity	 in	6-week	
old	 male	 BALB/c	 nude	 mice	 receiving	 CBZ	 was	 observed,	 although	 this	 did	 not	 reach	
statistical	 significance	 (CTRL:	 13.98	 ±	 1.06	 vs.	 CBZ:	 18.52	 ±	 1.90,Fig.47B).	 CBZ-induced	
effects	on	osteoclast	number	were	rapidly	reversed	after	treatment	termination	(Day	10:	
CTRL:	8.29	±	0.39	vs.	CBZ:	6.78	±	0.49;	Day	15:	7.55	±	0.45	vs.	CBZ:	7.80	±	0.23;	Day	22:		
CTRL:	 9.84	 ±	 0.35	 vs.	 CBZ:	 9.99	 ±	 0.60,	 Fig.49C),	 and	 osteoclast	 activity	 appeared	 to	 be	
elevated	 compared	 to	 control	 12	 days	 after	 administration	 of	 the	 last	 dose	 of	 CBZ,	
however	no	significant	difference	was	determined	(CTRL:	9.55	±	0.85	U/L	vs.	CBZ:	13.23	±	
1.35	U/L,	two-way	ANOVA,	Fig.49A).	
	
Figure	46	Representative	TRAP-stained	histological	sections	of	tibiae	after	8	administrations	of	
Cabozantinib	
Representative	 TRAP	 stained	 histological	 sections	 of	 6-week	 old	 female	 BALB/c	 nude	 mice	 are	
shown	 in	 (A&B).	 Black	 asterisk	 highlights	 osteoclasts,	 black	 arrowheads	 indicate	 osteoblasts,	 40x	
objective,	scale	bar	is	50µm.	
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Figure	47	Effects	of	8	doses	of	CBZ	on	osteoclasts	in	vivo.		
(A,C,E)	Osteoclast	number/mm	trabecular	bone	surface	and	(B,D,F)	osteoclast	activity	(measured	as	
serum	TRAP	 levels)	were	 determined	 after	 8	 doses	 of	 30mg/kg	 Cabozantinib	 (CBZ)	 or	 sterile	H2O	
control	(CTRL)	in	6-week	old	male	BALB/c	nude	mice	(n=4/group,	A&B),	6-week	old	female	BALB/c	
nude	(n=5/group,	C&D)	and	9-week	old	female	GFP	Ob+	mice	(n=4/group,	E&F)	Student’s	t-test:	ns	is	
non-significant,	*	is	p≤0.05.	All	data	show	Mean±SEM.	
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Figure	48	Effects	of	8	doses	of	CBZ	on	osteoclast	size	in	vivo.		
Effects	of	CBZ	on	osteoclast	 size	was	determined	after	8	doses	of	30mg/kg	Cabozantinib	 (CBZ)	or	
sterile	 H2O	 control	 (CTRL)	 in	 (A)	 6-week	 old	male	 BALB/c	 nude	mice	 (n=4/group),	 (B)	 6-week	 old	
female	BALB/c	nude	(n=5/group)	and	(C)	9-week	old	female	GFP	Ob+	mice	(n=4/group)	Student’s	t-
test:	ns	is	non	significant,	*	is	p≤0.05.	All	data	show	Mean±SEM.	
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Figure	49	Treatment	follow-up	of	8	doses	of	CBZ	on	osteoblasts	and	osteoclasts.	
6-week	 old	 female	 BALB/c	 nude	mice	 received	 8	 doses	 of	 Cabozantinib	 (CBZ,	 30mg/kg)	 or	 sterile	
H2O	control	(CTRL).	(A)	Osteoclast	activiy	(measured	by	serum	TRAP	levels),	(C)	osteoclast	number,	
(B)	 osteoblast	 activity	 (serum	PINP	 levels)	 and	 (D)	 osteoblast	 number	was	 determined	 on	 day	 10	
(day	of	 treatment	 termination)	and	effects	on	bone	cells	 followed	up	5	 (Day	15)	and	12	 (Day	22)	
days	post	treatment	termination.	n=5/day	and	group.	All	data	show	Mean±SEM.	two-way	ANOVA,	
Bonferroni	post-test,	*	is	p≤0.05	no	statistical	significance	at	all	other	time	points.		
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4.6.2.3. Effects	on	bone	volume	and	structure	
I	 next	 assessed	 if	 8	 doses	 of	 CBZ	 (cumulative	 dose:	 240mg/kg)	 caused	 alterations	 in	
trabecular	 bone	 volume,	 number	 and/or	 thickness	 of	 proximal	 tibiae.	 CBZ	 resulted	 in	
significantly	 increased	 trabecular	 thickness	 in	 all	 the	 animal	 models	 (p≤0.01,	 Table	 18)	
when	compared	to	control.	9-week	old	GFP	Ob+	mice	treated	with	CBZ,	also	demonstrated	
increased	trabecular	number	(p≤0.05,	Table	18;	24%	increase)	and	volume	(p≤0.01,	Table	
18,	≈39%	increase).	These	parameters	were	not	significantly	affected	in	BALB/c	nude	mice	
(Table	 18)	 although	 there	 was	 a	 trend	 towards	 increased	 trabecular	 bone	 volume	 in	 6-
week	 old	 male	 BALB/c	 nude	 mice	 (p=0.0694,	 Table	 18).	 The	 CBZ-induced	 increase	 in	
trabecular	 thickness	 was	 transient	 and	 normalised	 to	 control	 levels,	 5	 days	 after	
termination	of	treatment	(Day	15,	Table	18).	Cortical	bone	volume	remained	unaffected	by	
8	administrations	of	CBZ	in	all	animal	models	studied	(Table	19).	
	
Table	18	Effects	of	CBZ	on	bone	volume.	
	Students	t-test		or	(1)	two-way	ANOVA	with	Bonferroni	post-test	was	used	for	statistical	analysis.	ns	
is	non-significant,	*	is	p≤0.05,	**	is	p≤0.001.	All	data	show	Mean±SEM.	
		
Analysis	of	treatment	effects	on	bone	volume	and	structure	
	 BV/TV	(%)	 Tb.N.	(mm
-1)	 Tb.Th.	(mm)	
5-day	treatment	schedule	
	 CTRL	 CBZ	 p	 CTRL	 CBZ	 p	 CTRL	 CBZ	 p	
GFP	Ob+	mice	
8-9-week	old	
12.97	±	
0.36	
13.04	±	
1.60	 ns	
2.86	±	
0.05	
2.77	±	
0.36	 ns	
0.045	±	
0.001	
0.047	
±	
0.001	
ns	
GFP	Ob+	mice	
17-week	old	
14.53	±	
0.22	
16.42	±	
0.35	
**	
	
2.57	±	
0.09	
2.72	±	
0.05	
ns	
	
0.057	±	
0.002	
0.060	
±	
0.002	
ns	
	
10-day	treatment	schedule	
Male	BALB/c	
nude	
6-week	old	
12.16	±	
0.84	
16.01	±	
1.53	 ns	
3.39	±	
0.24	
3.84	±	
0.30	 ns	
0.036	±	
0.001	
0.042	
±	
0.001	
**	
Female	BALB/c	
nude	6-week	
old	
11.61	±	
1.31	
12.18	±	
1.47	 ns	
3.21	±	
0.31	
2.82	±	
0.303	 ns	
0.036	±	
0.001	
0.043	
±	
0.001	
**	
Female	GFP	
Ob+	mice	
9-week	old	
13.48	±	
0.54	
18.75	±	
1.09	
**	
	
2.65	±	
0.13	
3.29	±	
0.15	 *	
0.051	±	
0.001	
0.057	
±	
0.001	
**	
Follow	up	treatment	(6-week	old	female	BALB/c	nude)	
5	days	post	
treatment	
termination	
11.07	±	
1.29	
9.86	±	
0.95	
ns	
(1)	
2.86	±	
0.33	
2.41	±	
0.18	
ns	
(1)	
0.039	±	
0.001	
0.041	
±	
0.001	
ns	(1)	
12	days	post	
treatment	
termination	
10.49	±	
0.85	
11.64	±	
1.49	
ns	
(1)	
2.65	±	
0.19	
2.83	±	
0,30	
ns	
(1)	
0.039	±	
0.001	
0.041	
±	
0.002	
ns	(1)	
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Table	19	Effects	of	CBZ	on	cortical	bone	volume	
Students	t-test	or	(1)	two-way	ANOVA	with	Bonferroni	post-test	was	used	for	statistical	analysis.	ns	is	
non-significant,	*	is	p≤0.05,	**	is	p≤0.001.	All	data	show	Mean±SEM.	
	
Cortical	bone	volume	[mm3]	
	 CTRL	 CBZ	 p	
5	doses	of	CBZ	
8-9-week	old	GFP	Ob+	mice	 0.75	±	0.02	 0.77	±	0.03	 ns	
17-week	old	GFP	Ob+	mice	 0.90	±	0.03	 0.97	±	0.04	 ns	
8	doses	of	CBZ	
6-week	old	male	BALB/c	nude	 0.60	±	0.03		 0.65	±	0.05	 ns	
6	week	old	female	BALB/c	nude	 0.53	±	0.03	 0.56	±	0.02	 ns		
9-week	old	female	GFP	Ob+	 0.83	±	0.02		 0.84	±	0.03	 ns	
Treatment	follow-up	
5	days	post	treatment	
termination	 0.62	±	0.03	 0.56	±	0.03	 ns	
(1)	
12	days	post	treatment	
termination	 0.62	±	0.03	 0.64	±	0.03	 ns	
(1)		
4.6.2.4. Effects	on	bone	formation	
To	monitor	 the	 rate	of	new	bone	 formation,	 I	 analysed	 incorporation	of	 calcein	 labels	 in	
vertebra	 (n=4/group)	 from	 6-week	 old	 female	 BALB/c	 nude	 mice	 receiving	 8	 doses	 of	
30mg/kg	CBZ	or	CTRL	respectively.		
Cabozantinib	treated	animals	had	 increased	rate	of	bone	formation	(CTRL:	0.58	±	
0.09	 mm2	 x10-3/mm/day	 vs.	 CBZ:	 0.96	 ±	 0.09	 mm2x10-3/mm/day,	 p≤0.05,	 Fig.50C).	 No	
significant	 effect	 on	 mineral	 apposition	 (CTRL:	 1.97	 ±	 0.26	 µm/day	 vs.	 CBZ	 2.51	 ±	 0.21	
µm/day,	Fig.50B)	or	double-labelled	width	(CTRL:	7.88	±	1.03	µm	vs.	CBZ:	10.05	±	0.85	µm,	
Fig.50D)	 were	 observed.	 However,	 a	 trend	 towards	 increased	 mineralising	 surface	 was	
observed	 following	 CBZ	 administration	 (CTRL:	 30.06	 ±	 3.25	 %	 vs.	 CBZ:	 38.13	 ±	 1.52	 %,	
p=0.0655,	Fig.50A).	
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Figure	50	Effects	of	CBZ	on	bone	formation.		
The	 rate	of	new	bone	 formation	was	assessed	 in	 lumbar	vertebra	4	of	6-week	old	 female	BALB/c	
nude	mice	 receiving	 8	 doses	 of	 30mg/kg	 Cabozantinib	 (CBZ)	 or	 control	 (CTRL),	 n=4/group.	 It	was	
interactively	drawn	around	the	calcein	labels	to	determine	differences	in	(A)	mineralisation	surface,	
(B)	 Mineral	 apposition	 rate,	 (C)	 Bone	 formation	 and	 (D)	 the	 Mean	 Interlabel	 Width	 between	
treatment	groups.	ns	is	non-significant	*	is	p<0.05,	Student‘s	t-test.	Only	one	level	per	sample	was	
assessed.	All	data	show	Mean±SEM.		
4.6.3. Effects	of	Cabozantinib	on	the	epiphyseal	growth	plate		
The	epiphyseal	growth	plate	is	comprised	of	cartilage	producing	chondrocytes	embedded	
in	a	proteoglycan-rich	extracellular	matrix.	Significant	modifications	of	the	epiphysis	in	CBZ	
treated	animals	were	observed	and	therefore	I	quantified	the	area	of	resting/proliferating	
and	hypertrophic	chondrocytes,	respectively	(in	mm2,	Fig.38,	Fig.51A)	after	a	5-	and	8-dose	
regimen	of	CBZ	or	CTRL.	Additionally	I	analysed	tumour-free	tibiae	collected	in	previously	
published	tumour	models	[231,	233],	to	assess	effects	of	longer-term	CBZ	treatment.	
Five	 daily	 administrations	 of	 CBZ	 resulted	 in	 a	 significant	 increase	 in	 the	
hypertrophic	chondrocyte	zone	in	both,	8-9-	(p≤0.0001,	≈76%	increase,	Fig.51B,	Table	20)	
and	 17-week	 old	 female	 GFP	 Ob+	 mice	 (p≤0.001,	 Fig.51B,	 ≈135%	 increase,	 Table	 20)	
Similarly,	 a	 10-day	 course	 (8	 administrations)	 of	 CBZ	 increased	 the	 hypertrophic	
chondrocyte	area	 in	all	 the	animal	models	when	compared	 to	 control	 ((6-week	old	male	
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BALB/c	nude:	p≤0.001,	Fig.51C,	≈98%	increase;	9-week	old	GFP	Ob+:	p≤0.01,	Fig.50D,	≈49%	
increase;	 6-week	 old	 female	 BALB/c	 nude:	 p≤0.001,	 Fig.52A,	 ≈85%	 increase;	 Table	 20).	
Next	to	the	elongated	hypertrophic	zones,	the	chondrocyte	stacks	appeared	disorganized	
in	 CBZ	 treated	 animals	 compared	 to	 control	 (Fig.51D&F).	 The	 CBZ-induced	 increase	 in	
growth	 plate	 thickness	 was	 reversed	 to	 control	 levels	 within	 5	 days	 of	 treatment	
termination	 (Fig.52A,	 Table	 20).	 In	 addition	 to	 the	 increased	 hypertrophic	 chondrocyte	
area,	 the	 resting/proliferating	 chondrocyte	 area	 was	 significantly	 smaller	 in	 animals	
receiving	5	(8-9-week	old	GFP	Ob+:	p≤0.05,	≈24%	decrease;	17-week	old	female	GFP	Ob+:	
p≤0.05,	 Fig.51B,	 ≈18%	 decrease,	 Table	 20)	 and	 10	 doses	 of	 CBZ	 (9-week	 old	 GFP	 Ob+:	
p≤0.001,	 ≈37%	 decrease,	 Fig.50D,	 Table	 20;	 6-week	 old	 female	 BALB/c	 nude:	 p≤0.01,	
Fig.52A,	 ≈30%	 decrease;	 Table	 20).	 Treatment	 follow-up	 analysis	 in	 6-week	 old	 female	
BALB/c	 nude	 mice	 revealed	 that	 the	 resting/proliferating	 chondrocyte	 area	 returned	 to	
control	 levels	as	within	5	days	post	CBZ	treatment	termination	(Fig.52A,	Table	20).	These	
results	 suggest	 that	CBZ	 induces	 reversible	alterations	 to	 the	epiphyseal	 growth	plate	by	
disrupting	 chondrocyte	 differentiation.	 Archived	 material	 from	 previously	 published	
studies	allowed	me	to	determine	the	effects	on	the	growth	plate	on	histological	samples	
from	contralateral,	tumour	free	tibiae	following	longer-term	treatment	with	CBZ	(Table	20)	
[231,	233].	In	agreement	with	the	short-term	studies,	castrated	male	NOD/SCID	mice	that	
had	received	daily	administration	of	30mg/kg	CBZ	for	15	days	had	a	significantly	elongated	
hypertrophic	chondrocyte	area	when	compared	to	control	mice		(p≤0.001,	Fig.	52B,	≈107%	
increase,	 Table	 20).	 Similar	 results	were	observed	 after	 6-week	 treatment	with	 60mg/kg	
CBZ		(p≤0.01,	≈83%	increase	Fig	52C)	of	castrated	male	beige	SCID	mice	and	no	alteration	
in	 the	 proliferative/resting	 chondrocyte	 zone	 was	 determined	 in	 either	 of	 these	
experiments	(Fig.52B&C,	Table	20).	
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Table	20	Treatment	effects	of	Cabozantinib	(CBZ)	on	growth	plate	zones.		
The	hypertrophic	and	resting/proliferating	chondrocyte	zone	of	the	epiphyseal	growth	plate	area	(in	
mm2)	was	 analysed	 after	 5	 and	8	 dose	 regimen	of	 30mg/kg	CBZ	or	 control	 (CTRL)	 on	histological	
sections	of	tibiae	using	OsteoMeasure	software	and	normalised	to	total	growth	plate	area	(in	mm2).	
Student’s	t-test	was	used	for	statistical	analysis	or	(1)	two-way	ANOVA	with	Bonferroni	post-test.	ns	
is	 non-significant,	 *	 is	 p≤0.05,	 **	 is	 p≤0.01,	 ***	 is	 p≤0.001,	 ****	 is	 p≤0.0001.	 All	 data	 show	
Mean±SEM.	
				
Hypertrophic	chondrocyte	zone	area	(mm2)	/total	growth	plate	area	(mm2)	
	 CTRL	 CBZ	 p	
5	doses	of	CBZ	
8-9-week	old	GFP	Ob+	mice	 0.305	±	0.015	 0.537	±	0.017	 ****	
17-week	old	GFP	Ob+	mice	 0.171	±	0.010	 0.403	±	0.025	 ***	
8	doses	of	CBZ	
6-week	old	male	BALB/c	nude	 0.276	±	0.004	 0.549	±	0.041	 ***	
6	week	old	female	BALB/c	nude	 0.278	±	0.016	 0.514	±	0.035	 ***	
8-9-week	old	female	GFP	Ob+	 0.275	±	0.018	 0.409	±	0.028	 **	
Treatment	follow-up	
5	days	post	treatment	termination	 0.292	±	0.022	 0.319	±	0.005	 ns	(1)	
12	days	post	treatment	termination	 0.335	±	0.020	 0.282	±	0.019	 ns	(1)	
Longer	term	treatment	
Castrated	male	NOD/SCID	mice	 0.232	±	0.024	 0.481	±	0.034	 ***	
Castrated	male	beige	SCID	mice	 0.203	±	0.023	 0.372	±	0.047	 **	
Resting/Proliferating	chondrocyte	zone	area	(mm2)/total	growth	plate	area	(mm2)	
	 CTRL	 CBZ	 p	
5	doses	of	CBZ	
8-9-week	old	GFP	Ob+	 0.297	±	0.019	 0.226	±	0.012	 *	
17-week	old	GFP	Ob+	 0.254	±	0.016	 0.207	±	0.009	 *	
8	doses	of	CBZ	
6-week	old	male	BALB/c	nude	 0.269	±	0.048	 0.211	±	0.018	 ns	
6	week	old	female	BALB/c	nude	 0.406	±	0.021	 0.285	±	0.017	 **	
8-9-week	old	female	GFP	Ob+	 0.337	±	0.014	 0.212	±	0.006	 ***	
Treatment	follow-up	(6-week	old	female	BALB/c	nude)	
5	days	post	treatment	termination	 0.387	±	0.008	 0.381	±	0.016	 ns	(1)	
12	days	post	treatment	termination	 0.414	±	0.011	 0.392	±	0.014	 ns	(1)	
Longer	term	treatment	
Castrated	male	NOD/SCID	mice	 0.238	±	0.021	 0.205	±	0.013	 ns	
Castrated	male	beige	SCID	mice	 0.174	±	0.013	 0.200	±	0.019	 ns	
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Figure	51	Effects	of	CBZ	on	the	epiphyseal	growth	plate.		
(A)	 Schematic	 illustration	 of	 growth	 plate	 areas	 quantified	 after	 administration	 of	 30mg/kg	
Cabozantinib	(CBZ)	or	sterile	H2O	control	(CTRL).	It	was	interactively	drawn	around	the	hypertrophic	
(Hyp)	 and	 resting/proliferating	 (Res/Prol)	 chondrocyte	 zone	 of	 the	 epiphysis	 using	OsteoMeasure	
software.	Effects	of	5	doses	(n=4/group)	of	CBZ	or	CTRL	on	the	epiphyseal	growth	plate	are	shown	in	
(B)	for	8–9-	and	17-week	old	female	GFP	Ob+mice.	Alterations	in	growth	plate	composition	following	
8	doses	of	CBZ	or	CTRL	are	presented	 in	 (C)	6-week	old	male	BALB/c	nude	(n=4/group)	and	 (E)	9-
week	old	GFP	Ob+	(n=4/group)	mice.	Representative	Safranin-O	stained	sections	of	tibiae	are	shown	
in	(D)	for	6-week	old	male	BALB/c	nude	and	(F)	9-week	old	GFP	Ob+	mice.	20x	objective,	scale	bar	is	
50	μm.	Student's	t-test	*	 is	p	≤	0.05,	**	is	p	≤	0.01,	***	is	p	≤	0.001,	****	is	p	≤0.0001,	ns	 is	non-
significant.	AOI	is	area	of	interest.	All	data	show	mean	±	SEM.	
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Figure	52	Effects	of	Cabozantinib	on	the	epiphyseal	growth	plate,	follow-up	and	longer-term	
treatment.		
The	hypertrophic	(hyp)	and	resting/proliferating	(res/prol)	growth	plate	areas	were	quantified	after	
administration	 of	 30mg/kg	 Cabozantinib	 (CBZ)	 or	 sterile	 H2O	 control	 (CTRL)	 using	 OsteoMeasure	
software.	Alterations	in	growth	plate	composition	following	8	doses	of	CBZ	or	CTRL	are	presented	in	
(A)	 for	 6-week	 old	 female	 BALB/c	 nude	mice	 (day	 10:	 n=4	 CBZ	 otherwise	 n=5/group/time	 point).	
Treatment	was	terminated	at	Day	10	and	effects	on	growth	plate	areas	assessed	5	and	12	days	post	
treatment	termination.	Effects	on	the	growth	plate	after	30mg/kg	CBZ	or	CTRL	daily	for	15	days	in	
castrated	 NOD/SCID	 mice	 (n=6	 CTRL,	 n=7	 CBZ),	 are	 presented	 in	 (D).	 (E)	 highlights	 effects	 after	
60mg/kg	CBZ	or	CTRL	5x	weekly	for	6	weeks	in	6-week	old	of	castrated	male	beige	SCID	mice	(n=9	
CTRL,	n=10	CBZ).	Student's	t-test	(B&C)	or	two-way	ANOVA	with	Bonferroni	post-test	(A),	**	is	p	≤	
0.01,	***	is	p	≤	0.001,	****	is	p	≤0.0001,	ns	is	non-significant.	AOI	is	area	of	interest.	All	data	show	
mean	±	SEM.	
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4.6.4. Effects	of	Cabozantinib	on	bone	marrow	composition	
4.6.4.1. Effects	on	bone	marrow	megakaryocytes	
During	 sample	 analyses	 I	 observed	 that	 CBZ	 caused	 alterations	 in	 bone	 marrow	
composition.	 In	 particular,	 CBZ-treated	 animals	 appeared	 to	 have	 increased	 numbers	 of	
red	blood	cells	in	the	bone	marrow	associated	with	numerous	megakaryocytes.	I	therefore	
determined	 the	 effects	 of	 CBZ	 on	 the	 number	 of	 megakaryocytes/mm2	 bone	 tissue	 by	
scoring	 H&E	 stained	 sections	 of	 tibiae	 as	 illustrated	 in	 Fig.	 53A.	 In	 BALB/c	 nude	mice,	 8	
administrations	of	CBZ	resulted	in	increased	numbers	of	megakaryocytes/mm2	tissue	area	
when	compared	to	control	 (Male	BALB/c	nude:	CTRL:	42.50	±	3.09	vs.	CBZ:	58.52	±	0.88,	
p≤0.01,	Fig.	53B;	Female	BALB/c	nude:	CTRL:	38.91	±	2.37	vs.	CBZ:	47.30	±	1.77,	p≤0.05,	
Fig.53B-D).	Megakaryocyte	numbers	were	reduced	5	days	after	the	 last	administration	of	
CBZ	(CTRL:	37.76	±	1.95	vs.	CBZ:	27.43	±	2.30,	Fig.53C)	and	normalised	to	control	levels	by	
day	12	(CTRL:	39.25	±	5.66	vs.	CBZ:	37.44	±	1.24,	Fig.	53C).		
4.6.4.2. Effects	on	the	bone	marrow	vasculature	and	haematopoietic	cells	
On	the	day	of	sacrifice	dissected	hind	legs	revealed	significant	alterations	in	bone	marrow	
composition.	Flushed	bone	marrow	from	mice	receiving	8	doses	of	30mg/kg	CBZ	appeared	
bright	red	when	compared	to	bone	marrow	from	CTRL	treated	mice	(Fig.54A&B)	indicating	
a	potential	increase	in	the	number	of	erythrocytes	and/or	bleeding	abnormalities.	Excised	
spleens,	a	major	site	of	blood	formation,	did	not	vary	in	size.	However	3.5hrs	after	the	last	
administration	the	spleen	of	the	CBZ	treated	mouse	appeared	bright	red	when	compared	
to	the	CTRL	mouse	–	this	would	however	require	confirmation	due	to	a	lack	of	animals	for	
this	 time	 point	 (Fig.54E).	 Similar	 effects	 were	 observed	 throughout	 all	 experiments	
performed,	 however	 less	 prominent	 in	 animals	 receiving	 5	 administrations	 of	 CBZ	 only.	
Figure	54	represents	observations	in	10-week	old	male	C57BL/6J	mice.	
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Figure	53	Effects	of	Cabozantinib	on	bone	marrow	megakaryocytes.		
(A)	 Megakaryocytes/mm2	 tissue	 area	 were	 scored	 125	 μm	 away	 from	 the	 growth	 plate	 as	
illustrated.	An	area	with	a	total	 length	of	1250μm	was	scored.	(B)	Number	of	megakaryocytes	was	
scored	after	8	administrations	of	30	mg/kg	Cabozantinib	(CBZ)	or	sterile	H2O	control	 (CTRL)	for	10	
days	 using	 6-week	 old	 male	 (n=4/group)	 and	 female	 (n=	 4-5/group)	 BALB/c	 nude	 mice.	 (C)	
Megakaryocyte	number	5	(day	15)	and	12	days	(day	22)	after	the	last	CBZ	administration	in	6-week	
old	 female	 BALB/c	 nude	 mice.	 Representative	 H&E	 stained	 tissue	 sections	 illustrating	 effects	 on	
megakaryocytes	 and	 bone	marrow	 cellularity	 are	 demonstrated	 in	 (D),	 20x	 objective,	 scale	 bar	 is	
50μm.	Black	asterisk	points	out	megakaryocytes.	(B)	Student's	t-test,	*	is	p	≤	0.05,	**	is	p	≤	0.01.	(C)	
Two-way	ANOVA	with	Bonferroni	post-test.	All	data	show	Mean	±	SEM.	
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Figure	54	visualisation	of	alterations	in	bone	marrow	cellulatrity	following	Cabozantinib	
treatment.		
(A)	and	(B)	show	bone	marrow	flushes	from	10-week	old	male	C57BL/6J	mice	that	had	received	8	
administrations	of	30mg/kg	Cabozantinib	 (CBZ)	or	control	 (CTRL).	Excised	hind	 limbs	are	shown	 in	
(C)	3.5hrs	and	(D)	24hrs	after	the	last	treatment	administrations.	(E)	presents	excised	spleens.	
	
In	addition	to	the	changes	to	the	BME	described	previously,	histological	analysis	revealed	
that	overall	bone	marrow	cellularity	was	notably	reduced	in	CBZ	treated	animals	compared	
to	 control.	 Administration	 of	 8	 doses	 of	 CBZ	 resulted	 in	 vascular	 ectasia	 and	 spillage	 of	
mature	(non-nucleated)	red	blood	cells	amongst	the	extra	vascular	bone	marrow	cells	(Fig.	
55D).	 Haemangioma-like	 bone	 marrow	 blood	 vessels,	 densely	 filled	 with	 erythrocytes,	
were	 observed,	 locally	 replacing	 the	 normal	 haematopoietic	 bone	 marrow.	 The	 dilated	
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vessels	 appeared	 thin	 walled	 compared	 to	 the	 ones	 observed	 in	 control	 bone	 marrow	
(Fig.55A-D).	 In	 addition	 there	 appeared	 to	 be	 a	 reduction	 in	 Endomucin+ve	 vascular	
endothelial	 cells	 in	 the	 area	 adjacent	 to	 the	 epiphyseal	 growth	 plate	 (Fig.56A-F).	
Assumptions	about	alterations	in	bone	marrow	vasculature	are	based	on	observations	only	
and	 would	 require	 confirmation	 and	 further	 investigation.	 The	 effects	 were	 most	
prominent	 after	 8	 administrations	 of	 CBZ,	 with	 similar	 but	 less	 prominent	 alterations	
observed	after	5	doses	(Fig.56A-F).	Alterations	in	bone	marrow	vasculature	and	spillage	of	
erythrocytes	 were	 rapidly	 lost	 once	 CBZ	 treatment	 was	 terminated,	 with	 normal	 bone	
marrow	restored	by	day	15	(Fig.53D).		
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	Figure	55	Effects	of	8	doses	of	Cabozantinib	on	the	bone	marrow	vasculature	in	vivo.	
Immunofluorescence	staining	against	the	vascular	endothelial	marker	Endomucin	was	performed	on	
3µm	paraffin	 embedded	 sections	of	 tibiae	 from	6-week	old	male	BALB/c	nude	mice	 receiving	 (A)	
sterile	H2O	control	(CTRL)	or	(B)	30mg/kg	Cabozantinib	(CBZ)	5x	weekly	for	10	days	(8	doses	in	total).	
Bone	marrow	vessels	appeared	dilated	and	thin	walled	in	CBZ	receiving	animals.	Note	the	spillage	of	
mature	erythrocytes	into	the	extravascular	bone	marrow	in	visualised	in	(C)	by	immunofluorescence	
and	(D)	by	H&E	staining.	White	arrowheads	point	out	Endomucin	positive	vessels	(in	red).	(A&C)	20x	
objective	Nikon	A1	Confocal	microscope;	(D)	Leica	DMRB	upright	microscope	20x	objective.	
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Figure	56	Effects	of	Cabozantinib	on	the	bone	marrow	vasculature	in	the	metaphysis.		
Immunofluorescence	staining	against	the	vascular	endothelial	marker	Endomucin	was	performed	on	
3µm	paraffin	embedded	sections	of	 tibiae	 from	6-week	old	 (A&B)	male	and	 (C&D)	 female	BALB/c	
nude	mice	receiving	sterile	H2O	control	 (CTRL)	or	30mg/kg	Cabozantinib	(CBZ)	5x	weekly	 for	10	(8	
doses	 in	total)	or	5	days	(E&F,	8-9-week	old	female	GFP	Ob+	mice).	Representative	Endomucin+ve	
vasculature	pointed	out	by	white	arrow	head,	for	GFP	Ob+	mice	GFP+ve	osteoblastic	cells	are	shown	
in	 green	 (E&F),	 DAPI	 for	 nuclear	 cells	 in	 blue.	White	 dotted	 line	 illustrates	 the	 last	 hypertrophic	
chondrocyte	stacks	of	the	growth	plate	(GP).	Tb	is	trabecular	bone.	20x	objective,	Leica	DMI4000B.	
Scale	bar	is	50	or	75µm	respectively.	
To	 quantify	 the	 alterations	 in	 bone	 marrow	 cellularity	 observed	 after	 8	 doses	 of	 CBZ	
treatment	 flow	 cytometric	 analysis	 using	 antibodies	 against	 Ter119	 (marker	 for	
erythrocytes),	 CD45	 (cells	 of	 haematopoietic	 origin)	 and	 CD41	 (platelets)	were	 used	 in	 a	
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pilot	experiment.	Erythrocytes	were	identified	as	Ter119+/CD41-/CD45-;	platelets	as	CD41+,	
Ter119-/CD45-.	Analysis	of	CD45+ve	cells	revealed	effects	on	haematopoietic	cells.	
As	observed	by	histology	10-week	old	male	C57BL/6J	mice	treated	with	30mg/kg	
CBZ	 for	 10	 days	 showed	 increased	percentage	of	 erythrocytes	 in	 analysed	bone	marrow	
flushes	at	both	time	points	(3.5hrs	post	treatment:	CTRL:	47.8%	vs.	CBZ:	81.2%,	n=1/group,	
Fig.57A;	24hrs	after	treatment:	CTRL:	53.53	±	4.28%	vs.	CBZ:	75.50	±	8.60%,	n=2-3/group,	
Fig.57B).	 In	 CBZ	 treated	 animals	 the	 percentage	 of	 nuclear	 haematopoietic	 cells	 in	 the	
bone	marrow	was	reduced	when	compared	to	control	receiving	mice	3.5hrs	(CTRL:	37.7%	
vs.	 CBZ:	 15.6%,	 Fig.57B,	 n=1/group,)	 and	 24hrs	 (CTRL:	 36.57	 ±	 4.13%	 vs.	 CBZ:	 20.10	 ±	
7.00%,	 FIg.57D,	 n=2-3/group)	 after	 the	 last	 treatment	 administration.	 The	 previously	
determined	 increase	 in	megakaryocyte	number	may	account	 for	 their	 inability	 to	 release	
platelets,	 their	 terminal	 differentiation	 state.	 Interestingly	 3.5hrs	 after	 the	 last	 dose	 a	
lower	percentage	of	CD41+ve	cells	was	found	in	the	bone	marrow	of	the	animals	receiving	
CBZ	(CTRL:	0.4%	vs.	CBZ:	0.1%,	Fig.57E,	n=1/group).	No	obvious	alterations	in	CD41+ve	cells	
was	 determined	 24hrs	 after	 treatment	 termination	 (CTRL:	 0.13	 ±	 0.03%	 vs.	 CBZ:	 0.15	 ±	
0.05%	 n=2-3/group,	 Fig.57F).	 The	 flow	 cytometric	 analysis	 was	 performed	 in	 a	 small	
amount	of	animals	only	and	would	therefore	require	confirmation	in	a	larger	sample	set.	
Taken	 together,	 these	 data	 show	 that	 CBZ	 affects	 the	 BME	 through	 modification	 of	
multiple	cell	types,	including	bone	cells	and	cells	of	the	haematopoietic	marrow.	
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Figure	57	Assessing	effects	of	Cabozantinib	treatment	on	bone	marrow	cellularity	using	flow	
cytometry.		
10-week	 old	male	 C57BL/6J	mice	 received	 8	 doses	 of	 30mg/kg	 Cabozantinib	 (CBZ)	 or	 sterile	 H2O	
control	 (CTRL)	 and	 alterations	 in	 bone	 marrow	 cellularity	 were	 assessed	 using	 flow	 cytometric	
analysis	3.5	(A,C,E)	and	24hrs	(B,D,F)	after	the	last	CBZ	administration.	To	quantify	the	alterations	in	
bone	marrow	 cellularity	 observed	 after	 8	 doses	 of	 CBZ	 treatment	 flow	 cytometric	 analysis	 using	
antibodies	against	Ter119	(marker	for	erythrocytes),	CD45	(cells	of	hematopoietic	origin)	and	CD41	
(platelets)	were	used.	Erythrocytes	 (A&B)	were	 identified	as	Ter119+/CD41-/CD45-;	platelets	 (E&F)	
as	CD41+/Ter119-/CD45-.	Analysis	 of	CD45+ve	 cells	 revealed	effects	on	hematopoietic	 cells	 (C&D).	
(G)	shows	representative	flow	cytometry	readout	for	CD45+	cells.	3.5hrs	post	treatment	termination	
n=1/group,	24hrs	post	treatment	termination	n=3	for	CTRL	and	n=2	for	CBZ.	All	data	show	Mean	±	
SEM.	
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4.6.5. Effects	 of	 Cabozantinib	 on	 the	 expression	 of	 genes	 associated	 with	 bone	
remodelling	
As	 I	 observed	 rapid	 alteration	 in	 bone	 cell	 number	 and	 bone	 structure	 following	 CBZ	
administration	I	assessed	if	treatment	alters	the	expression	of	genes	associated	with	bone	
remodelling,	 in	 particular	 RANK,	 RANKL	 and	 OPG,	 by	 qRT-PCR.	 In	 addition	 I	 determined	
gene	 expression	 levels	 of	 VEGFa	 and	 Sox9,	 a	 gene	 associated	 with	 chondrocyte	
proliferation.	 Samples	 used	 for	 gene	 expression	 analysis	 included	 tibiae	 and	 femurs	 of	
animals	 from	 treated	 or	 control	 groups	 respectively.	 5	 doses	 of	 CBZ	 did	 not	 alter	 the	
expression	levels	of	any	of	assessed	genes	in	8-9-week	old	female	GFP	Ob+	mice	(Table	21).	
In	9-week	old	female	GFP	Ob+	mice	8	doses	of	CBZ	resulted	in	increased	expression	(=lower	
dCT	value)	of	 Sox9	 (CTRL:	7.24	±	0.14	vs.	CBZ:	6.53	±	0.06,	p≤0.01,	Table	22)	and	RANKL	
(CTRL:	9.10±	0.06	vs.	CBZ:	8.73	±	0.07,	p≤0.01,	Table	22)	when	compared	to	control	mice	
potentially	 representing	 the	 alterations	 in	 the	 epiphyseal	 growth	 plate	 observed	 by	
histology.	
	
Table	21	Alteration	in	gene	expression	following	5	doses	of	Cabozantinib.		
Animals	received	5	administrations	of	30mg/kg	Cabozantinib	(CBZ)	or	sterile	H2O	control	(CTRL)	and	
gene	expression	of	RANK,	RANKL,	OPG,	Vegfa	and	Sox9	were	assessed.	Bone	marrow	was	scraped	
out	manually	and	tibia	and	femur	pooled	for	each	mouse.	Biological	replicates:	n=4	for	CTRL,	n=3	for	
CBZ.	All	data	show	Mean	±	SEM.	
				
8-9-week	old	female	GFP	Ob+	
	 Average	Ct	 dCT	 Fold	change	 	
Gene	 CTRL	 CBZ	 CTRL	 CBZ	 CTRL	 CBZ	 p	
RANK	 27.08	±	0.25	
27.92	±	
0.28	
8.756	±	
0.24	 9.48	±	0.32	 1	 0.61	 ns	
RANKL	 27.02	±	0.13	
27.26	±	
0.12	 8.69	±	0.11	 8.82	±	0.10	 1	 0.92	 ns	
OPG	 25.56	±	0.21	
26.36	±	
0.11	 7.23	±	0.25	 7.92	±	0.07	 1	 0.62	 ns	
Vegfa	 24.71	±	0.42	
24.25	±	
0.48	 8.69	±	0.11	 8.82	±	0.10	 1	 1.53	 ns	
Sox9	 25.25	±	0.55	
25.79	±	
0.67	 6.93	±	0.34	 7.30	±	0.44	 1	 0.77	 ns	
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Table	22	Alteration	in	gene	expression	following	8	doses	of	Cabozantinib.	
Animals	received	8	administrations	of	30mg/kg	Cabozantinib	(CBZ)	or	sterile	H2O	control	(CTRL)	and	
gene	expression	of	RANK,	RANKL,	OPG,	Vegfa	and	Sox9	were	assessed.	Bone	marrow	was	scraped	
out	manually	 and	 the	 tibia	 and	 femur	 pooled	 for	 each	mouse.	 n=4/group.	All	 data	 show	Mean	 ±	
SEM.	
9-week	old	female	GFP	Ob+	
	 Average	Ct	 dCT	 Fold	change	 	
Gene	 CTRL	 CBZ	 CTRL	 CBZ	 CTRL	 CBZ	 	
RANK	 26.63	±	0.19	
26.84	±	
0.34	 8.20	±	0.13	 8.66	±	0.25	 1	 0.72	 ns	
RANKL	 27.54	±	0.09	
26.91	±	
0.25	 9.10	±	0.06	 8.73	±	0.07	 1	 1.29	 **	
OPG	 25.83	±	0.14	
25.51	±	
0.31	 7.39	±	0.08	 7.33	±	0.13	 1	 1.05	 ns	
Vegfa	 24.37	±	0.39	
23.89	±	
0.11	 5.71	±	0.18	 5.16	±	0.34	 1	 1.17	 ns	
Sox9	 25.68	±	0.13	
24.75	±	
0.29	 7.24	±	0.14	 6.53	±	0.06	 1	 1.59	 **	
	
4.6.6. Assessment	of	the	presence	of	MET	and	MET	receptor	phosphorylation	
Yakes	 and	 colleagues	 assessed	 expression	 of	 MET	 and	 phosphorylation	 of	 MET	 (pMET)	
receptor	 in	 liver	 samples	 of	 naïve	 female	 nu/nu	 mice	 2,	 4,	 8,	 24,	 and	 48hrs	 post	
administration	of	100mg/kg	CBZ	or	water	vehicle	[218].	In	these	experiments	animals	were	
administered	 10mg	HGF	 intravenously	 10min	 pre	 harvest	 in	 order	 to	 stimulate	 receptor	
phosphorylation.	 I	 aimed	 to	 assess	MET	 and	 pMET	 levels	 in	my	 experiments	 using	 liver	
samples	 from	 10-week	 old	 male	 C57BL/6J	 mice	 that	 had	 received	 8	 administrations	 of	
30mg/kg	CBZ	5x	weekly.	 	 Yakes	et	al.	observed	 inhibition	of	 receptor	phosphorylation	2-
8hrs	post	CBZ	treatment	upon	HGF	stimulation. In	contrast	to	I	did	not	detect	differences	
in	MET	and	pMET	levels	in	liver	lysates	between	control	and	CBZ	treated	animals	(Fig.58).	
However,	 in	 this	 study	 I	 did	 not	 use	 HGF	 stimulation	 as	 described	 in	 [218]	which	might	
account	for	the	discrepancy	in	observed	results. 
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Figure	58		Assessment	or	MET	receptor	phosphorylation	(pMET)	and	MET	expression	by	
westernblot	analysis.		
Met	levels	were	assessed	in	liver	lysates	from	10-week	old	male	C57BL/6J	mice	receiving	30mg/kg	
Cabozantinib	 (CBZ)	 or	 sterile	 H2O	 control	 (CTRL)	 5x	weekly	 for	 10	 days	 using	Western	 blot.	 Total	
protein	concentration	loaded	was	30ng/µL.	GAPDH	was	used	as	a	loading	control.	Loading:	(1)	CTRL,	
3.5hrs	 post	 administration,	 (2-4)	 –	 CTRL,	 24hrs	 post	 administration,	 (5)	 CBZ;	 3.5hrs	 post	
administration,	 (6+8)	 CBZ;	 24hrs	 post	 administration,	 (7)	 animal	 had	 to	 be	 sacrificed	 immediately	
after	treatment,	liver	sample	was	collected	1hr	post	cull.	
	 	
GAPDH&
MET&
pMET&
CTRL& CBZ&
GAPDH&
1& 2& 3& 4& 5& 6& 7& 8&
45&kDa&α;
subunit&
145&kDa&β;
subunit&
37&kDa&
37&kDa&
Figure'(X)'Assessment'or'MET'receptor'phosphoryla:on'(pMET)'and'MET'expression'by'
westernblot'analysis.'CAMet'levels'were'assessed'in'liver'lysates'from'mice'receiving'
30mg/kg'Cabozan:nib'(CBZ)'or'sterile'H2O'control'(CTRL)'5x'weekly'for'10'days'using'
Western'blot.'Total'protein'concentra:on'loaded'was'30ng/µL.'GAPDH'was'used'as'a'
loading'control.'
Loading:'(1)'CTRL;'3.5hrs'post'administra:on,'(2A4)'–'CTRL;'24hrs'post'administra:on,'
(5)'CBZ;'3.5hrs'post'administra:on,'(6+8)'CBZ;'24hrs'post'administra:on,'(7)'animal'had'
to'be'sacriﬁced'immediately'aaer'treatment,'liver'sample'was'collected'1hr'post'cull.'
'
	 188	
4.7. Discussion	
The	 main	 objective	 of	 this	 study	 was	 to	 characterise	 the	 effects	 of	 the	 tyrosine	 kinase	
inhibitor	(TKI)	CBZ	on	the	BME	in	the	absence	of	tumour.	Due	to	their	expression	on	cells	
other	than	the	tumour	cells	multiple	TKIs	such	as	Cabozantinib	target	signalling	pathways	
(e.g.	RET,	VEGFR,	MET)	involved	in	tumourigenesis,	angiogenesis	and	osteogenesis.	Various	
TKI	have	been	shown	to	affect	bone	metabolism	raising	the	need	to	establish	their	impact	
on	the	BME.	Imatinib,	Dasatinib,	Saracatinib	and	Sunitinib	for	example	have	demonstrated	
to	 reduce	 and	 or	 inhibit	 osteoclast	 resorption	 [208,	 278,	 279].	 In	 2006	 Berman	 et	 al.	
reported	 a	 reduction	 in	 bone	 formation	 and	 resorption	marker	 (osteocalcin	 and	NTX)	 in	
patients	receiving	long-term	therapy	of	Imatinib,	a	BCR-ABL,	C-KIT	and	PDGFR	targeted	TKI	
[278].	This	highlights	that	the	effects	of	TKI	including	CBZ	on	bone	cells	combined	with	anti-
tumour	effects	could	reduce	skeletal-related	morbidity	in	patients	with	bone	metastasis.	
4.7.1. Effects	on	bone	cells		
Prior	to	the	research	presented	in	this	chapter	the	in	vivo	effects	of	CBZ	on	osteoblasts	and	
osteoclasts	 in	 the	 absence	 of	 tumour	 cells	 have	 not	 been	 investigated	 in	 detail.	 The	
majority	 of	 experiments	 investigating	 CBZ	 effects	 on	 tumour	 growth	 in	 bone	 have	 been	
performed	in	models	of	advanced	prostate	cancer	[230,	231,	233],	where	substantial	bone	
loss	 and	 large	 tumour	 burden	 has	 hampered	 analysis	 of	 CBZ	 responses	 on	 bone.	 	 This	
chapter	 therefore	 presents	 the	 first	 comprehensive	 analysis	 of	 the	 short-term	 effects	 of	
CBZ	on	osteoblast	and	osteoclast	number	 in	a	 range	of	BMEs	 including	mice	of	different	
ages,	sex	and	strain.		
Osteoblasts	and	osteoclasts	are	key	players	in	the	vicious	cycle	driving	progression	
of	 bone	metastasis	 [121],	 and	 crucially	 both	 cell	 types	 express	 receptors	 (e.g.	MET	 and	
VEGFR-2)	targeted	by	CBZ	[209,	210,	212].	In	support	of	my	hypothesis	that	CBZ	mediates	
treatment	response	by	 inducing	alterations	to	bone	remodelling,	 I	 found	that	CBZ	rapidly	
reduced	 the	 number	 of	 osteoclasts/mm	 trabecular	 bone	 surface,	 resulting	 in	 increased	
trabecular	 thickness	 after	 a	 cumulative	 dose	 of	 240mg/kg	 (8	 administrations)	 in	 naïve	
female	mouse	models.	These	findings	are	in	agreement	with	data	from	studies	performed	
in	models	 of	 prostate	 cancer-induced	 bone	 disease	 [230,	 233],	 where	 effects	 of	 CBZ	 on	
osteoclasts	were	 assessed	 in	 tumour-free,	 contralateral	 tibiae	 [230,	 232]	 and/or	 tumour	
free	 mice	 [233].	 	 The	 authors	 reported	 reduced	 number	 of	 osteoclasts/mm	 trabecular	
bone	surface	along	the	edge	of	the	growth	plate	(male	NOD/SCID	mice,	daily	30mg/kg	CBZ	
for	15	days)[233]	and	decreased	osteoclast	perimeter	(male	SCID	mice,	daily	60mg/kg	CBZ	
for	 3	 weeks)	 [230].	 In	 contrast	 others	 report	 no	 effect	 of	 CBZ	 on	 osteoclasts	 in	 mouse	
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models	of	prostate	cancer	[232].	In	contrast	to	female	mice,	I	did	not	determine	alterations	
in	osteoclast	number	in	male	BALB/c	nude	mice	after	8	doses	of	CBZ.	However,	CBZ	caused	
an	 increased	 osteoclast	 size	 in	 these	 male	 mice,	 indicating	 a	 potential	 loss	 of	 activity.	
Previous	publications	report	an	inhibition	of	differentiation	and	resorptive	activity	in	RAW	
pre-osteoclasts	 [230,	 276]	 but	 no	 effects	 of	 CBZ	 on	 the	 ability	 of	mature	 osteoclasts	 to	
resorb	 bone	 in	 vitro	 [232].	 TRAP5b	 levels	 were	 increased	 in	 male	 SCID	 mice	 but	 these	
findings	could	be	masked	by	the	presence	of	tumour	in	this	model	[230].		Based	on	their	in	
vitro	and	in	vivo	observations	the	authors	suggest	that	CBZ	might	not	affect	the	resorptive	
activity	of	osteoclasts	but	rather	inhibit	osteoclast	maturation	and/or	reduce	their	number	
[230].	 The	highly	 significant	 increase	 in	 the	 length	of	 the	hypertrophic	 chondrocyte	 zone	
after	treatment	termination	however	suggested	that	resorption	may	be	impaired	by	CBZ.	
However,	TRAP	serum	levels	remained	unaffected	after	5	and	8	doses	of	CBZ	in	all	animal	
models,	suggesting	that	short-term	treatment	with	CBZ	may	not	affect	bone	resorption	in	
vivo	in	the	absence	of	tumour.		
Osteoblast	number/mm	trabecular	bone	was	significantly	 increased	after	5	doses	
of	CBZ	(150mg/kg	cumulative	dose)	however	no	effects	on	osteoblasts	were	observed	after	
8	administrations	 in	 female	animals.	 In	 contrast	male	BALB/c	nude	mice	 showed	a	 slight	
increase	 in	osteoblast	 numbers.	Others	 report	 reduced	 viability	 and	osteocalcin	 levels	 (a	
marker	 for	 late	osteoblast	differentiation)	 in	pre-osteoblastic	MC3T3-E1	and	mouse	bone	
marrow	stromal	ST-2	cell	 cultures	determined	 following	CBZ	 treatment	 (0.01-5µmol/L)	 in	
vitro	[230].	Data	are	contradictory	with	regards	to	effects	on	alkaline	phosphatase	activity	
(ALP,	marker	 for	early	osteoblast	differentiation)	and	mineralisation	[230-232]	suggesting	
that	CBZ	may	act	on	bone	through	more	than	one	mechanism.	The	biphasic	effects	on	ALP	
could	be	caused	by	different	concentrations	of	CBZ	used	in	these	experiments.	Nude	mice	
injected	intratibially	with	the	prostate	cancer	cell	line	ARCaPM	receiving	10	or	30mg/kg	CBZ	
daily	 for	 7	 weeks	 showed	 increased	 numbers	 of	 osteoblasts	 [232].	 Similar	 results	 were	
determined	in	non-tumour	bearing	tibiae	of	male	SCID	mice	with	intratibial	PC-3luc	prostate	
tumours,	 following	 daily	 administration	 of	 60mg/kg	 CBZ	 for	 3	 weeks	 [230].	 Beside	 the	
alterations	in	bone	cell	number	serum	PINP	levels	remained	unaffected	after	5	and	8	doses	
of	CBZ.	This	is	in	agreement	with	others	who	found	that	serum	PINP	and	osteocalcin	levels	
were	 unaffected	 by	 CBZ	 (60mg/kg/day)	 [230].	 Calcein	 analysis	 of	 vertebrae	 from	 female	
mice	receiving	8	doses	of	CBZ	demonstrated	that	these	animals	had	slightly	increased	bone	
formation	rate	(BFR)	when	compared	to	control;	BFR	takes	 into	account	how	much	bone	
surface	 is	 actively	 mineralising	 and	 is	 therefore	 depending	 on	 the	 number	 of	 active	
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osteoblasts).	 In	contrast	serum	PINP	levels	were	significantly	 lower	 in	CBZ	treated	mice	5	
days	post	treatment	termination	relative	to	control	receiving	mice.		
Most	likely	the	bone	serum	marker	levels	(TRAP	and	PINP)	did	not	correspond	with	
the	 observed	 alterations	 in	 bone	 cell	 number	 in	 my	 experiments,	 due	 to	 experimental	
design.	Serum	samples	for	bone	marker	measurements	were	only	collected	at	the	end	of	
the	experiment,	reflecting	one	point	in	time	and	taking	repeated	blood	samples	is	also	not	
an	 option	 on	 our	 current	 project	 license.	 In	 contrast,	 histological	 analysis	 quantifies	
accumulated	 effects	 of	 CBZ	 over	 the	 entire	 experimental	 period.	 Additionally,	 serum	
TRAP/PINP	 levels	 represent	 levels	 released	 from	 the	 entire	 skeleton	 whereas	 I	 only	
quantified	 bone	 cell	 number	 in	 tibia/bone	 formation	 rate	 in	 vertebrae	 (representing	
accumulating	 effects),	 potentially	 contributing	 to	 the	 observed	 differences.	 In	 a	 recent	
Phase	 II	 randomized	 discontinuation	 trial	 (patients	 with	 castration	 resistant	 prostate	
cancer	who	received	100mg	CBZ	daily)	serum	ALP	and	CTX	were	reduced	by	50%	in	57%	of	
evaluable	patients	[234].	Similar	results	-	reduced	levels	of	CTX	and	NTX	-	were	obtained	in	
a	Phase	II	Nonrandomised	Expansion	Study	conducted	in	patients	with	chemotherapy	pre-
treated	 metastatic	 castration-resistant	 prostate	 cancer	 [235],	 supporting	 the	 hypothesis	
that	CBZ	partially	mediates	treatment	effects	by	targeting	the	BME.	
In	 summary,	 it	 remains	unclear	why	differential	effects	of	CBZ	on	osteoblast	and	
osteoclasts	 were	 observed	 in	 mice	 of	 different	 sex;	 and	 highlight	 the	 need	 to	 perform	
studies	 in	 different	 animal	 ages/sex	 in	 order	 to	 demonstrate	 consistency	 of	 therapeutic	
effects	 in	model	systems.	My	studies	showed	potential	of	CBZ	to	affect	both	cell	types	 in	
vivo	however	the	tight	coupling	between	osteoblasts	and	osteoclasts	makes	 it	difficult	to	
separate	the	direct/indirect	effects	of	therapeutic	agents	on	these	cells,	in	particular	when	
both	 cell	 types	 express	 the	 target	 receptor(s).	 It	 is	 possible	 that	 CBZ	 reduced	 RANKL	
expression	by	the	osteoblasts	 in	 these	studies,	 resulting	 in	decreased	osteoclast	number.	
However	it	is	not	possible	to	accurately	measure	the	levels	of	active	RANKL	in	the	BME	and	
the	 role	 of	 soluble	 RANKL	 in	 regulating	 bone	 turnover	 is	 unclear.	 Given	 that	 short-term	
treatment	with	CBZ	did	not	 alter	 bone	 remodelling	 throughout	 the	 animal	models	 used,	
further	cell	types	of	the	BME	were	suggested	as	potential	mediators	of	treatment	effects.	
This	 is	 supported	 by	 the	 observations	 that	 CBZ-induced	 alterations	 of	 megakaryocyte	
number,	 bone	 marrow	 vasculature,	 trabecular	 thickness	 and	 elongated	 hypertrophic	
chondrocyte	 zone	 in	 the	 epiphyseal	 growth	 plate	 area	were	 all	 consistently	 observed	 in	
both	male	and	female	mice.		
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4.7.2. Effects	on	bone	volume	and	structure		
Although	5	administrations	of	CBZ	increased	osteoblast	and	decreased	osteoclast	numbers,	
this	 short-term	 schedule	 did	 not	 result	 in	 any	 significant	 increase	 in	 trabecular	 bone	
volume,	 apart	 from	 in	 17-week	 old	 female	 GFP	 Ob+	 mice.	 Increasing	 the	 schedule	 to	 8	
doses	 of	 CBZ	 over	 10	 days	 did	 result	 in	 increased	 trabecular	 thickness	 in	 all	 the	models	
evaluated	 in	 addition	 to	 increased	 trabecular	 bone	 volume	 and	 number	 in	 9-week	 old	
female	GFP	Ob+	mice	(Table	18).	This	increase	was	rapidly	lost,	returning	to	control	levels	5	
days	after	the	last	administration	of	CBZ	(Table	18).	Although	the	GFP	Ob+	mice	represent	a	
slightly	 different	 BME	 compared	 to	BALB/c	 nude	mice,	 the	 differential	 effects	 of	 CBZ	on	
trabecular	 bone	 is	 potentially	 due	 to	 the	 difference	 in	 bone	 turnover	 between	 the	mice	
aged	 6	 and	 9	weeks.	 	 These	 findings	 highlight	 that	 long-term	 and	 continuous	 treatment	
might	be	required	for	bone	volume	to	be	altered,	but	following	cessation	of	treatment	the	
BME	has	 the	 capacity	 to	 reverse	 the	 alterations.	 In	 contrast	 others	 found	no	 increase	 in	
bone	mineral	 content	 in	 tumour-free	 tibiae	 of	mice	 receiving	 60mg/kg	 CBZ	 for	 3	weeks	
(PC3	tumours)	and	5	weeks	(Ace1	and	C4-2B	tumours),	respectively	suggesting	that	it	may	
take	 longer	 to	 see	 treatment	 effects	 on	 bone	 than	 the	 7-week	 treatment	 course	 [230].	
However,	6-week	treatment	with	60mg/kg	CBZ	in	castrated	and	intact	mice	injected	with	
LnCaP	23.1	prostate	cancer	cells	resulted	in	significantly	increased	trabecular	bone	volume	
and	number	 in	contralateral	non-tumour	bearing	 tibiae	 [231].	These	differential	effect	of	
CBZ	on	bone	volume	and	 structure	between	 studies	may	be	due	 to	 the	models	 and	CBZ	
schedules	used,	and	further	studies	are	required	to	firmly	establish	the	optimal	CBZ	dosing	
regimen	required	to	increase	bone	volume.	
4.7.3. Effects	on	growth	plate	composition	
Importantly,	 my	 study	 is	 the	 first	 reporting	 effects	 of	 CBZ	 on	 chondrocytes	 in	 vivo.	 I	
observed	 substantial	 alterations	 in	 the	 epiphyseal	 growth	 plate	 of	 CBZ	 treated	 mice,	
including	an	expansion	of	 the	hypertrophic	chondrocyte	zone.	This	was	prominent	 in	 the	
epiphysis	of	all	 animals	 irrespective	of	age,	 sex	and	 treatment	 schedule.	When	analysing	
growth	 plates	 of	 tumour-free	 tibiae	 from	 animals	 receiving	 longer-term	 CBZ	 treatment	
[231,	 233],	 similar	 effects	 were	 observed.	 During	 endochondral	 ossification,	 newly	
synthesised	 cartilage	 is	 replaced	 by	woven	 bone	 in	 a	 highly	 organised	 process	 involving	
chondrocyte	proliferation,	maturation,	hypertrophy	and	 finally	matrix	 calcification.	There	
are	 conflicting	 views	 about	 the	 terminal	 fate	 of	 the	 chondrocyte,	 including	 their	
differentiation	 into	 osteoblastic	 cells	 [280]	 or	 apoptosis	 (reviewed	 in	 [281]).	 It	 has	
previously	 been	 reported	 that	 inhibition	 of	 VEGF	 signalling	 results	 in	 growth	 plate	
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thickening	as	 a	 consequence	of	 the	expanded	hypertrophic	 chondrocyte	 zone	 [212,	282]	
and	 this	 could	 also	 be	 the	mechanism	 involved	 in	 the	 CBZ-induced	 effects.	 The	 growth	
plate	normalised	to	control	thickness	12	days	after	treatment	termination,	coinciding	with	
an	 increase	 in	 osteoclast	 activity.	 During	 endochondral	 ossification,	 osteoclasts	 are	
recruited	to	the	mineralising	front	of	the	growth	plate,	allowing	resorption	of	cartilage	and	
invasion	of	osteoblasts	 to	mineralise	 the	matrix,	which	 is	 a	potential	 explanation	 for	 the	
sudden	 increase	 in	osteoclast	activity	once	CBZ	administration	 ceased.	New	blood	vessel	
formation	 is	 apparent	 in	 the	 developing	 epiphysis	 and	 anti-VEGF	 treatment	 has	 been	
shown	to	modify	the	growth	plate	[283-285].	Similarly,	CBZ	treated	mice	appeared	to	have	
fewer	 Endomucin	 positive	 vessels	 in	 the	 epiphysis	 when	 compared	 to	 control	 mice	
(observations	only).	Children	with	open	growth	plates	therefore	require	close	monitoring	
when	 receiving	 anti-angiogenic	 therapy	 as	 they	 are	 in	 risk	 of	 developing	 growth	 plate	
abnormalities	[286].	This	approach	might	be	appropriate	also	for	CBZ,	although	preliminary	
safety	data	from	a	phase	1	trial	of	CBZ	in	paediatric	cancer	patients	did	not	indicate	clinical	
consequences	of	potential	growth	plate	effects	[287].		
4.7.4. Effects	on	bone	marrow	composition		
During	histological	analysis	I	also	noted	alterations	in	the	bone	marrow	composition	in	CBZ	
treated	animals	compared	to	control,	including	vascular	ectasia	and	spillage	of	mature	red	
blood	cells	 in	 the	extra	vascular	bone	marrow.	CBZ	 rapidly	altered	 the	 structure	of	bone	
marrow	 vascular	 endothelial	 cells	 resulting	 in	 dilated	 blood	 vessels	 densely	 filled	 with	
erythrocytes	 in	mice	 that	 had	 received	 8	 administrations	 of	 CBZ.	 Vessels	 appeared	 thin	
walled	 and	 the	 observed	 spillage	 of	 erythrocytes	 into	 the	 extravascular	 bone	 marrow	
suggests	 disintegration	 of	 the	 bone	 marrow	 vasculature.	 However,	 this	 would	 require	
further	 confirmation.	 Mice	 that	 received	 15	 days	 of	 treatment	 [233]	 appeared	 to	 have	
reduced	 haematopoietic	 cells	 in	 the	 marrow,	 increased	 numbers	 of	 adipocytes	 and	
reduced	megakaryocyte	cytoplasm,	although	I	was	unable	to	accurately	quantify	this	due	
to	 the	 limited	number	of	 samples	available	 from	this	 study	 [233].	Analysis	of	histological	
sections	 from	tibiae	of	mice	 receiving	60mg/kg	CBZ	5x	weekly	 for	6	weeks	 [231]	showed	
similar	changes	 in	bone	marrow	composition	 in	3	out	of	8	assessed	mice,	with	additional	
animals	displaying	a	more	modest	effect.	These	responses	are	likely	a	result	of	inhibition	of	
VEGFR	affecting	 the	bone	microvasculature.	 In	 support	of	 this,	 a	 study	using	 the	 soluble	
VEGF	receptor	chimeric	protein	Flt(1-3)-IgG	reported	an	increase	in	thickness	of	secondary	
trabeculi	 in	 vivo	 in	 addition	 to	 disorganised	 and	 dilated	 blood	 vessels	 adjacent	 to	 the	
hypertrophic	 chondrocyte	 zone	 [212]	with	 similar	morphology	 as	 observed	 in	my	 study.	
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Recently	 others	 report	 that	 human-tumour-derived	 VEGF	 induces	 bone	 marrow	 vessel	
dilation	and	observe	 similar	effects	 in	bone	marrow	vasculature	 in	VEGF-tumour	bearing	
mice	as	the	here	reported	effects	of	CBZ	on	bone	marrow	vasculature.	The	authors	suggest	
that	bone	marrow	cell	mobilisation	and	vessel	dilation	is	VEGFR-2	dependent	[288].		
Moreover,	 alterations	 in	 endochondral	 ossification,	 in	 particular	 the	 transition	
from	 cartilage	 to	 bone,	 might	 affect	 the	 haematopoietic	 niche	 located	 within	 the	 bone	
marrow	 potentially	 accounting	 for	 the	 observed	 alterations	 in	 the	 haematopoietic	
composition	 after	 CBZ	 treatment.	 By	 generating	 transgenic	 mice	 expressing	 defective	
collagen	 X	 variants,	 Jacenko	 et	 al.	 demonstrated	 the	 close	 interdependence	 of	
endochondral	 ossification	 and	 haematopoiesis	 in	 the	 bone	 marrow	 [289].	 In	 these	
experiments	the	authors	observed	a	compression	in	the	tibial	growth	plate	and	a	reduction	
in	 the	 number	 of	 hypertrophic	 chondrocytes.	 Interestingly,	 histology	 and	 observations	
made	on	day	of	dissections	from	aging	transgenic	mice	revealed	marrow	hypoplasia	(fatty	
marrow),	 and	 a	 bone	 marrow	 with	 a	 predominance	 of	 erythrocytes	 –	 similar	 to	
observations	 made	 following	 CBZ	 treatment.	 In	 three-week	 old	 mice	 they	 observed	 a	
reduction	in	the	overall	number	of	nucleated	cells	within	the	bone	marrow	[289],		similar	
to	 data	 obtained	 in	 my	 experiments.	 This	 highlights	 the	 importance	 of	 endochondral	
ossification	in	maintaining	haematopoiesis	and	might	partially	explain	observed	effects	on	
bone	marrow	composition	following	CBZ	treatment.		
Next	 to	 fatigue,	 hypertension	 and	 hand-foot	 syndrome	were	 the	most	 common	
experienced	 grade	 3	 adverse	 events	 caused	 by	 CBZ	 in	 patients	 with	 advanced	 prostate	
cancer	 [234];	 lymphopenia,	 neutropenia	 and	 thrombocytopenia	 in	 addition	 to	
haemorrhage	have	been	 reported	as	 common	haematological	 adverse	effects	 [229].	 The	
bone	marrow	effects	we	observed	may	therefore	reflect	some	of	the	known	complications	
experienced	by	patients	 treated	with	CBZ.	All	 animals	appeared	healthy	after	 short-term	
treatment	used	in	my	study	but	at	the	biological	level	this	does	support	the	use	of	in	vivo	
models	to	investigate	effects	on	the	BME.		
One	of	the	most	intriguing	findings	in	my	studies	was	that	CBZ	treatment	caused	a	
significant	increase	in	the	number	of	megakaryocytes	in	the	bone	marrow,	indicating	that	
CBZ	 may	 have	 impaired	 terminal	 differentiation	 of	 megakaryocytes	 and	 release	 of	
platelets.	 The	 increase	 in	 red	 blood	 cells	 in	 the	 marrow	 could	 be	 in	 agreement	 with	
thrombocytopenia	reported	as	a	common	laboratory	abnormality	in	patients	receiving	CBZ	
[229].	However,	as	with	all	the	CBZ-induced	effects	detected,	megakaryocyte	numbers	and	
the	 associated	bone	marrow	effects	 rapidly	 normalised	 to	 control	 levels	 once	 treatment	
	 194	
was	 terminated.	 	Megakaryocytes	 also	 play	 a	 role	 in	 bone	 homeostasis,	 including	 in	 the	
maintenance	of	bone	mass	 [290].	Mice	deficient	 in	 the	 transcription	 factors	 required	 for	
megakaryocyte	 differentiation	 and	 maturation	 have	 high	 numbers	 of	 immature	
megakaryocytes	 in	 the	 bone	marrow,	 accompanied	 by	 dramatically	 increased	 osteoblast	
numbers	 and	 bone	 volume	 [80].	 In	 vitro,	 osteoblast	 proliferation	 is	 increased	 by	 the	
presence	 of	 megakaryocytes	 and	 direct	 cell-to	 cell	 contact	 between	 both	 cell	 types	 is	
suggested	 to	occur	via	gap	 junctions	 [81]	and/or	 integrins	 [82].	However,	 to	what	extent	
osteoblasts	and	megakaryocytes	are	in	direct	contact	in	vivo	remains	to	be	established.	In	
the	present	study,	megakaryocytes	did	not	appear	to	be	in	close	proximity	to	osteoblasts	
in	 2D	 histological	 sections	 of	 tibiae.	 Megakaryocytes	 have	 also	 been	 demonstrated	 to	
inhibit	 formation	 of	 osteoclasts	 when	 added	 to	 pre-osteoclast	 cultures	 and	 to	 impair	
osteoclast	function	[291,	292].	It	is	therefore	possible	that	CBZ	may	increase	bone	volume	
not	only	through	direct	effects	on	osteoblasts	and	osteoclasts,	but	also	indirectly	through	
increasing	 the	 number	 of	megakaryocytes	 that	 in	 turn	 stimulate	 osteoblasts	 and	 inhibit	
osteoclast	activity	and	maturation.	
4.7.5. Gene	expression	
To	determine	 if	expression	of	key	genes	 involved	 in	bone	turnover	were	affected	by	CBZ	
treatment,	I	assessed	expression	levels	of	genes	associated	with	bone	remodelling	(RANK,	
RANKL,	OPG,	Vegfa,	and	Sox9)	in	long	bones	of	mice	after	5	and	8	doses	of	CBZ	treatment.	
	5	 day	 treatment	with	 CBZ	 did	 not	 affect	 expression	 of	 assessed	 genes	whereas	
RANKL	and	Sox9	levels	were	increased	following	8	doses	of	CBZ	in	9-week	old	female	GFP	
Ob+	mice.	Required	for	full	osteoclastic	differentiation,	RANKL	is	expressed	by	a	variety	of	
cells	 in	the	bone	marrow	including	osteoblasts,	chondrocytes,	osteocytes	and	endothelial	
cells	 [69].	CBZ	 treatment	did	not	 result	 in	alterations	 in	osteoblast	number	after	8	doses	
suggesting	 that	 osteoblastic	 cells	 might	 not	 be	 one	 of	 the	 sources	 of	 increased	 RANKL	
expression	in	these	experiments.	Another	source	of	increased	RANKL	expression	could	be	
the	 hypertrophic	 chondrocyte.	 This	 would	 be	 in	 agreement	 with	 the	 observations	 of	
significantly	 enlarged	 hypertrophic	 chondrocyte	 zone	 in	 growth	 plates	 of	 CBZ	 receiving	
mice	 when	 compared	 to	 control.	 RANKL	 derived	 from	 hypertrophic	 chondrocytes	 is	
necessary	 for	 regulating	 osteoclast	 mediated	 bone	 resorption	 at	 the	 calcified	
bone:cartilage	 junction	 in	 bone.	 In	 agreement	 with	 this,	 various	 studies	 detected	 RANK	
expression	 in	 hypertrophic	 chondrocytes	 [293].	 In	 addition,	 Collin-Osdoby	 et	 al.	 have	
shown	that	human	microvascular	endothelial	cells	express	RANKL	mRNA	in	vitro	and	might	
play	an	important	role	in	bone	remodelling	as	well	as	osteoclastogenesis	[294].	One	of	the	
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major	sources	of	RANKL	in	bone	is	the	osteocyte	[295,	296].	I	did	not	investigate	effects	of	
CBZ	on	osteocytes,	however,	these	cells	could	also	be	altered	by	drug	administration	and	
account	for	the	observed	effects	on	gene	expression.		
Sox9	 is	 required	 for	 maintaining	 growth	 plate	 functionality	 by	 regulating	
chondrocyte	 proliferation	 and	 inducing	 hypertrophy	 –	 this	 was	 shown	 by	 Dy	 et.	 al	 who	
generated	doxocycline	 inducible	Cre	transgene	and	Sox	9	null	alleles	 in	mice	[297].	Sox	9	
has	 first	 been	 suggested	 to	 inhibit	 chondrocyte	 proliferation	 but	 has	 also	 been	
demonstrated	 to	 be	 required	 for	 early	 chondrocyte	 differentiation	 [298].	 Sox	 9	 was	
subsequently	 suggested	 to	 be	 a	 mediator	 of	 survival	 and	 hypertrophy	 and	 terminal	
maturation	of	chondrocytes	[299].	The	alteration	in	Sox	9	gene	expression	levels	after	CBZ	
treatment	could	therefore	be	a	consequence	of	the	observed	increase	in	the	hypertrophic	
chondrocyte	zone	in	CBZ	treated	mice.	
4.8. Summary	and	Conclusion	
In	 summary,	 these	data	demonstrate	 that	CBZ	exerts	effects	on	various	 cell	 types	 in	 the	
BME	 (Table	 23).	 Data	 on	 osteoblasts	 and	 osteoclasts	 varied	 depending	 on	 animal	model	
and	 treatment	 schedule	 used;	 suggesting	 that	 short-term	 treatment	 with	 CBZ	 does	 not	
affect	 bone	 remodelling	 in	 the	 absence	 of	 tumour.	 However	 further	 cell	 types	 including	
megakaryocytes,	 bone	marrow	 vascular	 endothelial	 cells	 and	 chondrocytes	were	 rapidly	
affected	by	CBZ	suggesting	that	these	cell	types	may	contribute	to	the	therapeutic	effects	
of	 CBZ	 as	well	 as	 off	 target	 effects.	 Response	 of	 key	 bone	 cells	 to	 CBZ	 administration	 is	
rapid	and	reversible	once	treatment	is	stopped,	supporting	the	conclusion	that	continuous	
administration	is	required	in	order	to	maintain	the	effects	of	this	agent	(see	Table	23	for	a	
summary	of	treatment	effects).	
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Table	23	Summary	of	the	effects	of	CBZ	on	the	bone	microenvironment.	
✕ =	no	effect,	↑	=	increased,	↓	=	decreased,	Ob.N.=	Osteoblast	number,	Ob.A.=	Osteoblast	activity,	
Oc.N.=	 Osteoclast	 number,	 Oc.A.=	 Osteoclast	 activity,	 GP	 =	 Growth	 plate	 area,	MK	 =	 Number	 of	
megakaryocytes,	n.a	=	not	assessed.	
	 	
Summary	of	treatment	effects	
Model	system	 Ob.N.	 Ob.A.	 Oc.N.	 Oc.A	 GP	 MK	
5	doses	of	CBZ	
8-9-week	old		GFP	Ob+		mice	 ↑	 ✕	 ↓	 ✕	 ↑	 ✕	
17-week	old		GFP	Ob+		mice	 ↑	 ✕	 ✕	 ✕	 ↑	 ✕	
8	doses	of	CBZ	
6-week	old	male	BALB/c	nude	 ↑	 ✕	 ✕	 ✕	 ↑	 ↑	
6-week	old	female	BALB/c	nude	 ✕	 ✕	 ↓	 ✕	 ↑	 ↑	
9-week	old	femiale	GFP	Ob+	mice	 ✕	 ✕	 ↓	 ✕	 ↑	 ✕	
Treatment	follow-up	
6-week	old	female	BALB/c	nude	
5	days	post	treatment	termination	 ✕	 ✕	 ✕	 ✕	 ↓	 ↓	
12	days	post	treatment	termination	
12	days	post	treatment	termination	 ✕	 ✕	 ✕	 ↑	 ✕	 ✕	
Longer-term	treatment	
Castrated	male	NOD/SCID	mice	 n.a	 n.a	 n.a	 n.a	 ↑	 n.a	
6-week	old	castrated	male	beige	SCID	
mice	 n.a	 n.a	 n.a	 n.a	 ↑	 n.a	
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Chapter	5	-	The	role	of	the	
bone	microenvironment	in	
peripheral	breast	tumour	re-
growth	following	successful	
combination	therapy	
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5.1. Summary		
Cancer	 patients	 often	 receive	 a	 combination	 of	 therapies	 to	 increase	 their	 treatment	
response.	Combined	treatment	with	doxorubicin	(DOX)	followed	by	Zoledronic	acid	(ZOL)	is	
shown	 to	 cause	 suppression	of	 peripheral	 breast	 tumour	 growth	 in	 vivo	 in	 experimental	
models	 [241,	260].	Several	 clinical	 studies	have	suggested	beneficial	effects	of	ZOL	when	
added	to	chemotherapy	in	the	neoadjuvant	setting	[191,	192],	and	a	recent	meta	analysis	
demonstrated	a	significant	increase	in	complete	pathological	response	in	the	breast	when	
ZOL	was	added	to	chemotherapy	in	postmenopausal	women	[193].		The	exact	mechanism	
underlying	 the	 observed	 anti-tumour	 effects	 remain	 to	 be	 established.	 However,	
combining	 an	 anti-resorptive	 agent	 with	 chemotherapy	 supports	 a	 role	 for	 bone	 in	 the	
growth	of	primary	breast	tumours.		
Signals	 from	 the	 bone	 microenvironment	 (BME)	 	 -	 including	 for	 example	
osteoclastic	 bone	 resorption	 –	 can	 cause	 bone	 marrow	 derived	 cells	 (BMDCs)	 including	
haematopoietic	stem	cells	(HSCs)	to	leave	their	niche,	proliferate	and	differentiate.	BMDCs	
include	 cells	 that	 can	 produce	 tumour-growth-promoting	 factors	 and/or	 are	 recruited	
directly	to	the	site	of	tumour	growth.	
The	hypothesis	to	be	tested	in	this	chapter	is	that	ZOL-induced	modification	of	the	
BME	reduces	peripheral	breast	cancer	re-growth	after	cessation	of	combination	therapy	
of	the	primary	tumour.	This	is	the	first	study	to	determine	whether	reduced	subcutaneous	
tumour	 growth	 following	 combination	 therapy	 is	 reversed	 by	 transplanting	 the	 tumours	
into	new	recipients	with	a	modified	BME.	This	will	also	give	insight	into	whether	effects	of	
combination	therapy	are	due	to	direct	interactions	between	the	drugs	and	tumour	cells	or	
through	ZOL-induced	alterations	to	the	BME.	
Weekly	 combination	 therapy	 successfully	 suppressed	 tumour	 growth	 whereas	
growth	of	re-transplanted	tumour	fragments	resumed	at	equal	rates	whether	transplanted	
into	ZOL	or	PBS	pre-treated	hosts.	Both	ZOL	and	combination	therapy	caused	modifications	
to	numerous	cell	 types	 in	 the	BME.	However,	modification	of	 the	BME	with	ZOL	was	not	
sufficient	 to	 suppress	 peripheral	 breast	 cancer	 re-growth	 following	 cessation	 of	
combination	 therapy	 suggesting	 that	 modification	 of	 the	 BME	 only	 is	 not	 sufficient	 for	
sustained	anti-tumour	effects.	
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5.2. Introduction	
5.2.1. Primary	tumour	growth	and	bone	marrow-derived	cells	
Primary	breast	tumours	are	comprised	of	multiple	components	including	both	tumour	cells	
as	 well	 as	 stromal	 cells.	 Stromal	 cells	 are	 increasingly	 recognised	 as	 key	 mediators	 of	
tumour	development	and	disease	progression	 [10].	Given	 that	many	of	 the	 stromal	 cells	
present	within	 the	 TME	 are	mobilised	 host	 cells	 from	 distant	 tissues	 including	 the	 bone	
marrow	and	spleen,	growing	attention	is	paid	to	bone	marrow-derived	cells	(BMDCs)	and	
their	contribution	to	breast	cancer	growth.	Upon	cancer-cell-derived	signals	(cytokines	and	
growth	 factors	 including	 G-CSF,	 VEGF,	 TGF-β,	 OPN,	 LOX	 and	 SDF-1	 [27-29])	 BMDCs	
including	 but	 not	 limited	 to	 cancer-associated	 fibroblasts,	 tumour-associated	
macrophages,	infiltrating	immune	cells,	myeloid-derived	suppressor	cells	or	corresponding	
precursors	 are	 actively	 recruited	 to	 the	 site	 of	 tumour	 growth,	 where	 they	 promote	
disease	progression.	Given	that	the	bone	marrow	acts	as	a	reservoir	of	BMDCs	that	can	be	
recruited	 to	 the	 site	 of	 primary	 tumour	 growth,	 therapeutics	 that	 modulate	 the	 BME	
(including	ZOL)	may	have	consequences	on	primary	breast	cancer	(re-)	growth.		
5.2.2. Combination	therapy	–	clinical	setting	
In	 clinical	 practice,	 patients	with	 advanced	breast	 cancer	often	 receive	 a	 combination	of	
treatments	that	include	bisphosphonates	(BPs),	chemotherapy	and	anti-hormone	therapy.	
However,	 exact	 treatment	 intervals	 and	 sequence	 are	 not	 standardised	 and	 vary	widely	
depending	on	disease	progression.	Bone-targeted	agents,	 including	BPs,	 and	Denosumab	
are	 approved	 for	 treatment	 of	 patients	 with	 established	 bone	 metastases,	 but	 recent	
clinical	 trials	 also	 support	 their	 use	 in	 patients	without	 evidence	of	 skeletal	 involvement	
both	 in	 the	 adjuvant	 and	 neoadjuvant	 setting.	 Several	 studies	 have	 suggested	 beneficial	
effects	of	adding	ZOL	 to	 chemotherapy	 in	 the	neoadjuvant	 setting	 [191,	192].	A	 recently	
published	 meta-analysis	 assessed	 data	 from	 750	 patients	 with	 stage	 II/III	 breast	 cancer	
enrolled	in	4	different	randomised	clinical	trials	comparing	the	use	of	ZOL	in	combination	
with	 neoadjuvant	 chemotherapy.	 Subgroup	 analysis	 showed	 that	 pathological	 response	
(pCR),	 the	 ultimate	 aim	 in	 neoadjuvant	 therapy,	 was	 nearly	 doubled	 in	 postmenopausal	
women;	results	similar	as	described	with	regards	to	the	differential	menopausal	effect	of	
ZOL	 in	 adjuvant	 therapy	 [132,	 192].	 Given	 these	 clinical	 trials	 the	 use	 of	 BPs	 in	 patients	
without	 evidence	 of	 skeletal	 involvement	 will	 increase.	 However,	 it	 remains	 speculative	
whether	 and	 how	 the	 BME	 mediates	 primary	 breast	 cancer	 (re-)	 growth	 and	 if	 this	 is	
influenced	by	bone-targeted	agents.		
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5.2.3. Combination	therapy	–	pre-clinical	setting	
Chemotherapeutic	 regimes	 used	 to	 treat	 breast	 cancer	 patients	 often	 include	 the	
anthracycline	 doxorubicin	 (Adriamycin®,	 herein	 referred	 to	 as	 DOX)	 or	 epirubicin	
(Ellence®).	 Neoadjuvant	 chemotherapies	 used	 in	 the	 AZURE	 trial	 included	 anthracyclines	
[192]	and	previous	experiments	in	our	laboratory	have	shown	beneficial	effects	of	clinically	
relevant	doses	of	 the	anthracyclin	DOX	 in	combination	with	ZOL	on	peripheral	as	well	as	
skeletal	breast	cancer	growth	[241,	247].	
Briefly,	 DOX	 acts	 on	 cancer	 cells	 by	 inhibiting	 topoisomerase-II-mediated	 DNA	
repair,	 interfering	 with	 DNA	 unwinding	 [300]	 and	 generating	 free	 oxygen	 radicals	 that	
damage	 cell	 membranes	 [301].	 Doxorubicin	 has	 been	 shown	 to	 decrease	 proliferation	
[302],	 to	 induce	 senescence	 [303]	 and	 cell	 death	 in	 breast	 cancer	 cells	 in	 vitro	 [139].	 In	
clinical	practice	DOX	is	administered	intravenously	at	a	dose	of	60-75mg/m2	once	every	21	
days,	or	at	40-60mg/m2	when	used	in	combination	with	other	chemotherapy	drugs.	
The	nitrogen	containing	bisphosphonate	ZOL,	rapidly	binds	to	bone	mineral	where	
it	targets	the	bone	resorbing	osteoclast	-	its	main	target,	by	inhibiting	key	enzymes	of	the	
mevalonate	pathway	[138].	In	vitro	ZOL	is	also	suggested	to	have	direct	anti-tumour	effects	
as	 it	 induces	apoptosis	 in	a	number	of	breast	 cancer	 cells	 including	MCF7	and	MDA-MB-
231	[304,	305].	Numerous	in	vitro	studies	have	also	demonstrated	direct	potential	of	ZOL	
to	affect	 tumour	cell	adhesion,	 invasion,	proliferation	and	survival	 (briefly	summarised	 in	
[140]).	These	studies	however,	did	not	use	clinically	relevant	doses	and	time	points.	In	my	
studies	 I	 therefore	 decided	 to	 use	 100µg/kg	 ZOL,	 comparable	 to	 the	 4mg	 dose	
administered	to	patients	with	cancer-induced	bone	disease.	However,	the	weekly	schedule	
used	in	this	study	is	not	comparable	to	the	clinical	practice	of	ZOL	administration	every	3-4	
weeks.	
In	vitro	combination	of	the	bone	targeted	agent	ZOL	with	chemotherapy	(e.g.	ZOL	
+	paclitaxel	 in	 vitro	 [304],	 ZOL	+	DOX	 in	 vitro	and	 in	 vivo	 [139,	 241,	 259,	 260])	 has	been	
shown	to	be	more	effective	than	each	agent	on	its	own	in	inducing	tumour	cell	apoptosis	
and	reducing	tumour	growth	[139,	241,	260,	304].	Initial	in	vitro	studies	by	Neville-Webbe	
and	colleagues	revealed	the	importance	of	sequence	and	schedule	of	DOX	and	ZOL	when	
given	in	combination	[139].	In	MCF-7	and	MDA-MB-436	breast	cancer	cells,	DOX	(0.05µM)	
treatment	 for	 24hrs	 followed	 by	 1hr	 treatment	 with	 ZOL	 (25µM)	 induced	 apoptosis	
whereas	neither	treatment	alone	or	the	reverse	order	resulted	in	significant	alterations	in	
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tumour	cell	apoptosis	[139].	Similar	results	were	observed	in	the	PC3	prostate	cancer	cell	
line	 [139].	 Combination	 of	 DOX	 with	 clodronate	 (500µM)	 –	 a	 less	 potent	 non-nitrogen	
containing	BP	–	did	not	synergistically	induce	apoptosis	in	MCF7	cells.	However,	sequential	
treatment	 of	 DOX	 followed	 by	 alendronate	 (AL),	 a	 nitrogen	 containing	 BP,	 increased	
apoptosis,	 although	 this	was	 less	 prominent	 than	 combination	 therapy	 of	DOX	with	 ZOL	
[139].	Similar	findings	are	reported	using	ZOL	(10µM)	in	combination	with	(2nM)	paclitaxel	
–	with	a	5-	or	4-	fold	increase	in	apoptosis	of	MCF-7	cells	upon	combination	therapy	when	
compared	to	ZOL	or	paclitaxel	given	alone	[304].	
In	clinical	practice	administration	schedules	vary	widely	and	treatments	might	be	
administered	at	 irregular	 intervals	whereas	these	studies	suggest	that	the	order	 in	which	
therapeutic	 agents	 are	 administered	 and	 the	 interval	 between	 them	 could	 be	 vital	 to	
treatment	success.	Previous	work	in	our	group	has	investigated	the	anti-tumour	effects	of	
DOX	and	ZOL	in	vivo	[154,	241,	247,	259,	260]	with	effects	on	both	breast	cancer	growth	in	
bone,	 as	 well	 as	 extra-skeletal	 tumour	 growth.	 Administration	 of	 single	 agents	 initially	
reduced	 peripheral	 tumour	 growth	 but	 had	 no	 effect	 in	 the	 later	 stages,	 whereas	
peripheral	tumour	growth	was	nearly	abolished	 in	mice	receiving	sequential	combination	
therapy	[241,	260].	Importantly	suppression	of	tumour	growth	was	sustained	for	over	160	
days	post	treatment	termination,	although	the	mechanisms	regulating	this	effect	remain	to	
be	established	[260].	These	intriguing	data	clearly	suggest	a	role	of	the	BME	in	peripheral	
tumour	growth	with	potential	to	be	mediated	via	the	addition	of	bone-targeted	agents.		
In	vivo	the	exposure	of	breast	cancer	cells	to	ZOL	is	most	likely	quite	short	due	to	
the	high	affinity	of	the	drug	to	bone	and	its	short	half-life	in	circulation.	Administered	as	a	
4mg	dose	 infusion	every	3-4	weeks	 in	the	treatment	of	cancer	 induced	bone	disease	ZOL	
has	 a	 plasma	 half-life	 of	 105min	 with	 a	 peak	 plasma	 concentration	 of	 1-2µM	 [306].	
Whereas	 in	 bone,	 a	 combination	 of	 direct	 and	 indirect	 effects	 of	 BPs	 contribute	 to	
inhibition	of	tumour	growth	and	cancer-induced	bone	disease,	though	little	is	known	about	
whether	 modification	 of	 the	 BME	 affects	 tumour	 growth	 distant	 to	 the	 bone,	 and	 the	
interaction	of	the	BME	and	peripheral	tumours	remains	speculative.	
The	majority	of	studies	investigating	the	effects	of	BPs	as	single	agents	established	
their	ability	to	inhibit	bone	metastases	[143,	149,	257,	307]	and	only	a	limited	number	of	
studies	have	investigated	the	effects	of	bone-targeted	agents	on	peripheral	tumour	growth	
(summarised	in	Table	24).	A	study	by	Coscia	et	al.	has	elegantly	demonstrated	ZOL’s	impact	
and	benefit	on	 tumour	growth	outside	 the	bone	 in	an	experimental	 in	vivo	model	 [171].	
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However,	the	studies	in	Table	24	used	multiple	doses	and	continuous	treatment,	making	it	
impossible	 to	 establish	whether	 any	 observed	 treatment	 effects	 are	mediated	 via	 direct	
effects	of	BPs	on	the	tumour	cells	or	via	modification	of	the	BME,	or	both.	
5.2.4. Targeting	the	BME	in	peripheral	breast	cancer	growth	
The	 bone	 marrow	 hosts	 two	 distinct	 stem	 cell	 populations	 with	 each	 having	 different	
progenies	–	haematopoietic	and	mesenchymal	stem	cells	(HSCs	and	MSCs).	HSCs	give	rise	
to	 all	 lymphoid	 and	myeloid	 lineage	 cells	 that	 finally	 produce	 blood	 circulating	 cells	 and	
immune	 cells	 [50].	MSCs,	 in	 contrast,	 differentiate	 to	 give	 rise	 to	 adipocytes,	 bone	 and	
connective	 tissue	 cells.	 In	 addition	 the	 bone	 marrow	 contains	 numerous	 blood	 vessels,	
endothelial	cells	arising	from	hemangioblasts	similar	to	HSCs	[30].		All	of	these	mature	cell	
populations	(in	the	following	chapter	referred	to	as	bone	marrow	derived	cells	(BMDCs))	as	
well	as	their	precursors	may	be	affected	by	BP	treatment	and	thereby	directly	or	indirectly	
contribute	 to	 primary	 tumour	 growth	 (Table	 25,	 osteoblasts	 and	 osteoclasts	 are	 not	
included	as	previously	discussed	in	depth	in	Chapter	3,	Figure	59	below).	
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Table	24	In	vivo	studies	investigating	the	effects	of	BPs	on	extra	skeletal	(breast)	cancer	growth	
Bisphosphonate	 Mouse	model	 Cell	line	 Effect	on	peripheral	tumour	growth	 Ref.	
Risedronate	-	
150µg/kg	daily	
for	25	days,	once	
palpable	
athymic	BALB/c	
B02-GFP/βGal	
cells	(5x106),	
subcutaneous	
No	effect	 [148]	
NE-58051	-	
150µg/kg	daily	
for	25	days,	once	
palpable	
athymic	BALB/c	
B02-GFP/βGal	
cells	(5x106),	
subcutaneous	
No	effect	 [148]	
ZOL	-	0.1mg/kg	
ZOL	or	
Pamidronate	–	
2mg/kg	5	days	a	
week	
BALB-neuT	
expressing	rat	
oncogene	c-erbB-
2	(HER-2/neu)	
Spontaneous	
mammary	
carcinoma	
formation	
Delayed	tumour	onset,	
reduced	tumour	
volume,	reduced	
numbers	of	infiltrating	
CD11b/Gr-1/F4/80	
positive	cells	within	
the	tumour	stroma	
[37]	
ZOL	-	5µg/mouse	
2x	weekly,	once	
tumours	reached	
200mg	
6-8-week-old	
male	Fox	Chase	
SCID	
mice	
2x106	
PC-3	cells	or	
subcutaneously	
implanted	
LuCaP	23.1	
tumour	bits	
No	effect	 	[307]	
ZOL	-	100µg/kg	
once	weekly	for	4	
weeks,	cycle	
repeated	after	3	
weeks	of	rest	
7-week	old		BALB-
neuT	mice	
Spontaneous	
mammary	
carcinoma	
formation	
Extension	in	tumour-
free	survival,	reduction	
in	tumour	multiplicity,	
growth	delay,	
prolonged	survival,	
reduced	number	of	
infiltrating	CD11b+	
macrophages	
[171]	
Risedronate	
analogue	-	
AF647-RIS		
0.9mg/kg	or	
Pamidronate	
analogue	-			
OsteoSense	680	
0.7mg/kg;	once	
palpable	
6-8-week	old	
BALB/c	nude	
	
5x105	4T1-luc2	
breast	cancer	
cells	in	the	
mammary	fat	
pad	
	
NBPs	were	internalised	
by	TAMs	
[39]	
Risedronate	at	
150	µg/kg	body	
weight	every	
other	day	for	14	
days;	once	
50mm3	tumour	
volume	
5-week-old	
female	non	obese	
diabetic/severe	
combined	
immunodeficient	
(NOD/SCID)		
5x	106	B02	or	
T47D	cells,	
subcutaneous	
No	inhibition	of	T47D	
and	B02	
tumour	growth	
[175]	
2mg/kg	
Doxorubicin	
follwed	24hrs	by	
100µg/kg	ZOL;		
27	days	post	
tumour	injection	
5-week-old	
female	nonobese	
diabetic/severe	
combined	
immunodeficient	
(NOD/SCID)	
B02	cells,	
subcutaneous	
Slowed	down	tumour	
growth	compared	to	
placebo		
[175]	
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Figure	59	Schematic	illustration	of	the	hypothesis	that	ZOL-induced	modification	of	the	BME	
affects	primary	breast	cancer	growth.		
The	primary	breast	cancer	is	a	heterogeneous	microenvironment	composed	of	various	stromal	cells.	
These	 stromal	 cells	 are	 recruited	 from	 haematopoietic	 organs	 including	 the	 bone	 marrow.	
Zoledronic	acid	 (ZOL)	 is	known	to	affect	a	variety	of	BMDCs	and	 the	availability	of	 soluble	 factors	
that	could	all	contribute	to	peripheral	tumour	growth.		
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Table	25	Effects	of	bisphosphonate	(BP)	treatment	on	BMDCs.		
PAM=Pamidronate,	AL=Alendronate,	IB=Ibandronate	
Cellular	components	of	the	BME	
Cell	type	 BP		 Effect	
Endothelial	
cells	
-	Human	
dermal	
microvascular	
endothelial	
cell	
(HuDMEC)	
[163]	
	
-	Human	
umbilical	vein	
endothelial	
cells	(HUVEC)	
[161,	162]	
	
	
In	vitro:		
-	ZOL:	25-50µM	[163],	0.3-30µM	[161],	
5	-	500μM	[162]	
-	PAM/IB:	5	-	500	μmol	[162]	
In	vivo:		
-	ZOL:	50-150	µg/kg	daily	in	8-week	old	
male	CD1	nude	mice	[163]	
-	ZOL:	(1-100	µg/kg	s.c)	daily	for	6	days	
in	female	Tiflbm:MAG	mice	[161]	
-	ZOL:	1mM	Chicken	Egg	
Chorioallantoic	Membrane	Assay	[161]	
-	ZOL:	200µg/kg,	2x	weekly;	4-week	old	
male	C57BL/6J	mice)	[159]	
Ex	vivo:			
-	ZOL:	50µM	Aortic	ring	assay	[161]	
Patients:		
-	ZOL:	4mg	or	PAM	90mg	every	3-4	
weeks	[164]	
Overall:	Anti-angiogenic	
In	vitro:		
-	Increased	accumulation	of	Rap1a	in	
HuDMEC	and	inhibited	cell	
proliferation	[163]	
-	Dose	dependent	inhibition	of	
proliferation	[161]	
-	Decreased	cell	viability	[162]	
In	vivo:	
-No	effect	on	venular	or	arteriolar	
diameters	[163]	
-	Inhibition	of	bFGF	induced	
angiogenic	response[161]	
-	Reduced	vessel	thickness	and	
increased	vessel	numbers	with	overall	
vessel	volume	fraction	not	being	
affected	[159]	
In	clinic:		
-	Decreased	levels	of	circulating	
endothelial	progenitor	cells[164]	
Ex	vivo:		
-	Inhibition	of	capillary	sprouting	[161]	
Haematopoie
tic	stem	cells	
In	vivo:	
-ZOL:	200µg/kg,	2x	weekly;	4-week	old	
male	C57BL/6J	mice)	[159]	
	
In	vivo:	
-	Expansion	of	HSC	niche	
-	Increase	in	haematopoietic	
progenitor	cells	in	bone	marrow		
-	Trend	towards	increased	numbers	of	
long-term	reconstitution	
haematopoietic	stem	cells	in	bone	
marrow	
γδ	T	cells	 In	vitro:		
-	 PAM:	 5	 to	 10	 μM	 [176],	 0.4-40µM	
[174]	
In	patients:	
-	PAM:	60	or	90mg	[176]	
	
In	vitro:	
-	 Dose	 dependent	 expansion	 of	 γδ	 T	
cells	[174]	
-	Induce	proliferation	[174]	
-	Activation	and	selective	expansion	of	
γδ	 T	 cells	 in	 cultures	 of	 peripheral-
blood	mononuclear	cells	from	healthy	
subjects	[176]	
-	 Increased	 secretion	 of	 interferon-γ	
[176]	
In	patients:	
-	 Acute-phase	 reaction	!	 increased	
presence	 of	 CD3+	 γδ	 T	 cells	 in	
peripheral	 blood	 after	 first	
pamidronate	treatment	[176]	
Fibroblasts	
-human	
gingival	
fibroblasts	
In	vitro:	
-	ZOL/PAM/IB:	5	-	500μM	[162]	
	
In	vitro:	
-	Inhibition	of	viability	[162]	
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In	 addition	 to	 various	 cell	 types	 also	 circulating	 cytokines	 that	 are	 known	 to	 promote	
tumour	growth	are	affected	by	BP	treatment	(Table	26).	
	
	
	
	
Cell	type	 BP		 Effect	
Macrophages	
-	J774	and	
RAW264	
[156]	
	
-	J774	
macrophages		
[38]	
	
-	Mouse	
macrophage-
like	J774.1	
cells	[308]	
	
In	vitro:		
-	PAM,	IB,	AL:	100µM	[156]	
-	ZOL:	5µM	[38]	
-	AL,	PAM,	IB,	ZOL:	10-6	to	10-4	M	[308]	
In	vivo:		
-	ZOL:	100µg/kg	[38]		
-	ZOL:	100µg/kg	once	weekly	for	4	
weeks,	cycle	repeated	after	3	weeks	of	
rest;	7-week	old	BALB-neuT	mice	[171]	
-	ZOL	or	PAM	-	0.1mg/kg	ZOL	or	PAM	–	
2mg/kg	5	days	a	week	[37]	
	-	ZOL:	100µg/kg,	daily;	K14-HPV16	
transgenic	mice	[309]	
In	vitro:	
-	Apoptosis	of	J774	cells	[156]	
-	Apoptosis,	increased	levels	of	
uRap1A	[38]	
-	Apoptosis	J774.1	[308]	
In	vivo:		
-	Increased	accumulation	of	uRap1A	
[38]	
-	Reduced	infiltration	of	CD11b+ve	
macrophages	in	s.c.	tumours	[37,	171]	
	-	Reduced	MMP-9	expression	[37]	
-	Decreased	infiltration	of	
macrophages	in	tumour	stroma	[309]	
-	Reduced	MMP-9	expression	in	
tumour	macrophages	[309]		
Bone	marrow	
monocytes	
(CD14+ve)	
In	vivo:		
-	 RIS	 analogues:	 single	 injection	 with	
0.9	mg/kg	 AF647-RIS	 (3	 day	 old)	 New	
Zealand	White	rabbits	[172]	
In	vivo:		
-	Uptake	of	 fluorescently	 labelled	BPs	
and	accumulation	of	uRap1a	[172]	
Human	
placental	
mesenchymal	
stem	 cells	
(pMSCs)	
In	vitro:	
-	ZOL,	AL:	0.25-200µM	[165]	
In	vitro:	
-	Negative	effect	on	proliferation	and	
migration		
	-	Reduced	tube	formation		
-	 Inhibited	 differentiation	 of	 pMSCs	
into	endothelial	cells		
CD11b+/Gr1+	
Myeloid-	
derived	
suppressor	
cells	
-	total	bone	
marrow	cells	
cultured	with	
M-CSF	OR	
30%	tumour	
supernatant	
[168]	
	
	
In	vitro:		
-	ZOL:	0.03,	0.15	or	0.3	µM	for	6	days	
[168]	
In	vivo:	
-	ZOL:	100µg/kg,	daily,	6-8-week	old	
CBA-j	mice	[168]	
-	ZOL:	0.1mg/kg	ZOL	5x	weekly	BALB-
neuT	mice[37]	
	
In	vitro:	
-	Inhibiton	of	myeloid	differentiation	
into	macrophages	[168]	
In	vivo:	
-	Increased	MDSC	in	the	spleen	[168]	
-	Reduced	presence	of	macrophages	
in	spleen	of	ZOL	treated	mice	
suggesting	impaired	differentiation	of	
MDSCs	upon	ZOL	treatment	[168]	
-	Reduced	number	of	CD11b+/Gr-
1+/F4+/80+	cells	in	tumour	stroma	and	
peripheral	blood	[37]	
Reduction	in	clonogenic	colony-
forming	progenitor	cells	present	in	
bone	marrow	[37]	
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Table	26	Effects	of	bisphosphonates	(BP)	on	cytokines	and	growth	factors	
PAM=Pamidronate,	AL=Alendronate,	IB=Ibandronate	
			
As	 illustrated	 and	 summarised	 above,	 BPs	 have	 the	 potential	 to	 affect	 a	wide	 variety	 of	
BMDCs	 in	 addition	 to	 modifying	 the	 levels	 of	 growth	 factors	 and	 cytokines	 involved	 in	
tumour	 growth.	 This	 supports	 the	 hypothesis	 that	 treatment	 of	 the	 BME	with	 ZOL	may	
have	consequences	on	extra-skeletal	tumour	growth.	
	
	
	 	
Factor	 BP	 Effect	
VEGF	
serum/plasma	
levels	
In	patients:		
-	PAM	(90mg)	[166]		
-	ZOL	(4mg)	[167]	
	
In	vivo:		
-	ZOL:	100µg/kg	once	weekly	
for	4	weeks,	cycle	repeated	
after	3	weeks	of	rest;	7-week	
old		BALB-neuT	mice	[171]	
-	ZOL:	100µg/kg	daily	for	5	
days	a	week;	BALB-neuT	mice	
[37]		
In	patients:	
-	Reduced	1,	2	and	7	days	post	PAM	infusion	
[166]	
-	Reduced	2,	7	and	21	days	post	ZOL	infusion	
[167]	
	
In	vivo:		
-	Decreased	serum	VEGF	levels	[37,	171]	
γ-IFN	 and	 IL-6	
serum/plasma	
levels	
In	patients:		
-	PAM	(90mg)	[166]	
In	patients:		
-	 Increased	 1	 day	 after	 infusion	 but	 rapidly	
decreased	after	2	days	[166]	
PDGF	
serum/plasma	
levels	
In	patients:		
-	ZOL	(4mg)	[167]	
In	patients:		
-	Decreased	1	day	after	ZOL	infusion	[167]	
Interleukins		
-	 effusion	 fluid	
from	 the	
peritoneal	
cavity	
In	vivo:	
-	 ZOL:	 100µg/kg,	 daily	 for	 25	
days,	 6-8-week	 old	 CBA-j	
mice	(mesothelioma	bearing)	
In	vivo:		
-	Increase	in	IL-6,	IL-12	and	IL-1b	[168]	
Matrix	 metallo	
proteinases	
-	MMP-9		
In	vivo:		
-	 ZOL:	 0.1mg/kg	 5x	 weekly,	
BALB-neuT	mice		
In	vivo:		
-	Decreased	pro-MMP9	serum	levels		[37]	
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5.3. Hypothesis	
The	hypothesis	to	be	tested	in	this	chapter	is	that	modification	of	the	BME	with	the	bone-
targeted	agent	ZOL	reduces	re-growth	of	transplanted	tumour	fragments	after	successful	
combination	therapy	by	altering	the	availability	of	growth-supporitng	BMDCs.	
5.4. Aims	and	Objectives	
• Establish	an	in	vivo	re-implantation	model	to	study	the	role	of	the	BME	in	primary	
breast	cancer	re-growth.	
• Assess	 whether	 reduced	 tumour	 growth	 after	 DOX/ZOL	 combination	 therapy	 is	
reversed	 or	 maintained	 when	 tumours	 are	 transplanted	 into	 animals	 with	 a	
modified	BME	induced	by	ZOL	pre-treatment.	
• Determine	 if	 reduced	 tumour	growth	 following	 combination	 therapy	 is	mediated	
via	modification	of	BMDCs.	 	
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5.5. Material	and	Methods	
Here	 I	 investigated	 whether	 combination	 therapy	 (DOX	 +	 ZOL)	 affects	 subcutaneous	
tumour	 growth	 through	 modifying	 the	 BME,	 and	 determined	 whether	 tumour	 growth	
resumes	 following	 transplantation	 of	 treated	 tumour	 fragments	 (DOX+ZOL	 combination	
therapy)	 into	hosts	with	a	therapeutically	altered	BME.	 	This	aims	to	 investigate	whether	
modification	of	the	bone	microenvironment	is	sufficient	to	initiate	anti-tumour	effects	or	if	
both	the	tumour	and	BME	need	to	be	targeted.	A	summary	of	materials	and	methods	can	
be	seen	in	Table	27	below.	
Table	27	A	summary	of	material	and	methods	for	Chapter	5.	
Method	 Parameters	analysed	 Equipment	
Microcomputed	
tomography		
Bone	integrity	of	tibiae	
-Trabecular	bone	volume	(BV/TV	in	%)	
-Trabecular	number	(TB.N.	in	mm-1)	
-Trabecular	thickness	(Tb.Th.	in	mm)	
• -SkyScan	1272	scanner	(SkyScan)	
• -NRecon	software	
• -CTAn	software	
Histological	assessment	
CD34	staining		 • CD34+ve	tumour	vasculature	–	
microvascular	density	
-Leica	DMI1000	microscope	
• -Chalkley	grid	
CD31	staining	 • CD31+ve	tumour	vasculature	–	
microvascular	density	
-Leica	DMI1000	microscope	
• -Chalkley	grid	
Haematoxylin	and	
Eosin	 staining	
(H&E)	
• Nectotic	core	 • -OsteoMeasure	software	
(OsteoMetrics)	
• -DMRB	upright	microscope	
• -Olympus	BX53	microscope	
Ki-67	staining	 • Tumour	cell	proliferation	 • -OsteoMeasure	software	
(OsteoMetrics)	
• -Olympus	BX53	microscope	
Immunofluoresce
nce/confocal	
microscopy	
• Visualisation	of	Endomucin	positive	
vascular	endothelial	cells		in	bone	
	
• -Nikon	A1	confocal	microscope	
with	NIS	Elements	software	(40x	
objective)	
• Nikon	inverted	Ti	eclipse,	NIS-
Elements	software	Version	4.30,	
Plan	Apo	20x	(NA	0.75)	
• -Cryostat	(MICROM	HM560)	
In	vivo	work	
Monitoring	
tumour	growth	
• Subcutaneous	tumour	growth		 • -Calipers	
	
Effects	on	Bone	Marrow	Derived	Cells	
Flowcytometry	 • Presence	of	CD11b+/Gr1+	cells	in	bone	
marrow	flushes	
• -LSRII	
Statistical	analysis	
Statistical	analysis	• Experimental	datasets	 • -Prism	GraphPad	
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5.5.1. Subcutaneous	growth	of	MDA-G8	cells	in	vivo	
The	human	 triple	negative	breast	 cancer	 cell	 line	MDA-MB-436	 (hereafter	 referred	 to	 as	
MDA-G8)	 were	 transfected	 with	 GFP	 and	 kindly	 provided	 by	 Dr.	 Ottewell	 (University	 of	
Sheffield)	[241].	Cells	were	cultured	in	RPMI	supplemented	with	10%	FBS	at	37°C,	5%	CO2.	
On	the	day	of	tumour	cell	injection,	cells	were	harvested	as	described	in	Chapter	2,	Section	
2.2.3.	100µL	cell	suspension	(5x106	cells/mL	sterile	PBS)	was	subcutaneously	injected	into	
the	 right	 flank	 of	 mice	 using	 1mL	 syringes	 with	 25G	 needles.	 Tumour	 size	 (depicted	 as	
tumour	volume	 in	mm3)	was	measured	2-3	 times	weekly	using	callipers.	Tumour	volume	
was	calculated	assuming	spherical	dimensions	by	using	the	formula	V = !!×π×r!	where	r	
=	
( !"#$%&'( !!"#$%"&'() !"#$%&%'! )! .	 Animals	were	 culled	 according	 to	 regulated	procedures	once	
maximum	 tumour	 volume	 (1000mm3)	 was	 reached,	 or	 earlier	 if	 severe	 skin	 blistering	
(ulceration)	or	signs	of	morbidity	were	observed.		
5.5.2. Drug	preparation	and	administration	
5.5.2.1. Zoledronic	acid	
Zoledronic	acid	(ZOL)	was	prepared	as	described	in	Chapter	2,	Section	2.2.8.5.	A	100µg/kg	
suspension	was	prepared	fresh	prior	 to	 injection,	sterile	 filtered	and	100µL	 injected	 intra	
peritoneal	 using	 1mL	 syringes	 (25-gauge	 needle).	 The	 100µg/kg	 dose	 used	 in	 these	
experiments	is	equivalent	to	the	4mg	clinical	dose	used	in	the	treatment	of	cancer-induced	
bone	 disease.	 However,	 the	 regime	 is	 different	 with	 ZOL	 administered	 weekly	 when	
compared	to	the	clinical	administration	of	every	3-4	weeks.	
5.5.2.2. Doxorubicin	
Doxorubicin	(2mg/kg,	DOX)	was	prepared	in	PBS	fresh	on	the	day	of	use	and	sterile	filtered	
prior	to	injection	(Chapter	2,	Section	2.2.8.4).	Animals	were	placed	in	an	incubator	at	35°C	
for	 at	 least	 15min	 to	 dilate	 the	 tail	 veins	 and	 facilitate	 intravenous	 drug	 administration.	
Mice	were	placed	 in	a	bench	 top	restrainer	 fitted	onto	a	heating	pad.	100µL	of	 the	drug	
suspension	 were	 slowly	 injected	 into	 the	 tail	 vein	 using	 1mL	 insulin	 syringes	 (27-gauge	
needle).	Clinical	grade	doxorubicin	at	a	stock	concentration	of	2mg/mL	was	kindly	provided	
from	Weston	Park	Cancer	Hospital,	Sheffield,	UK.	
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5.5.3. Experimental	design	of	in	vivo	studies	
5.5.3.1. Animal	models	 	
Experiments	to	 investigate	the	role	of	the	BME	as	a	mediator	of	peripheral	breast	cancer	
growth	 were	 performed	 twice,	 one	 pilot	 experiment	 to	 establish	 the	 suitability	 of	 the	
model	followed	by	an	experiment	with	increased	animal	numbers.	Mouse	models	included	
in	both	experiments	are	listed	in	Table	28	below.	
Table	28	Animal	models	used	to	establish	the	role	of	the	BME	as	a	mediator	of	peripheral	breast	
cancer	growth.	
5.5.3.2. Combination	therapy	schedule	
	Previous	reports	using	 in	vitro	experiments	have	shown	the	importance	of	sequence	and	
schedule	 of	 DOX	 and	 ZOL	 when	 given	 as	 combination	 therapy	 [139].	 DOX	 (0.05µM)	
treatment	for	24hrs	followed	by	1hr	treatment	with	ZOL	(25µM)	induced	apoptosis	in	the	
human	oestrogen-dependent	breast	cancer	cell	line	MCF7,	the	oestrogen-independent	cell	
line	 MDA-MB-436	 and	 androgen-independent	 prostate	 cancer	 cells	 PC3.	 Based	 on	 the	
reported	importance	of	administration	sequence,	I	administered	DOX	(2mg/kg,	100µL,	i.v.)	
24hrs	prior	to	ZOL	(100µg/kg,	100µL,	i.p.)	once	weekly	to	mice	bearing	MDA-G8	tumours,	a	
dosing	regime	that	has	previously	been	demonstrated	to	abolish	subcutaneous	growth	of	
this	 cell	 line	 in	 female	 MF1	 nu/nu	 mice	 [241].	 In	 the	 following	 sections	 this	 treatment	
regime	is	referred	to	as	‘’combination	therapy’’.	
Mice	 were	 randomly	 assigned	 into	 two	 treatment	 groups	 receiving	 either	 (1)	
2mg/kg	Doxorubicin	(100µL,	i.v.)	followed	24hrs	later	by	100µg/kg	Zoledronic	acid	(100µL,	
i.p.)	 or	 (2)	 PBS	 (100µL,	 i.v.)	 followed	 24hrs	 later	 by	 PBS	 (100µL,	 i.p.),	 once	weekly	 for	 5	
weeks.	Combination	therapy	was	administered	to	7-9-week	old	female	BALB/c	nude	mice	
(Charles	 River,	 UK;	 BALB/c-Nude[Foxn1-Crl],	 n=14	 DOX/ZOL,	 n=10	 PBS)	 or	 6-8-week	 old	
female	BALB/c	nude	mice	 (BALB/c-Nude[Foxn1-Crl],	 Charles	River,	UK,	n=9	DOX/ZOL	and	
n=6	PBS)	–	see	Table	28,	Fig.60;	with	treatment	being	initiated	7-17	days	post	tumour	cell	
Pi
lo
t	e
xp
er
im
en
t	 Mouse	strain	 Age	at	study	start	 Treatment	 Referred	to	
Female	BALB/c-
Nude[Foxn1-Crl]	
(n=15)	
6-8-week	old	 1x	weekly	combination	
therapy	for	5	weeks	
(DOX/ZOL:	n=9,	PBS:	n=6)	
Tumour	
fragment	
donor	
Female	
BALB/cOlaHsd-
Foxn1nu	(n=6)	
9-11-week	old	 1x	weekly	ZOL	(100µg/kg)	for	2	
weeks	
(n=3/group)	
Tumour	
fragment	
recipient	
Fu
ll	
st
ud
y	
Female	BALB/c-
Nude[Foxn1-Crl]	
(n=24)	
7-9-week	old	 1x	weekly	combination	
therapy	for	5	weeks		
(DOX/ZOL:	n=14,	PBS:	n=10)	
Tumour	
fragment	
donor	
Female	BALB/c-
Nude[Foxn1-Crl]	
(n=16)	
6-7-week	old	 1x	weekly	ZOL	(100µg/kg)	for	2	
weeks	
(n=8/group)	
Tumour	
fragment	
recipient	
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injection	(Fig.60).	These	mice	are	 in	the	following	method	section	referred	to	as	“tumour	
donors”.	
	
Figure	60	Experimental	outline	for	combination	therapy	administration.		
(A)	 6-8-week	 and	 (B)	 7-9-week	 old	 female	 BALB/c	 nude	mice	were	 subcutaneously	 injected	with	
5x105	MDA-G8	breast	cancer	cells.	Combination	therapy	(2mg/kg	Doxorubicin	(DOX)	followed	24hrs	
later	 by	 100µg/kg	 Zoledronic	 acid	 (ZOL),	 1x	 weekly	 or	 PBS	 controls	 via	 respective	 administration	
routes	was	started	(B)	7	and	(A)	17	days	post	tumour	cell	injection.				
Week$
7"9"week'old'female'BALB/c'nude''
'(n=10'PBS,'n=14'DOX/ZOL)'
5x105'MDA"G8'breast'cancer'cells,'
s.c.'
0$ 1$ 2$ 3$ 4$ 5$
•  100µg/kg$ZOL$(i.p.)$$followed$24hrs$later$by$2mg/kg$DOX$(i.v.)$$
•  $PBS$control'
Experimental$outline$–$CombinaPon$therapy$B$
Week$
6"8"week'old'female'BALB/c'nude''
(n=6'PBS,'n=9'DOX/ZOL)'
5x105'MDA"G8'breast'cancer'
cells,'s.c.'
Q3$ 1$ 2$ 3$ 4$ 5$
•  100µg/kg$ZOL$(i.p.)$$followed$24hrs$later$by$2mg/kg$DOX$(i.v.)$$
•  $PBS$control'
Pilot$experiment$–$CombinaPon$therapy$A$
Fig.X' Experimental' outli e' for' combinaRon' therapy' administraRon.' (A)' 6"8"week' and' (B)' 7"9"week'old'
female'BALB/c'nude'mice'were'subcutaneously'inj cted'with'5x105'MDA"G8'cells.'CombinaRon'therapy'
(2mg/kg' Doxorubicin' (DOX)' followe ' 24hrs' later' by' 100µg/kg' Zoledronic' acid' (ZOL),1x' weekly' or' PBS'
controls'via'respecRve'administraRon'routes'was'started'(B)'7'and'(A)'17'days'post'tumour'cell'injecRon.'
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5.5.3.3. Zoledronic	acid	pre-treatment	
In	previous	experiments	I	have	determined	that	ZOL	rapidly	induces	changes	to	the	in	vivo	
BME,	 including	 alterations	 in	 bone	 volume,	 bone	 cell	 number	 and	 extracellular	 matrix	
composition	[158].	ZOL	(2	doses)	or	PBS	control	was	therefore	used	to	induce	therapeutic	
modification	to	the	BME	of	6-7-week	old	female	BALB/c	nude	mice	(BALB/c-Nude	[Foxn1-
Crl],	 n=8/group,	 Charles	 River,	 UK)	 or	 9-11-week	 old	 female	 BALB/c	 nude	 mice	
(BALB/cOlaHsd-Foxn1nu,	Harlan	UK,	 n=3/group);	 the	 tumour	 fragment	 recipients	 -	 Table	
28.		
5.5.3.4. Transplantation	of	tumour	fragments	
Transplantation	of	tumour	fragments	was	performed	24hrs	after	both	tumour	donor	and	
recipient	mice	had	received	the	last	dose	of	ZOL	(Fig.62).		
Tumour	donor	mice	(DOX+ZOL	treated	mice)	were	culled	by	using	an	overdose	of	
pentobarbitone	 and	 blood	 collected	 by	 cardiac	 puncture.	 Subcutaneous	 tumours	 were	
excised	using	sterile,	autoclaved	dissection	 tools	and	 immediately	 transferred	 into	sterile	
PBS.	Tumours	were	then	split	into	pieces	of	approximately	equal	size	and	remained	in	PBS	
until	transplantation	(within	the	next	10	minutes).		
	 Fragments	 were	 transplanted	 into	 mice	 that	 had	 either	 received	 ZOL	 pre-
treatment	or	PBS	control.	Recipient	mice	were	anaesthetised	using	isoflurane,	and	a	small	
incision	made	on	the	back.	A	pocket	was	formed	underneath	the	skin	using	blunt	scissors	
and	 the	 previously	 dissected	 tumour	 pieces	 positioned	 inside	 the	 pocket	 using	 sterile	
forceps.	Wounds	were	closed	using	wound	clippers	(Harvard	Apparatus).	Wound	clips	were	
removed	 1	 week	 after	 surgery	 to	 ensure	 complete	 wound	 closure	 at	 the	 incision	 site	
(Fig.61).	Surgery	was	kindly	taught	and	assisted	by	Dr.	Ottewell,	University	of	Sheffield,	UK.		
A	 schematic	 summary	 of	 the	 experiments	 to	 establish	 the	 role	 of	 the	 BME	 in	
peripheral	breast	cancer	growth	can	be	seen	in	Figure	62	below.	
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Figure	61	Tumour	fragment	transplantation.	
24hrs	 after	 both	 tumour	 donor	 and	 recipient	 mice	 had	 received	 their	 last	 dose	 of	
Zoledronic	acid,	transplantation	of	tumour	fragments	was	performed.	Subcutaneous	MDA-
G8	 tumours	 were	 isolated	 from	 “donor	 mice“	 (A),	 split	 into	 quarters	 (B)	 and	
subcutaneously	transplanted	into	the	right	flank	of	“recipient	mice“	(C).	
															
	
Fig.X.&Tumour&fragment&transplanta4on.&Subcutaneous+tumours+were+isolated+
from+“donor+mice“+(A),+split+into+quarters+(B)+and+subcutaneously+transplanted+
into+the+right+ﬂa k+of+“recipient+mice“+(C).+
+
Transplanta4on&of&tumour&fragments&
A&
B&
C&
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Figure	62	Experimental	outline	to	establish	the	role	of	the	bone	microenvironment	in	mediating	
peripheral	breast	cancer	growth.		
Subcutaneous	 tumours	 (MDA-G8	 cells)	 from	 mice	 receiving	 5	 weeks	 of	 combination	 therapy	
(2mg/kg	Doxorubicin	(DOX)	followed	24hrs	later	by	100µg/kg	Zoledronic	acid	(ZOL),1x	weekly)	were	
collected	 at	 experimental	 endpoint	 (A).	 Tumours	 were	 split	 into	 pieces	 and	 subcutaneously	
transplanted	 into	female	BALB/c	nude	mice	(n=3-8/group).	Recipient	mice	received	either	2	doses	
of	 ZOL	 (100µg/kg,	 100µL,	 1x	weekly)	 or	 PBS	 control	 (100µL)	 (B).	 Two	 separate	 experiments	were	
performed	using	6-8-week	old	 (n=8/group,	age	 indicated	at	pre-treatment	start)	or	9-11-week	old	
female	BALB/c	nude	(age	indicated	at	pre-treatment	start,	n=3/group	mice)	as	tumour	recipients.	
	
	
	
	
	
Experimental,outline,–,establish,the,role,of,the,bone,
microenvironment,in,media7ng,peripheral,breast,cancer,growth,
7"9"week'old'female'BALB/c'nude'
6"8"week'old'female'BALB/c'nude'
''
2mg/kg,DOX,(i.v.),
followed,24hrs,later,
by,100µg/kg,ZOL,(i.p.),
(weekly,,5,weeks),
L8, 0, 33,L1,
•  100µg/kg,ZOL,(s.c.),
•  PBS,(s.c.),
Day,
9"11"week'old'female'BALB/c'nude'
6"8"week'old'female'BALB/c'nude'
''
Tumour,donors,
Tumour,recipients,
Fig.X,Experimental,outline, to,establish, the, role,of, the,bone,microenvironment, in,media7ng,
peripheral, breast, cancer, growth., Subcutaneous' tumours' from' mice' receiving' 5' weeks' of'
combinaA n' therapy' (2mg/kg'Doxorubicin' (DOX)' followed'24hrs' later'by'100µg/kg'Zoledronic'
a id' (ZOL),1 ' weekly)' were' collected' at' experimantal' endpoint' (A).' Tumours' were' split' into'
pieces'and'subcutaneously'transplanted'into'female'BALB/c'nud 'mice'(n=3"8/group).'R cipient'
mice' received'either'2'doses'of' ZOL' (100µg/kg,'100µL,'1x'weekly)'or'PBS' control' (100µL)' (B).'
Two' separate' experiments' were' performed' using' 6"8"week' old' (n=8/group,' age' indicated' at'
pre"treatment' start)' or' 9"11"week' old' female' BALB/c' nude' (age' indicated' at' pre"treatment'
start,'n=3/group'mice)'as'tumour'recipients.'
A,
B,
	 216	
5.5.4. Assessing	 effects	 of	 combination	 therapy	 on	 myeloid-derived	 suppressor	 cells	
using	flow	cytometry	
Myeloid-derived	 suppressor	 cells	 (MDSCs)	 are	 known	 to	 be	 overproduced	 in	 the	 bone	
marrow	and	 spleen	of	 cancer	patients	 [170].	 In	addition	 they	 infiltrate	 into	 tumours	and	
increase	 angiogenesis	 by	 expressing	 high	 levels	 of	 MMPs,	 thereby	 stimulating	 tumour	
growth	 [37,	 41,	 310],	 a	 process	 known	 the	 be	 reduced	 after	 ZOL	 treatment	 [170].	 To	
determine	 if	 combination	 therapy	 induces	 alterations	 in	 the	 MDSC-pool	 in	 the	 bone	
marrow	I	quantified	the	percentage	of	this	cell	population	using	flow	cytometry.		In	murine	
models	 MDSCs	 are	 classified	 as	 CD11b	 (a	 marker	 for	 myeloid	 cells	 of	 the	 macrophage	
lineage)	and	Gr-1	(a	marker	for	granulocytes)	positive	[41,	170].	
5.5.4.1. Collection	of	bone	marrow	derived	cells	(BMDCs)	for	flow	cytometry:	
To	 collect	 BMDCs	 from	mouse	 long	 bones	 I	was	 kindly	 provided	with	 a	 protocol	 from	 J-	
Ubellacker,	Boston,	USA.	Briefly,	on	the	day	of	cull	excised	femurs	of	mice	were	placed	in	
ice-cold	sterile	PBS.	Next	the	distal	portion	of	the	femur	(attached	to	the	hip)	was	cut	off	to	
expose	the	bone	shaft.	25-G	needles	were	used	to	punch	a	hole	into	the	bottom	of	a	PCR-
tube,	which	was	 then	placed	 into	an	eppendorf	 tube.	 Femurs	were	placed	 into	 the	PCR-
tubes	 and	 BMDCs	 obtained	 by	 centrifugation	 at	 8000rpm	 (Heraeus	 FRESCO21;	 ≈6200xg) 
for	 4min	 at	 4°C.	 Red	 blood	 cells	 were	 lysed	 using	 RBC	 lysis	 buffer	 from	 eBioscience	
according	 to	manufacturers	 instructions.	 Cells	were	 resuspended	 in	 3mL	 lysis	 buffer	 and	
incubated	 for	 5min	 at	 ambient	 temperature	 followed	 by	 termination	 of	 the	 reaction	 by	
adding	PBS.	Next,	 samples	were	 centrifuged	at	 1500rpm	 (MSE	Mistral	 2000;	 ≈403xg)	 for	
5min	 and	washed	 2x	 in	 FACS	 buffer	 (2%	 FBS	 in	 PBS).	Where	 possible	 one	marrow	 from	
both	 femurs	of	each	mouse	were	collected,	pooled	and	 frozen	down	 in	2	aliquots	 in	FBS	
containing	10%	DMSO.	Samples	were	stored	at	-80°C	over	night	followed	by	transferral	to	
liquid	nitrogen	until	further	analysis. 
5.5.4.2. Staining	of	bone	marrow	samples	for	flow	cytometry	
Bone	marrow	cells	were	rapidly	thawed	in	a	37°C	water	bath	and	resuspended	in	5mL	FACS	
buffer	 (2%FBS	 in	 PBS).	 The	 cell	 suspension	 was	 passed	 through	 a	 100µm	 nylon	 mesh,	
centrifuged	 at	 1500rpm	 (5810R,	 Eppendorf;	 ≈	 370xg)	 for	 5min	 and	 resuspended	 in	 5mL	
FACS	 buffer.	 Cell	 number	 was	 determined	 using	 a	 haemocytometer	 and	 1x106	 cells	
transferred	 into	 eppendorf	 tubes	 followed	 by	 centrifugation	 at	 1500rpm	 Heraeus	
FRESCO21;	≈200xg)	for	5min	at	4°C.	For	analysis	bone	marrow	samples	from	2	mice/group	
were	 pooled	 (3	 independent	 repeats	 to	 have	 n=3).	 Cell	 pellets	 were	 resuspended	 in	
corresponding	antibody	solutions	(prepared	in	PBS,	see	Table	29	below,	Anti-Mouse	CD11b	
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Alexa	 Fluor®	 488,	 eBioscience,	 Clone	M1-70,	 Cat.No.:53-0112-80;	 Pe-Cy7	 anti-mouse	 Ly-
6G/Ly-6C	(Gr-1),	Clone	RB6-8C5,	Cat.No.:108415)	and	incubated	for	30min	at	4°C	followed	
by	2	washes	in	FACS	buffer.	Samples	were	resuspended	in	500µL	FACS	buffer	and	analysed	
using	 the	 LSRII	 flow	 cytometer.	 Using	 a	 low	 flow	 rate	 1x104	 events	 per	 sample	 were	
recorded.	Viability	 in	each	sample	was	assessed	using	TOPRO3.	Samples	were	run	by	the	
Flow	 Cytometry	 Core	 Facility	 or	 by	 myself.	 The	 gating	 strategy	 used	 to	 obtain	 the	
percentage	of	viable	CD11b+/Gr1+	cells	 in	bone	marrow	samples	 is	shown	below	(Fig.63).	
Analysis	 was	 performed	 with	 kind	 assistance	 from	 Dr.	 Russell	 Hughes,	 University	 of	
Sheffield.	 
Table	29	Sample	preparation	for	flow	cytometry	
Tube	 Ab	 Cells	detected	
1	 Unstained	 All	cell	populations	
2	
CD11b	(0.005µg/µL*)	
	
TOPRO3	was	added	
later	on	to	assess	
viability	
Expressed	on	all	cells	of	the	myeloid	linage,	including	
leukocytes	(mostly	neutrophils),	NK	cells,	mononuclear	
phagocytes	(e.g.	macrophages),	granulocytes	[311]	
3	
Gr-1	
(0.0003125µg/µL*)	
	
TOPRO3	was	added	
later	on	to	assess	
viability	
Composed	of	Ly-6C	and	Ly-6G	
Enriched	on	granulocytes;	useful	to	determine	relative	
amounts	of	granulocytes	and	monocytes	or	macrophages	
[311]	
Ly-6C	expressed	on	50%	of	bone	marrow	cells	[312]	
including	CD8+	T-cells,	on	neutrophils	and	monocytes	in	
bone	marrow	[313]	
Ly-6G	in	bone	marrow	primarily	on	granulocytes	[313]	
4	
CD11b	(0.005µg/µL)	+	
Gr-1	
(0.0003125µg/µL)	
	
TOPRO3	was	added	
later	on	to	assess	
viability	
Myeloid	Derived	Supressor	Cells	(MDSCs)	[41]	
• immunosuppressive	effects	by	inhibiting	NK-,	B-	and	
T-cells	
• infiltrate	into	tumours	where	they	promote	
angiogenesis	by	expressing	high	levels	of	MMP9	
• MDSCs	are	composed	of	immature	myeloid	cells	at	
their	early	stages	of	differentiation	
5	 Unstained	+	TOPRO3	 Allows	differentiation	between	viable	and	dead	cells	
*	Antibodies	were	carefully	titrated	to	determine	the	optimal	working	concentration.	Serial	
dilutions	were	performed	around	the	working	concentration	recommended	by	the	manufacturer	
(CD11b:	0.00125	µg/µL	-0.01	µg/µL;	Gr-1:	0.000015625	µg/µL-	0.000250µg/µL).	Cell	number,	
temperature	and	instrument	settings	were	kept	constant.	
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Figure	63	Gating	strategy	to	assess	the	presence	of	CD11b+/Gr1+	myeloid-derived	suppressor	cells	
in	bone	marrow	samples.		
Presence	 of	 CD11b+/Gr1+	 cells	 in	 bone	 marrow	 samples	 from	 mice	 receiving	 5	 rounds	 of	
combination	 therapy	 (DOX	 (2mg/kg)	 followed	 24hrs	 later	 by	 ZOL	 (100µg/kg))	 was	 compared	 to	
control	 mice.	 Forward-scatter	 side-scatter	 was	 used	 to	 gate	 on	 the	 total	 population	 of	 interest,	
followed	by	exclusion	of	dead	cells	based	on	positivity	for	TOPRO-3.	Next	a	gate	was	drawn	around	
CD11b+ve	(Alexa	Fluor488)	and	Gr1+ve	(Pe-Cy7)	cells.		
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5.5.5. Analysis	of	tumour	samples	by	immunohistochemistry	
For	 histological	 analysis	 subcutaneous	 tumour	 fragments	 were	 excised,	 fixed	 in	 ice	 cold	
4%PFA	(pH	7.4)	for	48hrs	followed	by	transferral	into	70%	ethanol	and	paraffin	embedding.	
For	 immunohistochemistry	 3µm	 thick	 sections	 were	 dewaxed	 in	 xylene,	 rehydrated	
through	alcohols	and	stained	as	described	below.	
5.5.5.1. Analysis	of	tumour	samples	by	immunohistochemistry	
Optimisation	of	the	CD31	(1:200	–	1:400;	DIA-310,	Dianova)	and	CD34	(MCA1825GA,	AbD	
Serotec;	 1:200	 to	 1:400)	 antibody	 used	 in	 this	 chapter	 has	 kindly	 been	 performed	 by	
Maggie	Glover	(Histology	Technician,	University	of	Sheffield)	and	Jacob	Skinner	(placement	
student,	 Sheffield	 Hallam	 University).	 The	 Ki67	 antibody	 (DAKO,	 Clone	MIB-1)	 has	 been	
optimised	and	routinely	applied	to	visualise	proliferating	tumour	cells	 in	our	group	at	the	
concentration	of	1:125	as	published	in	[241].	
5.5.5.2. Immunohistochemistry	to	visualise	CD31+ve	vascular	endothelial	cells		
To	 assess	 if	 anti-cancer	 therapy	 affects	 the	 presence	 of	 CD31+ve	 microvasculature	 of	
subcutaneous	 tumours,	 immunohistochemistry	 against	 the	 vascular	 endothelial	 cell	
marker	 CD31	 was	 performed.	 CD31	 (or	 platelet	 endothelial	 cell	 adhesion	 molecule-1,	
PECAM-1)	 is	 expressed	 on	 cell	 surfaces	 of	 platelets,	 neutrophils,	 embryonic	 and	 adult	
endothelial	cells;	and	involved	in	cell-to-cell	adhesion.	
	Following	 dewaxing	 (Xylene	 2x	 5min)	 and	 rehydration	 through	 alcohols	 (100%	 -	
70%,	 1min	 each)	 slides	 were	 incubated	 in	 3%	 H2O2	 in	 methanol	 for	 30min	 at	 ambient	
temperature.	 Next	 slides	were	washed	 in	 running	 tap	water	 for	 5min	 and	 heat-induced	
antigen	retrieval	performed	using	the	Dako	Target	Retrieval	Solution	(S1699)	in	a	pressure	
cooker	 (2hrs).	 Non-specific	 staining	 was	 blocked	 using	 Avidin/Biotin	 blocking	 solution	
(Vector	 Laboratories)	 followed	by	 incubation	 in	 10%	 goat	 serum/1%	 casein	 for	 30min	 at	
ambient	 temperature.	 The	 primary	 antibody	 (1:200,	 CD31,	 DIA-310,	 Dianova)	 was	
incubated	 in	 2%	 goat	 serum	 over	 night	 at	 4°C.	 After	 3	 washes	 in	 PBS+0.1%	 Tween	 the	
secondary	 antibody	 (1:200,	 1hr	 RT,	 BA-9401,	 Vector)	 was	 applied	 for	 1hr	 followed	 by	
washing	 in	 PBS+0.1%	 Tween	 with	 30min	 incubation	 in	 ABC	 solution,	 DAB-reagent	 and	
mounting.	 Appropriate	 negative	 controls	were	 included	 (omitting	 the	 primary	 antibody).	
Vascular	staining	was	kindly	assisted	by	Jacob	Skinner	(placement	student,	Sheffield	Hallam	
University).	
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5.5.5.3. Immunohistochemistry	for	CD34+ve	vascular	endothelial	cells		
CD34	 is	expressed	on	haematopoietic	 stem	and	progenitor	cells	and	vascular	endothelial	
progenitors.	In	addition	CD34	has	recently	been	associated	with	endothelial	tip	cells,	that	
guide	 the	 sprouting	 capillary	 through	 the	 ECM	 to	 an	 angiogenic	 stimulus	 [314]	 and	 it	 is	
commonly	used	to	indicate	the	presence	of	immature	vessels.			
	Briefly,	 following	 dewaxing	 (Xylene	 2x	 5min)	 and	 rehydration	 through	 alcohols	
(100%	 -	 70%,	 1min	 each)	 slides	 were	 incubation	 in	 3%	 H2O2	 in	 methanol	 for	 30min	 at	
ambient	 temperature	 followed	 by	 antigen	 retrieval	 in	 0.01M	 citrate	 buffer	 (1.92g	 Citric	
Acid	(GPR™	27780)	+	0.5mL	Tween®	20	+	1000mL	dH2O,	adjusted	to	pH	6	with	1M	NaOH,	
microwaved	 on	 high	 for	 4min)	 for	 20min.	 Slides	were	washed	 in	 PBS+0.1%	 Tween,	 non-
specific	 binding	 of	 the	 antigen	 was	 blocked	 using	 the	 Avidin/Biotin	 blocking	 kit	 (Vector	
Laboratories)	followed	by	30min	incubation	in	10%	normal	goat	serum/1%casein.	Primary	
antibody	(CD34,	MCA1825GA,	AbD	Serotec,	1:400	in	PBS)	was	incubated	at	4˚C	over	night.		
On	the	following	day	samples	were	washed	in	PBS-Tween,	and	the	secondary	antibody	was	
applied	 for	 1hr	 at	 ambient	 temperature	 (BA-9401	Biotinylated	Goat-anti-Rat	 IgG,	 1:200).	
This	was	followed	by	 incubation	using	the	ABC-kit,	staining	visualised	using	DAB,	washing	
and	 mounting	 of	 the	 slides.	 Appropriate	 negative	 controls	 were	 included	 (omitting	 the	
primary	antibody).	
5.5.5.4. Quantification	of	microvessel	density	of	tumour	samples	
To	determine	 if	 the	 anti-cancer	 treatment	modifies	microvessel	 density	of	 subcutaneous	
MDA-G8	 tumours,	 a	 Chalkley	 grid	 was	 used.	 Briefly,	 the	 Chalkley	 grid	 contains	 25	 dots	
within	 4	 quarters;	 each	 vessel	 that	 hits	 a	 dot	 is	 regarded	 as	 a	 Chalkley	 score.	 Where	
tumour	 size	allowed,	Chalkley	 scores	of	5	 randomly	chosen	 fields	of	 view	 (10x	objective,	
Leica	 DMI1000)	 were	 recorded.	 Necrotic	 cores	 and	 apoptotic	 areas	 were	 avoided	 for	
analysis.	3	 individual	 levels	 (20µm	apart)	 for	each	tumour	sample	were	assessed	and	the	
average	score	for	all	fields	of	view	per	sample	determined.	The	average	scores	per	sample	
were	 then	 divided	 by	 0.79cm2	 (the	 area	 of	 the	 Chalkley	 graticule).	 The	 data	 are	
represented	as	Micro	Vessel	Density	(MVD,	being	the	average	Chalkley	score/cm2).		
5.5.5.5. Immunohistochemistry	for	Ki-67+ve	tumour	cells		
Immunohistochemistry	 for	 the	 cellular	 proliferation	 marker	 Ki-67	 was	 used	 to	 visualise	
treatment	effects	on	 tumour	 cell	proliferation.	 Following	dewaxing	 (Xylene	2x	5min)	and	
rehydration	through	alcohols	(100%	-	70%,	1min	each)	slides	were	incubated	in	3%	H2O2	in	
methanol	 for	 10min	 at	 ambient	 temperature.	 Next	 slides	 were	 washed	 in	 PBS+0.1%	
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Tween,	 followed	by	 antigen-retrieval	 in	 citrate	buffer	 (microwave	using	5min	high	 and	5	
min	low	power).	After	additional	washing,	samples	were	incubated	in	1X	Casein/PBS+0.1%	
Tween	 for	 30min	 at	 ambient	 temperature	 followed	 by	 addition	 of	 human	 Ki-67	 specific	
primary	 antibody	 (1:125,	 DAKO,	 Clone	 MIB-1,	 prepared	 in	 1X	 Casein/PBS+0.1%	 Tween)	
over	night	at	4°C.	On	the	following	day	the	secondary	antibody	(anti-mouse	biotin,	Vector	
BA-2000,	1:200	diluted	 in	1X	Casein/PBS+0.1%	Tween)	was	applied	 for	30min	at	ambient	
temperature,	 followed	 by	 incubation	 in	 ABC-kit,	 visualisation	 of	 staining	 using	 DAB,	
washing	and	mounting	of	the	slides.	Appropriate	negative	controls	were	included	(emitting	
the	primary	antibody).	
5.5.5.6. Quantification	of	Ki-67+ve	tumour	cells	
To	determine	if	the	anti-cancer	treatment	modifies	proliferation	of	subcutaneous	MDA-G8	
tumours	 the	number	of	Ki-67+ve	 tumour	 cells/mm2	 tumour	 tissue	was	 scored	on	3	non-
serial	histological	sections	per	sample.	Where	sample	size	allowed,	Ki-67+	tumour	cells	in	5	
randomly	 selected	 fields	 of	 view	 per	 section	 were	 counted	 using	 a	 20x	 objective,	
OsteoMeasure	software	and	a	BX53	Olympus	microscope.		
5.5.6. Analysis	of	bone	samples	
Bone	samples	were	embedded	in	paraffin	or	gelatine	as	described	in	Methods	section	(see	
Chapter	2,	section	2.2.10.3).	
5.5.6.1. µCT	analysis	
To	 assess	 treatment-induced	 alterations	 in	 bone	 volume	 and	 structure	 left	 tibiae	 were	
collected	in	4%	PFA,	scanned	using	the	Skyscan	1272	as	previously	described	in	Chapter	2,	
section	2.2.10.4.	Scans	were	reconstructed	using	Nrecon	software	and	trabecular	as	well	as	
total	bone	volume	determined	using	CTan	software,	a	lower	threshold	of	95	and	an	upper	
threshold	of	255	were	used.	
5.5.6.2. Visualisation	of	treatment	induced	alteration	to	bone	marrow	vasculature	
Immunofluorescence	 staining	 for	 the	 vascular	 endothelial	 cell	 marker	 Endomucin	 was	
performed	 as	 described	 in	Methods	 Chapter	 2,	 Section	 2.2.10.6.2.2.	 Slides	were	 imaged	
using	the	Nikon	A1	confocal	microscope,	NIS-Elements	software,	403nm	and	562nm	lasers	
and	a	20x	oil	objective.	Pixel	 size	was	set	 to	1024x1024	and	Z-stacks	with	a	20µm	depth	
were	scanned	and	reconstructed	using	Fiji	 (Image>Stacks>3D	projections).	3D	projections	
were	then	converted	to	RGB	images.	For	a	subset	of	samples	tile	scans	(6x6)	were	imaged	
using	 the	Nikon	Dual	 cam	system	with	Nikon	Eclipse	 inverted	microscope,	20x	objective.	
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Appropriate	negative	controls	were	 included	 (emitting	 the	primary	antibody).	Qualitative	
analysis	 (structural	 changes	 in	 the	 vascular	 organisation)	 was	 confirmed	 by	 Prof.	 Nicola	
Brown,	University	of	Sheffield,	UK.	 	
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5.6. Results	
5.6.1. Establishing	optimal	study	conditions	–	a	pilot	experiment	
To	establish	an	 in	vivo	model	to	study	the	effects	of	the	BME	on	peripheral	breast	cancer	
(re-)	 growth,	 6-8-week	old	 female	 BALB/c	 nude	mice	were	 subcutaneously	 injected	with	
5x105	MDA-G8	cells	on	day	0.	Palpable	tumours	developed	in	87%	(13	out	of	15)	of	mice	4	
days	 post	 subcutaneous	 injection	 of	 MDA-G8	 cells.	 For	 a	 subset	 of	 mice	 (n=3)	
administration	 of	 combination	 therapy	 was	 initiated	 13	 days	 post	 injection	 of	 MDA-G8	
cells,	 when	 tumours	 had	 reached	 an	 average	 size	 of	 92mm3.	 For	 the	 remaining	 mice,	
treatment	was	started	17	days	after	 injection	at	an	average	tumour	size	of	44mm3	in	the	
combination	therapy	group	and	27mm3	in	the	control	group.	
5.6.1.1. Response	to	combination	therapy	–	pilot	study	data	
Starting	 the	administration	of	 combination	 therapy	at	 an	average	 tumour	 size	of	92mm3	
did	not	reduce	the	growth	rate	of	subcutaneous	MDA-G8	cells,	with	either	3	or	4	rounds	of	
combination	 therapy.	 The	 tumours	were	 growing	 faster	 in	 these	 three	mice	 and	 tumour	
volume	was	increased	32	days	post	injection	when	compared	to	control	mice	(Day	32:	PBS:	
119.9	±	35.59mm3,	n=4	vs.	ZOL:	385.9	±	94.04	mm3,	n=3,	p=0.0571,	Fig.64A-D).		
In	this	pilot	experiment	the	anticipated	5-week	course	of	combination	therapy	could	only	
be	 administered	 to	 3	 out	 of	 9	 mice	 whereas	 the	 others	 had	 to	 be	 culled	 prior	 to	 the	
experimental	 endpoint	 as	 a	 consequence	 of	 severe	 skin	 blistering,	 scabbing	 and/or	
ulceration	in	the	tumour	area	–	Table	30.		
Table	30	Rounds	of	combination	therapy	administered	to	mice	included	in	this	study.	
Number	of	mice	 Rounds	of	combination	therapy	(2mg/kg	DOX	followed	24hrs	later	by	100µg/kg	ZOL)	
4	 3	
2	 4	
3	 5		
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Figure	64	Response	to	combination	therapy	when	treatment	was	started	at	an	average	tumour	
volume	of	92mm3.		
5x105	MDA-G8	breast	cancer	cells	were	subcutaneously	injected	into	the	right	flank	of	6-8-week	old	
female	 BALB/c	 nude	 mice.	 Administration	 of	 combination	 therapy	 (Doxorubicn	 (DOX)	 2mg/kg	
followed	 24hrs	 later	 by	 Zoledronic	 acid	 (ZOL)	 100µg/kg)	 was	 started	 13	 days	 post	 tumour	 cell	
injection	 when	 tumours	 had	 reached	 an	 average	 size	 of	 92mm3.	 Combination	 therapy	 was	
administered	 once	 weekly.	 (A-C)	 Individual	 growth	 curves	 of	 subcutaneously	 implanted	MDA-G8	
cells.	Black	arrowheads	indicate	treatment	administration.	Dashed	red	line	indicates	tumour	volume	
at	treatment	start.	 (D)	Comparison	of	tumour	volume	at	Day	32	(PBS:	n=4,	DOX/ZOL:	n=3),	Mann-
Whitney	test,	Data	show	Mean±SEM.	
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The	 three	 remaining	mice	 had	 an	 average	 tumour	 volume	 of	 27mm3	when	 combination	
therapy	was	initiated.	In	these	mice	combination	therapy	inhibited	growth	of	MDA-G8	cells	
in	 2	mice	 and	 reduced	 the	 growth	 rate	 in	 the	 third	 one	 (Fig.65).	 Five	 rounds	 of	 weekly	
combination	therapy	therefore	significantly	reduced	subcutaneous	growth	of	MDA-G8	cells	
when	compared	to	control	(Day	46:	p≤0.01,	2way	ANOVA,	Fig.65A)	resulting	in	decreased	
tumour	 volume	at	 experimental	 endpoint	 (Day	46:	 PBS:	328.7	±	88.28mm3	vs.	DOX/ZOL:	
90.89	±	66.15mm3,	n=3/group,	Fig.65A).		
These	findings	suggest	that	5	rounds	of	combination	therapy	slow	down	the	rate	of	
subcutaneous	breast	cancer	growth	in	this	model.	However,	administration	of	combination	
therapy	has	to	be	started	at	the	early	stages	of	tumour	formation	to	be	effective,	before	
the	 tumour	 volume	 reaches	 approximately	 30mm3.	 At	 this	 size	 there	 might	 have	 been	
sufficient	 recruitment	 of	 growth-promoting	 stromal	 cell	 precursors	 resulting	 in	 the	
tumours	growing	independent	of	the	BME.	
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Figure	65	Effects	of	combination	therapy	on	subcutaneous	growth	of	breast	cancer	–	pilot	data.		
5x105	MDA-G8	breast	cancer	cells	were	subcutaneously	injected	into	the	right	flank	of	6-8-week	old	
female	 BALB/c	 nude	 mice.	 Administration	 of	 combination	 therapy	 (Doxorubicn	 (DOX)	 2mg/kg	
followed	 24hrs	 later	 by	 Zoledronic	 acid	 (ZOL)	 100µg/kg)	 was	 started	 17	 days	 post	 tumour	 cell	
injection.	 Combination	 therapy	 was	 administered	 once	 weekly.	 Control	 mice	 (n=3)	 received	 PBS	
control.	 (A)	 Comparison	 of	 tumour	 growth	 over	 time	 between	 the	 two	 treatment	 groups.	 Black	
arrowheads	 indicate	 treatment	 days.	 Two-way	 ANOVA	 with	 Bonferroni’s	 post-test,	 Data	 show	
Mean±SEM.	Individual	growth	curves	of	subcutaneously	 implanted	MDA-G8	cells	 in	mice	receiving	
combination	therapy	(B)	or	PBS	control	(C).		
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5.6.1.2. Transplantation	of	tumour	fragments	into	hosts	with	a	modified	BME	–	pilot	
study	
The	 role	 of	 the	 BME	 in	 mediating	 peripheral	 (primary)	 breast	 cancer	 remains	 poorly	
investigated.	 To	 assess	 if	 therapeutic	modification	of	 the	BME	affects	 peripheral	 tumour	
growth,	 isolated	tumour	fragments	 (average	size	of	22mm3)	 from	mice	having	received	5	
rounds	of	combination	therapy	were	subcutaneously	transplanted	into	recipients	that	had	
either	been	pre-treated	with	ZOL	 (100µg/kg,	1x	weekly	 for	2	weeks,	n=3)	or	PBS	 control	
(n=3).	
At	 experimental	 endpoint	 (Day	 27)	 the	 mean	 tumour	 volume	 reached	 232.3	 ±	
35.67mm3	 in	 the	PBS	pre-treated	and	154.3	±	71.68mm3	 in	 the	ZOL	pre-treatment	group	
(Fig.	66A-C).	Two	of	the	tumour	fragments	that	were	subcutaneously	transplanted	into	ZOL	
pre-treated	 recipients	 (Day	 27:	 113.04mm3	 and	 56.09mm3	 respectively)	 demonstrated	 a	
slower	growth	rate	whereas	the	third	fragment	demonstrated	exponential	growth	from	22	
days	post	transplantation		onwards	(Fig.66C).	In	contrast,	after	an	initial	lag-phase	all	three	
tumour	fragments	transplanted	into	control	mice	grew	exponentially	at	comparable	rates	
(Fig.66B).	These	findings	supported	the	hypothesis	that	the	BME	may	influence	peripheral	
breast	cancer	growth.		
These	data	demonstrate	that	fragments	from	tumours	responding	to	combination	therapy	
are	 able	 to	 re-grow	when	 transplanted	 into	 recipient	mice;	 providing	 evidence	 that	 the	
study	 should	be	 repeated	with	 sufficient	power	 to	detect	 any	differences	 in	 influence	of	
BME	ZOL	pre-treatment	on	peripheral	tumour	growth.		
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Figure	66	Re-growth	of	subcutaneously	transplanted	tumour	fragments	after	cessation	of	
combination	therapy.		
MDA-G8	breast	tumour	fragments	(22mm3)	from	mice	receiving	combination	therapy	(Doxorubicn	
(DOX)	 2mg/kg	 followed	 24hrs	 later	 by	 Zoledronic	 acid	 (ZOL)	 100µg/kg)	 were	 subcutaneously	
transplanted	 into	 the	 right	 flank	 of	 9-11-week	 old	 female	 BALB/c	 nude	mice.	 Recipient	mice	 had	
either	received	2	pre-treatments	with	ZOL	(100µg/kg,	i.p.,	1x	weekly	for	2	weeks)	or	PBS	control.	(A)	
shows	tumour	growth	over	time	(n=3/group),	individual	growth	curves	are	shown	in	(B)	for	PBS	and	
(C)	for	ZOL	pre-treated	mice.	Data	show	Mean±SEM.				
Fig.X.&Growth&of&subcutaneously&transplanted&tumour&fragments.&Tumour&fragments&(22mm3)&from&
mice& receiving& combina6on& therapy& (2mg/kg&Doxorubicin& (DOX)& followed&24hrs& later& by& 100µg/kg&
Zoledr ic&acid&(ZOL))&were&subcutaneously&transplanted&into&the&right&ﬂank&of&9K11Kweek&olf&female&
BALB/c& nude& mice.& Recipient& mice& had& either& received& 2& preKtreatments& with& ZOL& (100µg/kg,& 1x&
weekly& for& 2& weeks)& or& PBS& control.& (A)& shows& tumour& growth& over& 6me& (n=3/group),& individual&
growth& curves& of& transplanted& tumour& fragments& are& shown& in& (B)& for& PBS& and& (C)& for& ZOL& preK
treated&mice.&Data&show&Mean±SEM.&
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5.6.2. Full	study	to	assess	the	role	of	the	BME	in	peripheral	tumour	growth	
5.6.2.1. Tumour	volume	and	survival	upon	combination	therapy	
Briefly,	 7-9-week	 old	 female	 BALB/c	 nude	 mice	 injected	 with	 5x105	 MDA-G8	 cells	
developed	palpable	tumours	by	day	4	 (n=24,	 tumour	take	rate	was	100%).	10	mice	were	
randomly	assigned	 to	 a	PBS-receiving	 control	 group	and	 the	 remaining	14	mice	 received	
combination	therapy	(2mg/kg	DOX	followed	24hrs	later	by	100µg/kg	ZOL)	once	weekly	for	
5	weeks.	As	the	previously	performed	pilot	experiment	showed	that	combination	therapy	
needs	 to	 be	 administered	 at	 the	 early	 stages	 of	 tumour	 development,	 treatment	 was	
started	 7	 days	 after	 tumour	 cell	 injection	 once	 tumour	 growth	was	 confirmed	 by	 a	 GFP	
signal	(Light	Tools).	Average	tumour	volume	at	treatment	start	was	≤10mm3.	
	 To	 assess	 effects	 of	 weekly	 combination	 therapy	 	 on	 subcutaneous	 growth	 of	
MDA-G8	 cells,	 tumour	 volume	 was	 monitored	 2-3x	 weekly	 using	 calipers.	 Prior	 to	 the	
experimental	endpoint	 (Day	35)	8	mice	 in	 the	control	 group	had	 to	be	culled	due	 to	 the	
subcutaneous	tumours	reaching	maximum	size	and/or	ulceration.	In	contrast,	only	3	mice	
receiving	combination	therapy	were	culled	as	a	consequence	of	skin	blistering/ulceration.	
Animals	 treated	 sequentially	 with	 DOX	 followed	 by	 ZOL	 therefore	 exhibited	 significant	
increases	in	survival	due	to	reduced	tumour	size;	only	8%	of	mice	in	the	PBS	group	survived	
the	 entire	 experiment	 where	 as	 treatment	 with	 DOX+ZOL	 increased	 survival	 to	 79%		
(Fig.67).	
The	last	tumour	measurements	allowing	statistical	analysis	were	taken	on	Day	33	
post	 tumour	 cell	 inoculation	 (PBS:	 n=5,	 DOX/ZOL:	 n=13).	 Weekly	 administration	 of	
combination	 therapy	 slowed	 down	 subcutaneous	 tumour	 growth	 (Day	 33:	 p<0.0001,	
Fig.68A),	with	a	significantly	reduced	tumour	volume	when	compared	to	control	(Day	33:	
PBS:	330.9	±	125.3mm3	vs.	DOX/ZOL:	82.86	±	13.93mm3,	p≤0.05,	Fig.68B).	
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Figure	67	Combination	therapy	increases	survival.	
7-9-week	old	 female	BALB/c	nude	mice	were	 subcutaneously	 injected	with	5x105	MDA-G8	breast	
cancer	 cells.	 Prior	 to	 the	 experimental	 endpoint	 (Day	 35)	 8	mice	 in	 the	 control	 group	 had	 to	 be	
culled	due	to	the	subcutaneous	tumours	reaching	maximum	size	and/or	ulceration.	In	contrast,	only	
3	mice	 receiving	 combination	 therapy	were	 culled	 in	 the	 treatment	 group.	 Log-rank	 (Mantel-Cox)	
test.	
		
Figure	68	Effects	of	combination	therapy	on	subcutaneous	growth	of	MDA-G8	tumours.		
5x105	 MDA-G8	 cells	 were	 subcutaneously	 injected	 into	 the	 right	 flank	 of	 7-9-week	 old	 female	
BALB/c	nude	mice.	Mice	received	combination	therapy	 (Doxorubicn	 (DOX)	2mg/kg	 followed	24hrs	
later	by	Zoledronic	acid	(ZOL)	100µg/kg)	or	PBS	control	1x	weekly	for	5	weeks	(indicated	with	black	
arrow	heads).	Tumour	growth	was	monitored	2-3x	weekly	using	calipers.	Data	show	Mean±SEM.	(A)	
tumour	 growth	 over	 time,	 2-way	ANOVA	with	 Bonferroni‘s	 post	 test	 (B)	Mann-Whitney	 test,	 *	 is	
≤0.05.	Day	33:	n=5	for	PBS	and	n=13	for	DOX/ZOL.	EoP	=	end	of	protocol.	
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5.6.2.2. Effects	 of	 combination	 therapy	 on	 proliferation	 and	 vascularisation	 of	
subcutaneous	tumours	
To	 assess	 if	 combination	 therapy	 alters	 proliferation	 of	 subcutaneous	 tumours,	 staining	
against	 the	 cellular	 proliferation	 marker	 Ki-67	 was	 performed	 on	 a	 subset	 of	 tumour	
samples.	 Ki-67	 positive	 cells	 in	 5	 randomly	 selected	 fields	 of	 view	were	 quantified	 on	 3	
non-serial	 levels	per	sample.	This	analysis	showed	a	significant	reduction	in	Ki-67+ve	cells	
after	5	rounds	of	combination	therapy	when	compared	to	control	(PBS:	951.7±111.6/mm2	
vs.	DOX/ZOL:	607.7±44.95,	p≤0.05,	Fig.69A),	suggesting	reduced	tumour	cell	proliferation	
upon	DOX/ZOL	 treatment	 –	 representative	 Ki-67	 stained	 histological	 sections	 are	 shown	
below	(Fig.69B).	
	
Figure	69	Effects	of	combination	therapy	on	proliferation	of	MDA-G8	tumour	cells	(Ki-67+ve).		
Differences	in	proliferation	of	subcutaneous	MDA-G8	tumours	from	mice	receiving	PBS	control	or	5	
rounds	of	 combination	 therapy	 (2mg/kg	Doxorubicin	 (DOX,	 i.v.)	 followed	24hrs	 later	by	100µg/kg	
Zoledronic	acid	(ZOL,	i.p.))	was	determined	by	scoring	the	presence	of	Ki-67+ve	cells	on	three	non-
serial	 levels	 per	 sample.	 (A)	 shows	 data	 with	 3	 levels	 pre	 sample	 averaged,	 (B)	 representative	
sections,	 Ki-67+ve	 cells	 in	 brown.	 n=4/group.	Data	 show	Median±Range.	Mann-Whitney	 test.	 40x	
objective,	scale	bar	is	20µm,	*	is	p<0.05.	
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Effects	 of	 combination	 therapy	 on	 CD34	 and	 CD31	 positive	 vasculature	 within	 the	
subcutaneous	 tumours	of	DOX/ZOL	 treated	mice	was	quantified	by	using	a	Chalkley	 grid	
method	and	compared	to	respective	controls.		
Microvascular	 density	 (here	 represented	 as	 Average	 Chalkley	 score/cm2)	 of	
CD34+ve	 tumour	 vasculature	 was	 significantly	 reduced	 after	 combination	 therapy	 when	
compared	 to	 control	 (PBS:	 2.58	 ±	 0.25cm2	 vs.	 ZOL:	 1.43	 ±	 0.14cm2,	 p≤0.05,	 Fig.	 70A&B,	
representative	histological	slides	shown	in	70C&D).	Similar	effects	were	determined	when	
analysing	sections	stained	for	CD31+ve	tumour	vasculature,	however	this	trend	(p=0.0571)	
did	not	reach	statistical	significance	(PBS:	3.85	±	0.35/cm2	vs.	DOX/ZOL:		2.64	±	0.07/cm2,	
Fig.	71A&B,	representative	histological	slides	shown	in	Fig.71C&D).		
Collectively	 these	 data	 suggest	 that	 vascular	 density	 in	 tumours	 treated	 with	 DOX/ZOL	
combination	therapy	is	reduced	when	compared	to	tumours	of	control	mice.	
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Figure	70	Effects	of	combination	therapy	on	CD34	positive	vasculature	of	subcutaneous	MDA-G8	
breast	tumours.		
Microvessel	density	(MVD,	here	represented	as	Average	Chalkley	Score/cm2)	of	subcutaneous	MDA-
G8	 tumours	 from	mice	 receiving	 (C)	PBS	 control	or	 (D)	5	 rounds	of	 combination	 therapy	 (2mg/kg	
Doxorubicin	(DOX,	i.v.)	followed	24hrs	later	by	100µg/kg	Zoledronic	acid	(ZOL,	i.p.)	was	determined	
using	a	Chalkley	grid.	Three	non-serial	levels	were	assessed	per	sample.	(A)	shows	data	with	3	levels	
averaged,	 (B)	 shows	 individual	 scoring	 data	 (no	 statistical	 analysis	 performed).	 n=4/group.	 Data	
show	 Median±Range.	 Mann-Whitney	 test,	 *	 is	 p<0.05.	 CD34+ve	 vasculature	 shown	 in	 brown,	
representative	 vasculature	 pointed	 out	 by	 black	 arrowheads,	 20x	 objective,	 scale	 bar	 is	 50µm.	
Olympus	BX53,	cellSense	software.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Eﬀects	of	combina/on	therapy	on	CD34	posi/ve	vasculature	of	subcutaneous	tumours.	Micro	vessel	density	(MVD)	of	
subcutaneous	tumours	from	mice	receiving	(C)	PBS	control	or	(D)	5	rounds	of	combina>on	therapy	(2mg/kg	Doxorubicin	
(DOX,	i.v.)	followed	24hrs	later	by	100µg/kg	Zoledronic	acid	(ZOL,	i.p.)	was	deter ined	using	a	Chalkley	grid.	Three	non-
serial	 levels	were	 assessed	 per	 sample.	 (A)	 shows	 data	with	 3	 levels	 averaged,	 (B)	 sh ws	 individual	 scoring	 data,	 no	
sta>s>cal	a alysis	performed).	n=4/group.	Data	show	Median±Range.	Mann	Whitney	test 	CD34+	vasculature	shown	in	
brown,	representa>ve	vasculature	pointed	out	by	black	 rrow	heads,	20x	objec>ve,	scale	bar	is	50µm.	
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Figure	71	Effects	of	combination	therapy	on	CD31	positive	vasculature	of	subcutaneous	MDA-G8	
tumours.	
Microvessel	density	(MVD,	here	represented	as	Average	Chalkley	Score/cm2)	of	subcutaneous	MDA-
G8	 breast	 tumours	 from	mice	 receiving	 (C)	 PBS	 control	 or	 (D)	 5	 rounds	 of	 combination	 therapy	
(2mg/kg	 Doxorubicin	 (DOX,	 i.v.)	 followed	 24hrs	 later	 by	 100µg/kg	 Zoledronic	 acid	 (ZOL,	 i.p.)	 was	
determined	using	a	Chalkley	grid.	Three	non-serial	levels	were	assessed	per	sample.	(A)	shows	data	
of	3	non-serial	levels	averaged,	(B)	shows	individual	scoring	data	(no	statistical	analysis	performed).	
n=4	for	PBS	and	n=3	DOX/ZOL.	Data	show	Median±Range.	Mann-Whitney	test.	CD31+ve	vasculature	
shown	 in	 brown,	 representative	 vasculature	 indicated	with	 black	 arrowhead,	 20x	 objective,	 scale	
bar	is	50µm.	Olympus	BX53,	cellSense	software.		
	
	
	
	
	
Eﬀects	of	combina/on	therapy	on	CD31	posi/ve	vasculature	of	subcutaneous	tumours.	Micro	vessel	density	
(MVD)	of	subcutaneous	tumours	from	mice	receiving	(C)	PBS	control	or	(D)	5	rounds	of	combina>on	therapy	
(2mg/kg	Doxorubicin	(DOX,	i.v.)	followed	24hrs	later	by	100µg/kg	Zoledronic	acid	(ZOL,	i.p.)	was	determined	
using	a	Chalkley	grid.	Three	non-serial	levels	were	assessed	per	sample.	(A)	shows	data	of	3	non-serial	levels	
averaged,	(B)	shows	individual	scoring	data	(no	sta>s>cal	analysis	performed).	n=4	for	PBS	and	n=3	DOX/ZOL.	
Data	show	Median±Range.	Mann	Whitney	test.	CD31+	vasculature	shown	in	brown,	representa>ve	vasculature		
indicated	with	black	arrow	head,	20x	objec>ve,	scale	bar	is	50µm.	
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5.6.2.3. Effects	of	combination	therapy	on	bone	and	the	BME	
5.6.2.3.1. Effects	of	combination	therapy	on	bone	volume	and	structure	
Excised	 tibiae	 of	 3	 mice	 per	 group	 were	 randomly	 selected	 and	 effects	 of	 combination	
therapy	 on	 trabecular	 bone	 volume	 assessed	 using	 µCT	 analysis.	 The	 anti-resorptive	
capacity	 of	 ZOL	 is	well	 established	 and	 the	dose	used	 in	 this	 experiment	 (100µg/kg)	 has	
shown	to	reduce	osteoclast	activity	and	number,	as	well	as	 increased	bone	volume	[154,	
158,	 241].	 In	 agreement	 with	 this	 5	 administrations	 of	 combination	 therapy	 increased	
trabecular	bone	volume	(PBS:	10.25	±	0.36%	vs.	DOX/ZOL:	15.53	±	0.91,	p≤0.01,	Fig.72A,D)	
and	 trabecular	 number	 (PBS:	 2.40	 ±	 0.12mm-1	 vs.	 DOX/ZOL:	 3.55	 ±	 0.12	 mm-1,	 p≤0.01	
Fig.72B,D)	when	 compared	 to	 control.	 Similarly,	 total	 bone	 volume	 (covering	 a	height	of	
interest	 of	 3.0mm	 from	 the	 top	 bit	 of	 the	 tibia)	 was	 increased	 after	 5	 rounds	 of	
combination	 therapy	 (PBS:	 3.22	 ±	 0.06mm3	 vs.	 DOX/ZOL:	 4.27	 ±	 0.15mm3,	 p≤0.01,	 Fig.	
72E&F).	There	was	no	effect	of	DOX/ZOL	on	trabecular	thickness	(PBS:	0.04	±	0.001mm	vs.	
DOX/ZOL:	0.04	±	0.001mm3,	Fig.72C).		
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Figure	72	Effects	of	combination	therapy	on	bone	volume	of	tibiae.		
7-9-week	old	 female	BALB/c	nude	mice	 received	 combination	 therapy	 (Doxorubicn	 (DOX)	2mg/kg	
followed	 24hrs	 later	 by	 Zoledronic	 acid	 (ZOL)	 100µg/kg)	 or	 PBS	 control	 1x	 weekly	 for	 5	 weeks.	
Effects	 on	 (A)	 trabecular	 bone	 volume	 (in%),	 (B)	 trabecular	 number	 (in	mm-1)	 and	 (C)	 trabecular	
thickness	(in	mm)	were	assessed	using	µCT	analysis.	(D)	Representative	cross	sections	of	tibiae.	(E)	
Bone	 volume	 of	 the	whole	 tibia	 (3mm	 in	 length)	was	 determined	 (in	mm3),	 representative	 X-ray	
images	shown	in	(F)	(n=3/group),	Data	show	Mean±SEM,	Student’s	t-test,	**	is	p<0.01.		
	
	
	
	
5.6.2.3.2. Effects	of	combination	therapy	on	the	bone	marrow	vasculature	
In	 addition	 to	modifying	 subcutaneous	 breast	 cancer	 growth,	 sequential	 treatment	with	
DOX	and	ZOL	has	also	shown	to	reduce	growth	of	MDA-MB-436	cells	 in	bone	 [247],	 	but	
PBS DOX/ZOL
0
1
2
3
4
5
B
V 
[m
m
-3
]
Total Bone Volume
**
PBS DOX/ZOL
0.00
0.02
0.04
0.06
Tb
.T
h 
[m
m
]
Trabecular Thickness
PBS DOX/ZOL
0
1
2
3
4
5
Tb
.N
 [m
m
-1
]
Trabecular Number
**
PBS DOX/ZOL
0
5
10
15
20
B
V/
TV
  [
%
]
Trabecular Bone Volume
**
PBS$ DOX/ZOL$
A$ B$
C$ D$
Fig.X.$Eﬀects$of$combina=on$therapy$on$bone$volume$of$=biae.!7#9#week!old!female!BALB/c!nude!
mice! received! combina9on! therapy! (Doxorubicn! (DOX)! 2mg/kg! followed!24hrs! later! by! Zoledronic!
acid!(ZOL)!100µg/kg)!or!PBS!control!1x!weekly!for!5!weeks.!Eﬀects!on!(A)!trabecular!bone!volume!(in
%),! (B)! trabecular!number! (in!mm#1)!and!(C)! trabecular! thickness! (in!mm)!were!assessed!using!µCT!
analysis.!(D)!Representa9ve!cross!sec9ons!of!9biae.!(n=3/group),!Data!show!Mean±SEM.!
E$ F$
	 237	
the	 precise	 mechanisms	 by	 which	 this	 occurs	 remain	 to	 be	 established.	 To	 assess	 if	
treatment	induces	alterations	in	the	bone	marrow	vasculature	in	the	metaphysis,	an	area	
preferentially	 colonised	by	breast	 cancer	 cells	 [90],	 immunofluorescence	 staining	 against	
the	vascular	endothelial	cell	marker	Endomucin	was	performed	on	30µm	thick	sections	of	
tibiae.	Scanning	Z-stacks	with	a	20µm	depth	allowed	visualisation	of	the	three-dimensional	
bone	 marrow	 vasculature	 in	 the	 metaphysis,	 and	 tile	 scans	 (6x6)	 allowed	 qualitative	
assessment	of	the	total	bone	marrow	vasculature	after	combination	therapy.	
The	microvasculature	 extending	 from	 the	 edge	 of	 the	 epiphysis	 appeared	 highly	
branched	 and	 interconnected	 in	 the	 PBS	 treated	 mice	 (Fig.73).	 In	 contrast,	 in	 DOX/ZOL	
treated	mice	the	vasculature	extending	from	the	epiphysis	 into	the	metaphysis	appeared	
tubular	and	column	like	with	limited	presence	of	connection	loops	or	arches.	Whether	this	
is	a	result	of	the	altered	bone	structure	in	this	area	(increased	trabecular	number)	or	direct	
therapeutic	effects	on	endothelial	cells	remains	to	be	established.	Tile	scans	did	not	reveal	
any	overt	alterations	in	structural	organisation	or	density	of	total	bone	marrow	vasculature	
(qualitative	data	only,	Fig.73A-H).	
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Figure	73	Effects	of	combination	therapy	to	the	bone	marrow	vasculature.	
	7-9-week	 old	 female	 BALB/c	 nude	 mice	 bearing	 subcutaneous	 MDA-G8	 tumours	 received	
combination	 therapy	 (Doxorubicn	 (DOX)	 2mg/kg	 followed	 24hrs	 later	 by	 Zoledronic	 acid	 (ZOL)	
100µg/kg)	 or	 PBS	 control	 1x	 weekly	 for	 5	 weeks.	 Effects	 on	 bone	 marrow	 vasculature	 were	
visualised	 using	 immunofluorescence	 against	 the	 vascular	 endothelial	 cell	 marker	 Endomucin	
(Endomucin	positive	cells	shown	in	green,	nuclei	shown	in	blue	(DAPI)).	(A-C)	shows	representative	
3D	projections	of	30µm	thick	gelatine	embedded	sections	of	tibiae	from	PBS	treated	mice	and	(D-F)	
for	 combination	 therapy	 treated	 mice.	 Images	 were	 acquired	 using	 the	 Nikon	 A1	 confocal	
microscope,	20x	oil	objective.	Z	stacks	of	20µm	depth	were	scanned	and	3D	projections	merged	into	
one	RGB	image.	White	triangles	=	branched	vessels,	white	asterisk	=	columnar	vasculature,	dashed	
line	=	growth	plate	boarder,	GP	=	growth	plate.	Scale	bar	is	100µm.	Representative	tile	scans	(6x6)	
showing	vasculature	within	the	whole	bone	after	(G)	PBS	and	(H)	DOX/ZOL.	Images	acquired	using	
the	Nikon	Eclipse	Dual	Cam	system,	20x	objective,	Scale	bar	is	250µm.	For	(G&H):	GP=growth	plate,	
met	=	metaphysis,	dia	=	diaphysis,	transition	form	met	to	dia	indicated	by	dashed	line.	
Fig$ X.$ Eﬀects$ of$ combina3on$ therapy$ to$ the$ bone$marrow$ vasculature.$ 7=9=week$ old$ female$ BALB/c$ nude$mice$
brearing$subcutaneous$MDA=G8$tumours$received$combina3on$therapy$(Doxorubicn$(DOX)$2mg/kg$followed$24hrs$
later$by$Zoledronic$acid$(ZOL)$100µg/kg)$or$PBS$control$1x$weekly$for$5$weeks.$Eﬀects$on$bone$marrow$vasculature$
were$ visualised$ using$ immunoﬂuorescence$ against$ the$ vascular$ endothelial$ cell$ marker$ Endomucin$ (Endomucin$
posi3v $ cells$ shown$ in$ green,$ nuclei$ shown$ in$ blue$ (DAPI)).$ (A=C)$ shows$ represent 3ve$ 3D$ cprojec3ons$ of$ 30µm$
thick$gela3n$embedded$sec3ons$of$3biae$from$PBS$tr ated$mice$and$(D=F)$ for$combina3on$therapy$treated$mice.$
Images$were$ acquired$ using$ the$ Nikon$ A2$ confocal$microscope,$ 20x$ oil$ objec3ve.$ Z$ stacks$ of$ 20µm$ depth$were$
scanned$ and$ 3D$ projec3ons$ merged$ into$ one$ RGB$ image.$ White$ triangles$ =$ branched$ vessles,$ white$ asterix$ =$
columnar$vasculature,$dashed$line$=$growth$plate$boarder,$GP$=$growth$plate.$Representa3ve$3le$scans$(6x)$showing$
vasculature$wih3n$ the$whole$bone$aber$ (G)$PBS$and$ (H)$DOX/ZOL.$ Images$acquired$using$ the$Nikon$Eclipse$Dual$
Cam$system,$20x$objec3ve,$Scale$bar$is$250µm.$
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5.6.2.3.3. Effects	of	combination	therapy	on	MDSCs	cells		
CD11b+/Gr1+	MDSCs	are	known	 to	be	overproduced	 in	both	 spleen	and	bone	marrow	of	
tumour	bearing	mice	and	patients	[170],	and	are	associated	with	tumour	progression.	To	
determine	 if	 DOX/ZOL	 combination	 therapy	 reduces	 subcutaneous	 tumour	 growth	 via	
reducing	 the	 levels	 of	 CD11b+/Gr1+	 cells	 in	 bone	 marrow	 and/or	 impairing	 their	
recruitment	 to	 the	 site	 of	 tumour	 growth,	 the	 presence	 of	 CD11b+/Gr1+	 cells	 in	murine	
bone	marrow	flushes	was	quantified	using	flow	cytometry.	
There	was	a	small	but	non-significant	 increase	(apr.	6%)	 in	the	presence	of	viable	
CD11b+ve	myeloid	cells	in	the	bone	marrow	of	DOX/ZOL	treated	mice	(PBS:	73.83±0.49%,	
vs,	DOX/ZOL:	80.20	±	2.950,	Fig.74A).	No	difference	in	Gr-1+ve	cells	within	the	CD11b+ve	
population	 was	 determined	 (PBS:	 94.13±0.50%	 vs.	 DOX/ZOL:	 94.63±0.91%,	 Fig.74B).	
Similar	 to	 the	 percentage	 of	 CD11b+ve	 cells	 the	 percentage	 of	 viable	 CD11b+/Gr1+	 dual	
positive	 cells	 showed	 a	 small	 but	 non-significant	 increase	 after	 DOX/ZOL	 treatment	
(69.53±0.83%	vs.	75.97±3.52%,	Fig.74C).	
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Figure	74	Effects	of	combination	therapy	on	MDSCs.		
7-9-week	 old	 female	 BALB/c	 nude	 mice	 bearing	 subcutaneous	 MDA-G8	 tumours	 received	
combination	 therapy	 (Doxorubicn	 (DOX)	 2mg/kg	 followed	 24hrs	 later	 by	 Zoledronic	 acid	 (ZOL)	
100µg/kg)	or	PBS	control	1x	weekly	for	5	weeks.	On	day	of	sacrifice	bone	marrow	was	collected	to	
analyse	the	presence	of	(A)	CD11b+ve	myeloid	cells,	(B)	proportion	of	CD11b+	myeloid	cells	that	are	
positive	 for	 Gr1	 and	 (C)	 MDSCs	 dual	 positive	 for	 CD11b/Gr1	 by	 flow	 cytometry.	 Data	 show	
Mean±SEM,	Student’s	t-test.	n=3/group,	2	mice	per	sample	pooled.		
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5.6.3. Does	 ZOL-induced	 modification	 of	 the	 BME	 affect	 growth	 of	 subcutaneously	
implanted	tumour	fragments	from	DOX/ZOL	treated	hosts?	
5.6.3.1. Confirmation	of	ZOL	effects	on	bone	
To	confirm	that	ZOL	administration	actively	induced	alterations	to	the	BME	µCT	analysis	a	
subset	 of	 tibiae	 collected	 at	 the	 experimental	 endpoint	 was	 performed	 (PBS:	 n=6,	 ZOL:	
n=4).	 As	 expected,	 ZOL	 pre-treatment	 (100µg/kg,	 1x	 weekly	 for	 2	 weeks)	 caused	 a	
significant	increase	in	trabecular	bone	volume	(ZOL:	37.04	±	1.80%	vs.	PBS:	9.59	±	0.40%,	
p≤0.0001,	 Fig.75A&C)	 and	 number	 (ZOL:	 14.17	 ±	 0.93mm-1	 vs.	 PBS:	 2.92	 ±	 0.14mm-1,	
p≤0.0001,	Fig.75B),	thus	providing	a	significantly	altered	BME.		
	
Figure	75	Effects	of	ZOL	pre-treatment	on	trabecular	bone	volume.		
6-8-week	old	female	BALB/c	nude	mice	received	1x	weekly	treatment	with	100µg/kg	Zoledronic	acid	
(ZOL)	or	PBS	control	for	2	weeks,	prior	to	tumour	fragment	transplantation.	Bones	were	collected	33	
days	 post	 tumour	 fragment	 transplantation.	 Effects	 on	 (A)	 trabecular	 bone	 volume	 (in%)	 and	 (B)	
trabecular	number	(in	mm-1)	were	assessed	using	µCT	analysis.	(C)	Representative	cross	sections	of	
tibiae.	(n=6	for	PBS,	n=4	for	ZOL),	Student’s	t-test	test,	****	is	p≤0.0001,	Data	show	Mean±SEM.	
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5.6.3.2. Re-growth	of	tumour	transplants	
As	shown	previously	5	weekly	administrations	of	combination	therapy	significantly	slowed	
down	 growth	 of	 subcutaneous	 MDA-G8	 tumours	 when	 compared	 to	 control.	 Tumours	
from	DOX/ZOL	 treated	mice	were	 isolated,	 subdivided	 into	quarters	 (average	of	 14mm3)	
and	 subcutaneously	 transplanted	 into	 recipient	 mice	 that	 were	 either	 pre-treated	 with	
100µg/kg	 ZOL	 (1x	weekly	 for	 2	weeks)	 or	 PBS	 control	 (n=8/group).	 	 To	 assess	 if	 tumour	
growth	resumes	at	equal	rates,	tumour	size	was	monitored	2-3x	weekly	using	calipers.	
One	mouse	of	 the	ZOL	pre-treatment	group	was	culled	on	Day	30,	3	days	before	
the	experimental	endpoint	due	to	skin	blistering;	2	mice	 (n=1/group)	were	culled	on	day	
32.	 No	 difference	 in	 tumour	 volume	 between	 the	 groups	 was	 determined	 at	 the	
experimental	endpoint	(PBS:	185.9	±	51.05mm3	vs.	ZOL	pre-treatment:	191.8	±	36.99,	PBS:	
n=6,	 ZOL:	 n=7	 at	 day	 33,	 Fig.76A&B).	 After	 the	 re-transplantation,	 tumour	 fragments	
started	to	re-grow	in	both	recipients	that	were	pre-treated	with	ZOL	or	PBS.	Although	re-
growth	of	fragments	transplanted	into	ZOL	pre-treated	hosts	appeared	to	be	slower	in	the	
initial	stages,	no	difference	in	tumour	size	was	determined	at	the	experimental	endpoint,	
potentially	also	due	to	the	high	variability	within	each	experimental	group	(Fig.76C&D).		
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Figure	76	Re-growth	of	subcutaneously	transplanted	MDA-G8	tumour	fragments.		
Isolated	 MDA-G8	 tumour	 fragments	 from	 female	 BALB/c	 nude	 mice	 treated	 with	 combination	
therapy	 (Doxorubicn	 (DOX)	 2mg/kg	 followed	 24hrs	 later	 by	 Zoledronic	 acid	 (ZOL)	 100µg/kg)	 1x	
weekly	for	5	weeks	were	subcutaneously	transplanted	into	7-9-week	old	female	BALB/c	nude	mice.	
Recipient	mice	 had	 either	 received	 pre-treatment	with	 100µg/kg	 ZOL	 or	 PBS	 control.	 (A)	 tumour	
growth	over	 time	and	 (B)	 Tumour	 volume	at	experimental	 endpoint.	Day	33:	PBS:	n=6,	 ZOL:	n=7.	
Data	show	Mean±SEM.	Individual	growth	rates	for	tumour	fragments	transplanted	into	PBS	(C)	and	
ZOL	pre-treated	(D)	recipients.	
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5.6.3.3. Presence	of	CD34+ve	and	CD31+ve	tumour	vasculature	
To	determine	whether	pre-treating	 tumour	 recipients	with	 ZOL	affects	 vascularisation	of	
transplanted	tumour	fragments,	CD34+ve	and	CD31+ve	tumour	vasculature	for	a	subset	of	
mice	was	quantified	using	the	Chalkley	grid	method.	There	was	no	significant	difference	in	
the	 number	 of	 CD31+ve	 (PBS:	 4.50±0.18	 vs.	 ZOL	 pre-treated:	 3.88±0.24,	 Fig.77A&B)	 or	
CD34+	(PBS:	2.66±0.36	vs.	ZOL	pre-treated:	2.23±0.26,	Fig.77C&D)	tumour	blood	vessels.		
	
Figure	77	Effects	of	ZOL	pre-treatment	on	CD34+ve	and	CD31+ve	vasculature	of	subcutaneously	
transplanted	MDA-G8	tumour	fragments	from	DOX/ZOL	treated	hosts.		
Microvessel	 density	 (MVD,	 presented	 as	 Average	 Chalkley	 score/cm2)	 of	 subcutaneous	 MDA-G8	
tumours	from	mice	receiving	PBS	control	or	100µg/kg	Zoledronic	acid	pre-treatment	(ZOL,	i.p.)	prior	
to	 transplantation	 of	 DOX/ZOL	 treated	 tumour	 fragments	 was	 determined	 using	 a	 Chalkley	 grid.	
Three	non-serial	levels	were	assessed	per	sample.	(A&C)	shows	data	with	3	levels	averaged,	(B&D)	
shows	 individual	 scoring	 data.	 n=3-5/group.	 Data	 show	 Median±Range.	 Mann-Whitney	 test.	 No	
statistical	test	applied	for	(B&D),	shows	individual	scoring	data	only.				
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5.6.3.4. Effects	on	tumour	cell	necrosis	
I	also	investigated	whether	there	was	a	difference	in	tumour	cell	necrosis	between	the	two	
groups	of	mice.	The	necrotic	tumour	area	on	3	non-serial	levels	per	sample	was	quantified	
using	OsteoMeasure	 (performed	by	Maria	 ErazoBastidas,	 Research	 technician,	University	
of	 Sheffield).	 No	 difference	 in	 necrotic	 area	 was	 determined	 between	 the	 treatment	
groups,	 suggesting	 that	 ZOL	 pre-treatment	 does	 not	 affect	 necrosis	 of	 subcutaneously	
transplanted	tumour	fragments	(PBS:	29.52	±	6.84%	vs.	ZOL	pre-treatment:	31.66	±	4.57%,	
Fig.78). 	
	
Figure	78	Effects	of	ZOL	pre-treatment	on	necrotic	cores	of	subcutaneously	transplanted	MDA-G8	
tumour	fragments	from	DOX/ZOL	treated	hosts.		
The	 percentage	 of	 the	 necrotic	 area	 of	 subcutaneous	MDA-G8	 tumours	 from	mice	 receiving	 PBS	
control	or	100µg/kg	Zoledronic	acid	pre-treatment	 (ZOL,	 i.p.)	prior	 to	 transplantation	of	DOX/ZOL	
treated	 tumour	 fragments	 was	 determined	 using	 OsteoMeasure.	 Three	 non-serial	 levels	 were	
assessed	per	sample.	PBS:	n=6,	ZOL:	n=7).	Data	show	Median±Range,	Mann-Whitney	test.	
5.6.3.5. Effects	on	tumour	cell	proliferation	
Ki-67	was	used	as	a	marker	to	identify	proliferating	tumour	cells	on	histological	sections	of	
transplanted	 tumour	 fragments.	 Immunohistochemistry	 confirmed	 that	 both	 pre-treated	
and	 control	 tumours	 were	 actively	 proliferating,	 irrespective	 of	 tumour	 size	 at	
experimental	endpoint	(Fig.79).	
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Figure	79	Effects	of	ZOL	pre-treatment	on	proliferation	of	subcutaneously	transplanted	MDA-G8	
tumour	fragments.		
Presence	 of	 proliferating	 (Ki-67+ve)	 MDA-G8	 tumour	 cells	 (in	 brown)	 in	 tumour	 fragments	 from	
mice	 receiving	 PBS	 control	 or	 100µg/kg	 Zoledronic	 acid	 pre-treatment	 (ZOL,	 i.p.).	 20x	 objective,	
Olympus	BX53,	cellSense	software,	Scale	bar	is	50µm.	Numbers	indicate	tumour	volume	at	cull	day.	
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5.7. Discussion	
This	study	aimed	to	investigate	the	role	of	the	bone	microenvironment	(BME)	in	mediating	
peripheral	 breast	 cancer	 (re)-growth.	 Experiments	 were	 designed	 to	 establish	 whether	
subcutaneous	 tumour	 growth	 resumes	 after	 successful	 combination	 therapy	 (DOX/ZOL),	
when	tumour	fragments	are	transplanted	into	recipients	with	a	modified	BME.	
5.7.1. Effects	of	combination	therapy	on	subcutaneous	breast	cancer	growth	
In	 clinical	 practice	 patients	with	 advanced	 breast	 cancer	 often	 receive	 a	 combination	 of	
therapies,	 for	example	cytotoxic	drugs	accompanied	with	palliative	bisphosphonate	 (BPs)	
treatment;	 and	 combination	 of	 therapies	 have	 shown	 synergistic	 anti-cancer	 response	
both	in	vitro	and	in	vivo	[154,	241,	247,	259,	260]	(reviewed	in	[315]).		
The	 majority	 of	 studies	 in	 breast	 cancer	 have	 investigated	 BPs	 in	 combination	
therapy	in	the	metastatic	setting,	with	only	a	 limited	number	of	studies	 investigating	soft	
tissue	and	or	peripheral	tumours.	Hiraga	and	colleagues	observed	an	enhanced	reduction	
in	the	area	of	established	bone	metastases	in	the	4T1/luc	mouse	model	after	combination	
therapy	with	tegafur-uracil	(UFT,	20mg/kg/day,	days	14-21)	and	ZOL	(250µg/kg	on	day	7),	
when	compared	 to	UFT	or	ZOL	alone.	However,	no	effects	were	demonstrated	using	 the	
single	agent	or	the	combination	on	orthotopic	mammary	fat	tumours	[316].	Combination	
of	ZOL	 (0.2µg/mouse	every	other	day,	 started	3	days	prior	 to	 tumour	cell	 injection)	with	
doxycyline	 releasing	 pellets	 (10mg	 pellets	 with	 timed-release	 over	 21	 days,	 resulting	 in	
15mg/kg/day,	initiated	at	the	same	time	as	ZOL	treatment)	decreased	MDA-MB-231	breast	
cancer	burden	in	bone	and	the	surrounding	bone	associated	soft	tissues	in	female	BALB/c	
nu/nu	 mice	 [317].	 	 Studies	 by	 Ottewell	 and	 colleagues,	 demonstrated	 reduced	
intraosseous	 MDA-MB-231/BO2	 tumour	 burden,	 reduced	 presence	 of	 BrdU	 positive	
tumour	cells	accompanied	by	a	reduction	 in	caspase-3	positive	tumour	cells	 in	nude	mice	
using	 combination	 therapy	of	DOX	 followed	24hrs	 later	by	ZOL,	which	was	not	observed	
with	single	agents	[259].	BPs	in	combination	therapy	have	also	been	investigated	in	other	
cancer	 types	 including	prostate,	 lung	and	 colon	 (reviewed	 in	 greater	detail	 in	 [147]).	 For	
example,	ZOL	(0.1mg/kg,	twice	weekly)	 in	combination	with	Docetaxel	 (20mg/kg,	every	2	
weeks)	 for	 7	 weeks	 significantly	 reduced	 prostate	 specific	 antigen	 (PSA)	 serum	 levels,	 a	
measure	of	reduced	tumour	growth,	 in	male	SCID	mice	bearing	intratibial	LnCap	prostate	
cancer	 cells	 when	 compared	 to	 single	 agents.	 However,	 ZOL	 as	 single	 agent	 decreased	
tumour	volume,	but	as	 this	was	 further	enhanced	with	combination	 therapy	 the	authors	
suggested	that	ZOL	sensitizes	LuCap	cells	 to	docetaxel	 treatment,	 resulting	 in	an	additive	
rather	than	synergistic	anti-tumour	effect	of	the	two	drugs	[318].  
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Given	 that	 most	 studies	 explored	 treatment	 effects	 in	 bone	 metastases,	 the	
models	used	do	not	 allow	us	 to	determine	whether	 the	anti-tumour	effects	 are	 induced	
directly,	indirectly	via	the	BME,	or	a	combination	of	the	two.	Recently	ZOL	in	combination	
with	the	anti-EGFR	monoclonal	antibodies	cetuximab	has	been	shown	to	reduce	growth	of	
subcutaneous	LS147T	and	SW48	colon	tumours	 in	male	BALB/c	nu/nu	mice	compared	to	
control	 or	 treatment	 with	 single	 agents.	 This	 suggests	 synergy	 between	 the	 two	
therapeutic	 agents	 [319]	 and	 supports	 the	 hypothesis	 that	 addition	 of	 bone-targeted	
therapy	modifies	peripheral	tumour	growth.	
Here	 I	 show	 that	 5	 rounds	 of	 combination	 therapy	 (DOX+ZOL)	 are	 effective	 in	
reducing	 subcutaneous	MDA-G8	 breast	 cancer	 growth,	 as	 in	 agreement	 with	 previously	
published	 studies	 by	 Ottewell	 et	 al.	 [241,	 260].	 However,	 the	 current	 study	 did	 not	
demonstrate	complete	suppression	of	 tumour	growth	as	described	 in	these	studies	[241,	
260].	 This	might	 be	 due	 to	 experimental	 variables	 including	 the	 use	 of	 different	 animal	
models	(e.g.	6-week	old	female	MF1	nude	or	CD1	nu/nu	mice	[241,	260]	vs.	6-9-week	old	
female	BALB/c	nude	mice);	or	differential	tumour	volume	at	treatment	start,	a	factor	that	I	
determined	to	be	crucial	for	effective	response	to	combination	therapy.	A	human	specific	
antibody	was	used	to	determine	differences	in	tumour	cell	proliferation	upon	combination	
therapy	showing	a	significant	reduction	in	the	number	of	Ki-67+ve	cells/mm2	tumour	tissue	
area	after	combination	therapy	when	compared	to	control,	supporting	the	tumour	volume	
measurements.	 	 In	 addition	 I	 observed	 reduced	 microvascular	 density	 (CD34+ve	 and	
CD31+ve	 vasculature)	 of	 subcutaneous	 tumours	 after	 5	 rounds	 of	 combination	 therapy.	
Single	 treatments	 with	 ZOL	 and	 DOX	 have	 previously	 been	 described	 not	 to	 affect	
microvascular	density	of	subcutaneous	MDA-G8	tumours	when	administered	for	6	weeks;	
reduced	 presence	 of	 CD34+ve	 vasculature	 was	 only	 observed	 when	 both	 agents	 were	
combined	[259].		
5.7.2. Effects	of	combination	therapy	on	the	BME	
Besides	 alterations	 in	 tumour	 microvasculature,	 the	 bone	 microvasculature	 appeared	
altered	 following	 combination	 therapy.	 In	 particular,	 the	 structural	 organisation	 of	
Endomucin	 positive	 vascular	 endothelial	 cells	 in	 the	metaphysis	 changed	 from	 a	 distinct	
branched,	 tubular	 and	 interconnected	 network	 in	 the	 control	 mice	 to	 column	 like	
vasculature	 extending	 from	 the	 epiphysis	 in	 the	 treatment	 group.	 These	 observations	
require	confirmation	and	quantification	in	independent	experiments.	In	addition,	it	is	well	
established	that	a	single	dose	as	well	as	repeated	administration	of	combination	therapy	
increases	 trabecular	 bone	 volume	 [154,	 241]	 and	 this	 was	 also	 observed	 in	 my	
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experiments.	 However,	 whether	 alterations	 observed	 in	 the	 organisation	 of	 the	
metaphyseal	bone	marrow	microvasculature	after	combination	therapy	are	due	to	direct	
effects	on	vascular	endothelial	cells	and/or	due	to	the	 increase	 in	trabecular	bone	 in	this	
particular	area,	reducing	physical	space,	remains	subject	to	further	analysis.	Whereas	the	
role	 of	 the	 bone	 marrow	 vasculature	 in	 both	 aging	 and	 tumour	 cell	 colonisation	 and	
dormancy	has	been	identified/explored	[51,	52,	160,	320],	the	consequences	of	treatment-
induced	 alteration	 to	 the	 bone	 marrow	 microvasculature	 and	 any	 resulted	 effects	 on	
peripheral	breast	cancer	growth	is	unknown.	
Given	 that	 tumour-growth-promoting	 cells	 (CAFs,	 TAM,	 etc.)	 are	 recruited	 from	
haematopoietic	 organs	 including	 the	 bone	 marrow	 to	 support	 disease	 progression,	 this	
suggests	 that	 an	 intact	 bone	 marrow	 vascular	 network	 is	 crucial	 for	 the	 trafficking	 of	
BMDCs	 and	 tumour-growth	 promoting	 soluble	 factors	 (e.g.	 VEGF,	 MMPs,	 etc.)	 that	 are	
released	 during	 bone	 remodelling.	 I	 therefore	 proposed	 that	 following	 combination	
therapy	 BMDCs	 including	 CD11b+/Gr1+	 myeloid	 derived	 suppressor	 cells	 (MDSCs)	 are	
retained	in	the	BM,	reducing	their	presence	in	the	circulation	and	their	recruitment	to	the	
peripheral	tumour,	which	could	partially	contribute	to	the	reduced	subcutaneous	tumour	
growth.		
Overall,	 I	 observed	 a	 small	 but	 non-significant	 increase	 in	 the	 percentage	 of	
CD11b+ve	myeloid	cells	in	the	bone	marrow	of	DOX/ZOL	treated	mice	when	compared	to	
control.	 CD11b	 is	 expressed	 on	 a	 variety	 of	 BMDCs	 including	 leukocytes,	 monocytes,	
neutrophils,	natural	killer	cells,	granulocytes	and	macrophages.	Therefore,	to	determine	if	
specific	 CD11b+ve	 cell	 populations	 increase	 in	 the	 bone	 marrow	 after	 combination	
therapy,	multiple	markers	would	 be	 needed	 (e.g.	mature	monocytes	 are-CD11b,	 CD11c,	
CD13,	 CD14,	 CD33,	 and	 CD64	 positive	 [321]).	 Well	 defined	 in	 murine	 models,	 the	
phenotype	of	 immature	myeloid	cells,	or	MDSCs,	consists	of	dual	expression	of	Gr-1	and	
CD11b;	 human	 phenotypes	 remain	 poorly	 defined.	 MDSCs	 have	 been	 described	 as	 a	
heterogeneous	 population	 of	 immature	 myeloid	 cells,	 generally	 overproduced	 in	
peripheral	 blood	 and	 bone	 marrow	 of	 cancer	 patients,	 associated	 with	 poor	 prognosis,	
clinical	 cancer	 stage	 and	 metastatic	 tumour	 burden	 [322].	 Gabitass	 and	 colleagues	 for	
example	 observed	 increased	 presence	 of	 MDSCs	 (HLADR-Lin1low/-	 CD33+CD11b+)	 in	
peripheral	blood	of	pancreatic,	oesophageal	and	gastric	cancer	patients	when	compared	to	
healthy	 volunteers	 [323].	 This	 is	 in	 agreement	 with	 data	 from	 Porembka	 et	 al.	
(CD15+CD11b+)	 [170],	 	 who	 also	 demonstrated,	 in	 humans,	 that	 these	 cells	 are	 actively	
recruited	 to	 pancreatic	 tumours	 thereby	 accelerating	 tumour	 growth	 [170].	 In	 the	 same	
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publication	 they	 report	 that	 ZOL	 treatment	 (30µg/kg	 3x	weekly)	 reduced	 intra-tumoural	
accumulation	of	MDSCs,	delayed	tumour	growth	as	well	as	increased	survival	 in	a	murine	
model	 of	 pancreatic	 cancer	 (0.1x106	 Pan02	pancreatic	 adenocarcinoma	 cells).	Given	 that	
the	 cell	 line	 used	 in	 these	 experiments	 is	 non-metastatic	 and	 the	 observed	 shift	 of	 the	
tumour	 microenvironment	 towards	 an	 immunostimulatory	 phenotype	 with	 increased	
levels	of	IFN-γ	accompanied	by	decreased	IL-10	levels	[170],	supports	the	hypothesis	that	
ZOL-induced	alterations	to	the	BME	affect	non-skeletal	tumour	growth.	Soki	et	al.	did	not	
observe	effects	on	Gr1+ve	cells	in	bone	marrow	of	ZOL	treated	4-week	old	C57BLJ/6	mice	
when	 compared	 to	 control	 (ZOL:	 200µg/kg	 2x	weekly	 for	 4	weeks)	 [159].	 Repeated	 and	
continuous	 ZOL	 treatment	 is	 also	 suggested	 to	 inhibit	 differentiation	 of	myeloid	 cells	 in	
vitro,	and	data	from	 in	vivo	studies	report	reduced	infiltration	of	CD11b+ve	macrophages	
into	 mammary	 carcinomas,	 decreased	 presence	 of	 macrophages	 in	 the	 spleen	 of	 ZOL	
treated	mice	 (mesothelioma	model)	 suggesting	 impaired	 differentiation	 of	MDSCs	 upon	
ZOL	treatment	[168],	with	others	showing	reduced	number	of	CD11b+/Gr-1+/F4+/80+	cells	
in	tumour	stroma		and	peripheral	blood	[37].	A	significant	increase	(about	37%)	in	MDSCs	
in	bone	marrow	of	myeloma	bearing	mice	when	compared	to	control,	paralleling	myeloma	
burden	 in	 bone,	 has	 also	 been	 reported.	 By	 isolating	 MDSCs	 from	 spleens	 of	 tumour	
bearing	mice,	studies	have	shown	differentiation	 into	bone	resorbing	osteoclasts	 in	vitro,	
whereas	 MDSCs	 isolated	 from	 naïve	 mice	 did	 not.	 In	 vitro	 ZOL	 inhibited	 osteoclast	
formation	 in	 tumour-induced	MDSC	 cultures	 and	 in	 vivo	 ZOL	 (0.1mg/kg,	 2x	weekly	 for	 4	
weeks)	reduced	the	increase	 in	MDSCs	by	30%	upon	development	of	myeloma	burden	in	
bone	when	compared	to	control	[324].	
	A	 study	 by	 Diaz-Montero	 et	 al.	 investigated	 levels	 of	MDSC	 in	 newly	 diagnosed	
cancer	 patients	 (solid	 malignancies)	 undergoing	 doxorubicin–cyclophosphamide	
chemotherapy.	There	was	a	significant	correlation	between	both	percentage	and	absolute	
number	of	circulating	MDSC	and	clinical	cancer	stage,	with	highest	levels	of	MDSCs	found	
in	 patients	 with	 metastatic	 cancer.	 Standard	 doxorubicin–cyclophosphamide	
chemotherapy	on	an	every	14-day	 schedule	was	associated	with	a	 significant	 increase	 in	
MDSC	in	peripheral	blood	of	breast	cancer	patients	[322].	In	the	4T1	breast	cancer	model	
administration	 of	 2.5mg	 and	 5mg/kg	 DOX	 significantly	 reduced	 the	 proportion	 and	
absolute	number	of	4T1	tumour-induced	MDSC	in	the	spleen	and	blood	when	compared	to	
control,	 potentially	 mediated	 by	 DOX-induced	 apoptosis	 of	 MDSCs	 [325].	 A	 key	
characteristic	 of	 MDSCs	 is	 their	 ability	 to	 suppress	 the	 activation	 and	 proliferation	 of	 T	
cells,	 however	 the	 immunosuppressive	 function	 of	 the	 residual	MDSCs	 was	 significantly	
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impaired	 [325].	 In	my	 experiments	 T-cell	 depleted	 BALB/c	 nude	mice	were	 used,	 so	 the	
immunosuppressive	 effect	 of	 MDSCs	 on	 T	 cells	 was	 not	 present	 and	 could	 not	 be	
evaluated.		
The	experiments	discussed	above	did	not	assess	effects	of	chemotherapy	on	bone	
marrow	 derived	 MDSCs.	 I	 could	 not	 detect	 any	 overt	 effects	 on	 the	 percentage	 of	
CD11b/Gr1+	 cells	 in	 the	 bone	 marrow	 after	 5	 rounds	 of	 weekly	 DOX/ZOL	 combination	
therapy	 when	 compared	 to	 control.	 These	 results	 suggest	 that	 this	 schedule	 of	
combination	 therapy	 does	 not	 modify	 CD11b+/Gr1+	 BMDCs,	 however,	 a	 more	 detailed	
analysis	with	increased	sample	size	and	multiple	markers	will	allow	a	more	comprehensive	
investigation	of	the	potential	consequences	of	the	treatment	regime	on	BMDCs.			
In	summary,	these	data	show	that	5	rounds	of	DOX/ZOL	combination	therapy	are	effective	
in	 reducing	subcutaneous	 tumour	growth,	highlighting	 that	 treatment	has	 to	be	 initiated	
early	 for	 successful	 therapy.	 However	 the	 precise	 molecular	 and	 cellular	 mechanisms	
regulating	the	synergistic	effects	of	DOX/ZOL	in	xenograft	models	of	subcutaneous	breast	
cancer	growth	remain	to	be	determined.		
5.7.3. Role	 of	 the	 BME	 in	 mediating	 peripheral	 breast	 cancer	 re-growth	 following	
cessation	of	combination	therapy		
Studies	by	Ottewell	et	al.	also	showed	that	suppression	of	peripheral	tumour	growth	was	
maintained	 once	 combination	 therapy	 was	 withdrawn	 [260].	 I	 therefore	 specifically	
designed	my	 experiments	 to	 elucidate	 the	 role	 of	 the	 BME	 in	 subcutaneous	 tumour	 re-
growth,	and	whether	this	was	affected	by	bone-targeted	therapy.	Isolated	fragments	from	
successfully	treated	DOX/ZOL	tumours	were	therefore	transplanted	into	hosts	with	a	ZOL-
modified	BME	or	control	mice.		
Only	 a	 limited	 number	 of	 studies	 have	 investigated	 the	 effects	 of	 bone-targeted	
agents	 on	 peripheral	 breast	 tumour	 growth,	 with	 the	 majority	 reporting	 minimal	 to	 no	
effect	 [37,	 39,	 148,	 307].	 In	 addition,	 when	 reduced	 tumour	 growth	 and/or	 increased	
survival	 was	 observed,	 all	 animals	 eventually	 died	 from	 progressive	 disease;	 similar	 to	
effects	observed	when	using	ZOL-monotherapy	in	animal	models	of	bone	metastases	[146,	
147,	273].	A	 recently	published	study	reports	beneficial	effects	of	ZOL	 in	prostate	cancer	
models	bearing	 subcutaneous	 tumours.	Here	 the	authors	 show	 that	ZOL	 (100µg/kg	once	
weekly	for	6	weeks)	prevents	cancer	associated	fibroblast	(CAF)-induced	enhancement	of	
subcutaneous	 prostate	 cancer	 cell	 growth	 (1x106	 PC3	 cells	 plus	 0.5x106	 CAFs	 were	
injected),	 potentially	 mediated	 via	 ZOL’s	 ability	 to	 impair	 stromal	 CAFs	 and	 fibroblast	
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reactivity	[169].	Nevertheless,	the	dose	and	administration	schedule	in	these	studies	were	
not	clinically	relevant,	thus	preventing	conclusions	to	be	drawn	as	to	whether	the	effects	
of	ZOL	on	peripheral	 tumours	were	direct	or	via	 the	BME.	 In	addition	 I	am	not	aware	of	
studies	 assessing	 the	 role	 of	 a	 ZOL-modified	 BME	 in	 primary	 breast	 cancer	 re-growth.	
Whereas	 BPs	 have	 been	 well	 studied	 in	 the	 adjuvant	 setting	 [135,	 180],	 their	 role	 in	
neoadjuvant	 therapy,	 given	 before	 the	 main	 treatment	 to	 reduce	 tumour	 size,	 remains	
poorly	defined.	A	 recent	meta-analysis	of	 clinical	 trials	 investigated	 the	effects	of	 adding	
ZOL	to	neoadjuvant	chemotherapy	in	patients	with	stage	II	and	III	breast	cancer	concluded	
that	there	was	no	benefit	of	adding	ZOL	to	neoadjuvant	chemotherapy	in	the	overall	study	
population	[193].	However,	addition	of	ZOL	resulted	in	significant	increase	in	pathological	
complete	response	in	the	breast	in	postmenopausal	women	[193].	The	models	used	in	my	
experiments	did	however	not	represent	a	post-menopausal	setting,	given	the	use	of	young	
animals	(6-8-weeks	at	treatment	start	without	ovariectomy).		
	 Myself	 and	 others	 have	 previously	 established	 that	 ZOL	 induces	 rapid	 and	
significant	alterations	to	the	BME	highlighting	that	although	the	main	target	of	BPs	 is	the	
osteoclast,	also	other	BMDCs	including	HSCs	[159],	osteoblasts	[158]	or	tumour	associated	
macrophages	[171]	could	contribute	to	the	observed	anti-tumour	effects	of	BPs	in	skeletal	
and	 extra-skeletal	 settings.	 	 Unpublished	 data	 from	 our	 group	 showed	 that	 following	
transplantation	of	 tumour	 fragments	 from	untreated	hosts	 into	recipients	 that	were	pre-
treated	with	DOX/ZOL	or	PBS	control	for	6	weeks,	tumour	growth	resumed	in	both	treated	
or	control	mice.	However	there	was	a	difference	in	doubling	time	(Untreated:	10	days	vs.	
Treated:	5	days).	 To	assess	 if	 growth	of	 regressed	 subcutaneous	 tumours	 resumes	when	
transplanted	 into	 hosts	 with	 a	 therapeutically	 altered	 microenvironment,	 Wind	 and	
colleagues	 then	 transplanted	 fragments	 from	 successfully	 treated	 DOX/ZOL	 treated	
tumours	 into	 mice	 that	 were	 either	 pre-treated	 with	 PBS	 control	 or	 6	 cycles	 of	 weekly	
DOX/ZOL	combination	 therapy.	These	experiments	 showed	 that	 regressed	 tumours	were	
able	to	continue	their	growth	irrespective	of	pre-treatment.	Similar	results	were	obtained	
in	my	experiments	where	I	transplanted	tumour	fragments	after	cessation	of	combination	
therapy	into	recipients	with	a	ZOL	pre-treated	microenvironment.	After	an	initial	lag-phase	
tumours	 started	 to	 grow	 exponentially	 in	 a	 subset	 of	 mice	 in	 both	 groups.	 These	 data	
suggest	that	re-growth	of	previously	treated	tumour	fragments	is	irrespective	of	the	BME.	
Although	 tumour	 fragments	 appeared	 to	 grow	 slower	 in	 the	 initial	 phase	 after	
transplantation	 no	 difference	 in	 doubling	 time	 or	 volume	 at	 experimental	 endpoint	was	
determined.	Active	tumour	cell	proliferation	was	confirmed	by	Ki-67	staining.	Observations	
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of	differences	 in	tumour	growth	rate	might	be	hampered	by	the	high	variance	of	tumour	
volumes	 in	 these	 studies	 (PBS:	 75.73mm3	 to	 563.57mm3	 and	 ZOL	 pre-treatment:	 40.17	
mm3	to	448.69mm3).	 In	addition	no	difference	 in	CD34+ve,	CD31+ve	vascular	cells	within	
the	tumour	or	tumour	cell	necrosis	was	observed.	However,	analysis	was	complicated,	as	
some	samples	were	split	into	pieces	prior	to	processing.		
Intratumoural	 heterogeneity,	 the	 existence	 of	multiple	 sub-clones	with	 different	
molecular	profiles	within	one	 tumour,	 as	well	 as	 the	 complex	 tumour	 stroma	provides	 a	
major	 clinical	 challenge	 [326].	 Using	 the	 tumour	 re-transplantation	 model	 rather	 than	
inoculating	 breast	 cancer	 cells	 into	 mice	 with	 a	 ZOL	 pre-treated	 BME	 allowed	 me	 to	
recapitulate	 this	 heterogenous	 tumour	 microenvironment.	 Injecting	 tumour	 cells	 rather	
than	transplanting	tumour	fragments	would	be	more	relevant	to	study	the	role	of	the	BME	
on	 peripheral	 breast	 cancer	 development.	My	 studies	 therefore	 aimed	 to	 represent	 the	
heterogeneity	 in	 a	 clinical	 setting,	 where	 small	 residual	 tumours	 regrow	 after	 initial	
therapy.	Although	care	was	taken	to	transplant	equally	sized	fragments	into	recipient	mice,	
the	above	mentioned	intratumoural	heterogeneity	does	also	complicate	the	analysis	of	the	
here-performed	 experiments.	 Given	 the	 nature	 of	 these	 studies	 transplanted	 tumour	
fragments	were	comprised	of	varying	cellular	composition	(tumour	heterogeneity,	necrotic	
areas,	stromal	cells).	Additionally	the	fate	of	these	fragments	during	the	 initial	days	after	
transplantation	are	speculative	given	the	initial	lack	of	blood	vessels	to	supply	oxygen	and	
nutrients	 as	well	 as	 hypoxia	 and	 tumour	 cell	 apoptosis.	 Indeed	 shrinkage	 of	 the	 tumour	
transplants	was	observed	during	the	first	days,	with	growth	resuming	at	later	time	points.	
In	 addition,	 transplanted	 tumour	 fragments	 may	 already	 contain	 sufficient	 infiltrated	
stromal	 cells	 that	 aid	 engraftment	 and	 re-growth	 following	 transplantation	 in	 the	 new	
host,	 irrespective	 of	 any	 newly	 recruited	 stroma.	 Any	 alterations	 in	 stroma-recruitment	
following	 ZOL	 treatment	 may	 therefore	 not	 be	 sufficient	 to	 affect	 re-growth	 of	
transplanted	tumour	fragments.	Thus,	the	nature	of	using	the	complex	system	of	tumour	
re-transplantation	 is	 a	 possible	 explanation	 for	 the	 high	 variation	 of	 tumour	 re-growth	
observed	 in	 the	 recipient	mice	 (both	 ZOL	 and	 control	 pre-treated).	 In	 separate,	 ongoing	
studies	we	have	demonstrated	that	effects	of	ZOL	in	expanding	cells	of	the	haematopoietic	
niche	 is	 rapid	 but	 also	 transient	 (Haider	 &	 Ubellacker,	 unpublished).	 Experimentally,	
tumour	fragments	were	transplanted	24hrs	after	recipient	mice	had	received	the	final	dose	
of	ZOL	and	whether	this	was	the	ideal	time	point	to	establish	the	full	consequences	of	the	
BME	on	peripheral	growth	remains	to	be	established.	Nevertheless	choosing	the	24hr	time	
point	guaranteed	that	circulating	levels	of	ZOL	were	minimal,	due	to	the	short	plasma	half-
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life	of	the	drug.	Besides	no	difference	in	tumour	size	I	could	also	not	determine	differences	
in	tumour	cell	necrosis	or	vascularisation	between	fragments	that	were	transplanted	into	
ZOL	or	control	pre-treated	recipients.	
5.8. Summary	and	Conclusion	
In	 summary	 these	 data	 show	 that	modification	 of	 the	 BME	with	 ZOL	 is	 not	 sufficient	 to	
supress	 peripheral	 breast	 cancer	 re-growth	 following	 cessation	 of	 combination	 therapy,	
suggesting	that	both	the	tumour	and	microenvironment	need	to	be	targeted	for	successful	
anti-cancer	therapy.		
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Chapter	6	–	Discussion,	Future	
Work	and	Conclusion	 	
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6.1. Discussion	and	future	work	
Breast	 cancer	 preferentially	 metastasises	 to	 bone,	 hence	 calling	 for	 therapeutic	
intervention	that	targets	not	only	the	tumour	but	also	the	bone	microenvironment	(BME).	
Decision-making	 for	 the	 use	 of	 anti-cancer	 therapy	 is	 primarily	 based	 on	 tumour	
characteristics.	However,	our	increased	understanding	of	the	interactions	between	cancer	
cells	 and	 their	 surrounding	 microenvironment	 (TME)	 highlights	 the	 importance	 of	
considering	the	response	of	the	TME	when	selecting	and	designing	treatment	approaches.	
In	metastatic	breast	cancer	the	presence	of	proliferating	tumour	cells	in	bone	disturbs	the	
physiological	 balance	 of	 bone	 remodelling	 due	 to	 increased	 osteoclast	 activity,	 which	
results	 in	 osteolytic	 lesions	 [121,	 130,	 327,	 328].	 To	 date	 bone-targeted	 therapeutics	
include	 the	 standard	of	 care	anti-resorptive	agents	 (e.g.	 Zoledronic	acid,	ZOL),	and	novel	
agents	 with	 promising	 results	 in	 clinical	 trials	 are	 emerging	 (e.g.	 the	 tyrosine	 kinase	
inhibitor	Cabozantinib,	CBZ).	Stromal	cells	including	osteoblasts	and	osteoclasts	as	well	as	
soluble	 factors	 in	 the	 TME	 are	 therefore	 increasingly	 investigated	 and	 enhanced	 anti-
cancer	effects	are	reported	when	combining	therapies	that	target	both	the	cancer	cells	and	
their	microenvironment	[241,	247,	259,	260].		
Work	 presented	 in	 this	 thesis	 has	 utilised	 a	 range	 of	 in	 vivo	 model	 systems	 and	
methodologies	 to	 investigate	 the	 response	of	 the	 in	 vivo	 BME	 to	anti-cancer	 therapy,	 its	
role	in	tumour	cell	homing	to	bone	and	peripheral	breast	cancer	re-growth.		
6.1.1. Modification	of	 the	BME	with	ZOL	and	consequences	on	tumour	cell	homing	to	
bone	
Although	the	BP	ZOL	has	shown	to	reduce	human	breast	cancer	recurrence	in	bone	and	its	
routine	use	to	reduce	skeletal-related	events	in	human	cancer-induced	bone	disease,	there	
was	minimal	data	available	on	the	effects	of	ZOL	on	cells	other	than	the	osteoclast	prior	to	
data	 presented	 in	 Chapter	 3.	 This	 seems	 somewhat	 surprising	 given	 that	 BPs	 were	
identified	by	chemists	in	the	middle	of	the	19th	century	and	used	in	skeletal	disorders	that	
are	 characterised	by	 excessive	bone	 resorption	 [329].	 	 Effects	 of	 BPs	on	osteoblasts	 and	
endothelial	 cells	 for	 example	 have	 been	 mainly	 investigated	 in	 vitro,	 and	 the	
pharmacological	property	of	the	drug	questions	the	relevance	of	these	data	[159,	161,	162,	
165,	249,	262,	267,	269].	The	lack	of	studies	exploring	the	effects	of	BPs	on	osteoblasts	in	
vivo	 is	 potentially	 due	 to	 the	 difficulty	 of	 identifying	 these	 cells	 on	 histological	 sections.	
Whereas	osteoclasts	are	easily	identified	based	on	their	bright,	pink	appearance	following	
TRAP-staining,	 the	 lack	 of	 specific	 markers	 to	 detect	 osteoblasts	 using	
immunohistochemistry	 for	 example	 makes	 quantification	 a	 challenge.	 Osteoblasts	 are	
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generally	identified	according	to	their	distinct	morphology	using	H&E	stained	sections	[90,	
330-332].	 To	 establish	 osteoblast	 quantification	 I	 received	 training	 by	 key	 experts	 at	 the	
University	of	Sheffield	and	my	histophatological	 results	were	 reviewed	and	confirmed	by	
pathologists	 Dr.	 Hunter	 and	 Dr.	 Heymann	 (both	 University	 of	 Sheffield).	 Others	 have	
previously	quantified	osteoblasts	lining	trabecular	bone	surfaces	using	pre-defined	areas	of	
0.75mm2	with	an	offset	of	0.25mm	from	the	growth	plate	[332,	333].	In	Chapter	3	I	present	
data	 that	 breast	 cancer	 cells	 preferentially	 localise	 to	 trabecular	 bone	 areas,	 and	 similar	
results	 have	 been	 reported	 by	 others	 [90];	 however,	 a	wide	 variation	 in	 the	 location	 of	
tumour	 cells	 within	 the	metaphysis	 has	 previously	 been	 observed	 [90].	 Experimentally	 I	
therefore	decided	to	quantify	the	number	of	osteoblasts	and	osteoclasts	on	all	trabecular	
bone	surfaces	125µm	away	from	the	growth	plate.	In	addition,	specialised	mouse	models	
expressing	 GFP	 +ve	 cells	 of	 the	 osteoblastic	 lineage	 were	 used	 in	 a	 proportion	 of	
experiments,	that	facilitate	the	visualisation	of	treatment	effects	on	these	cells.	
It	is	well	established	that	long-term	treatment	with	BPs	increases	bone	volume	due	
to	 reduced	 osteoclast	 activity	 [157,	 241,	 262,	 266].	 A	 study	 by	 Pozzi	 and	 colleagues	
demonstrated	activity	of	the	BP	ZOL	on	osteoblasts	 in	vivo,	with	a	trend	towards	reduced	
osteoblast	 numbers	 per	 bone	 perimeter	 after	 repeated	 treatment	 with	 0.5-1mg/kg	 ZOL	
weekly	for	3	weeks,	in	addition	to	significantly	reduced	serum	osteocalcin	levels	in	C57BL6	
mice.	 However,	 the	 dose	 and	 treatment	 schedules	 in	 these	 experiments	 are	 not	
comparable	 to	 the	 clinical	 setting	 [262].	 Here	 I	 present	 the	 first	 evidence	 that	 a	 single,	
clinical	relevant	dose	of	ZOL	(100µg/kg	in	mice)	causes	substantial	alterations	to	the	BME	
in	 vivo	 including	 an	 increase	 in	 trabecular	 bone	 volume	 and	 a	 reduction	 in	 number	 and	
activity	 of	 both	 osteoblasts	 and	 osteoclasts	 as	 early	 as	 3	 days	 post	 treatment	 when	
compared	 to	 control.	 In	 addition,	 ZOL	 appears	 to	 induce	 changes	 to	 the	 structural	
organisation	of	the	bone	marrow	vasculature	and	increases	the	presence	of	proteoglycan-
rich	 ECM	 in	 the	 metaphysis,	 with	 potential	 consequences	 for	 the	 physical	 location	 and	
cellular/molecular	interactions	of	the	metastasis	niche.		
Dissemination	 of	 tumour	 cells	 occurs	 early	 in	 the	 disease	 and	 in	 about	 30%	 of	
patients	with	early-stage	breast	cancer,	presence	of	micro-metastases	in	the	bone	marrow	
at	 the	 time	 of	 diagnosis	 has	 been	 reported	 [97].	 Although	 our	 knowledge	 covering	 how	
tumour	cells	influence	the	BME	and	vice	versa	continues	to	increase,	our	understanding	of	
the	 crucial,	 early	 events	 occurring	 in	 bone	metastasis	 remains	 speculative;	 this	 is	 largely	
due	to	the	lack	of	methodologies	to	accurately	study	these	early	events.	Others	have	used	
the	bioluminescence	signal	to	study	the	homing	of	B02	breast	cancer	cells	to	bone	14	days	
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post	 tumour	 cell	 inoculation	 in	 the	 presence	 and	 absence	 of	 ZOL	 treatment	 [146].	
However,	 this	 method	 does	 not	 allow	 the	 detection	 of	 individual	 tumour	 cells	 or	 their	
precise	 location	 in	 bone.	 Two-	 or	 multi-photon	 microscopy	 is	 therefore	 the	 current	
standard	technique	to	visualise	single	cancer	cells	in	bone	[85,	115].	Despite	this	technique	
allowing	high	resolution	imaging,	it	remains	challenging	to	investigate	the	surrounding	cells	
of	the	BME.	In	my	thesis	 I	combined	the	use	of	two-photon	and	fluorescence	microscopy	
with	 standard	 histology,	 to	 explore	 whether	 osteoblasts	 are	 key	 cells	 of	 the	 complex	
network	 of	 bone	 marrow-derived	 cells	 (BMDCs)	 that	 create	 the	 metastasis	 niche	 and	
determined	whether	tumour	cell	homing,	one	of	the	critical	key	step	in	the	development	
of	osteolytic	bone	disease,	is	affected	by	bone	targeted	therapy	(ZOL).		
Previous	 studies	 have	 injected	 breast	 cancer	 cells	 24hrs	 post	 ZOL	 pre-treatment	
[146],	 a	 time	 point	 where	 bone	 volume	 as	 well	 as	 osteoblasts	 and	 osteoclasts	 are	 not	
affected	by	 ZOL	 [158].	However	my	previous	 analysis	 on	 the	 early	 effects	 of	 ZOL	on	 the	
naïve	 BME	 allowed	me	 to	 determine	when	 tumour	 cells	 arrive	 in	 bone	 so	 this	 coincides	
with	the	time	point	when	ZOL-induced	BME	modifications	have	reached	their	peak	(Day	5	
post	 ZOL).	 In	 postmenopausal	 women	 ZOL	 has	 been	 shown	 to	 reduce	 breast	 cancer	
recurrence	 in	bone,	and	 increased	risk	of	bone	metastasis	has	been	associated	with	high	
PINP	 serum	 levels	 (marker	 of	 osteoblast	 activity)	 [132].	 This	 suggests	 a	 key	 role	 of	
osteoblasts	in	the	development	of	bone	metastasis	and	breast	cancer	recurrence	in	bone.	
However,	 in	vivo	the	tight	coupling	between	osteoblasts	and	osteoclasts	makes	it	difficult	
to	 separate	 the	 direct	 and	 indirect	 effects	 of	 therapeutic	 agents	 on	 these	 cells;	 a	 single	
quantification	of	the	bone	serum	marker	levels	(TRAP	and	PINP),	is	not	helpful,	so	repeated	
measurements	are	required.	
Previous	work	has	highlighted	the	prevalence	of	osteoblasts	in	the	BME	comprising	
microscopic	bone	lesions	[94],	and	suggests	that	osteoclasts	are	not	critical	in	the	earliest	
stages	 of	 bone	metastasis	 but	 rather	 at	 later	 stages	 of	 disease	 progression	 [93].	 This	 is	
supported	 by	 my	 data	 showing	 that	 inhibition	 of	 osteoclasts	 with	 ZOL	 does	 not	 inhibit	
tumour	cell	homing	 to	bone	 [158].	However,	 in	agreement	with	 findings	 from	Wang	and	
colleagues	 my	 data	 suggest	 that	 BCs	 preferentially	 home	 to	 osteoblast-rich	 trabecular	
areas.	 This	 is	 further	 strengthened	 by	 the	 observation	 that	 in	 breast	 cancer	 patients,	
actively	 proliferating	macrometastases	 have	 been	 found	 in	 close	 proximity	 to	 endosteal	
surfaces	[112],	and	that	heterotypic	adherens	junctions	between	E-cadherins	expressed	on	
breast	cancer	cells	and	N-cadherins	expressed	on	ALP+	osteogenic	cells	are	formed	during	
the	early	stages	of	bone	metastasis	[94].		
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However,	 BCs	 might	 not	 only	 localise	 close	 to	 endosteal	 surfaces	 due	 to	 the	
presence	 of	 osteoblasts,	 since	 these	 areas	 were	 also	 comprised	 of	 proteoglycan-rich	
extracellular	matrix	 (ECM).	Although	 tumour	cell	 adhesion	 to	 the	ECM	 is	 the	 first	 step	 in	
the	metastatic	cascade,	the	mechanism	by	which	ZOL	affects	 interaction	of	breast	cancer	
cells	with	ECM	components	such	as	for	example	proteoglycans	and	hyaluronan	implicated	
for	breast	cancer	cell	adhesion,	invasion,	proliferation	and	migration	are	less	well	reported.	
In	addition,	 integrins,	cell	surface	glycoproteins	mediating	cell-cell	and	cell-ECM	adhesion	
may	be	affected	by	ZOL	treatment	with	potential	consequences	on	the	metastatic	process.	
Indeed,	ZOL	has	been	shown	to	have	anti-adhesive	properties	in	breast	cancer	cells	in	vitro	
[334].	 When	 compared	 to	 control,	 ZOL	 (5-90μM	 for	 48	 and	 96hrs)	 caused	 a	 down-
regulation	of	the	integrin	heterodimers	αvβ3	(−34%),	αvβ5	(−98%)	as	well	as	α5β1	(−40%)	
in	 MDA-MB-231	 breast	 cancer	 cells,	 which	 was	 accompanied	 by	 reduced	 adhesion	 to	
various	ECM	matrices	in	vitro	[334].	In	breast	cancer	cells	ZOL	also	reduced	the	expression	
of	MMP-9	and	-2,	MMPs	that	play	a	crucial	 role	 in	 invasion	and	metastasis	 [334].	Others	
also	 reported	 that	 ZOL	 treatment	 significantly	 impaired	 the	 adhesion	 of	 MDA-MB-231	
breast	 cancer	 cells	 to	 vitronectin	 and	 gelatine	 matrices	 (both	 αvβ3	 ligands)	 when	
compared	to	control,	which	correlated	with	reduced	αv	and	αvβ3	cell	surface	expression.	
In	 contrast	 no	difference	 in	 adhesion	onto	 fibronectin	 (α5β1-ligand)	 and	 collagen	 type	1	
(α2β1-ligand)	was	 observed	 [335].	 These	 findings	may	 provide	 a	 further	 explanation	 for	
why	the	location	of	tumour	cells	in	bone	is	altered	in	a	ZOL-modified	BME.		
The	metaphysis	 is	a	highly	vascularised	structure.	Given	the	role	of	osteoblasts	 in	
bone	development,	regeneration,	and	remodelling	[336],	studies	have	suggested	coupled	
invasion	 of	 osteoblasts	 with	 growing	 PECAM-1+ve	 blood	 vessels	 to	 the	 site	 of	 bone	
turnover	in	response	to	environmental	cues	in	experimental	fracture	models	[53].	Studies	
by	 Kusumbe	 and	 colleagues	 revealed	 that	 osteoblasts	 are	 selectively	 positioned	 around	
endosteal	 EndomucinhighCD31high	 vessels	 in	 the	 metaphysis	 [51,	 160],	 the	 area	
preferentially	 colonised	 by	 breast	 cancer	 cells	 [90,	 158].	 These	 observations	 suggest	 a	
potential	 overlap	 of	 the	 endosteal	 and	 vascular	 niche	 in	 bone,	 and	 whether	 both	
contribute	 to	 tumour	 cell	 homing	 remains	 to	 be	 elucidated.	 However,	 given	 the	 tight	
coupling	between	osteogenesis	and	angiogenesis	[51],	alterations	in	tumour	cell	location	in	
bone	following	modification	of	both,	osteoblasts	and	endothelial	cells	in	my	experiments,	
strengthens	 the	 notion	 of	 a	 joint	 role	 for	 both	 niches	 in	 tumour	 cell	 homing	 to	 bone.	
Additionally	I	observed	single	tumour	cells	 in	close	proximity	to	both	vascular	endothelial	
cells	 and	 bone	 surfaces	 using	 immunofluorescence;	 however	 quantification	 methods	 to	
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determine	 the	 temporal-spatial	 relationship	 between	 bone	 marrow	 vasculature	 and	
tumour	cells	need	to	be	developed.	
For	 my	 studies	 I	 largely	 focused	 on	 the	 two	 key	 bone	 cells,	 osteoblasts	 and	
osteoclasts;	 although	 also	 other	 cells	 of	 the	 BME,	 including	 HSCs,	 may	 contribute	 to	
tumour	 cell	 homing.	 In	 collaboration	 with	 Dr.	 Sandra	 McAllisters	 group	 in	 Boston	 I	
investigated	 the	 effects	 of	 ZOL	 on	HSCs,	 another	 potential	 component	 of	 the	metastatic	
niche	[31,	95,	96].	Using	prostate	cancer	models	Shiozawa	and	colleagues	have	shown	that	
tumour	cells	compete	with	HSCs	for	the	occupancy	of	the	hematopoietic	niche	[95].		HSCs	
are	thought	to	reside	in	close	proximity	to	the	endosteal	and	vascular	niches	[101-103,	337,	
338].	It	is	well	established	that	elevated	numbers	of	osteoblasts	increase	HSCs	in	the	bone	
marrow	 [102-104],	 concomitantly	 osteoblast	 depletion	 decreases	 the	 numbers	 of	 HSCs	
[339].	 In	 addition	 osteoclast-induced	 bone	 resorption	 results	 in	 the	 release	 of	 soluble	
growth	factors	such	as	G-CSF,	TGF-β,	as	well	as	bone	minerals	and	proteins	that	affect	HSC	
maintenance	 and	 mobilisation	 [32].	 Homing	 of	 HSCs	 to	 the	 marrow	 niche	 is	 partially	
regulated	 by	 CXCR4/CXCL12	 chemotactic	 signalling	 [110],	 and	 there	 is	 evidence	 that	
tumour	cell	homing	to	bone	is	also	mediated	through	this	pathway	[95].		
Following	up	to	work	presented	in	my	thesis,	a	detailed,	real-time	characterisation	
of	 the	 temporal-spatial	 relationship	 between	 various	 niche	 components	 including	
osteoblasts,	vascular	endothelial	cells,	HSCs	and	tumour	cells	would	be	required.	By	using	
lipophilic	dyes	as	well	as	expression	of	fluorescent	reporters,	intra-vital	microscopy	would	
offer	a	significant	advantage	over	longitudinal	imaging	by	bioluminescence,	which	lacks	the	
resolution	to	detect	single	cells.	This	approach	remains	challenging	given	the	need	for	high-
resolution	 imaging	 and	 deep-tissue-penetration.	 Intra-vital	 imaging	 of	 cellular	 trafficking	
within	the	bone	marrow	space	has	been	successfully	applied	to	study	the	HSC	niche	[338,	
340]	and	bone	marrow	colonisation	by	multiple	myeloma	cells	 [115].	These	studies	were	
predominantly	 performed	 by	 imaging	 the	 calvarial	 bone	 marrow,	 whereas	 intra-vital	
imaging	of	the	long	bones,	the	location	where	xenograft	models	commonly	develop	breast	
cancer	bone	metastases,	remains	challenging.	To	my	knowledge	there	is	only	one	study	by	
McDonald	and	colleagues	who	have	developed	a	method	for	dynamic	longitudinal	imaging	
of	 dormant	myeloma	 cells	within	 intact	 long	 bones	 of	mice	 [115].	 In	 these	 experiments	
colonising	 myeloma	 cells	 migrating	 from	 the	 bone	 marrow	 space	 towards	 endocortical	
bone	 surfaces,	 where	 they	 appeared	 to	 arrest,	 were	 visualised.	 Performing	 similar	
experiments	in	breast	and/or	prostate	cancer	models	would	significantly	contribute	to	our	
understanding	of	how	the	BME	regulates	the	development	of	bone	metastases.	However,	
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longitudinal	 intra-vital	 imaging	 of	 the	 development	 of	 bone	 metastasis	 has	 various	
limitations	 including	 the	 stress	 of	 the	 procedure	 to	 animals,	 given	 the	 repeated	 and	
prolonged	anaesthesia	and	surgery.	In	addition,	the	critical	step	of	tumour	cell	homing	to	
bone	may	only	be	captured	within	the	first	hours	post	tumour	cell	injection.		
6.1.2. Characterise	the	effects	of	CBZ	on	the	BME	in	vivo	
Novel,	 small	molecule	 tyrosine	 kinase	 inhibitors	 such	as	CBZ,	have	been	 shown	 to	 affect	
bone	 [208,	 231,	 341],	 but	 most	 studies	 investigated	 the	 effects	 of	 such	 agents	 in	 the	
presence	of	tumour,	which	masks	the	specific	contribution	of	bone	cells	to	observed	anti-
cancer	 response.	 Currently	 CBZ	 is	 approved	 for	metastatic	medullary	 thyroid	 cancer	 and	
advanced	renal	cell	carcinoma	[229,	239];	clinical	trials	in	prostate	cancer	bone	metastasis	
[234,	 235]	 support	 the	 notion	 that	 treatment	 effects	 are	mediated	 via	 key	 bone	 cells.	 I	
carried	out	the	first	detailed	characterisation	of	the	response	of	the	naïve	 in	vivo	BME	to	
CBZ	 across	 a	 range	 of	 animal	 models	 (studies	 were	 kindly	 supported	 by	 Exelixis).	 This	
allowed	me	to	assess	the	response	of	the	BME	to	CBZ	in	different	microenvironments	with	
regards	to	age,	sex	and	strain.	With	aging	the	composition	of	the	BME	changes,	 including	
the	 presence	 of	 myeloid	 and	 lymphoid	 lineages	 in	 the	 bone	 marrow	 in	 addition	 to	
alterations	 in	 intrinsic	 HSC	 properties	 such	 as	 proliferation	 and	 differentiation	 [342].	 In	
addition,	mesenchymal	 stem	 cells	 change	 their	 proliferation	 and	 differentiation	 capacity	
during	 aging,	 which	 is	 potentially	 associated	with	 the	 increased	 bone	 loss	 in	 adulthood.	
Also	 BME-derived	 growth	 factors	 exhibit	 age-related	 changes	 [242].	 I	 therefore	 included	
young	 (6-week	 old)	 and	 older	 mice	 with	 a	 more	 mature	 skeleton	 (17-weeks)	 in	 my	
experiments	and	observed	differential	effects	of	CBZ	 in	 these	models.	Similar	differential	
effects	were	also	seen	in	male	vs.	female	mice,	potentially	due	to	presence	of	different	sex	
hormones	 and	 receptors.	 This	 emphasises	 the	 need	 to	 establish	 the	 response	 of	 anti-
cancer	 therapeutics	 in	 a	 variety	 of	 animal	 models	 to	 provide	 detailed	 mechanistic	
information.	The	models	used	in	my	studies	also	lacked	the	presence	of	an	active	immune	
system,	which	eliminates	the	ability	to	establish	the	role	of	the	adaptive	immune	system	in	
mediating	 the	 response	 to	 CBZ.	 Investigating	 the	 effects	 of	 CBZ	 in	 immunocompetent	
models	would	allow	evaluation	of	the	role	of	the	immune	system	in	the	response	to	drug	
treatment.	
Briefly,	 administration	 of	 CBZ	 caused	 substantial	 alterations	 to	 the	 different	 cell	
types	in	bone	irrespective	of	the	absence	of	tumour,	suggesting	a	key	role	of	bone	cells	in	
mediating	 the	 response	 to	 CBZ	 therapy.	 To	 date	 limited	 studies	 in	 xenograft	 models	 of	
breast	 cancer	 have	been	 conducted	 [218],	 and	 studies	 using	CBZ	 in	models	 of	 advanced	
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breast	cancer	should	be	performed.	Experiments	using	CBZ	in	combination	with	additional	
anti-cancer	 drugs	 may	 also	 provide	 increased	 efficacy	 when	 compared	 to	 the	 mono-
therapy.	 Indeed,	 CBZ	 has	 demonstrated	 promising	 effects	 in	 patients	 with	 advanced	
castration	 resistant	 prostate	 cancer	 who	 had	 received	 at	 least	 one	 previous	 docetaxel	
chemotherapy	regimen	[235].	CBZ	is	currently	also	being	investigated	in	combination	with	
fulvestran	(hormonal	therapy)	and	trastuzumab	(monoclonal	antibody	that	interferes	with	
the	 HER2/neu	 receptor)	 in	 patients	 with	 advanced	 breast	 cancer	 (Clinical	 trials.gov	
identifier	NCT01441947	and	NCT02260531).	Due	 to	 funding	 limitations	 I	was	not	 able	 to	
assess	 how	 the	 CBZ-mediated	 alterations	 of	 the	 BME	 may	 affect	 establishment	 and	
progression	of	breast	cancer	bone	metastasis.	 It	still	 remains	unclear	whether	changes	 in	
bone	scans	following	CBZ	treatment	are	due	to	bone	modulation	alone	or	due	to	a	specific	
anti-cancer	 effect	 on	 metastasis.	 Therefore	 serum	 bone	 markers	 such	 as	 alkaline-
phosphatase	 are	 still	 used	 as	 non-specific	 surrogate	 markers	 for	 response	 to	 CBZ	 in	
patients	with	advanced	prostate	cancer	alongside	PSA-levels	and	pain	assessment	[235].		
Based	on	 the	 findings	presented	 in	Chapter	4,	 the	 importance	of	considering	 the	BME	 in	
designing	 new	 anti-cancer	 treatment	 regimes	 has	 been	 established	 and	 will	 allow	 the	
design	of	treatment	regimes	with	enhanced	efficacy.	
6.1.3. The	role	of	the	BME	in	mediating	peripheral	breast	cancer	growth		
Patients	 with	 advanced	 breast	 cancer	 often	 receive	 a	 combination	 of	 drugs	 that	 target	
both	the	BME	and	the	tumour	cells	(e.g.	the	bone-targeted	agent	ZOL).	In	addition	to	the	
use	 in	 advanced	 breast	 cancer,	 ZOL	 is	 increasingly	 investigated	 in	 the	 adjuvant	 (therapy	
given	in	addition	to	the	main	therapy	to	maximise	treatment	effectiveness)	or	neoadjuvant	
setting	(given	before	the	main	treatment);	and	in	both	the	patients	menopausal	status	has	
emerged	as	the	critical	factor	for	treatment	success	[133,	135,	180,	182,	193]	–	see	Table	
2&3,	 Chapter	 1.	 However,	 the	 role	 of	 the	 BME	 in	 mediating	 peripheral	 breast	 cancer	
growth	remains	poorly	understood.		Based	on	the	intriguing	findings	in	clinical	trials	[133,	
135,	180,	182,	193],	two	interesting	questions	remain	to	be	addressed	[343],	which	are	as	
follows:	 (1)	“What	 is	 the	mechanism	of	action?”	and	(2)	“Why	are	benefits	observed	 in	
postmenopausal	women	 only?”.	One	potential	mechanism	of	 action	 in	 postmenopausal	
women	 was	 recently	 suggested	 by	 the	 ANZAC	 trial	 (AdditioN	 of	 Zoledronic	 Acid	 to	
Chemotherapy),	 which	 showed	 that	 addition	 of	 ZOL	 to	 neoadjuvant	 chemotherapy	
resulted	 in	 decreased	 serum	 levels	 of	 follistatin,	 an	 activin	 inhibitor	 and	member	 of	 the	
TGF-β	 family.	 Interestingly	 this	 was	 not	 observed	 in	 premenopausal	 women.	 Therefore	
postmenopausal	women	receiving	ZOL	may	therefore	have	a	higher	biological	availability	
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of	 activin	 compared	 to	 premenopausal	 women,	 thus	 promoting	 the	 tumour	 suppressor	
action	 of	 this	 TGF-β	 family	 member	 after	 ZOL	 treatment	 [196].	 In	 addition,	 given	 the	
reported	effects	of	ZOL	on	cells	other	 than	 the	osteoclast	 [154,	155,	159,	168,	171,	173,	
270,	 308],	 it	 is	 highly	 likely	 that	 treatment	 effects	 are	mediated	 via	 ZOL’s	 impact	 on	 the	
BME.			
Here	 I	present	the	first	experimental	evidence	that	modification	of	the	BME	with	
ZOL	 is	 not	 sufficient	 to	 supress	 peripheral	 MDA-G8	 breast	 cancer	 re-growth	 following	
cessation	of	combination	therapy;	suggesting	that	ZOL-induced	modification	of	the	BME	is	
not	 sufficient	 to	 reduce	 peripheral	 breast	 cancer	 re-growth.	 Briefly,	 tumour	 fragments	
from	 mice	 receiving	 combination	 therapy	 (Doxorubicin	 followed	 by	 ZOL)	 were	
subcutaneously	 transplanted	 into	 naïve	 BALB/c	 nude	mice	with	 either	 a	 physiological	 or	
therapeutically	 altered	BME	 (ZOL-pre-treatment).	 Despite	 ZOL-induced	 alterations	 to	 the	
BME,	growth	of	subcutaneously	re-transplanted	tumour	fragments	resumed	at	equal	rates	
whether	 transplanted	 into	 ZOL	 or	 PBS	 pre-treated	 hosts.	 Adjuvant	 and	 neoadjuvant	 ZOL	
only	demonstrated	benefits	 in	 clinical	 studies	 in	postmenopausal	women	 [133,	135,	180,	
182,	193],	and	my	experiments	were	not	performed	in	a	postmenopausal	model	system.	It	
would	 therefore	be	 relevant	 to	 repeat	 these	 studies	 in	ovariectomised	mice.	 In	addition,	
adjuvant	 Denosumab,	 another	 bone-targeted	 agent,	 has	 been	 demonstrated	 to	 prevent	
fractures	 in	 aromatase	 inhibitor-treated	 postmenopausal	 women	 [203].	 These	 findings	
highlight	 the	 potential	 to	 investigate	 whether	 the	 anti-RANKL-targeted	 Denosumab	 also	
improves	the	neoadjuvant	response	to	chemotherapy.	
Furthermore,	transplanted	tumour	fragments	are	likely	to	be	very	heterogeneous	
given	 that	different	cell	 types	and	various	stromal	cells	comprise	different	 regions	of	 the	
tumour.	Importantly,	breast	cancer	subtypes	show	significant	molecular	as	well	as	genetic	
heterogeneity	 [344,	 345],	 and	within	 each	 breast	 cancer	 different	mutations	 could	 drive	
disease	 progression.	 Intratumoural	 heterogeneity,	 the	 existence	 of	 multiple	 sub-clones	
with	 different	molecular	 profiles	 within	 one	 tumour,	 provides	 a	major	 clinical	 challenge	
[326].	 Therefore	 the	model	 of	 tumour-transplant	 in	my	 experiments	 does	 represent	 the	
heterogeneity	 in	 a	 clinical	 setting,	 where	 small	 residual	 tumours	 regrow	 after	 initial	
therapy.	However,	the	transplanted	tumour	heterogeneity	is	a	possible	explanation	for	the	
high	variation	of	 tumour	re-growth	observed	 in	the	recipient	mice	 (both	ZOL	and	control	
pre-treated).	 The	 tumours	 may	 have	 recruited	 sufficient	 BMDCs	 whilst	 still	 in	 the	 host,	
contributing	to	re-growth	upon	transplantation	irrespective	of	the	BME	and	precursor	cell	
recruitment	 in	 the	 recipients.	 There	 may	 have	 already	 been	 a	 switch	 from	
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microenvironment-dependent	to	microenvironment-independent	tumour	growth,	prior	to	
the	time	of	tumour	transplantation.			
It	 is	 currently	 not	 clear	 whether	 bone	 marrow-derived	 cells	 (BMDCs)	 are	 only	
required	 for	 the	 early	 stages	 of	 disease	 development	 or	 also	 for	 maintaining	 and	
promoting	 the	growth	established	 tumours.	 Studies	 from	Lyden	et	al.	 showed	 that	bone	
marrow-derived	precursor	cells	are	required	for	the	early	stages	of	 tumour	angiogenesis,	
whereas	residual	BMDCs	may	account	for	 later	growth	of	 intradermally	 implanted	B6RV2	
lymphoma	cells.	These	studies	also	showed	that	 impaired	recruitment	of	endothelial	and	
haematopoietic	progenitor	cells	 from	the	bone	marrow	 inhibits	tumour	angiogenesis	and	
thus	tumour	growth	[33].		
The	 contribution	 of	 BMDCs	 to	 tumour	 growth	 is	 complex,	 involving	 their	
mobilisation,	 recruitment	 and	 incorporation	 into	 the	 tumour	 stroma,	 with	 each	 step	
offering	 an	 individual	 therapeutic	window.	 Combining	 treatment	 approaches	 that	 target	
the	recruitment	and	mobilisation	of	BMDCs	 in	addition	 to	other	components	of	 the	TME	
may	provide	a	significant	improvement	in	the	efficacy	of	anti-cancer	therapy.		
Studies	 suggest	 that	 disease	 progression	 might	 not	 only	 be	 mediated	 via	 direct	
BMDC	recruitment	but	also	through	systemic	factors	[11,	27].	The	role	of	systemic	factors,	
derived	 from	 both	 the	 BME	 and	 the	 TME,	 in	 mediating	 breast	 cancer	 growth	 remains	
relatively	 unexplored.	 Soluble	 factors	 associated	 with	 BMDC	 mobilisation	 include	 VEGF,	
angiopoietin,	SDF-1	and	GM-CSF	[28,	32,	42,	255,	346].	Targeting	these	factors	and/or	their	
receptors	 is	 a	 potential	 therapeutic	 approach	 although	 this	 will	 not	 only	 affect	 BMDCs.	
Granulocyte-macrophagecolony-stimulating-factor	(GM-CSF)	for	example	is	known	to	have	
biphasic	effects	on	osteoclastogenesis	and	may	therefore	affect	peripheral	tumour	growth	
by	altering	the	levels	of	tumour-growth	promoting	factors	that	are	released	form	the	BME	
during	 active	 bone	 resorption.	 Dai	 and	 colleagues	 assessed	 whether	 blocking	 GM-CSF-
induced	osteoclastogenesis	by	ZOL	pre-treatment	prevents	GM-CSF-induced	breast	cancer	
growth	 in	bone	 in	a	mouse	model	of	chemotherapy-induced	 leukopenia.	 In	these	studies	
administration	of	murine	GM-CSF	increased	the	growth	of	MDA-231-lux	breast	cancer	cells	
in	 bone,	 which	 was	 associated	 with	 increased	 osteoclast	 activity	 when	 compared	 to	
control.	 In	 vitro	 GM-CSF	 had	 no	 effect	 on	 breast	 cancer	 cell	 proliferation	 supporting	 an	
indirect	mechanism	 in	 vivo	 [347].	 Elucidating	 if	 alteration	 of	 the	 BME	with	 GM-CSF	 and	
other	 stromal	 factors	 including	SDF-1,	 known	 to	 regulate	HSCs	and	progenitor	 trafficking	
[14,	 255],	 or	 CXCL5,	 responsible	 for	 recruitment	 of	 myeloid	 derived	 suppressor	 cells	
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(MDSCs)	 into	 the	 breast	 carcinoma	 TME	 [41]	 affects	 primary	 tumour	 growth	 would	 be	
interesting	to	explore.	With	regards	to	MDSCs,	I	aimed	to	explore	the	effects	of	DOX/ZOL	
combination	therapy	on	CD11b+/Gr1+	MDSCs.	Here	I	observed	a	small,	but	non-significant	
increase	 in	 the	 presence	 of	 these	 cells	 in	 the	 BM	 of	 treated	 mice	 when	 compared	 to	
control.	 Using	 more	 complex	 flow-cytometric	 experiments	 with	 multiple	 markers	 for	
different	 BMDC	 populations	 and	 their	 progenitors	 would	 establish	 if	 reduced	 peripheral	
breast	cancer	growth	after	combination	 therapy	 is	mediated	via	BMDCs	 (part	of	ongoing	
collaborative	 experiments	 with	 the	 McAllister	 group,	 Boston,	 USA).	 Although	 I	 have	
demonstrated	 that	ZOL	 (alone	or	 in	combination	 therapy)	 rapidly	affects	 the	cellular	and	
extra	cellular	composition	of	the	BME,	I	was	not	able	to	measure	the	effects	on	these	bone	
marrow-derived	cytokines	and	growth	factors	that	may	contribute	to	BMDCs	recruitment	
and	 mobilisation.	 Repeated	 blood	 sampling	 from	 animals	 was	 not	 permitted	 under	 the	
project	 license.	 This	may	 also	 not	 be	 practical	 as	 only	 limited	 amounts	 of	 blood	 can	 be	
taken	 each	 time,	 providing	 insufficient	 quantity	 of	 serum/plasma	 for	 down-stream	
analysis.		
In	 summary,	 further	 work	 is	 required	 to	 elucidate	 the	 extent	 of	 BMDCs	 and	 precursors	
contribution	 to	 the	 growth	 of	 peripheral	 tumours.	 In	 addition	 identifying	 the	 role	 of	
specific	molecules	that	may	play	a	key	role	in	cancer	progression	is	needed,	to	increase	our	
understanding	of	the	complex	tumour-stroma	interactions.	
6.2. Summary	of	future	work	
A	summary	of	proposed	future	work	to	follow-up	on	work	presented	in	this	thesis	is	listed	
below:	
• Establish	methodologies	 to	quantify	 the	effects	of	 anti-cancer	 therapy	on	 the	 in	 vivo	
bone	marrow	vasculature.	
• Visualise	 the	 temporal-spatial	 relation	 ship	of	disseminated	 tumour	 cells,	osteoblasts	
and	 vascular	 endothelial	 cells	 in	 bone	 using	 immunofluorescence	 (+/-	 therapeutic	
modification).	
• Obtain	 histological	 samples	 from	 patients	 with	 breast	 cancer	 bone	 metastasis	 to	
validate	whether	breast	 cancer	micrometastases	are	 indeed	 found	 in	 close	proximity	
to	 both	 endosteal	 and	 vascular	 niches.	 Ideally	 these	 samples	would	 include	 biopsies	
from	BP-treated	patients.	
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• Establish	 effects	 of	 bone-targeted	 agents	 on	 tumour	 growth	 promoting	 BMDCs	 and	
precursor	populations	using	a	variety	of	model	systems	(e.g.	immunocompromised	vs.	
immunocompetent,	pre-	vs.	post	menopausal,	male	vs.	female).		
• Establish	 whether	 tumour	 cell	 homing	 to	 bone	 and	 metastatic	 outgrowth	 differs	
between	subclones	of	breast	cancer	cells	with	differential	molecular	profile	(e.g.	a	GM-
CSFhigh	 vs	 GM-CSFlow	 breast	 cancer	 cell)	 and	 whether	 this	 is	 affected	 by	 a	 ZOL	 pre-
treated	BME	(this	 is	part	of	an	on-going	collaboration	with	Dr.	McAllister’s	 laboratory	
in	Boston,	USA).	
• Assess	 effects	 of	 bone-targeted	 agents	 on	 circulating	 cytokines,	 chemokines	 and	
growth	factors	(e.g.	LOX,	OPN,	VEGF,	GM-CSF	etc.)	associated	with	tumour	growth	and	
BMDCs	mobilisation	 using	 a	 variety	 of	model	 systems	 (e.g.	 immunocompromised	 vs.	
immunocompetent,	pre-	vs.	post	menopausal,	male	vs.	female).		
• Obtain	 clinical	 samples	 including	 blood,	 plasma,	 bone	 marrow	 or	 histopathological	
slides)	 from	 clinical	 trials	 (e.g.	 the	 AZURE	 trial)	 to	 determine	 effect	 of	 ZOL	 on	 bone	
marrow	cell	populations	in	the	adjuvant	setting.	
• Establish	 the	 effects	 of	 CBZ	 alone	 or	 in	 combination	 in	 immunocompetent	 mouse	
models	 and	 assess	 how	 the	 CBZ-mediated	 alterations	 of	 the	 BME	 may	 affect	
establishment	and	progression	of	breast	cancer	bone	metastasis.	
• Determine	response	of	the	 in	vivo	BME	to	CBZ	in	combination	with	other	therapeutic	
agents	 (e.g.	 bisphosphonates,	 chemotherapy,	 denosumab	 etc.)	 and	 potential	
consequences	in	xenograft	models	of	breast	cancer	bone	metastasis.	
• Establish	effects	of	combination	therapy	(DOX/ZOL)	on	BMDC	recruitment	to	periphral	
tumours	in	greater	detail.	
• Establish	 the	 role	 of	 primary-tumour	 derived	 systemic	 factors	 (e.g.	 OPN)	 on	 tumour	
cell	dormancy	and	metastatic	outgrowth	in	bone.	
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6.3. Conclusion	
This	thesis	provides	the	first	detailed	characterisation	of	the	acute	and	short-term	effects	
of	the	bisphosphonate	Zoledronic	acid	(ZOL)	and	the	tyrosine	kinase	inhibitor	Cabozantinib	
(CBZ)	on	the	naïve	in	vivo	bone	microenvironment	(BME)	and	highlights	the	importance	of	
the	 BME	 in	 mediating	 response	 to	 anti-cancer	 therapy.	 In	 addition	 I	 demonstrate	 that	
breast	 cancer	 cells	 appear	 to	 preferentially	 localise	 to	 trabecular	 bone	 surfaces	 that	 are	
rich	in	osteoblasts,	which	could	be	modulated	when	tumour	cells	arrive	in	a	therapeutically	
altered	microenvironment.	 An	 increased	 understanding	 of	 the	 role	 of	 osteoblasts	 in	 the	
early	stages	of	bone	metastasis	will	therefore	aid	in	providing	new	therapeutic	approaches	
for	inhibiting	the	disease	progression	towards	osteolytic	bone	disease,	which	still	remains	
incurable.	I	also	performed	the	first	studies	demonstrating	that	modification	of	the	BME	is	
not	 sufficient	 to	 supress	 peripheral	 breast	 cancer	 re-growth	 following	 cessation	 of	
combination	therapy,	suggesting	that	both	the	tumour	and	microenvironment	need	to	be	
targeted	for	successful	anti-cancer	therapy.		
Further	 work	 is	 required	 to	 elucidate	 the	 contribution	 of	 the	 BME	 to	 peripheral	 breast	
cancer	 growth.	 Increasing	 our	 understanding	 of	 the	 complex	 tumour-microenvironment	
crosstalk	will	ultimately	help	to	advance	current	treatment	options	as	well	as	the	design	of	
novel	therapeutic	approaches	for	both	primary	and	advanced	breast	cancer.	
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